# EDGAR Filing Document

**Accession Number:** 0000031462
**File Stem:** 0001104659-26-018357
**Filing Date:** 2026-2
**Character Count:** 536583
**Document Hash:** 0caccb5fc9a1078eb542183ed0742183
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-018357.hdr.sgml**: 20260223

**ACCESSION NUMBER**: 0001104659-26-018357

**CONFORMED SUBMISSION TYPE**: 10-K

**PUBLIC DOCUMENT COUNT**: 121

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260223

**DATE AS OF CHANGE**: 20260223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ECOLAB INC.
- **CENTRAL INDEX KEY:** 0000031462
- **STANDARD INDUSTRIAL CLASSIFICATION:** SOAP, DETERGENT, CLEANING PREPARATIONS, PERFUMES, COSMETICS [2840]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 410231510
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-09328
- **FILM NUMBER:** 26662137

**BUSINESS ADDRESS:**
- **STREET 1:** 1 ECOLAB PLACE
- **CITY:** SAINT PAUL
- **STATE:** MN
- **ZIP:** 55102
- **BUSINESS PHONE:** 18002326522

**MAIL ADDRESS:**
- **STREET 1:** 1 ECOLAB PLACE
- **CITY:** SAINT PAUL
- **STATE:** MN
- **ZIP:** 55102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ECOLAB INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ECONOMICS LABORATORY INC
- **DATE OF NAME CHANGE:** 19861203

?xml version='1.0' encoding='ASCII'? ECOLAB INC._December 31, 2025

[**Table of Contents**](#Toc)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-K**

☒ **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the fiscal year ended December 31, 2025**<br>

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**

**Commission File No. 1-9328**

**ECOLAB INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** |  | **41-0231510** |
| (State or other jurisdiction of <br>incorporation or organization) |  | (I.R.S. Employer <br>Identification No.) |
| **1 Ecolab Place, St. Paul, Minnesota 55102** | **1 Ecolab Place, St. Paul, Minnesota 55102** | **1 Ecolab Place, St. Paul, Minnesota 55102** |
| (Address of principal executive offices) (Zip Code) | (Address of principal executive offices) (Zip Code) | (Address of principal executive offices) (Zip Code) |
| &nbsp;&nbsp;&nbsp;Registrant's telephone number, including area code: **1-800-232-6522** | &nbsp;&nbsp;&nbsp;Registrant's telephone number, including area code: **1-800-232-6522** | &nbsp;&nbsp;&nbsp;Registrant's telephone number, including area code: **1-800-232-6522** |
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
| **Common Stock, $1.00 par value** | **ECL** | **New York Stock Exchange** |

---

Securities registered pursuant to Section 12(g) of the Act: **None**

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ⌧ Yes ◻ No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. ◻ Yes ⌧ No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ⌧ Yes ◻ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files. ⌧ Yes ◻ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Large accelerated filer ☒ | Accelerated filer ☐ |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-accelerated filer ☐ | Smaller reporting company ☐ |
|  | Emerging growth company ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive oﬃcers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ YES ☒ NO

Aggregate market value of voting and non-voting common equity held by non-affiliates of registrant on June 30, 2025, the last business day of the Registrant's most recently completed second fiscal quarter: $67,088,288,734 (see Item 12, under Part III hereof), based on a closing price of registrant's Common Stock of $269.44 per share.

The number of shares of registrant's Common Stock, par value $1.00 per share, outstanding as of January 30, 2026: 281,969,448 shares.

**DOCUMENTS INCORPORATED BY REFERENCE**

Portions of the registrant's Proxy Statement for the Annual Meeting of Stockholders to be held May 7, 2026, and to be filed within 120 days after the registrant's fiscal year ended December 31, 2025 (hereinafter referred to as "Proxy Statement"), are incorporated by reference into Part III.

------

[**Table of Contents**](#Toc)

**ECOLAB INC.**

**FORM 10-K**

**For the Year Ended December 31, 2025**

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;**BeginningPage** |
| &nbsp;&nbsp;[**PART I**](#PARTI_170437) |  |
| &nbsp;&nbsp;[**Item 1. Business**.](#Item1Business_15998) | &nbsp;&nbsp;**3** |
| &nbsp;&nbsp;[**Item 1A. Risk Factors**.](#Item1ARiskFactors_845860) | &nbsp;&nbsp;**16** |
| &nbsp;&nbsp;[**Item 1B. Unresolved Staff Comments**.](#Item1BUnresolved_831539) | &nbsp;&nbsp;**22** |
| &nbsp;&nbsp;[**Item 1C. Cybersecurity.**](#Item1C_Cybersecurity) | &nbsp;&nbsp;**22** |
| &nbsp;&nbsp;[**Item 2. Properties**.](#Item2Properties_698966) | &nbsp;&nbsp;**24** |
| &nbsp;&nbsp;[**Item 3. Legal Proceedings**.](#Item3Legal_229207) | &nbsp;&nbsp;**24** |
| &nbsp;&nbsp;[**Item 4. Mine Safety Disclosures.**](#Item4Mine_899042) | &nbsp;&nbsp;**24** |
| &nbsp;&nbsp;[**PART II**](#PARTII_194469) |  |
| &nbsp;&nbsp;[**Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities**.](#Item5Market_693030) | &nbsp;&nbsp;**25** |
| &nbsp;&nbsp;[**Item 6. \[Reserved\]**.](#Item6Reserved) | &nbsp;&nbsp;**25** |
| &nbsp;&nbsp;[**Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations**.](#Item7_ManagementDiscussionandAnalysis) | &nbsp;&nbsp;**26** |
| &nbsp;&nbsp;[**Item 7A. Quantitative and Qualitative Disclosures about Market Risk**.](#Item7AQuantitative_542771) | &nbsp;&nbsp;**47** |
| &nbsp;&nbsp;[**Item 8. Financial Statements and Supplementary Data**.](#Item8Financial_929330) | &nbsp;&nbsp;**47** |
| &nbsp;&nbsp;[**Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure**.](#Item9Changes_36116) | &nbsp;&nbsp;**96** |
| &nbsp;&nbsp;[**Item 9A. Controls and Procedures**.](#Item9AControls_983338) | &nbsp;&nbsp;**96** |
| &nbsp;&nbsp;[**Item 9B. Other Information**](#Item9BOtherInformation). | &nbsp;&nbsp;**96** |
| &nbsp;&nbsp;[**Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.**](#Item9CDisclosureRegardingForeignJurisdic) | &nbsp;&nbsp;**96** |
| &nbsp;&nbsp;[**PART III**](#PARTIII_604058) |  |
| &nbsp;&nbsp;[**Item 10. Directors, Executive Officers and Corporate Governance**.](#Item10Directors_332886) | &nbsp;&nbsp;**97** |
| &nbsp;&nbsp;[**Item 11. Executive Compensation**.](#Item11Executive_6722) | &nbsp;&nbsp;**97** |
| &nbsp;&nbsp;[**Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters**.](#Item12Security_61479) | &nbsp;&nbsp;**97** |
| &nbsp;&nbsp;[**Item 13. Certain Relationships and Related Transactions, and Director Independence**.](#Item13Certain_780095) | &nbsp;&nbsp;**97** |
| &nbsp;&nbsp;[**Item 14. Principal Accounting Fees and Services**.](#Item14Principal_569622) | &nbsp;&nbsp;**97** |
| &nbsp;&nbsp;[**PART IV**](#PARTIV) |  |
| &nbsp;&nbsp;[**Item 15. Exhibit and Financial Statement Schedules**.](#Item15Exhibits_78834) | &nbsp;&nbsp;**98** |
| &nbsp;&nbsp;[**Item 16. Form 10-K Summary.**](#Item16Form10KSummary) | &nbsp;&nbsp;**104** |

---

[**Table of Contents**](#Toc)

**PART I**

Except where the context otherwise requires, references in this Form 10-K to (i) "Ecolab," "Company," "we" and "our" are to Ecolab Inc. and its subsidiaries, collectively; (ii) "Nalco" are to Nalco Company LLC, a wholly-owned subsidiary of the Company; (iii) "Purolite" are to Purolite LLC, a wholly-owned subsidiary of the Company and its subsidiaries, collectively; and (iv) "Purolite transaction" are to the Company's acquisition of the shares of the subsidiaries and certain other affiliated entities of Purolite Corporation and substantially all of the assets of Purolite Corporation; and (iv) "Ovivo Electronics" are to Ovivo Inc., a wholly owned subsidiary of the Company and its subsidiaries, collectively.

**Item 1. Business.**

**General Development of Business.**

Ecolab was incorporated as a Delaware corporation in 1924. Our fiscal year is the calendar year ending December 31. International subsidiaries are included in the consolidated financial statements on the basis of their U.S. GAAP (accounting principles generally accepted in the United States of America) November 30 fiscal year ends to facilitate the timely inclusion of such entities in our consolidated financial reporting.

**Narrative Description of Business.**

**General**

A trusted partner for millions of customers, we are a global leader in water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. For more than a century, we have advanced innovation by integrating science-based solutions, data-driven insights, AI-technology and world-class service. This unique combination enables us to partner with customers to define what best-in-class looks like and scale it across their operations, helping them achieve peak performance. Today, we have $16 billion in annual sales, 48,000 associates and customers in more than 170 countries and 40 industries. We help protect one-third of the world's food production and a quarter of the power generated while delivering innovative solutions across food, healthcare, data centers, microelectronics, life sciences and hospitality. Our comprehensive approach protects what's vital, aiming by 2030 to help protect 2 billion people from infections and enough drinking water for 1 billion people while enhancing business performance.

We pursue a "One Ecolab" enterprise selling strategy, built on the legacy of 'circle the customer – circle the globe', where we provide an array of innovative programs, products and services designed to meet the operational and sustainability needs of our customers throughout the world. Through this strategy and the breadth of our product and service mix, one customer may utilize the offerings of several of our operating segments. Important in our value proposition for customers is our ability to produce improved results while reducing their water and energy use. With that in mind, we focus on continually innovating to optimize both our own operations and the solutions we provide to customers, aligning with our corporate strategy to address some of the world's most pressing and complex sustainability challenges, such as water scarcity and climate change. The work we do matters, and the way we do it matters to our employees, customers, investors and the communities in which we and our customers operate.

Sustainability is core to our business strategy. We deliver sustainable solutions that help companies around the world achieve their business goals while reducing environmental impacts. We partner with customers around the world to reduce water and energy use as well as greenhouse gas emissions through our high-efficiency solutions. By partnering with our customers to help them do more with less through the use of our innovative and differentiated solutions, we aim to help our customers conserve more than 300 billion gallons of water annually by 2030. In 2024, we helped our customers conserve more than 226 billion gallons of water and avoid more than 4.6 million metric tons of greenhouse gas emissions.

The following description of our business is based upon our reportable segments as reported in our consolidated financial statements for the year ended December 31, 2025, which are located in Item 8 of Part II of this Form 10-K. Operating segments that share similar economic characteristics and future prospects, including the nature of the products and production processes, end-use markets, channels of distribution and regulatory environment, have been aggregated into four reportable segments: Global Water, Global Institutional & Specialty, Global Pest Elimination, and Global Life Sciences.

[**Table of Contents**](#Toc)

**Global Water**

This reportable segment consists of the Light & Heavy, Food & Beverage and Paper operating segments, which provide water treatment and process applications and cleaning and sanitizing solutions, primarily to large industrial customers within the manufacturing, food and beverage processing, transportation, chemical, primary metals and mining, power generation, global refining, petrochemical, pulp and paper industries. The underlying operating segments exhibit similar manufacturing processes, distribution methods and economic characteristics. Descriptions of the three operating segments which comprise our Global Water reportable segment follow below.

***Light & Heavy***

Light & Heavy serves customers across industrial and institutional markets. Within Light & Heavy, our markets include food and beverage, manufacturing and transportation, institutional clients, including commercial buildings, hospitals, universities and hotels, and global high technology serving customers, including data centers and microelectronics. We also serve the power, chemicals, primary metals and mining and petroleum refining and fuels industries.

Light & Heavy provides water treatment products and technology programs for cooling water, ultra-pure water, wastewater, boiler water and process water applications. In addition to these solutions, we offer specialty programs to the petroleum and fuels industry – refining process applications, fuels and feedstocks additives. Our cooling water treatment programs are designed to control challenges associated with cooling water systems — corrosion, scale and microbial fouling and contamination — in open recirculating, once-through and closed systems. Our wastewater products and programs focus on improving overall plant economics, addressing compliance issues, optimizing equipment efficiency and improving operator capabilities and effectiveness. We provide integrated chemical and digitally-based solutions, process improvements and mechanical component modifications to optimize boiler performance and control corrosion and scale build-up. Our programs assist in more effectively managing water use for plant processes by optimizing the performance of treatment chemicals and equipment in order to minimize costs and maximize returns on investment.

Our offerings include specialty products such as scale and corrosion inhibitors, antifoulants, pre-treatment solutions, liquid cooling solutions, membrane treatments, coagulants and flocculants, anti-foamers, hydrogen sulfide removal, cold flow improvers, lubricity inhibitors, crude desalting and reactive monomer inhibitors, as well as our 3D TRASAR<sup>TM</sup> technologies, which combine chemistry, remote services and monitoring and control. We provide products and programs for water treatment and process applications aimed at combining environmental benefits with economic gains for our customers. Typically, water savings, energy savings and operating efficiency are among our primary sources of value creation for our customers, with product quality and production enhancement improvements also providing key differentiating features for many of our offerings. Our offerings are sold primarily by our corporate account and field sales employees. The majority of our Light & Heavy revenue is from product sales and is recognized at a point in time when the obligations in the contract with the customer are satisfied.

We believe we are one of the leading global suppliers of products and programs for chemical applications within the industrial water treatment and petroleum refining industries.

***Food & Beverage***

Food & Beverage provides cleaning and sanitation products and water programs to facilitate the processing of products for human consumption. Food & Beverage provides detergents, cleaners, sanitizers, lubricants, water solutions and animal health products, as well as cleaning systems, digitally-based dispensers, monitors and chemical injectors for the application of chemical products, primarily to dairy plants, dairy, swine and poultry farms, breweries and soft-drink bottling plants, as well as meat, poultry and other food processors. Food & Beverage is also a leading developer and marketer of antimicrobial products used in direct contact with meat, poultry, seafood and produce during processing in order to reduce microbial contamination. Food & Beverage also designs, engineers and installs clean-in-place process control systems and facility cleaning systems for its customer base. Water savings, energy savings, and operating efficiency are among our sources of value creation for our customers. Products for use in processing facilities are sold primarily by our corporate account and field sales employees, while products for use on farms are sold through dealers and independent, third-party distributors. The majority of our Food & Beverage revenue is from product and equipment sales and is recognized at a point in time when the obligations in the contract with the customer are satisfied.

We believe we are one of the leading global suppliers of cleaning and sanitizing products and water programs to the dairy plant, dairy, swine and poultry farm, food, meat and poultry, and beverage/brewery processing industries.

[**Table of Contents**](#Toc)

***Paper***

Paper provides water and process applications for the pulp and paper industry, offering a comprehensive portfolio of programs that are used in all principal steps of the papermaking process and across all grades of paper, including graphic grades, board and packaging, and tissue and towel. While Paper provides its customers with similar types of products and programs for water treatment and wastewater treatment as those offered by Light & Heavy, Paper also offers two specialty programs that differentiate its offerings from Light & Heavy —pulp applications and paper applications. Our pulp applications maximize process efficiency and increase pulp cleanliness and brightness in bleaching operations, as well as predict and monitor scaling potential utilizing on-line monitoring to design effective treatment programs and avoid costly failures. Our paper applications focus on improving our customers' operational efficiency, in part through water savings, energy savings and operating efficiency. Advanced digital sensing, monitoring and automation combine with innovative chemistries and detailed process knowledge to provide a broad range of customer solutions. Specialty products include flocculants, coagulants, dewatering aids and digester yield additives. Our offerings are sold primarily by our corporate account and field sales employees. The majority of our Paper revenue is from product sales and is recognized at a point in time when the obligations in the contract with the customer are satisfied.

We believe we are one of the leading global suppliers of water treatment products and process aids to the pulp and paper industry.

**Global Institutional & Specialty**

This reportable segment consists of the Institutional and Specialty operating segments, which provide specialized cleaning and sanitizing products to the foodservice, hospitality, lodging, government, education and retail industries. The underlying operating segments exhibit similar manufacturing processes, distribution methods and economic characteristics. Descriptions of the two operating segments which comprise our Global Institutional & Specialty reportable segment follow below.

***Institutional***

Institutional provides specialized cleaners and sanitizers, infection prevention solutions, food safety products and equipment, and a range of other products and programs to hospitality and healthcare institutions. Institutional sells specialized cleaners and sanitizers for washing dishes, glassware, flatware, foodservice utensils and kitchen equipment ("warewashing"), plus specialized cleaners for various applications throughout foodservice operations, on-premise laundries (typically used by hotel and healthcare customers) and general housekeeping functions. Further, we provide infection prevention solutions to acute care hospitals and long-term care centers, which include hand hygiene, hard surface disinfection, digital monitoring systems and instrument cleaning. We also sell food safety products and equipment, water filters, dishwasher racks and related kitchen sundries to the foodservice, lodging, educational and healthcare industries. Institutional also provides pool and spa treatment programs for hospitality and other commercial customers, as well as a broad range of janitorial cleaning and floor care products and programs to customers in hospitality, healthcare and commercial facilities. Institutional develops various digital monitoring and chemical dispensing systems which are used by our customers to efficiently and safely dispense our cleaners and sanitizers, and through these products, systems and our on-site sales and service expertise, develop better results for our customers including water savings, energy savings and operating efficiency. In addition, Institutional markets a lease program comprised of energy-efficient dishwashing machines, detergents, rinse additives and sanitizers, including full machine maintenance.

Institutional sells its products and programs primarily through its direct field sales and corporate account sales personnel. Corporate account sales personnel establish relationships and negotiate contracts with larger multi-unit or "chain" customers. We also utilize independent, third-party foodservice, broad-line, healthcare and janitorial distributors to provide logistics to end customers that prefer to work through these distributors. Many of these distributors also participate in marketing our product and service offerings to the end customers. Through our field sales personnel, we generally provide the same customer support to end-use customers supplied by these distributors as we do to direct customers. The majority of our Institutional revenue is from product sales and is recognized at a point in time when the obligations in the contract with the customer are satisfied.

We believe we are one of the leading global suppliers of warewashing and laundry products and programs and infection prevention solutions to the food service, hospitality, hospitals and long-term care markets.

***Specialty***

Specialty supplies cleaning and sanitizing products and related items primarily to regional, national and international quick service restaurant ("QSR") chains and food retailers (i.e., supermarkets and grocery stores). Its products include specialty and general purpose hard surface cleaners, degreasers, sanitizers, polishes, hand care products and assorted cleaning tools and equipment which are primarily sold under the "Ecolab" and "Kay" brand names. QSR's program also includes a lease program comprised of energy-efficient dishwashing machines, detergents, rinse additives and sanitizers, including full machine maintenance. Specialty's cleaning and sanitation programs are customized to meet the needs of the market segments it serves and are designed to provide highly effective cleaning performance, promote food safety, reduce labor, water and energy costs and enhance user and guest safety. A number of dispensing options are available for products in the core product range. Specialty supports its product sales with training programs and technical support designed to meet the special needs of its customers. Through our EcoSure Brand Protection business, Specialty also provides customized on-site evaluations, training and quality assurance services to foodservice and hospitality operations.

[**Table of Contents**](#Toc)

Both Specialty's QSR business and its food retail business utilize their corporate account sales force which manages relationships with customers at the corporate and regional office levels (and, in the QSR market segment, at the franchisee level) and their field sales force which provides program support at the individual restaurant or store level. QSR customers are primarily supplied through third party distributors while most food retail customers utilize their own distribution networks. While Specialty's customer base has broadened significantly over the years, Specialty's business remains largely dependent upon a limited number of major QSR chains and franchisees and large food retail customers.

Food Safety Solutions supplies a digital platform that combines software, hardware and multiple services to automate kitchen procedures for efficiency and compliance. It also offers a unique variety of products, tools and equipment for food preparation, food rotation labeling, temperature management, cleaning and employee safety across all food service customers. The majority of our Specialty revenue is from product sales and is recognized at a point in time when the obligations in the contract with the customer are satisfied.

We believe we are one of the leading suppliers of cleaning and sanitizing products to the global QSR market and the global food retail market.

**Global Pest Elimination**

This reportable segment consists of the Pest Elimination operating segment.

***Pest Elimination***

Pest Elimination provides services designed to detect, prevent and eliminate pests, such as rodents and insects, in full-service and quick-service restaurants, food and beverage processors, hotels, grocery operations and other commercial segments including education, life sciences and healthcare. The majority of our Pest Elimination revenue is from services and is recognized when the services are provided, which is over time.

In addition to the United States, which constitutes our largest operation, we operate in various regions, including in Asia Pacific, Greater China, Western Europe and Latin America.

We believe Pest Elimination is a leading service provider of effective, high-quality pest elimination programs that deliver high quality outcomes to commercial segments in the geographies it serves. As we expand the use of smart, connected devices, we believe our Pest Intelligence model will further contribute to our high-quality outcomes.

**Global Life Sciences**

This reportable segment consists of the Life Sciences operating segment.

***Life Sciences***

Life Sciences provides end-to-end cleaning and contamination control solutions to pharmaceutical and personal care manufacturers. These products are primarily sold under the "Ecolab" brand name, and include detergents, cleaners, sanitizers, disinfectants, surface wipes, as well as cleaning systems, electronic dispensers and chemical injectors for the application of chemical products. The Life Sciences portfolio includes premium fluid treatment and purification solutions with a broad range of unique products sold under the "Purolite" brand name, particularly focusing on biopharma purification solutions, active pharmaceutical ingredients ("APIs") and high value industrial applications. The Life Sciences portfolio also includes decontamination systems and services utilizing hydrogen peroxide vapor, which are sold under the "Bioquell" brand name. The pharmaceutical clean room environment is the primary area that Ecolab and Bioquell products are utilized. Products and programs are sold primarily through our field sales and corporate account personnel, and to a lesser extent through distributors. The majority of our Life Sciences revenue is from product sales and is recognized at a point in time when the obligations in the contract with the customer are satisfied.

Life Sciences is comprised of customers and accounts related to manufacturing in the following industries: pharmaceutical, animal health and medicine, blood purification and dialysis, biologic products, cosmetics and medical devices. Life Sciences also produces high performance purification resins that support critical separation processes across a range of industries, including power generation, food and beverage, and water treatment. Our tailored, comprehensive solutions and technical know-how focus on ensuring product quality, safety and compliance standards are met while improving operational efficiency in customers' cleaning, sanitation and disinfection processes. We believe we are one of the leading suppliers of process purification solutions in Europe and North America and of contamination control solutions in Europe, with a growing presence in North America and other regions.

[**Table of Contents**](#Toc)

**Additional Information**

***International Operations***

We directly operate in approximately 100 countries outside of the United States through wholly-owned subsidiaries or, in some cases, through a joint venture with a local partner. In certain countries, selected products are sold by our export operations to distributors, agents or licensees, although the volume of those sales is not significant in terms of our overall revenues. In general, our businesses conducted outside the United States are similar to those conducted in the United States.

Our business operations outside the United States are subject to the usual risks of foreign operations, including possible changes in trade and foreign investment laws, international business laws and regulations, tax laws, currency exchange rates and economic and political conditions. The profitability of our international operations is generally lower than the profitability of our businesses in the United States, due to (i) the additional cost of operating in numerous and diverse foreign jurisdictions with varying laws and regulations, (ii) higher costs of importing certain raw materials and finished goods in some regions, (iii) the smaller scale of international operations where certain operating locations are smaller in size and (iv) the additional reliance on distributors and agents in certain countries which can negatively impact our margins. Investments in sales and technical support are also necessary in certain geographies in order to facilitate the growth of our international operations.

***Competition***

In general, the markets in which the businesses in our Global Water reportable segment compete are led by a few large companies, with the rest of the market served by smaller entities focusing on more limited geographic regions or a smaller subset of products and services. Our businesses in this segment compete on the basis of their demonstrated value, technical expertise, innovation, digital technology, chemical formulations, global customer support, detection equipment, monitoring capabilities and dosing and metering equipment. Through the combination of our digitally enabled end-to-end water management and hygiene solutions, data-driven insights and personalized service, our Global Water businesses deliver outcomes that help our customers optimize water and energy use, improve productivity, advance food safety, and achieve sustainability and net zero goals, while optimizing total cost of operations.

The businesses in our Global Institutional & Specialty and Global Pest Elimination reportable segments have two significant classes of competitors. First, we compete with a small number of large companies selling directly or through distributors on a national or international scale. Second, we have numerous smaller regional or local competitors who focus on more limited geographies, product lines and/or end-use customer segments. We believe we compete principally by providing superior value, premium customer support, training, service, and innovative and differentiated products to help our customers protect their brand reputation and improve their operational efficiency.

Within the Global Life Sciences reportable segment, the business competes in the European market versus several mid-size and regional competitors and competes against two large and other mid-size or regional competitors in North America. Outside of North America and Europe competitors are much more fragmented and do not offer the same level of service or coverage as Ecolab. Our businesses in this segment compete by enabling our customers success through improved hygiene, digitally enabled programs in operating room and patient room space as well as a tailored approach to delivering key inputs that directly impact patients globally.

***Sales***

Our products, systems and services are primarily marketed in domestic and international markets by our Company-trained direct field sales personnel who also advise and assist our customers in the proper and most efficient use of the products and systems in order to meet a full range of cleaning and sanitation, water treatment and process chemistry needs. Independent, third-party distributors and, to a lesser extent, sales agents are utilized in several markets, as described in the segment descriptions found above. Currently the majority of our revenue is from product and sold equipment and is recognized at the point in time when the obligations in the contract with the customer are satisfied.

***Customers and Classes of Products***

We believe our business is not materially dependent upon a single customer. Additionally, although we have a diverse customer base and no customer or distributor constituted 10 percent or more of our consolidated revenues in 2025, 2024 or 2023, we do have customers and independent, third-party distributors, the loss of which could have a material adverse effect on results of operations for the affected earnings periods; however, we consider it unlikely that such an event would have a material adverse impact on our financial position. No material part of our business is subject to renegotiation or termination at the election of a governmental unit.

We sold one class of products within the Global Institutional & Specialty reportable segment which comprised 10% or more of consolidated net sales in the last three years. Sales of warewashing products were approximately 13% of consolidated net sales in 2025 and 12% in 2024 and 2023.

[**Table of Contents**](#Toc)

***Human Capital***

As of December 31, 2025, Ecolab employed approximately 48,000 employees. The largest component of our workforce is comprised of more than 25,000 sales and service employees. Our innovation efforts are supported by approximately 3,000 research, development, engineering and digital experts. Approximately 43% of our employees are employed in North America, 21% in Europe, 12% in Latin America, 8% in Asia Pacific, 8% in India, Middle East and Africa, and 8% in Greater China.

We believe that doing the right thing, the right way, is good for business. We believe that by driving performance and growing fast, we can deliver a net positive impact in our own operations and what we deliver for our customers. We believe that Ecolab's century-long growth, innovation and high performance have benefited from a workplace where individuals from all backgrounds are encouraged to reach their full potential. We believe in providing training and career development opportunities to all employees and in compensating and rewarding our employees equitably.

Our commitment to the safety of our employees, contractors, and customers is evident in the way we operate, the products we develop and the customers we serve. In addition, we are committed to promoting the health and well-being of our employees, our customers, and their customers by contributing to programs and initiatives that enhance the quality of life in the communities where they work and live. In support of these overall objectives, key areas of focus include:

*Workplace Culture:* Ecolab representatives engage daily with a diverse range of colleagues, customers and communities. We are committed to developing a culture where all voices are heard and equitable employment opportunities are available to everyone. To sustain our success, we work to embed our values of inclusivity and engagement throughout our people processes, including recruitment, retention and development.

We also have a vibrant and growing community of 12 Employee Resource Groups ("ERGs") that are open to all Ecolab associates, to help employees connect with colleagues, take part in career and leadership development experiences, and provide important insights that help advance our workplace culture. All employees are welcome and encouraged to join, participate, or become leaders and allies within any of our ERGs.

*Employee Training and Development:* Ecolab's growth has been characterized by a century of supporting customers by combining science, technology and innovation with the expertise of our associates. Beyond rigorous technical, functional, and business-specific training courses, our Global Corporate Flagship Development Programs for supervisors, managers and leaders are designed to deepen leadership capability and prepare potential successors for key leadership roles.

*Compensation and Benefits:* Ecolab has a market-competitive and performance-based pay philosophy, and we believe in compensating our employees fairly and equitably. We are committed to rewarding and recognizing employees for their contributions to the success of the organization. This includes our global merit increase program and our short- and long-term variable pay programs, which include goals and targets that are tied to the success of the business. We test our pay and wage data against compensation surveys to align our pay with the competitive external market. In the U.S., U.K., Ireland, and France, we conduct pay equity studies, and we are in the process of expanding our pay equity studies further to countries where we have a sizable presence.

Ecolab also provides market-competitive benefits based on country-specific needs and government requirements. While our benefits packages vary by market, they are designed to attract top talent and build long-term connections with our associates. Aligned to the applicable market and local regulations, elements of our benefits programs may include medical and dental insurance, retirement savings, employee stock purchase plan, paid time off, parental leave and adoption assistance, life and disability insurance, and employee assistance plans.

*Safety, Health, and Wellness:* At Ecolab, the safety of our employees and contractors is a priority and is embedded into our company values. Our safety goals are simple: zero accidents, zero injuries and zero violations. We communicate that this is a collective goal all employees commit to, own, and deliver on every day. Our leadership teams and a network of Safety, Health and Environment professionals around the world support employees with robust safety programs, processes and technologies. Understanding underlying and potential risks is a critical component to improving safety outcomes. Our Global Safety Dashboard tracks our performance on a range of leading and lagging safety indicators and helps us measure the effectiveness of our safety programs.

Additionally, a Be Well Program is available to U.S. employees and their families to empower, educate and support their personal journey to overall well-being by making positive lifestyle choices while creating a culture of wellness throughout Ecolab. Over the last year, we've expanded our physical, behavioral and financial well-being offerings with programs that leverage powerful technology and personalized coaching to support progress against wellness goals. Wellness initiatives outside the U.S. are aligned to country-specific needs and market practices; examples include employee assistance programs, caregiver support and programs focused on physical and mental health.

[**Table of Contents**](#Toc)

***Patents and Trademarks***

We own and license a number of patents, trademarks and other intellectual property. While we have an active program to protect our intellectual property by filing for patents or trademarks and pursuing legal action, when appropriate, to prevent infringement, except for the items listed below, we do not believe our overall business is materially dependent on any individual patent or trademark.

● Trademarks related to Ecolab, Nalco and 3D TRASAR, which collectively are material to all of our reportable segments. The Ecolab, Nalco and 3D TRASAR trademarks are registered or applied for in all of our key markets, and we anticipate maintaining them indefinitely.

***Seasonality***

We experience variability in our quarterly operating results due to seasonal sales volume and business mix fluctuations in our operating segments.

***Investments in Equipment***

We have invested, and plan to continue to invest, in process control and monitoring equipment and technology, consisting primarily of systems used by customers to dispense our products as well as to monitor water systems. The investment in such equipment is discussed under the heading "Investing Activities" in Part II, Item 7., "Management's Discussion and Analysis of Financial Condition and Results of Operations" (the "MD&A"), of this Form 10-K.

***Manufacturing and Distribution***

We manufacture most of our products and related equipment in Company-operated manufacturing facilities. Some products are also produced for us by third-party contract manufacturers. Other products and equipment are purchased from third-party suppliers. Additional information on product/equipment sourcing is found in the segment discussions above and additional information on our manufacturing facilities is located under Part I, Item 2., "Properties," of this Form 10-K.

Deliveries to customers are made from our manufacturing plants and a network of distribution centers and third-party logistics service providers. We use common carriers, our own delivery vehicles, and distributors for transport. Additional information on our plant and distribution facilities is located under Part I, Item 2., "Properties," of this Form 10-K.

***Raw Materials***

Raw materials purchased for use in manufacturing our products are inorganic chemicals, including alkalis, acids, biocides, phosphonates, phosphorous materials, silicates and salts; and organic chemicals, including acids, alcohols, amines, fatty acids, surfactants, solvents, monomers and polymers. Pesticides used by Pest Elimination are purchased as finished products under contract or purchase order from the producers or their distributors. We also purchase packaging materials for our manufactured products and components for our specialized cleaning equipment and systems. We purchase more than 10,000 raw materials, with the largest single raw material representing approximately five percent of raw material purchases. Our raw materials, with the exception of a few specialized chemicals which we manufacture, are generally purchased on an annual contract basis and are ordinarily available in adequate quantities from a diverse group of suppliers globally. When practical, global sourcing is used so that purchasing or production locations can be shifted to control product costs.

***Research and Development***

Our research and development program consists principally of developing and validating the performance of new products, processes, techniques and equipment, improving the efficiency of those already existing, improving service program content, evaluating the environmental compatibility of products and technical support. Key disciplines include analytical and formulation chemistry, microbiology, data science and predictive analytics, process and packaging engineering, digital and remote monitoring engineering and product dispensing technology. Substantially all of our principal products have been developed by our research, development and engineering personnel.

We believe continued research and development activities are critical to maintaining our leadership position within the industry and will provide us with a competitive advantage as we seek additional business with new and existing customers.

***Joint Ventures***

Over time, we have entered into partnerships or joint ventures in order to meet local ownership requirements, to achieve quicker operational scale, to expand our ability to provide our customers a more fully integrated offering or to provide other benefits to our business or customers. During 2025, the impact on our consolidated net income of our joint ventures, in the aggregate, was approximately two percent. We will continue to evaluate the potential for partnerships and joint ventures that can assist us in increasing our geographic, technological and product reach.

[**Table of Contents**](#Toc)

***Environmental and Regulatory Considerations***

Our businesses are subject to various legislative enactments and regulations relating to the protection of the environment and public health. While we cooperate with governmental authorities and take commercially practicable measures to meet regulatory requirements and avoid or limit environmental effects, some risks are inherent in our businesses. Among the risks are costs associated with transporting and managing hazardous materials and waste disposal and plant site clean-up, fines and penalties if we are found to be in violation of law, as well as modifications, disruptions or discontinuation of certain operations or types of operations including product recalls and reformulations. Similarly, the need for certain of our products and services is dependent upon or might be limited by governmental laws and regulations. Changes in such laws and regulations, including among others, air, water, chemical and product regulations, could impact the sales of some of our products or services. In addition to an increase in costs of manufacturing and delivering products, a change in production regulations or product regulations could result in interruptions to our business and potentially cause economic or consequential losses should we be unable to meet the demands of our customers for products.

Additionally, although we are not currently aware of any such circumstances, there can be no assurance that future legislation or enforcement policies will not have a material adverse effect on our consolidated results of operations, financial position or cash flows. Environmental and regulatory matters most significant to us are discussed below.

***Ingredient Legislation***: Various laws and regulations have been enacted by state, local and foreign jurisdictions pertaining to the sale of products which contain phosphorous, volatile organic compounds, per- and polyfluoroalkyl substances or other ingredients that may impact human health or the environment. Under California Proposition 65, for example, label disclosures are required for certain products containing chemicals listed by California. Chemical management initiatives that promote pollution prevention through research and development of safer chemicals and safer chemical processes are being advanced by several states.

Environmentally preferable purchasing programs for cleaning products have been enacted in a number of states to date, and in recent years have been considered by several other state legislatures. Cleaning product ingredient disclosure legislation has been introduced in the U.S. Congress in each of the past few years but has not passed, and several states are considering further regulations in this area. In 2017, California passed the Cleaning Product Right to Know Act of 2017, that required ingredient transparency on-line and on-label by 2020 and 2021, respectively. The U.S. Government is monitoring "green chemistry" initiatives through a variety of initiatives, including its "Design for the Environment" ("DfE")/"Safer Choice" program. DfE/Safer Choice has three broad areas of work (recognition of safer products on a DfE/Safer Choice label, development of best practices for industrial processes and evaluation of safer chemicals), and we are involved in these to varying degrees. Our Global Institutional and Global Water cleaning products are subject to the regulations and may incur additional stay-in-market expenses associated with conducting the required alternatives analyses for chemicals of concern. To date, we generally have been able to comply with such legislative requirements by reformulation or labeling modifications. Such legislation has not had a material adverse effect on our consolidated results of operations, financial position or cash flows to date.

***TSCA***: The nation's primary chemicals management law, the Toxic Substances Control Act ("TSCA"), was updated with the passage of the Frank R. Lautenberg Chemical Safety for the 21st Century Act ("LCSA") in 2016. The LCSA modernizes the original 1976 legislation, aiming to establish greater public confidence in the safety of chemical substances in commerce and improve the U.S. Environmental Protection Agency's ("EPA") capability and authority to regulate existing and new chemical substances. For Ecolab, the TSCA changes mainly impact testing and submission costs for new and existing chemical substances in the United States. As a result of reform and multiple administration changes, EPA reviews are resulting in the majority of new substances being regulated in some manner by the agency. As the agency continues to review existing chemistries, the likelihood that substances manufactured, imported, or processed by Ecolab may be subject to additional testing costs and/or risk management decisions is increasing. Future EPA risk evaluation decisions may result in the reduction or elimination of future uses for some products. Compliance with new requirements under TSCA are similar to the costs associated with REACH in the European Union, which is discussed below.

***REACH***: The European Union has enacted a regulatory framework for the Registration, Evaluation and Authorization of Chemicals ("REACH"), which aims to manage chemical safety risks. REACH established a European Chemicals Agency ("ECHA") in Helsinki, Finland, which is responsible for evaluating data to determine hazards and risks and to manage this program for authorizing chemicals for sale and distribution in Europe. We met all REACH registration requirements. To help manage this program, we have been simplifying our product lines and working with chemical suppliers to comply with registration requirements. In addition, Korea, Taiwan, Ukraine, Turkey, India, Peru, Chile and Colombia and other countries have implemented or are implementing similar requirements. In addition, the European Commission has announced a revision of the REACH Regulation, with a legislative proposal expected in the third quarter of 2026, introducing simplified but stricter chemical controls that may increase compliance requirements and affect parts of Ecolab's raw material portfolio; however, the potential financial impact is not yet fully quantifiable and is not expected to have a material adverse effect on our consolidated results of operations, cash flows, or financial position.

[**Table of Contents**](#Toc)

***GHS***: In 2003, the United Nations adopted a standard on hazard communication and labeling of chemical products known as the Globally Harmonized System of Classification and Labeling of Chemicals ("GHS"). GHS is designed to facilitate international trade and increase safe handling and use of hazardous chemicals through a worldwide system that classifies chemicals based on their intrinsic hazards and communicates information about those hazards through standardized product labels and safety data sheets ("SDSs"). As of 2026, most countries in which we operate have adopted or are expected to adopt GHS-related legislation. The primary cost of compliance revolves around reclassifying products and revising SDSs and product labels. We have met applicable deadlines and are working toward a phased-in approach to mitigate the costs of GHS implementation in remaining countries (e.g., Ukraine, Chile, India). We are also implementing updates, where applicable, of GHS revisions in countries where it is already present (e.g., US, Canada). Potential costs to us are not expected to have a material adverse effect on our consolidated results of operations or cash flows in any one reporting period or on our financial position.

***Pesticide and Biocide Legislation***: Various international, federal and state environmental laws and regulations govern the manufacture and/or use of pesticides. We manufacture and sell certain disinfecting, sanitizing and material preservation products that kill or reduce microorganisms (bacteria, viruses, fungi) on hard environmental surfaces, in process fluids and on certain food products. Such products constitute "pesticides" or "antimicrobial pesticides" under the current definitions of the Federal Insecticide, Fungicide, and Rodenticide Act ("FIFRA"), as amended by the Food Quality Protection Act of 1996, the principal federal statute governing the manufacture, labeling, handling and use of pesticides. We maintain several hundred product registrations with the U.S. Environmental Protection Agency ("EPA"). Registration entails the necessity to meet certain efficacy, toxicity and labeling requirements and to pay on-going registration fees. In addition, each state in which these products are sold requires registration and payment of a fee. In general, the states impose no substantive requirements different from those required by FIFRA. However, California and certain other states have adopted additional regulatory programs, and California imposes a tax on total pesticide sales in that state. While the cost of complying with rules as to pesticides has not had a material adverse effect on our consolidated results of operations, financial condition, or cash flows to date, the costs and delays in receiving necessary approvals for these products continue to increase. Total fees paid to the EPA and the states to obtain or maintain pesticide registrations are not expected to significantly affect our consolidated results of operations or cash flows in any one reporting period or our financial position.

In Europe, the Biocidal Products Regulation established a program to evaluate and authorize marketing of biocidal active substances and products. We are working with suppliers and industry groups to manage these requirements and have met all relevant deadlines of the program by the timely submission of dossiers for active substances and biocide products. Anticipated registration costs, which will be incurred through the multi-year phase-in period, will be significant; however, these costs are not expected to significantly affect our consolidated results of operations or cash flows in any one reporting period or our financial position. The same is true for emerging biocide regulations in Asia.

In addition, Pest Elimination applies restricted-use pesticides that it generally purchases from third parties. That business must comply with certain standards pertaining to the use of such pesticides and to the licensing of employees who apply such pesticides. Such regulations are enforced primarily by the states or local jurisdictions in conformity with federal regulations. We have not experienced material difficulties in complying with these requirements.

***FDA Antimicrobial Product Requirements***: Various laws and regulations have been enacted by federal, state, local and foreign jurisdictions regulating certain products manufactured and sold by us for controlling microbial growth on humans, animals and foods. In the United States, these requirements generally are administered by the U.S. Food and Drug Administration ("FDA"). However, the U.S. Department of Agriculture and EPA also may share in regulatory jurisdiction of antimicrobials applied to food. The FDA codifies regulations for these product categories in order to ensure product quality, safety and effectiveness. The FDA also has been expanding requirements applicable to such products, including proposing regulations for over-the-counter antiseptic drug products, which may impose additional requirements associated with antimicrobial hand care products and associated costs when finalized by the FDA.

***Medical Device, Drug and Cosmetic Product Requirements***: As a manufacturer, distributor and marketer of medical devices and human drugs, we also are subject to regulation by the FDA and corresponding regulatory agencies of the state, local and foreign governments in which we sell our products. These regulations govern the development, testing, manufacturing, packaging, labeling, distribution and marketing of medical devices and medicinal products, including APIs, excipients and resins for biopharmaceutical processing.

[**Table of Contents**](#Toc)

● In the **United States**, we are required to register with the FDA as a medical device, drug and cosmetic manufacturer, comply with post-market reporting (e.g., Adverse Event Reporting, MDR and Recall) requirements, and to comply with the FDA's current Good Manufacturing Practices and Good Practice Guidelines ("GxPs"), which ensure that products are consistently produced and controlled according to quality standards and must be approved by the competent authorities.

● Countries in the **European Union** require that certain products being sold within their jurisdictions obtain a "CE mark," an international symbol of adherence to quality assurance standards, and be manufactured in compliance with certain requirements (e.g., Medical Device Regulation (EU) 2017/745 ("MDR"), and ISO 13485). We have CE mark approval to sell various medical devices. Implementation of the MDR has required additional investments, including system, product, process, technical file and product improvements. Additionally, pharmaceutical products in the EU must comply with regulations such as the GxP.

● In **Australia**, products must comply with the regulations set by the Therapeutic Goods Administration. Medical devices must be included in the Australian Register of Therapeutic Goods and meet the Essential Principles for safety and performance. Therapeutic goods, including drugs and cosmetics, must adhere to specific standards and regulatory frameworks for safety, quality, efficacy, labelling, and claims.

● **Non-EU export markets** are also subject to government regulation and country-specific rules and regulations.

***Equipment:*** Ecolab's products are dispensed by equipment that is subject to state and local regulatory requirements, as well as being subject to UL, NSF, and other approval requirements. For certain digitally connected product offerings, Federal Communication Commission and corresponding international requirements are applicable. We have both dedicated manufacturing facilities and third-party production of our equipment. We are developing processes to monitor and manage changing regulatory regimes and assist with equipment systems compliance. To date, such requirements have not had a material adverse effect on our consolidated results of operations, financial position or cash flows.

***Other Environmental Legislation***: Our manufacturing plants are subject to federal, state, local or foreign jurisdiction laws and regulations relating to discharge of hazardous substances into the environment and to the transportation, handling and disposal of such substances. The primary federal statutes that apply to our activities in the United States are the Clean Air Act, the Clean Water Act and the Resource Conservation and Recovery Act. We are also subject to the Superfund Amendments and Reauthorization Act of 1986, which imposes certain reporting requirements as to emissions of hazardous substances into the air, land and water. The products we produce and distribute into Europe are also subject to directives governing electrical waste (WEEE Directive 2012/19/EU) and restrictive substances (RoHS Directive 2011/65/EU). Similar legal requirements apply to Ecolab's facilities globally. We make capital investments and expenditures to comply with environmental laws and regulations, to promote employee safety and to carry out our announced environmental sustainability principles. To date, such expenditures have not had a significant adverse effect on our consolidated results of operations, financial position or cash flows. Our capital expenditures for environmental, health and safety projects worldwide were approximately $62 million in 2025 and 2024, and $46 million in 2023. Approximately $59 million has been budgeted globally for projects in 2026.

***Climate Change***: Various laws and regulations addressing climate change are being implemented or considered at international, national, regional, and state levels, particularly focusing on reducing greenhouse gas ("GHG") emissions. Notable regulations include California's 2023 GHG emissions reporting regulations addressing emissions, climate-related risks, and reduction claims, and the European Commission's Corporate Sustainability Reporting Directive, which became effective January 2024 and is applicable to both EU and certain non-EU companies with a phased introduction. We are or may become subject to many of these laws. We continue to monitor and evaluate these regulations and incorporate reporting and disclosure obligations as appropriate.

Ecolab recognizes that climate change presents both risks and opportunities. We assess climate-related risks within our Enterprise Risk Management process, aligned with the Financial Stability Board's Task Force on Climate-related Financial Disclosures ("TCFD") recommendations. Our TCFD disclosures are available in our annual CDP Climate report on our website. Since our first TCFD-aligned climate risk assessment in 2021, we have continued to review and adapt our strategies to manage climate risks and leverage opportunities for customer impact. We also evaluate potential water-related risks in our operations, disclosing the results in our Growth and Impact Report. Future analyses will explore nature-related risks linked to climate and water, aligned with the Task Force on Nature-Related Financial Disclosures ("TNFD") recommendations.

As a corporate policy, we support a balanced approach to reducing GHG emissions while sustaining economic growth. We have established climate related goals to further our commitment. In 2019, we announced goals to reduce operational GHG emissions by half by 2030 and achieve net zero by 2050, in alignment with the UN Global Compact's Business Ambition for 1.5°C. In 2020, we further committed to move to 100% renewable energy by 2030 and set a science-based target ("SBT") for Scope 1, 2, and 3 GHG emissions. In 2024, our net zero target for Science Based Targets initiative validation was approved, including a near term Scope 3 target. Our near-term SBT aims to reduce absolute Scope 1 and 2 emissions by 50% from 2018 levels, and Scope 3 emissions by 25% from 2022 levels, by 2030.

[**Table of Contents**](#Toc)

In 2024, we invested $48 million and $4.3 million in capital and operating environmental program expenses, respectively. The investments resulted in a reduction of total energy consumption by almost 13.7 billion BTUs; reduction of emissions by 1,660.88 tCO2e; and over 48 million gallons (~184,000 cubic meters) of water savings from reduction and recycling projects. These reductions are calculated using direct measurements (such as meter readings and utility reports for water) and best-practice methodologies, with 2018 as the baseline year.

Beyond our operations, we help customers in over 170 countries reduce their energy and GHG emissions through high-efficiency solutions in cleaning, sanitation, water, paper, and energy services. Our 2030 goals include: customer GHG emissions reduction of 6.0 million metric tons; water stewardship to restore over 50% of our water withdrawal and achieve Alliance for Water Stewardship Standard certification in high-risk watersheds; and water conservation to reduce net water withdrawals by 40% per unit of production and help customers conserve over 300 billion gallons of water annually.

The science of sustainability is evolving. For factors that may affect our sustainability initiatives, goals, and targets, see Item 1A of Part I of this Form 10-K, entitled "Risk Factors."

***Environmental Remediation and Proceedings***: Along with numerous other potentially responsible parties ("PRP"), we are currently involved with waste disposal site clean-up activities imposed by the federal Comprehensive Environmental Response, Compensation and Liability Act ("CERCLA") or state equivalents at 16 sites in the United States. Additionally, we have similar liability at six sites outside the United States. In general, under CERCLA, we and each other PRP that actually contributed hazardous substances to a Superfund site are jointly and severally liable for the costs associated with cleaning up the site. Customarily, the PRPs will work with the EPA to agree and implement a plan for site remediation.

Based on an analysis of our experience with such environmental proceedings, our estimated share of all hazardous materials deposited on the sites referred to in the preceding paragraph, and our estimate of the contribution to be made by other PRPs which we believe have the financial ability to pay their shares, we have accrued our best estimate of our probable future costs relating to such known sites. In establishing accruals, potential insurance reimbursements are not included. The accrual is not discounted. It is not feasible to predict when the amounts accrued will be paid due to the uncertainties inherent in the environmental remediation and associated regulatory processes.

We have also been named as a defendant in a number of lawsuits alleging personal injury due to exposure to hazardous substances, including multi-party lawsuits alleging personal injury in connection with our products and services. While we do not believe that any of these suits will be material to us based upon present information, there can be no assurance that these environmental matters could not have, either individually or in the aggregate, a material adverse effect on our consolidated results of operations, financial position or cash flows.

We have also been named as a defendant in lawsuits where our products have not caused injuries, but the claimants wish to be monitored for potential future injuries. We cannot predict with certainty the outcome of any such tort claims or the involvement we or our products might have in such matters in the future, and there can be no assurance that the discovery of previously unknown conditions will not require significant expenditures. In each of these chemical exposure cases, our insurance carriers have accepted the claims on our behalf (with or without reservation) and our financial exposure should be limited to the amount of our deductible; however, we cannot predict the number of claims that we may have to defend in the future and we may not be able to continue to maintain such insurance.

Our worldwide net expenditures for contamination remediation were approximately $1.3 million in 2025, $0.7 million in 2024 and $0.3 million in 2023. Our worldwide accruals at December 31, 2025 for probable future remediation expenditures, excluding potential insurance reimbursements, totaled approximately $21.5 million. We review our exposure for contamination remediation costs periodically and our accruals are adjusted as considered appropriate. While the final resolution of these issues could result in costs below or above current accruals and, therefore, have an impact on our consolidated financial results in a future reporting period, we believe the ultimate resolution of these matters will not have a material effect on our consolidated results of operations, financial position or cash flows.

**Available Information.**

We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the SEC at https://www.sec.gov.

General information about us, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as any amendments and exhibits to those reports, are available free of charge through our website at https://investor.ecolab.com as soon as reasonably practicable after we file them with, or furnish them to, the SEC.

In addition, the following governance materials are available on our web site at https://investor.ecolab.com/governance/corporate-governance: (i) charters of the Audit, Compensation & Human Capital Management, Finance, Governance, and Safety, Health & Environment Committees of our Board of Directors; (ii) our Board's Corporate Governance Principles; and (iii) our Code of Conduct.

We include our website addresses throughout this report for reference only. The information contained on our websites, including the corporate responsibility, and climate reports identified in this report, is not incorporated by reference into this report.

[**Table of Contents**](#Toc)

**Information about our Executive Officers.**

The persons listed in the following table are our current executive officers. Officers are elected annually and as needed by the Board of Directors. The Board of Directors routinely reviews the Company's management structure and may make changes to the officers listed below at any time. There is no family relationship among any of the directors or executive officers and no executive officer has been involved during the past ten years in any legal proceedings described in applicable Securities and Exchange Commission regulations.

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Age** | **Office** | **Positions Held Since Jan. 1, 2021** |
| Nicholas J. Alfano | 64 | Executive Vice President and President – Global Water  | Apr. 2023 – Present |
|  |  | Executive Vice President and General Manager – Global Light Sector | Jan. 2021 – Mar. 2023 |
| Christophe Beck | 58 | Chairman and Chief Executive Officer | Oct. 2022 – Present |
|  |  | Chairman, Chief Executive Officer and President | May 2022 – Oct. 2022 |
|  |  | President and Chief Executive Officer | Jan. 2021 – May 2022 |
| Jandeen M. Boone | 52 | Executive Vice President, General Counsel and Secretary | Jan. 2025 – Present |
|  |  | Executive Vice President, General Counsel, Secretary and Interim Chief Compliance Officer | June 2024 – Jan. 2025 |
|  |  | Senior Vice President, Chief Compliance Officer and Interim General Counsel | May 2024 – June 2024 |
|  |  | Interim General Counsel and Assistant Secretary | Apr. 2024 – May 2024 |
|  |  | Sector General Counsel, Institutional and International Markets | Feb. 2023 – Apr. 2024 |
|  |  | Sector General Counsel, Institutional and Specialty | Jan. 2022 – Jan. 2023 |
|  |  | Associate General Counsel, Institutional | Jan. 2021 – Dec. 2021 |
| Jennifer J. Bradway | 49 | Senior Vice President and Corporate Controller | Jan. 2022 – Present |
|  |  | Senior Vice President Finance - Global Institutional | Jan. 2021 – Dec. 2021 |
| Darrell R. Brown | 62 | President and Chief Operating Officer | Oct. 2022 – Present |
|  |  | Executive Vice President and President – Global Industrial | Jan. 2021 – Sept. 2022 |
| Benjamin M. Clark (1) | 45 | Executive Vice President and Chief Supply Chain Officer | July 2025 – Present |
|  |  | Senior Vice President Finance – Global Supply Chain | Aug. 2023 – July 2025 |
| Gregory B. Cook | 57 | Executive Vice President and President – Institutional Group | Aug. 2023 – Present  |
|  |  | Executive Vice President and General Manager – Global Institutional  | June 2021 – July 2023 |
|  |  | Senior Vice President and General Manager – Global Pest | Jan. 2021 – May 2021 |
| Alexander A. De Boo | 58 | Executive Vice President and President – Global Markets | Feb. 2021 – Present |
|  |  | Executive Vice President and President – Western Europe | Jan. 2021 – Feb. 2021 |
| Alexandra M. A. Hlila | 50 | Executive Vice President and General Manager – Global Pest | Dec. 2024 – Present |
|  |  | Senior Vice President – Strategy Institutional Group | Mar. 2024 – Dec. 2024 |
|  |  | Senior Vice President & General Manager – Institutional Europe | May 2022 – Feb. 2024 |
|  |  | Vice President Global & Corporate Accounts – Institutional Europe | May 2021 – Apr. 2022 |
|  |  | Vice President Field Sales Europe – Institutional Division | Jan. 2021 – Apr. 2021 |
| Margeaux M. King (2) | 49 | Executive Vice President – Human Resources | Jan. 2025 – Present |
|  |  | Senior Vice President, Global Total Rewards & Talent | Feb. 2022 – July 2022 |
|  |  | Senior Vice President Compensation & Benefits | Jan. 2021 – Jan. 2022 |
| Scott D. Kirkland | 52 | Chief Financial Officer | Jan. 2022 – Present |
|  |  | Senior Vice President and Corporate Controller | Jan. 2021 – Dec. 2021 |
| Harpreet Saluja (3) | 57 | Executive Vice President – Corporate Strategy & Business Development | Nov. 2024 - Present |

---

(1) Prior to joining Ecolab in August 2023, Mr. Clark was employed by Flagstone Foods, one of the largest manufacturers and distributors of private label healthy snacks in North America, as Chief Operating Officer and Chief Financial Officer from November 2021 until August 2023. Prior to Flagstone Foods, Mr. Clark was employed by GE Healthcare, a leading global medical technology and digital solutions innovator, as Chief Financial Officer of Global Services & Supply Chain from November 2020 until November 2021.

(2) Prior to re-joining Ecolab in 2025, Ms. King was employed by The Toro Company, a global maker of lawn, snow, and irrigation equipment, as Vice President, Human Resources from August 2022 until December 2024.

(3) Prior to joining Ecolab in November 2024, Ms. Saluja was employed by Eaton Corporation plc, a power management company, as Senior Vice President, Corporate Development and Planning from 2013 until 2024.

[**Table of Contents**](#Toc)

**Forward-Looking Statements**

This Form 10-K, including Part I, Item 1, entitled "Business," and the MD&A within Part II, Item 7, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include expectations concerning items such as:

● amount, funding and timing of cash expenditures relating to our restructuring and other initiatives, as well as savings from such initiatives

● future cash flows, access to capital, targeted credit rating metrics and impact of credit rating downgrade

● adequacy of cash reserves

● uses for cash, including dividends, share repurchases, debt repayments, capital investments and strategic business acquisitions

● global economic and political environment

● long-term potential of our business

● impact of changes in exchange rates and interest rates, including the assessment and management of associated risks

● customer retention rate

● bad debt experience, non-performance of counterparties and losses due to concentration of credit risk

● disputes, claims and litigation

● environmental contingencies

● impact and cost of complying with laws and regulations

● sustainability and impact targets

● returns on pension plan assets

● contributions to pension and postretirement healthcare plans

● amortization expense

● impact of new accounting pronouncements

● income taxes, including tax attributes, valuation allowances, unrecognized tax benefits, permanent reinvestment assertions and goodwill deductibility

● recognition of share-based compensation expense

● payments under operating leases

● future benefit plan payments

● market position

Without limiting the foregoing, words or phrases such as "will likely result," "are expected to," "will be," "will continue," "is anticipated," "we believe," "we expect," "estimate," "project" (including the negative or variations thereof), "intends," "could," or similar terminology, generally identify forward-looking statements. Forward-looking statements may also represent challenging goals for us. These statements, which represent our expectations or beliefs concerning various future events, are based on current expectations that involve a number of risks and uncertainties that could cause actual results to differ materially from those of such forward-looking statements. We caution that undue reliance should not be placed on such forward-looking statements, which speak only as of the date made. For a further discussion of these and other factors which could cause results to differ from those expressed in any forward-looking statement, see Item 1A of Part I of this Form 10-K, entitled "Risk Factors." Except as may be required under applicable law, we undertake no duty to update our forward-looking statements.

Forward-looking and other statements in this document may also address our sustainability initiatives, goals, targets and progress, and the inclusion of such statements is not an indication that these contents are necessarily material to investors or required to be disclosed in our filings with the SEC. In addition, historical, current, and forward-looking sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future and performance against our goals and targets may differ from such forward-looking statements in such event.

[**Table of Contents**](#Toc)

**Item 1A. Risk Factors.**

The following are important factors which could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Form 10-K. See the section entitled "Forward-Looking Statements" set forth above.

We may also refer to this disclosure to identify factors that may cause results to differ materially from those expressed in other forward-looking statements, including those made in oral presentations, such as telephone conferences and/or webcasts open to the public.

Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below in addition to the other information set forth in this Annual Report on Form 10-K, including "Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operation" and our consolidated financial statements and the related notes, before making an investment decision. The risks described below are not the only risks or uncertainties we face. The occurrence of any of the following risks, additional risks and uncertainties not presently known to us, or risks that we currently believe to be immaterial, could materially and adversely affect our business, reputation, financial condition, prospects, or results of operations. In such case, the trading price of our common stock could decline, and you may lose all or part of your original investment. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks and uncertainties described below. The disclosures in this section reflect our beliefs and opinions as to factors that could materially and adversely affect us in the future. References to past events are provided by way of example only and are not intended to be a complete listing or a representation as to whether or not such factors have occurred in the past.

Additionally, macroeconomic and geopolitical developments, including public health crises, escalating global conflicts, supply chain disruptions, labor market constraints, rising rates of inflation and high interest rates, may amplify many of the risks discussed below to which we are subject. The extent of the impact of macroeconomic and geopolitical developments on our financial and operating performance depends significantly on the duration and severity of such macroeconomic and geopolitical developments, the actions taken to contain or mitigate its impact and any changes in consumer behaviors as a result thereof.

**Economic & Operational Risks**

***Our results are impacted by general worldwide economic factors.***

Over the past year, changes in global trade policies, including the imposition of tariffs, import and export restrictions, and retaliatory trade actions, as well as implications of geopolitical situations in Europe, the Middle East, China, and Russia, have resulted in economic and demand uncertainty. Previously, the COVID pandemic, geopolitical instability and other global events have resulted in supply chain challenges, inflation, high interest rates, foreign currency exchange volatility, and volatility in global capital markets, which have affected our business and could have a material adverse impact on our business in the future. Countries such as Argentina and Turkey have experienced economic upheaval and similar upheaval in other countries with Ecolab operations could have a material adverse impact on our consolidated results of operations, financial position and cash flows by negatively impacting economic activity, including in our key end-markets, and by further weakening the local currency versus the U.S. dollar, resulting in reduced sales and earnings from our foreign operations, which are generated in the local currency, and then translated to U.S. dollars.

***Our results depend upon the continued vitality of the markets we serve.***

Economic downturns, and in particular downturns in our larger markets, including the foodservice, hospitality, travel, health care, food processing, refining, pulp and paper, mining and steel industries, can adversely impact our customers, and we may find it difficult to restore margins by maintaining pricing due to easing inflation from slowing economic growth. Recently, the war and energy crisis in Europe have resulted in a more challenging macroeconomic environment with significantly impacted costs and demand. Previously, the COVID-19 pandemic negatively impacted the demand for our products and services provided to customers in the full-service restaurant, hospitality, lodging and entertainment industries. In prior years, a weaker global economic environment has also negatively impacted certain of our other end-markets. During these periods of weaker economic activity, our customers and potential customers may reduce or discontinue their volume of purchases of cleaning and sanitizing products and water treatment and process chemicals, which has had, and may continue to have, a material adverse effect on our business, financial condition, results of operation or cash flows.

***Our significant non-U.S. operations expose us to global economic, political and legal risks that could impact our profitability.***

We have significant operations outside the United States, including joint ventures and other alliances. We conduct business in more than 170 countries and, in 2025, approximately 47% of our net sales were generated from customers outside the United States. There are inherent risks in our international operations, including:

● exchange controls and currency restrictions;

● currency fluctuations and devaluations;

● changes in international trade policies, including the imposition of tariffs and other trade restrictions;

● export duties and quotas;

● changes in the availability and pricing of raw materials, energy and utilities;

● changes in local economic conditions;

● changes in laws and regulations, including the imposition of economic or trade sanctions affecting international commercial transactions;

[**Table of Contents**](#Toc)

● difficulties in managing international operations and the burden of complying with international and foreign laws;

● requirements to include local ownership or management in our business;

● economic and business objectives that differ from those of our joint venture partners;

● exposure to possible expropriation, nationalization or other government actions;

● restrictions on our ability to repatriate dividends from our subsidiaries;

● unsettled political conditions, military action, civil unrest, acts of terrorism, force majeure, war or other armed conflict, including the Russian invasion of Ukraine, the Israel-Hamas conflict and other hostilities in the Middle East; and

● countries whose governments have been hostile to U.S.-based businesses.

Following Russia's invasion of Ukraine and the United States' and other countries' sanctions against Russia, we have limited our Russian business to operations that are essential to life, providing minimal support for our healthcare, life sciences, food and beverage and certain water businesses, and we may further narrow our presence in Russia depending on developments in the conflict or otherwise. While our operations in Russia and areas experiencing conflict are not material to our business and financial results, the escalation of these conflicts, or the imposition of additional sanctions by the United States, may also heighten many other risks disclosed in our report on Form 10-K, any of which could materially and adversely affect our business and financial results. Such risks include, but are not limited to, adverse effects on macroeconomic conditions, including increased inflation, constraints on the availability of commodities, supply chain disruption and decreased business spending; disruptions to our or our business partners' global technology infrastructure, including through cyber-attack or cyber-intrusion; adverse changes in international trade policies and relations; claims, litigation and regulatory enforcement; our ability to implement and execute our business strategy; terrorist activities; our exposure to foreign currency fluctuations; reputational risk; and constraints, volatility, or disruption in the capital markets.

Additionally, changes in international trade policies by governments around the world, including the imposition or continuation of tariffs, could materially and adversely affect our business. During 2025, new tariffs were imposed in the U.S. for imports from a broad range of countries and materials. Several countries also implemented or proposed retaliatory tariffs on imports from the U.S., as well as other barriers to trade. Ongoing changes in U.S. trade policy through administrative action or litigation create a heightened level of uncertainty for our business. These tariffs, any new tariffs or policies imposed by governments around the world, or any resulting retaliatory measures, to the extent implemented, could increase our costs, reduce our sales and earnings or otherwise have an adverse effect on our operations.

Further, our operations outside the United States require us to comply with a number of United States and non-U.S. laws and regulations, including anti-corruption laws such as the United States Foreign Corrupt Practices Act and the United Kingdom Bribery Act, as well as U.S. and non-U.S. economic sanctions regulations. We have internal policies and procedures relating to such laws and regulations; however, there is risk that such policies and procedures will not always protect us from the misconduct or reckless acts of employees or representatives, particularly in the case of recently acquired operations that may not have significant training in applicable compliance policies and procedures. Violations of such laws and regulations could result in disruptive investigations, significant fines and sanctions, which could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

Also, because of uncertainties regarding the interpretation and application of laws and regulations and the enforceability of intellectual property and contract rights, we face risks in some countries that our intellectual property rights and contract rights would not be enforced by local governments. We are also periodically faced with the risk of economic uncertainty, which has impacted our business in some countries. Other risks in international business also include difficulties in staffing and managing local operations, including managing credit risk to local customers and distributors.

Our overall success as a global business depends, in part, upon our ability to succeed in differing economic, social, legal and political conditions. We may not continue to succeed in developing and implementing policies and strategies that are effective in each location where we do business, which could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

***Our increasing reliance on artificial intelligence ("AI") technologies in our products, services, and operations presents several risks that could adversely impact our business, financial condition, and results of operations.***

We are increasingly incorporating AI capabilities into the development of technologies and our business operations, and into our products and services. AI technology is complex and rapidly evolving and may subject us to significant competitive, legal, regulatory, operational and other risks, including the following:

● *Operational and Technical Risks*: AI technologies are complex and rapidly evolving. Flaws in AI algorithms, training methodologies, or datasets may lead to unintended consequences, such as operational disruptions, erroneous decision-making, or data loss. These issues could impair the effectiveness of our AI systems and result in significant operational challenges. Additionally, software we purchase or lease from third-party vendors could become inoperable (via an attack from a bad actor, network failure, code error, etc.), such that it adversely impacts Ecolab's ability to deliver products or services to its customers, resulting in financial losses, legal liabilities, and damage to our reputation.

● *Legal and Regulatory Risks*: The legal and regulatory landscape for AI is still developing and varies across jurisdictions. Compliance with evolving AI regulations may impose significant costs, limit our ability to incorporate AI capabilities, and expose us to legal liabilities. Additionally, new regulations could conflict with our current AI practices, requiring costly changes to our development and deployment strategies.

[**Table of Contents**](#Toc)

● *Reputational Risks*: The use of AI raises social and ethical concerns, which could harm our reputation if not managed responsibly. Incidents related to AI, such as biased outcomes or privacy breaches, could lead to negative publicity and reduce public trust in our AI solutions.

● *Competitive Risks*: Our competitors may develop and implement AI technologies more effectively, gaining a competitive advantage. If we fail to keep pace with advancements in AI, our market position could be weakened, adversely affecting our business performance.

● *Financial Risks*: The development, testing, and deployment of AI systems are resource-intensive and may increase our operational costs. There is no assurance that our investments in AI will yield the anticipated benefits or that customers will adopt our AI-enhanced offerings, potentially impacting our financial results.

● *Cybersecurity Risks*: AI systems can be vulnerable to cybersecurity threats, such as data breaches and unauthorized access. These threats could result in financial losses, legal liabilities, and damage to our reputation.

We are committed to developing and using AI responsibly, but there can be no guarantee that we will successfully mitigate all associated risks. Any failure in our AI initiatives could materially harm our business, financial condition, and results of operations.

***We are subject to information technology system failures, network disruptions and breaches in data security.***

We rely to a large extent upon information technology systems and infrastructure to operate our business. The size and complexity of our information technology systems and those of strategic vendors make them vulnerable to failure, malicious intrusion and random attack. Acquisitions have resulted in further de-centralization of systems and additional complexity in our systems infrastructure. Likewise, data security breaches by employees or others with permitted access to our systems or to the systems of strategic vendors pose a risk that sensitive data may be exposed to unauthorized persons or to the public. Geopolitical tensions or conflicts, such as Russia's invasion of Ukraine, may further heighten the risk of cybersecurity attacks. While we have continually matured our security program and capabilities and have had no material incidents to date, cyber threats continue to evolve, such as with the use of artificial intelligence, resulting in sophisticated new attack methods that are increasingly automated, targeted, and difficult to defend against, and there can be no assurance that our efforts will prevent cybersecurity attacks or breaches in our systems or in the systems of strategic vendors, including cloud providers, that could cause reputational damage, business disruption or legal and regulatory costs; could result in third-party claims; could result in compromise or misappropriation of our intellectual property, trade secrets or sensitive information; or could otherwise materially adversely affect our business, including our business strategy, results of operations, or financial condition. Certain of our customer offerings include digital components, such as remote monitoring of certain customer operations. A breach of those remote monitoring systems could expose customer data giving rise to potential third-party claims and reputational damage. Additionally, it may take considerable time for us to investigate and evaluate the full impact of cyber-attacks, particularly for sophisticated attacks, which may inhibit our ability to provide prompt, full, and reliable information about cybersecurity incidents to our customers, regulators, and the public. There may also be other related challenges and risks as we complete implementation of our ERP system upgrade, and businesses which we have acquired, or may in the future acquire, may have information technology system vulnerabilities which could increase our risk of cybersecurity attacks. Although we maintain insurance, our insurance coverage may not be sufficient in type or amount to prevent or recover losses resulting from cybersecurity attacks.

***Our results could be materially and adversely affected by difficulties in securing the supply of certain raw materials or by fluctuations in the cost of raw materials.***

The prices of raw materials used in our business fluctuate, and in recent years we have experienced periods of significant increased raw material costs. Changes in raw material prices, unavailability of adequate and reasonably priced raw materials or substitutes for those raw materials, or the inability to obtain or renew supply agreements on favorable terms has materially and adversely affected our business and can in the future materially and adversely affect our consolidated results of operations, financial position or cash flows. In addition, volatility and disruption in economic activity and conditions could disrupt or delay the performance of our suppliers and thus impact our ability to obtain raw materials at favorable prices or on favorable terms, which may materially and adversely affect our business.

***We may experience business disruption if we fail to execute organizational change and management transitions.***

Our continued success will depend on the efforts and abilities of our executive officers and certain other key employees, particularly those with sales and sales management responsibilities, to drive business growth, development and profitability. Our operations could be materially and adversely affected if for any reason we are unable to successfully execute organizational change and management transitions at leadership levels.

***Severe public health outbreaks not limited to COVID-19 may adversely impact our business.***

The COVID-19 pandemic had a rapid and significant negative impact on the global economy, including a significant downturn in the foodservice, hospitality and travel industries. Measures taken to alleviate the pandemic (such as stay-at-home orders and other responsive measures) significantly impacted our restaurant and hospitality customers and negatively affected demand for our products and services in these segments, resulting in a material adverse effect on our business and results of operations. Besides the COVID-19 pandemic, the United States and other countries have experienced, and may experience in the future, public health outbreaks such as Zika virus, Avian Flu, SARS and H1N1 influenza. A prolonged occurrence of a contagious disease such as these could result in a significant downturn in the foodservice, hospitality and travel industries and also may result in health or other government authorities imposing restrictions on travel further impacting our end markets. Any of these events could result in a significant drop in demand for some of our products and services and materially and adversely affect our business.

[**Table of Contents**](#Toc)

**Strategic Risks**

***If we are unsuccessful in integrating acquisitions our business could be materially and adversely affected.***

We seek to acquire complementary businesses as part of our long-term strategy. There can be no assurance that we will find attractive acquisition candidates or succeed at effectively managing the integration of acquired businesses. If the underlying business performance of such acquired businesses deteriorates, the expected synergies from such transactions do not materialize or we fail to successfully integrate new businesses into our existing businesses, our consolidated results of operations, financial position or cash flows could be materially and adversely affected.

***If we are unsuccessful in executing on key business initiatives, our business could be materially and adversely affected***.

We continue to execute key business initiatives as part of our ongoing efforts to improve our efficiency and returns. In particular, we are making supply chain investments to secure supply and add new capacity in our Life Sciences business. Additionally, we are continuing implementation of our ERP system upgrades, which are expected to continue in phases over the next several years. These upgrades, which include sales, supply chain and certain finance functions, are expected to improve the efficiency of certain financial and related transactional processes. These upgrades involve complex business process design and a failure of certain of these processes could result in business disruption. We are also undertaking restructuring programs including the One Ecolab initiative leveraging our digital technologies to realign the functional work done in many countries into global centers of excellence. This program is discussed along with other restructuring activities under Note 3, "Special (Gains) and Charges," of the Notes of this Form 10-K. If the projects in which we are investing or the initiatives which we are pursuing are not successfully executed, our consolidated results of operations, financial position or cash flows could materially and adversely be affected.

***Our growth depends upon our ability to compete successfully with respect to value, innovation and customer support*.**

We have numerous global, national, regional and local competitors. Our ability to compete depends in part on providing high quality and high value-added products, technology and service. We must also continue to identify, develop and commercialize innovative, profitable and high value-added products for niche applications and commercial digital applications. We have made significant investments in commercial digital product offerings, and our culture and expertise must continue to evolve to develop, support and profitably deploy commercial digital offerings, which are becoming an increasingly important part of our business. There can be no assurance that we will be able to accomplish our technology development goals or that technological developments by our competitors, including in the area of artificial intelligence, will not place certain of our products, technology or services at a competitive disadvantage in the future. In addition, certain of the new products that we have under development will be offered in markets in which we do not currently compete, and there can be no assurance that we will be able to compete successfully in those new markets. If we fail to introduce new technologies or commercialize our digital offerings on a timely and profitable basis, we may lose market share and our consolidated results of operations, financial position or cash flows could be materially and adversely affected.

***Consolidation of our customers and vendors could materially and adversely affect our results.***

Customers and vendors in the foodservice, hospitality, travel, healthcare, energy, life sciences, food processing and pulp and paper industries, as well as other industries we serve, have consolidated in recent years and that trend may continue. This consolidation could have a material adverse impact on our ability to retain customers and on our pricing, margins and consolidated results of operations.

***We enter into multi-year contracts with customers that could impact our results.***

Our multi-year contracts with some of our customers include terms affecting our pricing flexibility. There can be no assurance that these restraints will not have a material adverse impact on our margins and consolidated results of operations.

**Legal, Regulatory & Compliance Risks**

***Our business depends on our ability to comply with laws and governmental regulations and meet our contractual commitments and failure to do so could materially and adversely impact our business; and we may be materially and adversely affected by changes in laws and regulations****.*

Our business is subject to numerous laws and regulations relating to the environment, including evolving climate change standards, and to the manufacture, storage, distribution, sale and use of our products as well as to the conduct of our business generally, including employment and labor laws and anti-corruption laws. Furthermore, increasing public and governmental awareness and concern regarding the effects of climate change has led to significant legislative and regulatory efforts to limit greenhouse gas emissions and will likely result in further environmental and climate change laws and regulations. Compliance with these laws and regulations exposes us to potential financial liability and increases our operating costs. A violation of these laws and regulations could expose us to financial liability that may have a material adverse effect on our results of operations and cash flows. Regulation of our products and operations continues to increase with more stringent standards, causing increased costs of operations and potential for liability if a violation occurs. The potential cost to us relating to environmental and product registration laws and regulations is uncertain due to factors such as the unknown magnitude and type of possible contamination and clean-up costs, the complexity and evolving nature of laws and regulations, and the timing and expense of compliance. Changes to current laws (including tax laws), regulations and policies could impose new restrictions, costs or prohibitions on our current practices which would have a material adverse effect on our consolidated results of operations, financial position or cash flows. Changes to labor and employment laws and regulations, as well as related rulings by courts and administrative bodies, could materially and adversely affect our operations and expose us to potential financial liability.

Defense of litigation, particularly certain types of actions such as antitrust, patent infringement, personal injury, product liability, breach of contract, wage hour and class action lawsuits, can be costly and time consuming even if ultimately successful, and if not successful could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

[**Table of Contents**](#Toc)

***Our operations may present a safety risk to our employees and others.***

Notwithstanding our emphasis on safety and the precautions we take related to health and safety, we may be unable to avoid safety incidents relating to our operations that result in injuries or deaths of our employees, contractors or others. Certain safety incidents may result in legal or regulatory action that could result in increased expenses or reputational damage. We maintain workers' compensation and other insurances to address the risk of incurring material liabilities for injuries or deaths, but there can be no assurance that the insurance coverage will be adequate or will continue to be available on terms acceptable to us, or at all, which could result in material liabilities to us for any injuries or deaths. Changes to federal, state, and local employee health and safety regulations, and legislative, regulatory, or societal responses to safety incidents may result in heightened regulations or public scrutiny that may increase our compliance costs or result in reputational damage.

***A chemical spill or release could materially and adversely impact our business.***

As a manufacturer and supplier of chemical products, there is a potential for chemicals to be accidentally spilled, released or discharged, either in liquid or gaseous form, during production, transportation, storage or use. Such a release could result in environmental contamination as well as a human or animal health hazard. Accordingly, such a release could have a material adverse effect on our consolidated results of operations, financial position or cash flows.

***Potential indemnification liabilities pursuant to the separation and split-off of our Upstream Energy business could materially and adversely affect our business and financial statements.***

With respect to the separation and subsequent split-off of our Upstream Energy business, we entered into a separation and distribution agreement with ChampionX Holding Inc. and ChampionX Corporation (f/k/a Apergy Corporation and taken together with ChampionX Holding Inc., "ChampionX") as well as certain other agreements to govern the separation and related transactions and our relationship with ChampionX going forward. These agreements provide for specific indemnity and certain other obligations of each party and could lead to disputes between ChampionX and us. If we are required to indemnify ChampionX under the circumstances set forth in these agreements, we may be subject to substantial related liabilities. In addition, with respect to the liabilities for which ChampionX has agreed to indemnify us under these agreements, there can be no assurance that the indemnity rights we have against ChampionX will be sufficient to protect us against the full amount of such liabilities, or that ChampionX will be able to fully satisfy its indemnification obligations. Each of these risks could negatively affect our business and our consolidated results of operations, financial position or cash flows could be materially and adversely affected.

***Extraordinary events may significantly impact our business.***

The occurrence of (a) litigation or claims, (b) the loss or insolvency of a major customer or distributor, (c) repeated or prolonged federal government shutdowns or similar events, (d) war (including acts of terrorism or hostilities which impact our markets), (e) natural or manmade disasters, (f) water shortages or (g) severe weather conditions affecting our operations or the energy, foodservice, hospitality and travel industries may have a material adverse effect on our business.

While we have a diverse customer base and no customer or distributor constitutes 10 percent or more of our consolidated revenues, we do have customers and independent, third-party distributors, the loss of which could have a material adverse effect on our consolidated results of operations or cash flows for the affected earnings periods.

Government shutdowns can have a material adverse effect on our consolidated results of operations or cash flows by disrupting or delaying new product launches, renewals of registrations for existing products and receipt of import or export licenses for raw materials or products.

War (including acts of terrorism or hostilities), natural or manmade disasters, water shortages or severe weather conditions, including the effects of climate change, affecting the energy, foodservice, hospitality, travel, health care, food processing, pulp and paper, mining, steel and other industries can cause a downturn in the business of our customers, which in turn can have a material adverse effect on our consolidated results of operations, financial position or cash flows. In particular, the U.S. Gulf Coast is a region with significant refining, petrochemicals and chemicals operations which provide us raw materials, as well as being an important customer base for our Light & Heavy operating segment. Hurricanes or other severe weather events impacting the Gulf Coast, such as the winter freeze in Texas and the Gulf Coast in February 2021, can materially and adversely affect our ability to obtain raw materials at reasonable cost, or at all, and could adversely affect our business with our customers in the region.

***Our commitments, goals, targets, objectives and initiatives related to sustainability, and our public statements and disclosures regarding them, expose us to numerous risks.***

We have developed, and will continue to establish, goals, targets, and other objectives related to sustainability matters, including our sustainability goals in alignment with the United Nations Global Compact's Business Ambition for 1.5⁰C and our commitments to science-based targets addressing Scope 1, 2 and 3 GHG emissions, discussed in Item 1 of Part I of this Form 10-K, entitled "Business." Achieving these goals and commitments will require evolving our business, capital investment and the development of technology that might not currently exist. We might incur additional expense or be required to recognize impairment charges in connection with our efforts. These commitments, goals, targets and other objectives reflect our current plans and there is no guarantee that they will be achieved. Our efforts to research, establish, accomplish, and accurately report on these commitments, goals, targets, and objectives expose us to operational, reputational, financial, legal, and other risks. Our ability to achieve any stated commitment, goal, target, or objective is subject to factors and conditions, many of which are outside of our control, including the pace of changes in technology, the availability of requisite financing, and the availability of suppliers that can meet our sustainability and other standards.

[**Table of Contents**](#Toc)

Our business may face increased scrutiny from the investment community, other stakeholders, regulators, and the media related to our sustainability activities, including our commitments, goals, targets, and objectives, and our methodologies and timelines for pursuing them. If our sustainability practices do not meet the rapidly evolving, varied and often times conflicting investor or other stakeholder expectations and standards, our reputation, our ability to attract or retain employees, and our attractiveness as an investment, business partner, or as an acquiror could be negatively impacted. Similarly, our failure or perceived failure to pursue or fulfill our commitments, goals, targets, and objectives, to comply with ethical, environmental, or other standards, regulations, or expectations, or to satisfy reporting standards with respect to these matters, within the timelines we announce, or at all, could have operational, reputational, financial and legal impacts.

**Financial Risks**

***If the separation and split-off of our Upstream Energy business or certain internal transactions undertaken in anticipation of the divestiture are determined to be taxable in whole or in part, we and our stockholders may incur significant tax liabilities.***

In connection with the separation and split-off of our Upstream Energy business that was consummated on June 3, 2020, we obtained opinions of outside tax counsel that the related merger and exchange offer will qualify as tax-free transactions to us and our stockholders, except to the extent that cash was paid to Ecolab stockholders in lieu of fractional shares. We have not sought or obtained a ruling from the Internal Revenue Service ("IRS") on the tax consequences of these transactions. An opinion of counsel is not binding on the IRS or the courts, which may disagree with the opinion. Even if the merger and exchange offer otherwise qualified as tax-free transactions, they may become taxable to us if certain events occur that affect either Ecolab or ChampionX Corporation. While ChampionX Corporation has agreed not to take certain actions that could cause the transactions not to qualify as tax-free transactions and is generally obligated to indemnify us against any tax consequences if it breaches this agreement, the potential tax liabilities could have a material adverse effect on us if we were not entitled to indemnification or if the indemnification obligations were not fulfilled. If the merger or exchange offer were determined to be taxable, we could be subject to a substantial tax liability, and each U.S. holder of our common stock who participated in the exchange offer could be treated as exchanging the Ecolab shares surrendered for ChampionX Corporation shares in a taxable transaction.

***Changes in tax laws and unanticipated tax liabilities could materially and adversely affect the taxes we pay and our profitability.***

We are subject to income and other taxes in the United States and foreign jurisdictions, and our operations, plans and results are affected by tax and other initiatives around the world. We are also impacted by actions taken to tax-related matters by associations such as the Organization for Economic Co-operation and Development ("OECD"), which represents a coalition of member countries, and the European Commission which influence tax policies in countries where we operate. In particular, the OECD has coordinated negotiations among more than 140 jurisdictions with the goal of achieving consensus on various substantial changes to the international tax framework, including a 15% global minimum taxation regime ("Pillar Two"). Pillar Two took effect in several jurisdictions in which we operate starting in 2024 and will increase the burden and costs of our tax compliance. The enactment of the One Big Beautiful Bill Act ("OBBBA") in the U.S. introduced changes to U.S. international tax provisions. These changes may interact with Pillar Two in complex ways. Statements by the Group of Seven Nations ("G7") suggest a potential "side-by-side" framework that could exempt certain U.S. parented groups from all or certain aspects of Pillar Two rules but the final outcome remains uncertain. The evolving nature of these reforms may impact our tax profile, increase compliance costs, and create additional risks of double taxation or inconsistent treatment across jurisdictions. We continue to monitor Pillar Two legislative developments, which, based on information available, have not had material impacts on the 2025 financial statements. In addition, we are impacted by settlements of pending or any future adjustments proposed by the IRS or other taxing authorities in connection with our tax audits, all of which will depend on their timing, nature and scope. Increases in income tax rates, changes in income tax laws or unfavorable resolution of tax matters could have a material adverse impact on our financial results.

On July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was enacted in the U.S. The OBBBA includes significant provisions, such as permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. An estimate of the financial impact has been included in operating results as of December 31, 2025. While we expect certain provisions of OBBBA to change the timing of U.S. cash taxes related to the current and future periods, OBBBA did not have a material impact to the Company's income tax expense.

***Future events may impact our deferred tax position, including the utilization of foreign tax credits and undistributed earnings of international affiliates that are considered to be reinvested indefinitely.*** 

We evaluate the recoverability of deferred tax assets and the need for deferred tax liabilities based on available evidence. This process involves significant management judgment about assumptions that are subject to change from period to period based on changes in tax laws or variances between future projected operating performance and actual results. We are required to establish a valuation allowance for deferred tax assets if we determine, based on available evidence at the time the determination is made, that it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making this determination, we evaluate all positive and negative evidence as of the end of each reporting period. Future adjustments (either increases or decreases), to the deferred tax asset valuation allowance are determined based upon changes in the expected realization of the net deferred tax assets. The realization of the deferred tax assets ultimately depends on the existence of sufficient taxable income in either the carry-back or carry-forward periods under the tax law. Due to significant estimates used to establish the valuation allowance and the potential for changes in facts and circumstances, it is reasonably possible that we will be required to record adjustments to the valuation allowance in future reporting periods. Changes to the valuation allowance or the amount of deferred tax liabilities could have a material adverse effect on our consolidated results of operations or financial position. Further, should we change our assertion regarding the permanent reinvestment of the undistributed earnings of international affiliates, a deferred tax liability may need to be established.

[**Table of Contents**](#Toc)

***Our indebtedness may limit our operations and our use of our cash flow, and any failure to comply with the covenants that apply to our indebtedness could materially and adversely affect our liquidity and financial statements.***

As of December 31, 2025, we had approximately $8.2 billion in outstanding indebtedness, with approximately $1.5 billion in the form of floating rate debt. Our debt level and related debt service obligations may have negative consequences, including:

● requiring us to dedicate significant cash flow from operations to the payment of principal and interest on our debt, which reduces the funds we have available for other purposes such as acquisitions and capital investment;

● reducing our flexibility in planning for or reacting to changes in our business and market conditions;

● exposing us to interest rate risk since a portion of our debt obligations are at variable rates. For example, a one percentage point increase in the average interest rate on our floating rate debt at December 31, 2025 would increase future interest expense by approximately $15 million per year; and

● increasing our cost of funds and materially and adversely affecting our liquidity and access to the capital markets should we fail to maintain the credit ratings assigned to us by independent rating agencies.

If we add new debt, the risks described above could increase.

***We incur significant expenses related to the amortization of intangible assets and may be required to report losses resulting from the impairment of goodwill or other assets recorded in connection with the Nalco, Purolite and Ovivo Electronics transactions and other acquisitions.***

We expect to continue to complete selected acquisitions and joint venture transactions in the future. In connection with acquisition and joint venture transactions, applicable accounting rules generally require the tangible and intangible assets of the acquired business to be recorded on the balance sheet of the acquiring company at their fair values. Intangible assets other than goodwill are required to be amortized over their estimated useful lives and this expense may be significant. Any excess in the purchase price paid by the acquiring company over the fair value of tangible and intangible assets of the acquired business is recorded as goodwill. If it is later determined that the anticipated future cash flows from the acquired business may be less than the carrying values of the assets and goodwill of the acquired business, the assets or goodwill may be deemed to be impaired. In this case, the acquiring company may be required under applicable accounting rules to write down the value of the assets or goodwill on its balance sheet to reflect the extent of the impairment. This write-down of assets or goodwill is generally recognized as a non-cash expense in the statement of operations of the acquiring company for the accounting period during which the write down occurs. As of December 31, 2025, we had goodwill of $9.2 billion which is maintained in various reporting units, including goodwill from the Nalco, Purolite and Ovivo Electronics transactions. If we determine that any of the assets or goodwill recorded in connection with the Nalco, Purolite, and Ovivo Electronics transactions or any other prior or future acquisitions or joint venture transactions have become impaired, we will be required to record a loss resulting from the impairment. Impairment losses could be significant and could have a material adverse effect on our consolidated results of operations and financial position.

**Item 1B. Unresolved Staff Comments.**

None.

**Item 1C. Cybersecurity.**

Since 2014, when the Ecolab Cybersecurity program was established, we have continuously matured our cybersecurity program to proactively address evolving cybersecurity trends and risks. Ecolab has an Information Security Steering Committee ("ISSC"), a cross-functional team chaired by our Chief Information Security Officer ("CISO").

Our CISO, who holds a CISO certification, has been our CISO since 2024 and has more than 25 years of information systems experience in total, including in the financial services and defense sectors and the U.S. military, as well as serving in information security and other information technology leadership positions at Ecolab since 2017.

Senior management provides in-depth reviews of cybersecurity matters to the Board and the Audit Committee. Cybersecurity is also considered in the annual enterprise risk assessment presented to the Board by management as part of the Board's oversight of our enterprise risk management ("ERM") program.

Ecolab's cybersecurity policies, standards, processes, and practices are integrated into our ERM program and are based on recognized frameworks established by the National Institute of Standards and Technology ("NIST") Cybersecurity Framework ("CSF"), the International Organization for Standardization and other applicable industry standards. We are formally assessed by an independent third party against NIST CSF and industry standards, including peer benchmarking.

**Risk Management and Strategy**

Cybersecurity presents strategic and operating risks and is an area of continued focus for our Board and management under its ERM program. Ecolab's cybersecurity program addresses the following key areas:

● **Governance:** As discussed in more detail under the heading "Cybersecurity Governance," the Audit Committee and the Board of Directors provide oversight of cybersecurity risk management.

[**Table of Contents**](#Toc)

● **Technical Safeguards:** We have implemented multi-layer controls designed to protect our information systems from cybersecurity threats, including general, backup, recovery, resiliency, processing, access, change and risk controls. These controls are evaluated by Ecolab's cybersecurity team and enhanced through controls audits and assessments, internal testing, and third-party cybersecurity threat intelligence.

● **Incident Response and Recovery Planning:** We have established and maintain comprehensive cybersecurity incident response and recovery plans that coordinate multidisciplinary internal teams and cybersecurity partners to assess, triage, escalate, contain, mitigate, investigate, remediate, and recover from a potential cybersecurity incident. Through ongoing communications with these teams, management monitors the incidents and reports incidents to the Audit Committee when appropriate. Management is responsible for timely disclosure of cybersecurity incidents as required by law.

● **Third-Party Risk Management:** We maintain a risk-based approach to identify, monitor, and manage third-party cybersecurity risks associated with our use of third-party service providers who have access to our systems, data or are critical to our continued business operations. Additionally, cybersecurity considerations affect the selection and oversight of our third-party service providers. We require certain third-party vendors to agree to manage their cybersecurity risks in specified ways, and to agree to be subject to cybersecurity audits, which we conduct as appropriate.

● **Education and Awareness:** We provide training for personnel regarding cybersecurity trends and threats to equip them with the knowledge to recognize and tools to report suspected cybersecurity threats. We also conduct simulations for employees and contractors to enhance awareness and responsiveness to such possible threats. In addition, we send global cybersecurity awareness communications to our personnel.

● **Assessment:** We engage in the periodic assessment, testing and updating of our policies, standards, processes, and practices that are designed to address cybersecurity threats and incidents. These efforts include a wide range of activities, including audits, assessments, tabletop exercises, threat modeling, vulnerability testing and other exercises focused on evaluating the effectiveness of our cybersecurity measures, and planning. We engage third parties to perform assessments on our cybersecurity measures, including information security maturity assessments, audits and independent reviews of our information security control environment and operating effectiveness. Additionally, we leverage third party cybersecurity rating agency data to inform our assessment of risk. The results of such assessments, audits and reviews are reported to the Audit Committee and the Board.

While we have continually matured our security program and capabilities and have had no material incidents to date, cyber threats continue to evolve and there can be no assurance that our efforts will prevent cybersecurity attacks or breaches in our systems such as those described in the risk factor entitled, "We are subject to information technology system failures, network disruptions and breaches in data security" under "Item 1A. Risk Factors" of this Form 10-K.

**Cybersecurity Governance**

Ecolab's ISSC, chaired by our CISO, meets regularly and as needed. The Committee is comprised of executive leaders including the Executive Vice President and General Manager - Ecolab Digital ("EVP & GM Digital"), the Senior Vice President IT Enterprise Operations, the Chief Operating Officer, the Chief Financial Officer, the Chief Technical Officer, the General Counsel, the Executive Vice Presidents of our commercial divisions, the Executive Vice President Global Supply Chain, the Executive Vice President Human Resources, the Senior Vice President of Global Business Services, and the Vice President Audit Services.

The ISSC assists the CISO in fulfilling our responsibilities regarding our information security program to protect the confidentiality, integrity and availability of our information assets, financial assets, and information systems. ISSC responsibilities include, but are not limited to, evaluation of relevant information security risks, prioritization of information security initiatives, determination of, and advocacy for, appropriate investments, review of related legal and regulatory compliance initiatives, review of effective security communication initiatives, establishing specific requirements of the program in documented policies which all Ecolab associates, customers, and partners are obligated to follow, partner with Ecolab's business, functional and regional leaders to ensure effective, risk-based security controls and practices are in place to achieve the program's intent, and assist in monitoring the integrity and evaluating the effectiveness of the program.

The Board, in coordination with the Audit Committee, provides oversight of our ERM program, including the management of risks arising from cybersecurity threats. The Board receives an overview and the Audit Committee receives reports from our CISO regarding our cybersecurity threat risk management and strategy processes. These reports cover a wide range of topics, and may include current and emerging cybersecurity threat risks, third-party assessments, risk-mitigation tactics and programs, information security considerations arising with respect to our peers and third parties, and our incident response plan.

Through a risk-based approach consistent with Ecolab's ERM framework, the CISO identifies cyber incidents that are brought forward to a cross-functional cyber-incident response team including our CEO, CFO, EVP & GM Digital, General Counsel, CISO and Executive Vice President Supply Chain. This cyber incident response team, or, in the event of more minor incidents, the CISO and his team, takes steps to promptly assess and address the incident, including engaging third parties according to pre-established guidelines. The Board and the Audit Committee also receive prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds, including ongoing updates regarding any such incident until it has been addressed.

[**Table of Contents**](#Toc)

**Item 2. Properties.**

We operate 30 manufacturing facilities in 13 states in the U.S. Internationally, we operate 70 manufacturing facilities in 39 countries. We own most of our manufacturing locations. Our manufacturing philosophy is to manufacture products wherever an economic, process or quality assurance advantage exists or where proprietary manufacturing techniques dictate in-house production. Currently, most products that we sell are manufactured at our facilities. We position our manufacturing locations and warehouses in a manner to permit ready access to our customers. In general, manufacturing facilities located in the United States serve our U.S. markets and facilities located outside of the United States serve our international markets. However, most of the United States facilities do manufacture products for export. Many of our properties are used by multiple segments.

Our manufacturing facilities produce chemical products and equipment for all our operating segments, although Pest Elimination purchases the majority of their products and equipment from outside suppliers. Our chemical production process consists of blending purchased raw materials into finished products in powder, liquid, and solid form. Additionally, intermediates from reaction chemistries are used in some of the blends and are also packaged directly into finished goods. Our devices and equipment manufacturing operations consist of producing chemical product dispensers and injectors and other mechanical equipment, medical devices, dishwasher racks, related sundries, dish machine refurbishment and water monitoring and maintenance equipment system from purchased components and subassemblies.

Generally, our manufacturing facilities are adequate to meet our existing in-house production needs. We continue to invest in our plant sites to maintain viable operations and to add capacity as necessary to meet business imperatives.

Most of our manufacturing plants also serve as distribution centers. In addition, we operate distribution centers around the world, most of which are leased, and utilize third party logistics service providers to facilitate the distribution of our products and services.

Our corporate headquarters is comprised of a 17-story building that we own in St. Paul, Minnesota. We also own a 115-acre campus in Eagan, Minnesota that houses a significant research and development center and training facilities as well as several of our administrative functions. We also have a significant business presence in Naperville, Illinois, where our Light & Heavy and Paper operating segments maintain their principal administrative offices and research center, as well as in Greensboro, North Carolina, where our Specialty operating segment maintains its principal administrative offices and a research center. Our Light & Heavy operating segment leases administrative and research facilities in Houston, Texas. Our Life Sciences operating segment maintains leased and owned facilities in the greater King of Prussia, PA area for administrative functions, and research and development.

Significant regional administrative and/or research facilities are located in Campinas, Brazil; Leiden, Netherlands, which we own; and in Bangalore, India; Dubai, UAE; Monheim, Germany; Pune, India; Singapore; Shanghai, China; and Zurich, Switzerland, which we lease. We also have a limited network of small, leased sales offices throughout the world.

**Item 3. Legal Proceedings.**

Discussion of legal proceedings is incorporated by reference from Part II, Item 8, Note 15, "Commitments and Contingencies," of this Form 10-K and should be considered an integral part of Part I, Item 3, "Legal Proceedings."

Discussion of other environmental-related legal proceedings is incorporated by reference from Part I, Item 1 above, under the heading "Environmental and Regulatory Considerations."

In accordance with 17 CFR § 229.103(c)(iii)(3), we have established a threshold of $1 million for reporting potential monetary sanctions relating to administrative or judicial proceedings brought by a governmental authority under any Federal, State, or local provisions that have been enacted or adopted regulating the discharge of materials into the environment or primarily for the purpose of protecting the environment. We have no such proceedings exceeding this threshold to report.

**Item 4. Mine Safety Disclosures.**

Not applicable.

[**Table of Contents**](#Toc)

**PART II**

**Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.**

***Market Information***

Our common stock is listed on the New York Stock Exchange under the symbol "ECL." Our common stock is also traded on an unlisted basis on certain other United States exchanges.

***Dividends***

Dividends declared per common share in 2025 were $2.68 per share. In December 2025, we increased our quarterly cash dividend by 12% to $0.73 per share, representing our 34th consecutive annual dividend rate increase. We have paid cash dividends on our common shares for 89 consecutive years. Our outstanding dividend history reflects our long-term growth and development, strong cash flows, solid financial position and confidence in our business prospects for the years ahead.

***Holders***

On January 30, 2026, we had 4,333 holders of record of our Common Stock.

***Issuer Purchases of Equity Securities***

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  |  | Total number of shares | Maximum number of |
|  |  |  | purchased as part of | shares that may yet be |
|  | Total number of | Average price paid | publicly announced | purchased under the |
| Period | shares purchased | per share | plans or programs (1) | plans or programs (1) |
| October 1-31, 2025 | 241240 | $274.2840 | 241240 | 7170389 |
| November 1-30, 2025 | 951977 | 260.9840 | 951977 | 6218412 |
| December 1-31, 2025 | 321591 | 264.7744 | 321591 | 5896821 |
| &nbsp;&nbsp;Total | 1514808 | $263.9068 | 1514808 | 5896821 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) As announced on November 3, 2022, our Board of Directors authorized the repurchase of up to 10,000,000 common shares. Subject to market conditions, we expect to repurchase all shares under this authorization, for which no expiration date has been established, in open market or privately negotiated transactions, including pursuant to Rule 10b5-1 and accelerated share repurchase programs.

**Item 6. [Reserved].**

[**Table of Contents**](#Toc)

**Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

The following management discussion and analysis ("MD&A") provides information that we believe is useful in understanding our operating results, cash flows and financial condition. We provide quantitative or qualitative information about the material sales drivers including the impact of changes in volume and pricing and the effect of acquisitions and changes in foreign currency at the corporate and reportable segment level. We also provide quantitative information regarding special (gains) and charges, discrete tax items and other significant factors we believe are useful for understanding our results. Such quantitative drivers are supported by comments meant to be qualitative in nature. Qualitative factors are generally ordered based on estimated significance.

The discussion should be read in conjunction with the consolidated financial statements and related notes included in this Form 10-K. Our consolidated financial statements are prepared in accordance with U.S. GAAP. This discussion contains various Non-GAAP Financial Measures and also contains various forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statements and information set forth in the sections entitled "Non-GAAP Financial Measures" at the end of this MD&A, and "Forward-Looking Statements" and "Risk Factors" within Items 1 and 1A of this Form 10-K. We also refer readers to the tables within the section entitled "Results of Operations" of this MD&A for reconciliation information of Non-GAAP measures to U.S. GAAP.

**Comparability of Results**

***Ovivo Electronics Acquisition***

On December 16, 2025, we acquired Ovivo's electronics business ("Ovivo Electronics") for total consideration of $1.6 billion in cash. Ovivo Electronics is a leading and fast-growing global provider of breakthrough ultrapure water technologies for semiconductor manufacturing. Ovivo Electronics is reported within our Light & Heavy operating segment. Acquisition and integration charges are recorded within special (gains) and charges. The remaining impacts of the Ovivo Electronics acquisition, including operating results, acquisition-related amortization and interest expense related to the transaction, have also been excluded from adjusted results.

***Impact of Acquisitions and Divestitures***

Our non-GAAP financial measures for organic sales, organic operating income and organic operating income margin are at fixed currency and exclude the impact of special (gains) and charges, the results of our acquired businesses from the first twelve months post acquisition and the results of divested businesses from the twelve months prior to divestiture. In addition, as part of the separation of ChampionX in 2020, we continue to provide certain products to ChampionX which are recorded in product and equipment sales in the Global Water segment along with the related cost of sales. Further, due to the sale of the global surgical solutions business on August 1, 2024, we have excluded the results of that business for January through July 2024 from these organic measures for the year ended December 31, 2024 to remain comparable to the corresponding period in 2025. These transactions are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures.

***Comparability of Reportable Segments***

Effective January 1, 2025, the Company's former Global Industrial reportable segment was renamed Global Water and includes the Light & Heavy (previously named Water), Food & Beverage, and Paper operating segments. The Global Institutional & Specialty reportable segment continues to include the Institutional and Specialty operating segments. The Company's former healthcare operating segment moved into the Institutional operating segment. Global Life Sciences was elevated to a standalone reportable segment. The Global Pest Elimination segment remains a standalone reportable segment. After these changes, the Company has seven operating segments.

***Fixed Currency Foreign Exchange Rates***

Management evaluates the sales and operating income performance of our non-U.S. dollar functional currency international operations based on fixed currency exchange rates, which eliminate the impact of exchange rate fluctuations on our international operations. Fixed currency amounts are updated annually at the beginning of each year based on translation into U.S. dollars at foreign currency exchange rates established by management, with all periods presented using such rates. Public currency rate data provided within the "Segment Performance" section of this MD&A reflect amounts translated at actual public average rates of exchange prevailing during the corresponding period and is provided for informational purposes only.

[**Table of Contents**](#Toc)

**EXECUTIVE SUMMARY**

In 2025, we delivered record sales, operating income margin, adjusted diluted earnings per share, and free cash flows. Our team generated strong organic sales growth in Global Pest Elimination and Global Life Sciences, and good organic sales growth in Global Institutional & Specialty and Global Water. Organic operating income grew by double digits, as strong value pricing and improved productivity were partially offset by investments in the business.

***Sales***

Reported sales increased 2% to $16.1 billion in 2025 from $15.7 billion in 2024. When measured in fixed rates of foreign currency exchange, fixed currency sales increased 2% compared to the prior year. Organic sales increased 3% compared to the prior year.

***Gross Margin***

Our reported gross margin was 44.5% of sales for 2025, compared to our 2024 reported gross margin of 43.5%. Excluding the impact of special (gains) and charges and the Ovivo Electronics acquisition included in cost of sales, our adjusted gross margin was 44.5% in 2025 and 43.5% in 2024. Our gross margin increase reflected strong value pricing.

***Operating Income***

Reported operating income decreased 2% to $2.7 billion in 2025, compared to $2.8 billion in 2024. Adjusted operating income, excluding the impact of special (gains) and charges and the Ovivo Electronics acquisition increased 11% in 2025 as strong value pricing and improved productivity were partially offset by investments in the business. Organic operating income increased 13% in 2025.

***Earnings Attributable to Ecolab Per Common Share ("EPS")*** 

Reported diluted EPS decreased 1% to $7.28 in 2025, compared to $7.37 in 2024. Special (gains) and charges had an impact on both years. Special (gains) and charges in 2025 were primarily related to One Ecolab, while in 2024 they were driven primarily by the gain on sale of the global surgical solutions business and restructuring expense. Adjusted diluted EPS, which excludes the impact of special (gains) and charges, discrete tax items and the Ovivo Electronics acquisition increased 13% to $7.53 in 2025 compared to $6.65 in 2024 which reflected good organic sales growth and robust operating income margin expansion.

***Balance Sheet***

We remain committed to maintaining "A" range ratings metrics over the long-term, supported by our current credit ratings of A-/A3/A- by Standard & Poor's, Moody's Investor Services and Fitch, respectively. Our strong balance sheet has allowed us continued access to capital at attractive rates.

***Cash Flow***

Cash flow from operating activities was $3.0 billion in 2025, compared to $2.8 billion in 2024. We continued to generate strong cash flow from operations, allowing us to fund our ongoing operations, investments in our business, acquisitions, debt repayments, pension obligations and return cash to our shareholders through share repurchases and dividend payments.

***Dividends***

Dividends declared per common share in 2025 were $2.68 per share. In December 2025 we increased our quarterly cash dividend by 12% to $0.73 per share, representing our 34<sup>th</sup> consecutive annual dividend rate increase. We have paid cash dividends on our common shares for 89 consecutive years. Our outstanding dividend history reflects our long-term growth and development, strong cash flows, solid financial position and confidence in our business prospects for the years ahead.

[**Table of Contents**](#Toc)

**CRITICAL ACCOUNTING ESTIMATES**

Our consolidated financial statements are prepared in accordance with U.S. GAAP. We have adopted various accounting policies to prepare the consolidated financial statements in accordance with U.S. GAAP. Our significant accounting policies are disclosed in Note 2, "Significant Accounting Policies," of the Notes to the Consolidated Financial Statements ("Notes").

Preparation of our consolidated financial statements, in conformity with U.S. GAAP, requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are considered to be critical if they involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations.

Besides estimates that meet the "critical" estimate criteria, we make many other accounting estimates in preparing our financial statements and related disclosures. All estimates, whether or not deemed critical, affect reported amounts of assets, liabilities, revenues or expenses as well as disclosures of contingent assets and liabilities. Estimates are based on experience and other information available prior to the issuance of the financial statements. Materially different results can occur as circumstances change and additional information becomes known, even from estimates not deemed critical. Our critical accounting estimates include the following:

**Actuarially Determined Liabilities**

***Pension and Postretirement Healthcare Benefit Plans***

The measurement of our pension and postretirement benefit obligations are dependent on a variety of assumptions determined by management and used by our actuaries in their valuations and calculations. These assumptions affect the amount and timing of future pension contributions, benefit payments and expense or income recognized.

The significant assumptions used in developing the required estimates are the discount rates, expected returns on assets and projected salary and health care cost increases.

&nbsp;&nbsp;&nbsp;&nbsp;● The discount rate assumptions for our U.S. plans are assessed using a yield curve constructed from a subset of bonds yielding greater than the median return from a population of non-callable, corporate bonds that have an average rating of AA when averaging available Moody's Investor Services, Standard & Poor's and Fitch ratings. The discount rates are calculated by matching each plans' projected cash flows to the bond yield curve. For 2025 and 2024, we measured service and interest costs by applying the specific spot rates along that yield curve to the plans' liability cash flows. We believe this approach provides a more precise measurement of service and interest costs by aligning the timing of the plans' liability cash flows to the corresponding spot rates on the yield curve. In determining our U.S. pension obligations and U.S. postretirement health care obligation for 2025, our weighted-average discount rate decreased to 5.28% from 5.58% at year-end 2024.

&nbsp;&nbsp;&nbsp;&nbsp;● The expected rate of return on plan assets reflects asset allocations, investment strategies and views of investment advisors, and represents our expected long-term return on plan assets. Our weighted-average expected returns on U.S. plan assets used in determining the U.S. pension and U.S. postretirement health care expenses was 8.25% for 2025, 8.00% for 2024, and 7.75% for 2023.

&nbsp;&nbsp;&nbsp;&nbsp;● Projected salary is based on our long-term actual experience, the near-term outlook and assumed inflation. Our weighted-average projected salary increase used in determining the U.S. pension expenses was 3.60% for 2025, 3.60% for 2024, and 4.03% for 2023.

&nbsp;&nbsp;&nbsp;&nbsp;● For postretirement benefit measurement purposes as of December 31, 2025, the annual rates of increase in the per capita cost of covered health care were assumed to be 8.15% for pre-65 costs. Post-65 costs are no longer used. The rates are assumed to decrease each year until they reach 4.5% in 2035 and remain at those levels thereafter.

The effects of actual results differing from our assumptions, as well as changes in assumptions, are reflected in the unrecognized gains or losses and amortized into earnings in the future. Significant differences in actual experience or significant changes in assumptions may materially affect future pension and other postretirement obligations and income or expense. The unrecognized net losses on our U.S. qualified and non-qualified pension plans decreased to $486 million as of December 31, 2025, from $526 million as of December 31, 2024 (both before tax), primarily due to higher actual return on assets.

[**Table of Contents**](#Toc)

The effect of a decrease in the discount rate or in the expected return on assets assumption as of December 31, 2025, on the December 31, 2025 defined benefit obligation and 2026 expense is shown below, assuming no changes in benefit levels. Expense amounts reflect the accounting for gains or losses as a component of other comprehensive income or expense and recognition of the impacts into earnings over time:

---

| | | | |
|:---|:---|:---|:---|
|  | Effect on U.S. Pension Plans | Effect on U.S. Pension Plans | Effect on U.S. Pension Plans |
|  |  | Increase in | Higher |
|  | Assumption | Recorded | 2026 |
| (millions) | Change | Obligation | Expense |
| Discount rate | 0.25 pts | $33.1 | $2.5 |
| Expected return on assets | 0.25 pts | N/A | 4.4 |

---

---

| | | | |
|:---|:---|:---|:---|
|  | Effect on U.S. Postretirement | Effect on U.S. Postretirement | Effect on U.S. Postretirement |
|  | Health Care Benefits Plans | Health Care Benefits Plans | Health Care Benefits Plans |
|  |  | Increase in | Higher |
|  | Assumption | Recorded | 2026 |
| (millions) | Change | Obligation | Expense |
| Discount rate | 0.25 pts | $1.9 | $- |
| Expected return on assets | 0.25 pts | N/A | - |

---

Our international pension obligations and underlying plan assets represent approximately one third of our global pension plans, with the majority of the amounts held in the U.K. and Eurozone countries. We use assumptions similar to our U.S. plan assumptions to measure our international pension obligations, however, the assumptions used vary by country based on specific local country requirements and information.

Refer to Note 16, "Retirement Plans," of the Notes for further discussion concerning our accounting policies, estimates, funded status, contributions and overall financial positions of our pension and postretirement plan obligations.

***Self-Insurance***

Globally we have insurance policies with varying deductible levels for property and casualty losses. We are insured for losses in excess of these deductibles, subject to policy terms and conditions and have recorded both a liability and an offsetting receivable for amounts in excess of these deductibles. We are self-insured for health care claims for eligible participating employees, subject to certain deductibles and limitations. We determine our liabilities for claims on an actuarial basis.

**Income Taxes**

Judgment is required to determine the annual effective income tax rate, deferred tax assets and liabilities, valuation allowances recorded against net deferred tax assets and unrecognized tax benefits.

***Effective Income Tax Rate***

Our effective income tax rate is based on annual income, statutory tax rates and tax planning available in the various jurisdictions in which we operate. Our annual effective income tax rate includes the impact of unrecognized tax benefits. We recognize the amount of tax benefit that is greater than 50% likely of being realized upon settlement with a taxing authority. We adjust these liabilities for unrecognized tax benefits in light of changing facts and circumstances.

Tax regulations require items to be included in our tax returns at different times than the items are reflected in our financial statements. As a result, the effective income tax rate reflected in our financial statements differs from statutory tax rates. Some of these differences are permanent, such as expenses that are not deductible on our tax return, and some are temporary differences, such as depreciation expense.

***Deferred Tax Assets and Liabilities and Valuation Allowances***

Deferred tax assets and liabilities are determined based on temporary differences between the financial reporting and tax bases of assets and liabilities, applying enacted tax rates expected to be in effect for the year in which the differences are expected to reverse. Based on the evaluation of available evidence, both positive and negative, we recognize tax assets, such as net operating loss carryforwards and tax credit carryforwards, to the extent that realizing these benefits is considered to be more likely than not. Relevant factors in determining the realizability of deferred tax assets include historical results, sources of future taxable income, the expected timing of the reversal of temporary differences, tax planning strategies and the expiration dates of the various tax attributes.

[**Table of Contents**](#Toc)

***Unrecognized Tax Benefits***

A number of years may elapse before a particular tax matter, for which we have established a liability for unrecognized tax benefits, is audited and finally resolved. The number of tax years with open tax audits varies depending on the tax jurisdiction. The Internal Revenue Service ("IRS") has completed examinations of our U.S. federal income tax returns through 2018 and the years 2019 through 2020 are currently under audit. In addition to the U.S. federal examinations, we have ongoing audit activity in several U.S. state and foreign jurisdictions.

The tax positions we take are based on our interpretations of tax laws and regulations in the applicable federal, state and international jurisdictions. We believe our tax returns properly reflect the tax consequences of our operations, and our liabilities for unrecognized tax benefits are appropriate and sufficient for the positions taken. Because of the uncertainty of the final outcome of these examinations, we have established a liability for potential reductions of tax benefits (including related interest and penalties) for amounts that do not meet the more-likely-than-not thresholds for recognition and measurement as required by authoritative guidance. The liability for unrecognized tax benefits is reviewed throughout the year, taking into account new legislation, regulations, case law and audit results. Settlement of any particular issue could result in offsets to other balance sheet accounts, cash payments or receipts and/or adjustments to tax expense. Liabilities for unrecognized tax benefits are presented in the Consolidated Balance Sheets within other non-current liabilities. Our gross liability for unrecognized tax benefits was $53.9 million and $34.1 million as of December 31, 2025 and 2024, respectively. For additional information on income taxes refer to Note 12, "Income Taxes," of the Notes.

**Long-Lived Assets, Intangible Assets and Goodwill**

***Long-Lived and Amortizable Intangible Assets***

Purchased long-lived and amortizable intangible assets not acquired as part of a business combination are recorded as of their acquisition date at cost, whereas long-lived and amortizable assets acquired as part of a business combination are recorded as of their acquisition date at their fair values based on the fair value requirements defined in U.S. GAAP. This requires us to make significant estimates and assumptions relating to the present value of its future cash flows, such as growth rates, royalty rates or discount rates.

We review our long-lived and amortizable intangible assets, the net value of which was $7.5 billion and $6.5 billion as of December 31, 2025 and 2024, respectively, for impairment when significant events or changes in business circumstances indicate that the carrying amount of the assets may not be recoverable. Such circumstances may include a significant decrease in the market price of an asset or asset group, a significant adverse change in the manner in which asset or asset groups are being used or history of operating or cash flow losses associated with the use of the asset or asset group. Impairment losses could occur when the carrying amount of an asset or asset group exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset or asset group and its eventual disposition. The amount of the impairment loss to be recorded, if any, is calculated as the excess of the asset's or assets group's carrying amount over its estimated fair value.

We use the straight-line method to recognize amortization expense related to our amortizable intangible assets, including our customer relationships. We consider various factors when determining the appropriate method of amortization for our customer relationships, including projected sales data, customer attrition rates and length of key customer relationships.

Globally, we have a broad customer base. Our retention rate of significant customers has aligned with our acquisition assumptions, including the customer bases acquired from our Nalco, Laboratoires Anios ("Anios"), Copal Invest NV, including its primary operating entity CID Lines (collectively, "CID Lines"), Purolite and Ovivo Electronics transactions, which make up the majority of our unamortized customer relationships. Our historical retention rates, coupled with our consistent track record of keeping long-term relationships with our customers, support our expectation of consistent sales generation for the foreseeable future from the acquired customer bases. If our customer retention rates or other post-acquisition operational activities change materially, we would evaluate the financial impacts and significance of the events given rise to the change which could result in impairment of our customer relationship intangible assets, or absent an impairment, an acceleration of amortization expense.

In addition, we periodically reassess the estimated remaining useful lives of our long-lived and amortizable intangible assets. Changes to estimated useful lives would impact the amount of depreciation and amortization expense recorded in earnings. We have experienced no significant changes in the carrying amount or estimated remaining useful lives of our long-lived or amortizable intangible assets.

[**Table of Contents**](#Toc)

***Goodwill and Indefinite Life Intangible Assets***

Goodwill arises from our acquisitions and represents the excess of the fair value of the purchase consideration exchanged over the fair value of net assets acquired. We had total goodwill of $9.2 billion and $7.9 billion as of December 31, 2025 and 2024, respectively. We test our goodwill for impairment at the reporting unit level. Our reporting units are our seven operating segments. We assess goodwill for impairment on an annual basis during the second quarter. If circumstances change or events occur that demonstrate it is more likely than not that the carrying amount of a reporting unit exceeds its fair value, we complete an interim goodwill impairment assessment of that reporting unit prior to the next annual assessment. If the results of an annual or interim goodwill impairment assessment demonstrate the carrying amount of a reporting unit is greater than its fair value, we will recognize an impairment loss for the amount by which the reporting unit's carrying amount exceeds its fair value, but not to exceed the carrying amount of goodwill assigned to that reporting unit.

For our annual 2025 goodwill impairment assessment, we completed our impairment assessment for our seven reporting units using discounted cash flow analyses that incorporated assumptions regarding future growth rates, terminal values and discount rates. Our goodwill impairment assessments for 2025 indicated the estimated fair values of each of these seven reporting units exceeded the carrying amounts of the respective reporting units by a significant margin. No events were noted during the second half of 2025 that required completion of an interim goodwill impairment assessment in the second half of 2025 for any of our seven reporting units. There has been no impairment of goodwill in any of the periods presented.

The Nalco trade name is our only indefinite life intangible asset, which is tested for impairment on an annual basis during the second quarter. For our annual 2025 indefinite life intangible asset impairment assessment, we completed our impairment assessment of the Nalco trade name using the relief from royalty discounted cash flow method, which incorporates assumptions regarding future sales projections, royalty rates and discount rates. Our Nalco tradename impairment assessment for 2025 indicated the estimated fair value of the Nalco trade name exceeded its $1.2 billion carrying amount by a significant margin. No events were noted during the second half of 2025 that required completion of an interim impairment assessment of our Nalco trade name in the second half of 2025. There has been no impairment of the Nalco trade name intangible since it was acquired.

[**Table of Contents**](#Toc)

**RESULTS OF OPERATIONS**

**Net Sales**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  |  | Percent Change | Percent Change |
| (millions) | **2025** | 2024 | 2023 | **2025** | 2024 |
| &nbsp;&nbsp;Product and equipment sales | **$12618.5** | $12473.6 | $12316.8 |  |  |
| &nbsp;&nbsp;Service and lease sales | **3462.7** | 3267.8 | 3003.4 |  |  |
| Reported GAAP net sales | **16081.2** | 15741.4 | 15320.2 | **2%**  | 3% |
| &nbsp;&nbsp;Impact of Ovivo Electronics on net sales | **(3.7)** | - | - |  |  |
| Non-GAAP adjusted net sales | **16077.5** | 15741.4 | 15320.2 | **2%**  | 3% |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of foreign currency translation | **(514.0)** | (468.0) | (519.2) |  |  |
| Non-GAAP adjusted fixed currency sales | **15563.5** | 15273.4 | 14801.0 | **2%**  | 3% |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of acquisitions and divestitures | **(87.2)** | (248.4) | \* |  |  |
| Non-GAAP organic sales | **$15476.3** | $15025.0 | \* | **3%**  | \* |
| \* Not meaningful |  |  |  |  |  |

---

The percentage components of the year-over-year sales change are shown below:

---

| | | |
|:---|:---|:---|
| (percent) | **2025** | 2024 |
| &nbsp;&nbsp;Volume | **1%**  | \*% |
| &nbsp;&nbsp;Price changes | **2**  | \* |
| Organic sales change | **3**  | \* |
| &nbsp;&nbsp;Acquisitions and divestitures | **(1)** | \* |
| Fixed currency sales change | **2**  | 3  |
| &nbsp;&nbsp;Foreign currency translation | **-** | - |
| Reported GAAP net sales change | **2%**  | 3 %  |
| \* Not meaningful |  |  |

---

Amounts do not necessarily sum due to rounding.

**Cost of Sales ("COS") and Gross Profit Margin ("Gross Margin")**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **2025** | **2025** | 2024 | 2024 | 2023 | 2023 |
|  |  | Gross |  | Gross |  | Gross |
| (millions/percent) | COS | Margin | COS | Margin | COS | Margin |
| &nbsp;&nbsp;Product and equipment cost of sales | **$6955.8** |  | $6990.0 |  | $7389.2 |  |
| &nbsp;&nbsp;Service and lease cost of sales | **1975.0** |  | 1909.7 |  | 1765.7 |  |
| Reported GAAP COS and gross margin | **8930.8** | **44.5%**  | 8899.7 | 43.5% | 9154.9 | 40.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Special (gains) and charges | **7.7** |  | 5.3 |  | 22.5 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Impact of Ovivo Electronics on COS | **3.5** |  | - |  | - |  |
| Non-GAAP adjusted COS and gross margin | **$8919.6** | **44.5%**  | $8894.4 | 43.5% | $9132.4 | 40.4% |

---

Our COS values and corresponding gross margin are shown above. Our gross margin is defined as sales less cost of sales divided by sales.

Our reported gross margin was 44.5%, 43.5%, and 40.2% for 2025, 2024, and 2023, respectively. Our 2025, 2024 and 2023 reported gross margins were negatively impacted by special (gains) and charges of $7.7 million, $5.3 million, and $22.5 million, respectively. Special (gains) and charges items impacting COS are shown within the "Special (Gains) and Charges" table below.

Excluding the impact of special (gains) and charges and the Ovivo Electronics acquisition, our 2025 adjusted gross margin was 44.5% compared against a 2024 adjusted gross margin of 43.5%. Our adjusted gross margin increased when comparing 2025 against 2024 reflecting strong value pricing.

Excluding the impact of special (gains) and charges, our adjusted gross margin was 43.5% and 40.4% for 2024 and 2023, respectively. The increase primarily reflected strong value pricing and lower delivered product costs.

[**Table of Contents**](#Toc)

**Selling, General and Administrative Expenses ("SG&A")**

---

| | | | |
|:---|:---|:---|:---|
| (percent) | **2025** | 2024 | 2023 |
| SG&A Ratio | **26.5%**  | 26.9% | 26.5% |

---

The decreased SG&A ratio (SG&A expenses as a percentage of reported net sales) comparing 2025 against 2024 was driven by productivity which was partially offset by growth-oriented investments in the business. The increased SG&A ratio (SG&A expenses as a percentage of reported net sales) comparing 2024 against 2023 was driven by growth-oriented investments in the business which was partially offset by sales productivity.

**Special (Gains) and Charges**

Special (gains) and charges reported on the Consolidated Statements of Income included the following items:

---

| | | | |
|:---|:---|:---|:---|
| (millions) | **2025** | 2024 | 2023 |
| Cost of sales |  |  |  |
| &nbsp;&nbsp;One Ecolab | **$7.7** | $1.9 | $- |
| &nbsp;&nbsp;Other restructuring | **-** | 3.4 | 22.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of sales subtotal | **7.7** | 5.3 | 22.5 |
| Special (gains) and charges |  |  |  |
| &nbsp;&nbsp;One Ecolab | **140.2** | 98.3 | - |
| &nbsp;&nbsp;Other restructuring | **(12.0)** | 21.8 | 63.2 |
| &nbsp;&nbsp;Sale of global surgical solutions business | **3.0** | (340.3) | 10.3 |
| &nbsp;&nbsp;Acquisition and integration activities | **36.1** | 12.6 | 16.1 |
| &nbsp;&nbsp;Other | **(12.4)** | 18.7 | 21.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Special (gains) and charges subtotal | **154.9** | (188.9) | 111.4 |
| Total special (gains) and charges | **$162.6** | ($183.6) | $133.9 |

---

For segment reporting purposes, special (gains) and charges are not allocated to reportable segments, which is consistent with our internal management reporting. Per share amounts do not necessarily sum due to rounding.

***One Ecolab***

On July 30, 2024, we announced the One Ecolab initiative, which will enhance our growth and margin expansion journey. As a program within this initiative, we also announced that we commenced a restructuring plan to leverage our digital technologies to realign the functional work done in many countries into global centers of excellence. In February 2026, we expanded the One Ecolab initiative and anticipate total restructuring costs of $334 million ($261 million after tax) or $0.91 per diluted share and special charges of $91 million ($71 million after tax) or $0.25 per diluted share by the end of 2027. We anticipate that the restructuring costs will primarily be cash expenditures for severance costs relating to team realignment. We also expanded the estimated annualized cost savings to $325 million in continuing operations by 2027. One Ecolab has delivered $119 million of cumulative cost savings.

In anticipation of the One Ecolab initiative, a limited number of actions were taken in the first and second quarter of 2024. As a result, we reclassified $5.3 million ($4.0 million after tax) or $0.01 per diluted share from other restructuring to One Ecolab in the third quarter of 2024.

We recorded restructuring charges of $117.0 million ($90.5 million after tax), or $0.32 per diluted share and $76.5 million ($59.0 million after tax), or $0.21 per diluted share in 2025 and 2024, respectively, primarily related to severance and professional services. In addition, we recorded non-restructuring special charges of $30.9 million ($23.4 million after tax), or $0.08 per diluted share and $23.7 million ($17.9 million after tax), or $0.06 per diluted share in 2025 and 2024, respectively, primarily related to professional services. We have recorded $198.8 million ($153.5 million after tax), or $0.54 per diluted share of cumulative restructuring charges and $54.6 million ($41.3 million after tax), or $0.14 per diluted share of cumulative special charges under the One Ecolab initiative. Net cash payments were $75.8 million during 2025 and $26.9 million in 2024.

The net restructuring liability related to the One Ecolab initiative was $96.1 million and $54.9 million as of December 31, 2025 and 2024, respectively. The remaining liability is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities.

[**Table of Contents**](#Toc)

***Other restructuring***

Other restructuring is primarily related to the Combined Program which is described below. These activities have been included as a component of cost of sales and special (gains) and charges on the Consolidated Statements of Income. Restructuring liabilities have been classified as a component of other current and other noncurrent liabilities on the Consolidated Balance Sheets.

Further details related to our restructuring charges are included in Note 3, "Special (Gains) and Charges," of the Notes.

In November 2022, we approved a Europe cost savings program and subsequently expanded the program to focus on our Institutional and Healthcare businesses in other regions (the "Combined Program"). The restructuring activities were completed at the end of 2024, with total costs of $184.1 million ($151.5 million after tax), or $0.53 per diluted share. Subsequent to the completion of the Combined Program, we finalized the sale of a facility, resulting in a gain of $12.0 million ($9.2 million after tax), or $(0.03) per diluted share in the second quarter of 2025.

In 2024 and 2023, we recorded restructuring (gains) charges of $25.2 million ($18.6 million after tax) or $0.06 per diluted share, and $77.7 million ($66.4 million after tax), or $0.23 per diluted share, respectively, primarily related to severance and professional services in the Combined Program.

We reclassified $5.3 million ($4.0 million after tax), or $0.01 per diluted share from the combined restructuring program to other restructuring activities in the second quarter of 2024.

During 2024, we recorded restructuring charges of $10.6 million ($8.0 million after tax), or $0.03 per diluted share related to an immaterial restructuring plan approved in the second quarter of 2024. This plan became part of the One Ecolab initiative in the third quarter of 2024.

During 2023, we recorded restructuring charges of $8.0 million ($6.0 million after tax), or $0.03 per diluted share related to immaterial or subsequently concluded restructuring programs. The charges were primarily related to severance and asset write-offs.

The restructuring liability balance for all other restructuring plans excluding the One Ecolab Program was $8.8 million and $19.3 million as of December 31, 2025 and 2024, respectively. The remaining liability is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities. Cash payments during 2025 related to all other restructuring plans excluding the One Ecolab Program was $10.4 million.

***Sale of global surgical solutions business***

On April 27, 2024, we reached a definitive agreement to sell our global surgical solutions business, which closed on August 1, 2024. During 2024, we recorded a gain on sale of $355.9 million ($257.7 million after tax) or ($0.90) per diluted share, as described in Note 4, "Acquisitions and Dispositions," of the Notes. During 2025, we recorded charges of $3.0 million ($2.3 million after tax) or $0.01 per diluted share, which are primarily related to professional fees to support the sale. Excluding the gain on sale, we recorded charges of $15.6 million ($12.0 million after tax), or $0.05 per diluted share in 2024, which are primarily related to professional fees to support the sale. During 2023, we recorded charges of $10.3 million ($7.7 million after tax) or $0.03 per diluted share, primarily related to professional fees to support the sale.

***Acquisition and integration related costs***

Acquisition and integration related costs reported in special (gains) and charges on the Consolidated Statements of Income in 2025 include $36.1 million ($31.2 million after tax), or $0.11 per diluted share, primarily related to the Ovivo Electronics and Purolite transactions.

Acquisition and integration related costs reported in special (gains) and charges on the Consolidated Statements of Income in 2024 and 2023 include $12.6 million ($9.6 million after tax) or $0.03 per diluted share and $16.1 million ($12.0 million after tax), or $0.04 per diluted share, respectively, primarily related to the Purolite transaction.

***Other operating activities***

During 2025, we recorded other operating activities to special (gains) and charges on the Consolidated Statements of Income of ($12.4 million) ($10.8 million gain after tax), or ($0.04) per diluted share, relating primarily to the sale of an equity method investment.

During 2024, we recorded other operating activities to special (gains) and charges on the Consolidated Statements of Income of $18.7 million ($13.9 million after tax), or $0.05 per diluted share, relating primarily to a liability relating to a prior divestiture, COVID-19 activities, and certain legal charges. During 2023, we recorded other operating activities to special (gains) and charges on the Consolidated Statements of Income of $21.8 million ($16.7 million after tax), or $0.05 per diluted share, relating primarily to certain legal charges.

[**Table of Contents**](#Toc)

**Operating Income and Operating Income Margin**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  |  | Percent Change | Percent Change |
| (millions) | **2025** | 2024 | 2023 | **2025** | 2024 |
| Reported GAAP operating income | **$2737.6** | $2802.4 | $1992.3 | **(2)%**  | 41% |
| &nbsp;&nbsp;&nbsp;&nbsp;Special (gains) and charges | **162.6** | (183.6) | 133.9 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Impact of Ovivo Electronics on operating income | **0.5** | - | - |  |  |
| Non-GAAP adjusted operating income | **2900.7** | 2618.8 | 2126.2 | **11** | 23 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of foreign currency translation | **(115.9)** | (103.4) | (102.9) |  |  |
| Non-GAAP adjusted fixed currency operating income  | **2784.8** | 2515.4 | 2023.3 | **11** | 24 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of acquisitions and divestitures | **(10.6)** | (52.7) | \* |  |  |
| Non-GAAP organic operating income  | **$2774.2** | $2462.7 | \* | **13%**  | \* |
| \* Not meaningful |  |  |  |  |  |
| (percent) | **2025** | 2024 | 2023 |  |  |
| Reported GAAP operating income margin | **17.0%**  | 17.8% | 13.0% |  |  |
| Non-GAAP adjusted operating income margin | **18.0%**  | 16.6% | 13.9% |  |  |
| Non-GAAP adjusted fixed currency operating income margin  | **17.9%**  | 16.5% | 13.7% |  |  |
| Non-GAAP organic operating income margin | **17.9%**  | 16.4% | \* |  |  |
| \* Not meaningful |  |  |  |  |  |

---

Our operating income and corresponding operating income margin are shown in the previous tables. Operating income margin is defined as operating income divided by sales.

Our reported operating income was $2,737.6 million, $2,802.4 million, and $1,992.3 million, for 2025, 2024, and 2023, respectively. Our 2025, 2024 and 2023 operating incomes were negatively (positively) impacted by special (gains) and charges of $162.6 million, ($183.6 million) and $133.9 million, respectively.

Excluding the impacts of special (gains) and charges and the Ovivo Electronics acquisition, 2025 adjusted operating income increased 11% as strong value pricing and improved productivity were partially offset by investments in the business. Excluding the impacts of special (gains) and charges 2024 adjusted operating income increased 23% as strong value pricing, lower delivered product costs, and higher volumes were partially offset by investments in the business.

**Other (Income) Expense**

---

| | | | |
|:---|:---|:---|:---|
| (millions) | **2025** | 2024 | 2023 |
| Reported GAAP other (income) expense | **($51.4)** | ($51.3) | ($59.9) |

---

Our reported other income was $51.4 million, $51.3 million and $59.9 million, in 2025, 2024 and 2023, respectively. Other (income) expense was flat when comparing 2025 against 2024. Other (income) expense decreased when comparing 2024 against 2023 primarily due to higher pension costs.

**Interest Expense, Net**

---

| | | | |
|:---|:---|:---|:---|
| (millions) | **2025** | 2024 | 2023 |
| Reported GAAP interest expense, net | **$241.1** | $282.5 | $296.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impact of Ovivo Electronics on interest expense | **3.6** | - | - |
| Non-GAAP adjusted interest expense, net | **$237.5** | $282.5 | $296.7 |

---

Our reported net interest expense totaled $241.1 million, $282.5 million, and $296.7 million during 2025, 2024, and 2023, respectively.

Adjusted for the Ovivo Electronics acquisition, the decrease in net interest expense when comparing 2025 against 2024 reflects the impact from lower interest rates and a higher cash balance. The decrease in interest expense when comparing 2024 against 2023 was driven primarily by lower interest expense from the repayment of our January 2024 note and the impact from higher interest income earned on cash balances driven by strong free cash flows and proceeds from the sale of the global surgical solutions business.

[**Table of Contents**](#Toc)

**Provision for Income Taxes**

The following table provides a summary of our tax rate:

---

| | | | |
|:---|:---|:---|:---|
| (percent) | **2025** | 2024 | 2023 |
| Reported GAAP tax rate | **17.8%** | 17.1% | 20.6% |
| Tax rate impact of: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Special (gains) and charges | **0.3** | (1.1) | (0.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Discrete tax items | **2.1** | 3.3  | (0.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Ovivo Electronics tax impacts | **-** | - | - |
| Non-GAAP adjusted tax rate | **20.2%** | 19.3%  | 19.9%  |

---

Our reported tax rate was 17.8%, 17.1% and 20.6%, for 2025, 2024, and 2023, respectively. The change in our tax rate includes the tax impact of special (gains) and charges and discrete tax items, which have impacted the comparability of our historical reported tax rates, as amounts included in our special (gains) and charges are derived from tax jurisdictions with rates that vary from our tax rate, and discrete tax items are not necessarily consistent across periods. The tax impact of special (gains) and charges and discrete tax items will likely continue to impact comparability of our reported tax rate in the future.

We recognized a net tax benefit related to discrete tax items of $57.5 million during 2025. Discrete items include tax benefits of $21.5 million associated with recognition of deferred tax attributes and $16.8 million related to share-based compensation excess tax benefits. The remaining net discrete tax benefit of $19.2 million was primarily related to the filing of federal, state and foreign tax returns and other income tax adjustments including the impact of changes in tax laws, audit settlements, and other changes in estimates.

We recognized a net tax benefit related to discrete tax items of $78.6 million during 2024. Discrete items include tax benefits of $62.1 million associated with a change to the tax classification of a wholly-owned non-US subsidiary that resulted in recognizing a capital loss and benefit of $30.4 million due to additional basis of foreign intangible assets. The remaining net discrete tax expense of $13.9 million was primarily related to the filing of federal, state and foreign tax returns and other income tax adjustments including the impact of changes in tax laws, audit settlements, share-based compensation excess tax benefits, and other changes in estimates.

We recognized a net tax expense related to discrete tax items of $11.2 million during 2023. The net discrete tax expense was primarily related to the filing of federal, state and foreign tax returns and other income tax adjustments including the impact of changes in tax laws, audit settlements, share-based compensation excess tax benefits and other changes in estimates.

The change in our adjusted tax rates from 2024 to 2025 was primarily driven by geographic income mix. Future comparability of our adjusted tax rate may be impacted by various factors, including but not limited to other changes in global tax rules, further tax planning projects and geographic income mix.

**Net Income Attributable to Ecolab**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  |  | Percent Change | Percent Change |
| (millions) | **2025** | 2024 | 2023 | **2025** | 2024 |
| Reported GAAP net income attributable to Ecolab | **$2075.6** | $2112.4 | $1372.3 | **(2)%** | 54% |
| Adjustments: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Special (gains) and charges, after tax | **127.4** | (126.7) | 109.2 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Discrete tax net (benefit) expense | **(57.5)** | (78.6) | 11.2 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Impact of Ovivo Electronics on net income | **3.1** | - | - |  |  |
| Non-GAAP adjusted net income attributable to Ecolab | **$2148.6** | $1907.1 | $1492.7 | **13%** | 28% |

---

**Diluted EPS**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  |  | Percent Change | Percent Change |
| (dollars) | **2025** | 2024 | 2023 | **2025** | 2024 |
| Reported GAAP diluted EPS | **$7.28** | $7.37 | $4.79 | **(1)%** | 54% |
| Adjustments: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Special (gains) and charges, after tax | **0.45** | (0.44) | 0.38 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Discrete tax net (benefit) expense | **(0.21)** | (0.28) | 0.04 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Impact of Ovivo Electronics on diluted EPS | **0.01** | - | - |  |  |
| Non-GAAP adjusted diluted EPS | **$7.53** | $6.65 | $5.21 | **13%** | 28% |

---

Per share amounts do not necessarily sum due to rounding.

Currency translation had a favorable $0.04 impact on reported and adjusted diluted EPS when comparing 2025 to 2024 and unfavorable ($0.09) impact when comparing 2024 to 2023.

[**Table of Contents**](#Toc)

**SEGMENT PERFORMANCE**

The non-U.S. dollar functional currency international amounts included within our reportable segments are based on translation into U.S. dollars at the fixed currency exchange rates established by management for 2025. The difference between the fixed currency exchange rates and the actual currency exchange rates is reported as "effect of foreign currency translation" in the following tables. All other accounting policies of the reportable segments are consistent with U.S. GAAP and the accounting policies described in Note 2, "Significant Accounting Policies," of the Notes. Additional information about our reportable segments is included in Note 18, "Operating Segment and Geographic Information," of the Notes.

Fixed currency net sales and operating income for 2025, 2024 and 2023 for our reportable segments are shown in the following tables.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Net Sales** |  |  |  | Percent Change | Percent Change |
| (millions) | **2025** | 2024 | 2023 | **2025** | 2024 |
| Global Water | **$7679.9** | $7483.4 | $7284.1 | **3%**  | 3% |
| Global Institutional & Specialty | **5962.0** | 5979.4 | 5779.4 | **0** | 3 |
| Global Pest Elimination | **1219.2** | 1140.1 | 1044.3 | **7** | 9 |
| Global Life Sciences | **706.1** | 670.5 | 650.8 | **5** | 3 |
| Corporate | **-** | - | 42.4 | **\*** | \* |
| &nbsp;&nbsp;Subtotal at fixed currency | **15567.2** | 15273.4 | 14801.0 | **2** | 3 |
| Effect of foreign currency translation | **514.0** | 468.0 | 519.2 |  |  |
| Consolidated reported GAAP net sales | **$16081.2** | $15741.4 | $15320.2 | **2%**  | 3% |
| **Operating Income** |  |  |  | Percent Change | Percent Change |
| (millions) | **2025** | 2024 | 2023 | **2025** | 2024 |
| Global Water | **$1263.9** | $1207.2 | $1042.1 | **5%**  | 16% |
| Global Institutional & Specialty | **1357.8** | 1202.2 | 856.5 | **13** | 40 |
| Global Pest Elimination | **237.1** | 209.7 | 200.9 | **13** | 4 |
| Global Life Sciences | **120.7** | 91.8 | 118.9 | **31** | (23) |
| Corporate | **(353.2)** | (12.1) | (329.0) | **\*** | \* |
| &nbsp;&nbsp;Subtotal at fixed currency | **2626.3** | 2698.8 | 1889.4 | **(3)** | 43 |
| Effect of foreign currency translation | **111.3** | 103.6 | 102.9 |  |  |
| Consolidated reported GAAP operating income | **$2737.6** | $2802.4 | $1992.3 | **(2)%**  | 41% |

---

\* Not meaningful

The following tables reconcile the impact of acquisitions and divestitures within our reportable segments.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | Year ended  | Year ended  | Year ended  | Year ended  | Year ended  | Year ended  |
|  | December 31 | December 31 | December 31 | December 31 | December 31 | December 31 |
| **Net Sales** | **2025** | **2025** | **2025** | 2024 | 2024 | 2024 |
| (millions) | Fixed <br>Currency | Impact of Acquisitions and Divestitures | Organic | Fixed <br>Currency | Impact of Acquisitions and Divestitures | Organic |
| Global Water | **$7679.9** | **($80.2)** | **$7599.7** | $7483.4 | ($30.9) | $7452.5 |
| Global Institutional & Specialty | **5962.0** | **(1.4)** | **5960.6** | 5979.4 | (217.5) | 5761.9 |
| Global Pest Elimination | **1219.2** | **(9.3)** | **1209.9** | 1140.1 | - | 1140.1 |
| Global Life Sciences | **706.1** | **-** | **706.1** | 670.5 | - | 670.5 |
| &nbsp;&nbsp;Subtotal at fixed currency | **15567.2** | **(90.9)** | **15476.3** | 15273.4 | (248.4) | 15025.0 |
| Effect of foreign currency translation | **514.0** |  |  | 468.0 |  |  |
| Consolidated reported GAAP net sales | **$16081.2** |  |  | $15741.4 |  |  |
| **Operating Income** | **2025** | **2025** | **2025** | 2024 | 2024 | 2024 |
| (millions) | Fixed <br>Currency | Impact of Acquisitions and Divestitures | Organic | Fixed <br>Currency | Impact of Acquisitions and Divestitures | Organic |
| Global Water | **$1263.9** | **($10.1)** | **$1253.8** | $1207.2 | $0.2 | $1207.4 |
| Global Institutional & Specialty | **1357.8** | **0.5** | **1358.3** | 1202.2 | (52.9) | 1149.3 |
| Global Pest Elimination | **237.1** | **(0.5)** | **236.6** | 209.7 | - | 209.7 |
| Global Life Sciences | **120.7** | **-** | **120.7** | 91.8 | - | 91.8 |
| Corporate | **(195.2)** | **-** | **(195.2)** | (195.5) | - | (195.5) |
| &nbsp;&nbsp;Non-GAAP adjusted fixed currency operating income | **2784.3** | **(10.1)** | **2774.2** | 2515.4 | (52.7) | 2462.7 |
| &nbsp;&nbsp;Special (gains) and charges | **158.0** |  |  | (183.4) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal at fixed currency | **2626.3** |  |  | 2698.8 |  |  |
| Effect of foreign currency translation | **111.3** |  |  | 103.6 |  |  |
| Consolidated reported GAAP operating income | **$2737.6** |  |  | $2802.4 |  |  |

---

[**Table of Contents**](#Toc)

**Global Water**

---

| | | | |
|:---|:---|:---|:---|
|  | **2025** | 2024 | 2023 |
| Sales at fixed currency (millions) | **$7679.9** | $7483.4 | $7284.1 |
| Sales at public currency (millions) | **7982.4** | 7775.9 | 7625.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Organic sales change | **2%**  | \* |  |
| &nbsp;&nbsp;Acquisitions and divestitures | **1%**  | \* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Fixed currency sales change | **3%**  | 3% |  |
| &nbsp;&nbsp;Foreign currency translation | **-%**  | -% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Public currency sales change | **3%**  | 2% |  |
| Operating income at fixed currency (millions) | **$1263.9** | $1207.2 | $1042.1 |
| Operating income at public currency (millions) | **1332.9** | 1274.2 | 1115.4 |
| &nbsp;&nbsp;Fixed currency operating income change | **5%**  | 16% |  |
| &nbsp;&nbsp;Fixed currency operating income margin | **16.5%**  | 16.1% | 14.3% |
| &nbsp;&nbsp;Organic operating income change | **4%**  | \* |  |
| &nbsp;&nbsp;Organic operating income margin | **16.5%**  | 16.2% | \* |
| &nbsp;&nbsp;Public currency operating income change | **5%**  | 14% |  |

---

\* Not meaningful

Percentages in the above table do not necessarily sum due to rounding.

***Net Sales***

Fixed currency sales increased 3% in 2025. Organic sales for Global Water increased 2% in 2025 driven by growth in Food & Beverage and Light & Heavy. Organic sales increased in 2024 driven by strong new business wins and value pricing which overcame uneven end-market trends.

At an operating segment level, ***Light & Heavy*** organic sales increased 2% in 2025 reflecting double-digit growth in global high-tech, improved growth in downstream and solid manufacturing sales growth, which more than offset soft end-market demand in basic industries. Global high-tech reported strong double-digit sales growth driven by data centers and microelectronics. Downstream reported sales growth in North America was partially offset by softer sales in other international regions. Manufacturing reported solid growth driven by food & beverage. Basic Industries sales declined as new business wins were more than offset by continued soft end-market demand. Light & Heavy organic sales increased in 2024 reflecting strong growth in downstream and manufacturing. Downstream reported strong sales growth in 2024, driven by strong growth in refining and water management. Manufacturing reported strong sales growth in 2024 driven by strong performance across institutional, food & beverage and high-tech. Basic industries reported sales growth in 2024 driven by new business wins that overcame softer market trends. ***Food & Beverage*** organic sales increased 4% in 2025 as value pricing and new business wins overcame continued soft industry demand. Organic sales increased in 2024 as good new business wins more than offset continued soft industry demand. ***Paper*** organic sales declined 3% in 2025 as continued new business wins were more than offset by ongoing soft customer production rates. Organic sales were flat in 2024 as strong new business wins were offset by soft customer production rates.

***Operating Income***

Organic operating income and organic operating income margin for Global Water increased in both 2025 and 2024 when compared to prior periods.

Organic operating income margin increased 0.3 percentage points during 2025 compared to 2024, as the 1.1 percentage point positive impact of value pricing was partially offset by the 0.9 percentage point negative impact of investments in the business. Organic operating income margin increased in 2024 compared to 2023, as the positive impacts of lower delivered product costs, strong value pricing, and higher volumes were partially offset by the negative impacts of investments in business.

[**Table of Contents**](#Toc)

**Global Institutional & Specialty**

---

| | | | |
|:---|:---|:---|:---|
|  | **2025** | 2024 | 2023 |
| Sales at fixed currency (millions) | **$5962.0** | $5979.4 | $5779.4 |
| Sales at public currency (millions) | **6104.6** | 6103.4 | 5910.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Organic sales change | **3%**  | \* |  |
| &nbsp;&nbsp;Acquisitions and divestitures | **(4)%**  | \* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Fixed currency sales change | **-%**  | 3% |  |
| &nbsp;&nbsp;Foreign currency translation | **-%**  | -% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Public currency sales change | **-%**  | 3% |  |
| Operating income at fixed currency (millions) | **$1357.8** | $1202.2 | $856.5 |
| Operating income at public currency (millions) | **1385.9** | 1227.4 | 878.9 |
| &nbsp;&nbsp;Fixed currency operating income change | **13%**  | 40% |  |
| &nbsp;&nbsp;Fixed currency operating income margin | **22.8%**  | 20.1% | 14.8% |
| &nbsp;&nbsp;Organic operating income change | **18%**  | \* |  |
| &nbsp;&nbsp;Organic operating income margin | **22.8%**  | 19.9% | \* |
| &nbsp;&nbsp;Public currency operating income change | **13%**  | 40% |  |

---

\* Not meaningful

Percentages in the above table do not necessarily sum due to rounding.

***Net Sales***

Fixed currency sales were stable in 2025. Organic sales for Global Institutional & Specialty increased 3% in 2025 with growth in both operating segments. Organic sales increased in 2024 driven by outperformance of end-market trends.

At an operating segment level, ***Institutional*** organic sales increased 3% in 2025 reflecting sales growth to hospitality customers partially offset by modestly lower sales to hospitals. Organic sales increased in 2024 reflecting sales growth across restaurants and lodging. ***Specialty*** organic sales increased 5% in 2025 driven by new business wins and continued value pricing, which more than offset the impact from non-strategic, low margin business exits. Organic sales increased in 2024 reflecting growth in quick service and food retail.

***Operating Income***

Organic operating income and organic operating income margin for our Global Institutional & Specialty segment increased in both 2025 and 2024 when compared to prior periods.

Organic operating income margin increased 2.9 percentage points during 2025, as the 4.3 percentage point positive impacts from value pricing, lower supply chain costs and improved productivity were partially offset by the 1.0 percentage point negative impacts of investments in the business. Organic operating income margin increased during 2024, as the positive impacts from strong value pricing, lower supply chain costs and higher volumes were partially offset by the negative impacts of investments in the business.

[**Table of Contents**](#Toc)

**Global Pest Elimination**

---

| | | | |
|:---|:---|:---|:---|
|  | **2025** | 2024 | 2023 |
| Sales at fixed currency (millions) | **$1219.2** | $1140.1 | $1044.3 |
| Sales at public currency (millions) | **1246.3** | 1162.8 | 1066.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Organic sales change | **6%**  | \* |  |
| &nbsp;&nbsp;Acquisitions and divestitures | **1%**  | \* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Fixed currency sales change | **7%**  | 9% |  |
| &nbsp;&nbsp;Foreign currency translation | **-%**  | -% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Public currency sales change | **7%**  | 9% |  |
| Operating income at fixed currency (millions) | **$237.1** | $209.7 | $200.9 |
| Operating income at public currency (millions) | **242.9** | 214.3 | 205.3 |
| &nbsp;&nbsp;Fixed currency operating income change | **13%**  | 4% |  |
| &nbsp;&nbsp;Fixed currency operating income margin | **19.4%**  | 18.4% | 19.2% |
| &nbsp;&nbsp;Organic operating income change | **13%**  | \* |  |
| &nbsp;&nbsp;Organic operating income margin | **19.6%**  | 18.4% | \* |
| &nbsp;&nbsp;Public currency operating income change | **13%**  | 4% |  |

---

\* Not meaningful

Percentages in the above table do not necessarily sum due to rounding.

***Net Sales***

Fixed currency sales increased 7% and organic sales increased 6% in 2025. Organic sales for Global Pest Elimination increased in both 2025 and 2024 when compared to prior periods led by growth in food & beverage and restaurants.

***Operating Income***

Organic operating income for our Global Pest Elimination segment increased in both 2025 and 2024 when compared to prior periods. Organic operating income margin increased in 2025 and decreased in 2024 when compared to prior periods.

Organic operating income margin in Global Pest Elimination increased 1.2 percentage points in 2025, as the 3.7 percentage point positive impacts from value pricing and higher volumes were partially offset by the 3.1 percentage point negative impacts of investments in the business. Organic operating income margin decreased in 2024, as the positive impact from strong value pricing and higher volumes were more than offset by the negative impacts from investments in the business and costs associated with a fourth quarter spike in accidents.

[**Table of Contents**](#Toc)

**Global Life Sciences**

---

| | | | |
|:---|:---|:---|:---|
|  | **2025** | 2024 | 2023 |
| Sales at fixed currency (millions) | **$706.1** | $670.5 | $650.8 |
| Sales at public currency (millions) | **747.9** | 699.3 | 675.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Organic sales change | **5%**  | \* |  |
| &nbsp;&nbsp;Acquisitions and divestitures | **-%**  | \* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Fixed currency sales change | **5%**  | 3% |  |
| &nbsp;&nbsp;Foreign currency translation | **2%**  | -% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Public currency sales change | **7%**  | 4% |  |
| Operating income at fixed currency (millions) | **$120.7** | $91.8 | $118.9 |
| Operating income at public currency (millions) | **136.0** | 101.2 | 125.7 |
| &nbsp;&nbsp;Fixed currency operating income change | **31%**  | (23)% |  |
| &nbsp;&nbsp;Fixed currency operating income margin | **17.1%**  | 13.7% | 18.3% |
| &nbsp;&nbsp;Organic operating income change | **31%**  | \* |  |
| &nbsp;&nbsp;Organic operating income margin | **17.1%**  | 13.7% | \* |
| &nbsp;&nbsp;Public currency operating income change | **34%**  | (19)% |  |

---

\* Not meaningful

Percentages in the above table do not necessarily sum due to rounding.

***Net Sales***

Fixed currency sales increased 5% in 2025. Organic sales for Global Life Sciences increased 5% in 2025 as compared to 2024 driven by new business wins and progressively improving industry trends. Organic sales for Global Life Sciences increased in 2024 as compared to 2023 driven by new business wins and progressively improving industry trends.

***Operating Income***

Organic operating income and organic operating income margin for our Global Life Sciences segment both increased in 2025 when compared to 2024. Organic operating income increased and organic operating income margin decreased for our Global Life Sciences segment in 2024 when compared to 2023.

Organic operating income margin increased 3.4 percentage points in 2025, as the 5.9 percentage point positive impact from value pricing, higher volumes and lower delivered product costs were partially offset by the 2.2 percentage point negative impacts from investments in the business, including performance-based compensation. Organic operating income margin decreased in 2024, as the positive impact from value pricing was more than offset by the negative impacts from higher supply chain costs and investments in the business.

**Corporate**

Consistent with our internal management reporting, Corporate amounts in the table on page 37 include sales to ChampionX in accordance with the transitional supply agreement entered into with the transaction post-separation, as discussed in Note 17, "Revenues," intangible asset amortization specifically from the Nalco, Purolite and Ovivo Electronics transactions and special (gains) and charges that are not allocated to our reportable segments. Items included within special (gains) and charges are shown in the table on page 33.

[**Table of Contents**](#Toc)

**FINANCIAL POSITION, CASH FLOW AND LIQUIDITY**

**Financial Position**

Total assets were $24.7 billion as of December 31, 2025, compared to total assets of $22.4 billion as of December 31, 2024.

Total liabilities were $14.9 billion as of December 31, 2025, compared to total liabilities of $13.6 billion as of December 31, 2024. Total debt was $8.2 billion as of December 31, 2025 and $7.6 billion as of December 31, 2024. See further discussion of our debt activity within the "Liquidity and Capital Resources" section of this MD&A.

Our net debt to EBITDA is shown in the following table. EBITDA is a non-GAAP measure discussed further in the "Non-GAAP Financial Measures" section of this MD&A.

---

| | | | |
|:---|:---|:---|:---|
|  | **2025** | 2024 | 2023 |
| (ratio) |  |  |  |
| Net debt to EBITDA | **2.0** | 1.7 | 2.4 |
| (millions) |  |  |  |
| Total debt | **$8236.3** | $7564.9 | $8181.8 |
| Cash | **646.2** | 1256.8 | 919.5 |
| &nbsp;&nbsp;Net debt | **$7590.1** | $6308.1 | $7262.3 |
| Net income including noncontrolling interest | **$2093.3** | $2131.9 | $1393.0 |
| Provision for income taxes | **454.6** | 439.3 | 362.5 |
| Interest expense, net | **241.1** | 282.5 | 296.7 |
| Depreciation | **672.6** | 634.9 | 616.7 |
| Amortization | **303.8** | 300.5 | 306.9 |
| &nbsp;&nbsp;EBITDA | **$3765.4** | $3789.1 | $2975.8 |

---

**Cash Flows**

***Operating Activities***

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  |  | Dollar Change | Dollar Change |
| (millions) | **2025** | 2024 | 2023 | **2025** | 2024 |
| Cash provided by operating activities | **$2952.6** | $2813.9 | $2411.8 | **$138.7** | $402.1 |

---

We continue to generate cash flow from operations allowing us to fund our ongoing operations, acquisitions, investments in the business and pension obligations along with returning cash to our shareholders through dividend payments and share repurchases.

Cash provided by operating activities increased $139 million in 2025 compared to 2024, driven by a $219 million increase in net income, adjusted for the net gain on sale of surgical solutions business in 2024, partially offset by a $120 million unfavorable change in working capital. The cash flow impact from working capital was primarily driven by improvement in inventory due to optimization efforts offset by a decrease in accounts payable primarily associated with our inventory reduction efforts and timing impacts.

Cash provided by operating activities increased $402 million in 2024 compared to 2023, driven by a $739 million increase in net income less $258 million net gain on sale of global surgical solutions business.

The impact on operating cash flows of pension and postretirement plan contributions, cash activity related to restructuring, cash paid for income taxes and cash paid for interest, are shown in the following table:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  |  | Dollar Change | Dollar Change |
| (millions) | **2025** | 2024 | 2023 | **2025** | 2024 |
| Pensions and postretirement plan contributions | **$77.8** | $54.4 | $109.3 | **$23.4** | ($54.9) |
| Restructuring payments | **86.2** | 78.0 | 118.3 | **8.2** | (40.3) |
| Income tax payments | **548.1** | 647.4 | 469.2 | **(99.3)** | 178.2 |
| Interest payments | **302.6** | 342.6 | 324.8 | **(40.0)** | 17.8 |

---

[**Table of Contents**](#Toc)

***Investing Activities***

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  |  | Dollar Change | Dollar Change |
| (millions) | **2025** | 2024 | 2023 | **2025** | 2024 |
| Cash used for investing activities | **($2707.2)** | ($433.8) | ($990.5) | **($2273.4)** | $556.7 |

---

Cash provided by (used for) investing activities is primarily impacted by the timing of business acquisitions and dispositions as well as from capital investments in the business.

We continue to make capital investments in the business, including merchandising and customer equipment and manufacturing facilities. Total capital expenditures were $1.0 billion, $995 million, and $775 million in 2025, 2024, and 2023, respectively.

Cash used for acquisitions and investments in affiliates, net of cash acquired, in 2025, 2024 and 2023 was $1.6 billion, $313 million, and $180 million, respectively. Cash used for acquisitions and investments in affiliates, net of cash acquired, in 2025 primarily related to the Ovivo Electronics acquisition. Cash used for dispositions, net of cash divested, related to the divestiture of our global surgical solutions business was $15 million in 2025. Cash provided by dispositions, net of cash divested, related to the divestiture of our global surgical solutions business was $890 million in 2024. There was no cash used for or provided by dispositions in 2023. Our acquisitions and divestitures are discussed further in Note 4, "Acquisitions and Dispositions," of the Notes. We continue to target strategic business acquisitions which complement our growth strategy and expect to continue to make capital investments and acquisitions in the future to support our long-term growth.

***Financing Activities***

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  |  | Dollar Change | Dollar Change |
| (millions) | **2025** | 2024 | 2023 | **2025** | 2024 |
| Cash used for financing activities | **($853.3)** | ($2024.1) | ($1054.7) | **$1170.8** | ($969.4) |

---

Our cash flows from financing activities primarily reflect the issuances and repayment of debt, common stock repurchases, proceeds from common stock issuances related to our equity incentive programs and dividend payments.

We issued $1 billion aggregate principal amount and received $994 million in proceeds of fixed rate public notes in 2025. The proceeds received from the debt issuances were used for general corporate purposes, which included partial funding of the Ovivo Electronics acquisition. There were no long-term debt issuances in 2024 or 2023. In addition, we had commercial paper and notes payable net issuances of $98 million in 2025, $2 million in 2024 and net repayments of $2 million in 2023, respectively. We repaid €575 million ($674 million), €575 million ($630 million), and $500 million of long-term debt in 2025, 2024 and 2023, respectively.

Shares are repurchased for the purpose of partially offsetting the dilutive effect of our equity compensation plans, to manage our capital structure and to efficiently return capital to shareholders. We repurchased a total of $784 million, $987 million, and $14 million shares in 2025, 2024, and 2023, respectively.

The impact on financing cash flows of commercial paper and notes payable repayments, long-term debt borrowings and long-term debt repayments, are shown in the following table:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  |  | Dollar Change | Dollar Change |
| (millions) | **2025** | 2024 | 2023 | **2025** | 2024 |
| Net issuances (repayments) of commercial paper and notes payable | **$98.2** | $1.9 | ($1.9) | **$96.3** | $3.8 |
| Long-term debt borrowings | **1045.6** | - | - | **1045.6** | - |
| Long-term debt repayments | **(674.2)** | (630.4) | (500.0) | **(43.8)** | (130.4) |

---

In December 2025, we increased our quarterly dividend rate by 12%. This represents the 34<sup>th</sup> consecutive year we have increased our dividend. We have paid dividends on our common stock for 89 consecutive years. We paid dividends of $754 million, $664 million, and $617 million in 2025, 2024, and 2023, respectively. Cash dividends declared per share of common stock, by quarter, for each of the last three years were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | First<br>Quarter | Second<br>Quarter | Third<br>Quarter | Fourth<br>Quarter | <br>Year |
| **2025** | **$0.65** | **$0.65** | **$0.65** | **$0.73** | **$2.68** |
| 2024 | $0.57 | $0.57 | $0.57 | $0.65 | $2.36 |
| 2023 | $0.53 | $0.53 | $0.53 | $0.57 | $2.16 |

---

[**Table of Contents**](#Toc)

**Liquidity and Capital Resources**

We currently expect to fund all of our cash requirements which are reasonably foreseeable for the next twelve months, including scheduled debt repayments, new investments in the business, share repurchases, dividend payments, possible business acquisitions and pension and postretirement contributions with cash from operating activities, and as needed, additional short-term and/or long-term borrowings. We continue to expect our operating cash flow to remain strong.

As of December 31, 2025, we had $646 million of cash and cash equivalents on hand, of which $476 million was held outside of the U.S. As of December 31, 2024, we had $1,257 million of cash and cash equivalents on hand, of which $382 million was held outside of the U.S. We will continue to evaluate our cash position in light of future developments.

In July 2025 and January 2024, we repaid €575 million ($674 million), and €575 million ($630 million) of long-term debt, respectively.

As of December 31, 2024, we had a $2.0 billion multi-year revolving credit facility which was due to expire in April 2026. In March 2025, we entered into an amended and restated revolving credit facility which extended the maturity from April 2026 to March 2030. The credit facility has been established with a diverse syndicate of banks and supports our U.S. and Euro commercial paper programs. The maximum aggregate amount of commercial paper that may be issued under our U.S. commercial paper program and our Euro commercial paper program may not exceed $2.0 billion. At year end, we had $100 million in commercial paper outstanding under our U.S. program and none under our Euro program. There were no borrowings under our credit facility as of December 31, 2025 or 2024. As of December 31, 2025, both programs were rated A-2 by Standard & Poor's, P-2 by Moody's and F-1 by Fitch.

Additionally, we have uncommitted credit lines with major international banks and financial institutions. These credit lines support our daily global funding needs, primarily our global cash pooling structures. As of December 31, 2025, we had $217 million of bank supported letters of credit, short-term borrowings, surety bonds and guarantees outstanding in support of our commercial business transactions. We do not have any other significant unconditional purchase obligations or commercial commitments.

As of December 31, 2025, Standard & Poor's, Fitch and Moody's rated our long-term credit at A- (stable outlook), A- (stable outlook) and A3 (stable outlook), respectively. A reduction in our credit ratings could limit or preclude our ability to issue commercial paper under our current programs or could also adversely affect our ability to renew existing, or negotiate new, credit facilities in the future and could increase the cost of these facilities.

As of December 31, 2025, we were in compliance with our debt covenants and other requirements of our credit agreements and indentures.

A schedule of our various obligations as of December 31, 2025 are summarized in the following table:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  | Payments Due by Period | Payments Due by Period | Payments Due by Period | Payments Due by Period |
|  |  | Less |  |  | More |
|  |  | Than | 2-3 | 4-5 | Than |
| (millions) | Total | 1 Year | Years | Years | 5 Years |
| Commercial paper and notes payable | $111 | $111 | $- | $- | $- |
| One-time transition tax | 36 | 36 | - | - | - |
| Long-term debt | 8125 | 759 | 2017 | 699 | 4650 |
| Operating leases | 890 | 197 | 300 | 141 | 252 |
| Interest\* | 3451 | 313 | 494 | 395 | 2249 |
| Total | $12613 | $1416 | $2811 | $1235 | $7151 |

---

\*Interest on variable rate debt was calculated using the interest rate at December 31, 2025.

As of December 31, 2025, our gross liability for unrecognized tax benefits was $54 million. We are not able to reasonably estimate the amount by which the liability will increase or decrease over an extended period of time or whether a cash settlement of the liability will be required. Therefore, these amounts have been excluded from the schedule of contractual obligations.

We do not have required minimum cash contribution obligations for our qualified pension plans in 2025. We are required to fund certain international pension benefit plans in accordance with local legal requirements. We estimate contributions to be made to our international plans will approximate $39 million in 2026. These amounts have been excluded from the schedule of contractual obligations.

We lease certain sales and administrative office facilities, distribution centers, research and manufacturing facilities and other equipment under longer-term operating leases. Vehicle leases are generally shorter in duration. Vehicle leases have residual value requirements that have historically been satisfied primarily by the proceeds on the sale of the vehicles.

[**Table of Contents**](#Toc)

**Market Risk**

We enter into contractual arrangements (derivatives) in the ordinary course of business to manage foreign currency exposure and interest rate risks. We do not enter into derivatives for speculative or trading purposes. Our use of derivatives is subject to internal policies that provide guidelines for control, counterparty risk, and ongoing monitoring and reporting, and is designed to reduce the volatility associated with movements in foreign exchange and interest rates on our income statement and cash flows.

We enter into foreign currency forward contracts to hedge certain intercompany financial arrangements, and to hedge against the effect of exchange rate fluctuations on transactions related to cash flows denominated in currencies other than U.S. dollars. We use net investment hedges as hedging instruments to manage risks associated with our investments in foreign operations.

We enter into cross-currency swap derivative contracts to hedge certain Euro, Chinese Yuan ("CNY") and Canadian Dollar ("CAD") denominated exposures from our investments in certain of its respective denominated functional currency subsidiaries. We use net investment hedges as hedging instruments to manage risks associated with our investments in foreign operations. As of December 31, 2025, we had €2,275 million ($2,672 million), CNY 3,986 million ($570 million), and CAD 280 million ($204 million) contracts outstanding designated as net investment hedges.

We manage interest expense using a mix of fixed and floating rate debt. To help manage borrowing costs, we may enter into interest rate swap agreements. Under these arrangements, we agree to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. As of December 31, 2025, we had $1,500 million of interest rate swaps outstanding.

Refer to Note 8, "Derivatives and Hedging Transactions," of the Notes for further information on our hedging activity.

Based on a sensitivity analysis (assuming a 10% change in market rates) of our foreign exchange and interest rate derivatives and other financial instruments, changes in exchange rates or interest rates would increase/decrease our financial position and liquidity by approximately $388 million. The effect on our results of operations would be substantially offset by the impact of the hedged items.

**GLOBAL ECONOMIC AND POLITICAL ENVIRONMENT** 

**Global Economies**

Approximately half of our sales are outside of the U.S. Our international operations subject us to changes in economic conditions and foreign currency exchange rates as well as political uncertainty in some countries which could impact future operating results.

Argentina, Turkey and Egypt are classified as highly inflationary economies in accordance with U.S. GAAP, and the U.S. dollar is the functional currency for our subsidiaries in Argentina, Turkey and Egypt. During 2025, sales in Argentina, Turkey and Egypt represented approximately 1% of our consolidated sales. Assets held in Argentina, Turkey and Egypt at the end of 2025 represented approximately 1% of our consolidated assets.

In light of Russia's invasion of Ukraine and the sanctions against Russia by the United States and other countries, we have made the determination to limit our Russian business to operations that are essential to life, providing minimal support for our healthcare, life sciences, food and beverage and certain water businesses. We may further narrow our presence in Russia depending on future developments, such as the imposition of additional sanctions by the United States. Our Russian and Ukraine operations represented approximately 1% of our 2025 consolidated net sales. We recorded charges of $1.4 million in 2023, primarily related to recoverability risk of certain assets in both Russia and Ukraine. We cannot predict the progress or outcome of world geopolitical events, including the Russia and Ukraine conflict, or the consequences thereof.

**NEW ACCOUNTING PRONOUNCEMENTS**

Information regarding new accounting pronouncements is included in Note 2, "Significant Accounting Policies," of the Notes.

**SUBSEQUENT EVENTS**

In February 2026, we expanded our existing One Ecolab restructuring program. We now anticipate total restructuring costs of $334 million ($261 million after tax) and special charges of $91 million ($71 million after tax) by the end of 2027. We anticipate that the restructuring costs will primarily be cash expenditures for severance costs relating to team realignment.

In February 2026, we entered into cross-currency swap derivative contracts with aggregate notional amounts of 100 million Swiss Franc ("CHF"). These cross-currency swap derivative contracts are designated as net investment hedges of our CHF denominated exposures from our investments in certain of our CHF denominated functional currency subsidiaries.

[**Table of Contents**](#Toc)

**NON-GAAP FINANCIAL MEASURES**

This MD&A includes financial measures that have not been calculated in accordance with U.S. GAAP. These non-GAAP measures may include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Fixed currency sales

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Adjusted net sales

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Adjusted fixed currency sales

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Organic sales

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Adjusted cost of sales

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Adjusted gross margin

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Fixed currency operating income

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Fixed currency operating income margin

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Adjusted operating income

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Adjusted operating income margin

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Adjusted fixed currency operating income

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Adjusted fixed currency operating income margin

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Organic operating income

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Organic operating income margin

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Adjusted interest expense, net

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● EBITDA

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Adjusted tax rate

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Adjusted net income attributable to Ecolab

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Adjusted diluted EPS

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● Free cash flow

We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.

Our non-GAAP financial measures for adjusted net sales and adjusted interest expense, net exclude the impact of the Ovivo Electronics acquisition. Our non-GAAP financial measures for adjusted cost of sales, adjusted gross margin and adjusted operating income exclude the impact of special (gains) and charges and the Ovivo Electronics acquisition, and our non-GAAP financial measures for adjusted tax rate, adjusted net income attributable to Ecolab and adjusted diluted EPS further exclude the impact of discrete tax items. We include items within special (gains) and charges and discrete tax items that we believe can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results. After tax special (gains) and charges are derived by applying the applicable local jurisdictional tax rate to the corresponding pre-tax special (gains) and charges.

EBITDA is defined as net income including non-controlling interest with the sum of provision for income taxes, net interest expense, depreciation and amortization added back. Adjusted EBITDA further adds back special (gains) and charges impacting EBITDA. EBITDA and adjusted EBITDA are used in our net debt to EBITDA and net debt to adjusted EBITDA ratios, which we view as important indicators of the operational and financial health of our organization.

We evaluate the performance of our international operations based on fixed currency rates of foreign exchange, which eliminate the translation impact of exchange rate fluctuations on our international results. Fixed currency amounts included in this Form 10-K are based on translation into U.S. dollars at the fixed foreign currency exchange rates established by management at the beginning of 2025. We also provide our segment results based on public currency rates for informational purposes.

Our reportable segments do not include the impact of intangible asset amortization from the Nalco and Purolite transactions or the impact of special (gains) and charges as these are not allocated to our reportable segments.

Our non-GAAP financial measures for organic sales, organic operating income and organic operating income margin are at fixed currency and exclude: (i) the impact of special (gains) and charges where applicable, (ii) the impact of the Ovivo Electronics acquisition, (iii) the results of our acquired businesses from the first twelve months post acquisition and (iv) the results of divested businesses from the twelve months prior to divestiture. Further, due to the sale of the global surgical solutions business on August 1, 2024, we have excluded the results of the business for the nine-month period ended September 30, 2024 from these organic measures to remain comparable to the corresponding period in 2025. In addition, as part of the separation of ChampionX in 2020, we continue to provide certain products to ChampionX, which are recorded in product and equipment sales in the Global Water segment along with the related cost of sales. These transactions are removed from the consolidated results as part of the calculation of the impact of acquisitions and divestitures.

[**Table of Contents**](#Toc)

We define free cash flow as net cash provided by operating activities less cash outlays for capital expenditures. It should not be inferred that the entire free cash flow amount is available for discretionary expenditures. It should not be considered a substitute for income or cash flow data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. We believe free cash flow is meaningful to investors as it functions as a useful measure of performance and we use this measure as an indication of the strength of the Company and its ability to generate cash.

These non-GAAP measures are not in accordance with, or an alternative to U.S. GAAP and may be different from non-GAAP measures used by other companies. Investors should not rely on any single financial measure when evaluating our business. We recommend that investors view these measures in conjunction with the U.S. GAAP measures included in this MD&A and we have provided reconciliations of reported U.S. GAAP amounts to the non-GAAP amounts in this MD&A.

We do not provide reconciliations for non-GAAP estimates on a forward-looking basis (including those contained in this Form 10-K) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of various items that have not yet occurred, are out of our control and/or cannot be reasonably predicted, and that would impact reported earnings per share and the reported tax rate, the most directly comparable forward-looking GAAP financial measures to adjusted earnings per share and the adjusted tax rate. For the same reasons, we are unable to address the probable significance of the unavailable information.

**Item 7A. Quantitative and Qualitative Disclosures about Market Risk.**

The discussion under the heading entitled "Market Risk" and "Global Economic and Political Environment" is incorporated by reference from Part II, Item 7 of this Form 10-K.

**Item 8. Financial Statements and Supplementary Data.**

**REPORTS OF MANAGEMENT**

**To our Shareholders:**

**Management's Responsibility for Financial Statements**

Management is responsible for the integrity and objectivity of the consolidated financial statements. The statements have been prepared in accordance with accounting principles generally accepted in the United States of America and, accordingly, include certain amounts based on management's best estimates and judgments.

The Audit Committee of the Board of Directors, composed of solely of independent directors, is responsible for monitoring the quality and integrity of the corporation's consolidated financial statements, and management's system of internal control over financial reporting. The Audit Committee is directly responsible for the appointment of the Company's independent registered public accounting firm. It meets regularly with management, the internal auditors and the independent registered public accounting firm.

The independent registered public accounting firm has audited the consolidated financial statements included in this annual report and have expressed their opinion regarding whether these consolidated financial statements present fairly in all material respects our financial position and results of operation and cash flows as stated in their report presented separately herein.

**Management's Report on Internal Control Over Financial Reporting**

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Under the supervision and with the participation of management, including the principal executive officer and principal financial officer, an evaluation of the design and operating effectiveness of internal control over financial reporting was conducted based on the 2013 framework in *Internal Control — Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on the evaluation under the framework in *Internal Control — Integrated Framework*, management concluded that internal control over financial reporting was effective as of December 31, 2025.

The Company's independent registered public accounting firm, PricewaterhouseCoopers LLP, has audited the effectiveness of the Company's internal control over financial reporting as of December 31, 2025 as stated in their report which is included herein.

---

| | |
|:---|:---|
| ![Graphic](ecl-20251231x10k001.jpg) | ![Graphic](ecl-20251231x10k002.jpg) |
| Christophe Beck | Scott D. Kirkland |
| Chairman and Chief Executive Officer | Chief Financial Officer |

---

[**Table of Contents**](#Toc)

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

**To the Board of Directors and Shareholders of Ecolab Inc.**

***Opinions on the Financial Statements and Internal Control over Financial Reporting***

We have audited the accompanying consolidated balance sheets of Ecolab Inc. and its subsidiaries (the "Company") as of December 31, 2025 and 2024, and the related consolidated statements of income, of comprehensive income, of equity and of cash flows for each of the three years in the period ended December 31, 2025, including the related notes (collectively referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control - Integrated Framework* (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control - Integrated Framework* (2013) issued by the COSO.

***Basis for Opinions***

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express opinions on the Company's consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

***Definition and Limitations of Internal Control over Financial Reporting***

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

#### Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

[**Table of Contents**](#Toc)

*Valuation of Projected Benefit Obligation – U.S. Qualified Pension Plan*

As described in Note 16 to the consolidated financial statements, the Company's projected benefit obligations for the U.S. pension plans was $1,818 million as of December 31, 2025, of which $1,738 million related to the U.S. qualified pension plan. The measurement of the Company's pension benefit obligations are dependent on a variety of assumptions determined by management and used by actuaries in their valuation method and calculations. The significant assumptions used in developing the required estimates of the projected benefit obligations are the discount rates and projected salary increases.

The principal considerations for our determination that performing procedures relating to the valuation of the projected benefit obligation for the U.S. qualified pension plan is a critical audit matter are (i) the significant judgment by management when developing the estimate of the projected benefit obligation for the U.S. qualified pension plan; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management's significant assumption related to the discount rate; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management's valuation of the projected benefit obligations, including controls over the valuation of the projected benefit obligation for the U.S. qualified pension plan. These procedures also included, among others (i) testing management's process for developing the estimate of the projected benefit obligation for the U.S. qualified pension plan; (ii) evaluating the appropriateness of the actuarial valuation method used by management; (iii) testing the completeness and accuracy of the underlying data used in the actuarial valuation method; and (iv) evaluating the reasonableness of the significant assumption used by management related to the discount rate. Professionals with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the actuarial valuation method and (ii) the reasonableness of the discount rate assumption.

/s/ PricewaterhouseCoopers LLP

Minneapolis, Minnesota

February 23, 2026

We have served as the Company's auditor since 1970.

[**Table of Contents**](#Toc)

**CONSOLIDATED STATEMENTS OF INCOME**

---

| | | | |
|:---|:---|:---|:---|
| (millions, except per share amounts) | **2025** | 2024 | 2023 |
| &nbsp;&nbsp;Product and equipment sales | **$12618.5** | $12473.6 | $12316.8 |
| &nbsp;&nbsp;Service and lease sales | **3462.7** | 3267.8 | 3003.4 |
| Net sales | **16081.2** | 15741.4 | 15320.2 |
| &nbsp;&nbsp;Product and equipment cost of sales | **6955.8** | 6990.0 | 7389.2 |
| &nbsp;&nbsp;Service and lease cost of sales | **1975.0** | 1909.7 | 1765.7 |
| Cost of sales (including special charges (a)) | **8930.8** | 8899.7 | 9154.9 |
| &nbsp;&nbsp;Selling, general and administrative expenses | **4257.9** | 4228.2 | 4061.6 |
| &nbsp;&nbsp;Special (gains) and charges | **154.9** | (188.9) | 111.4 |
| Operating income | **2737.6** | 2802.4 | 1992.3 |
| Other (income) expense | **(51.4)** | (51.3) | (59.9) |
| Interest expense, net | **241.1** | 282.5 | 296.7 |
| Income before income taxes | **2547.9** | 2571.2 | 1755.5 |
| Provision for income taxes | **454.6** | 439.3 | 362.5 |
| Net income including noncontrolling interest | **2093.3** | 2131.9 | 1393.0 |
| Net income attributable to noncontrolling interest | **17.7** | 19.5 | 20.7 |
| Net income attributable to Ecolab | **$2075.6** | $2112.4 | $1372.3 |
| Earnings attributable to Ecolab per common share |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | **$7.33** | $7.43 | $4.82 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | **$7.28** | $7.37 | $4.79 |
| Weighted-average common shares outstanding |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | **283.3** | 284.3 | 285.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | **285.2** | 286.6 | 286.5 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(a) Cost of sales includes special (gains) and charges of $7.7 in 2025, $5.3 in 2024, and $14.5 in 2023, which is recorded in product and equipment cost of sales. Cost of sales includes special (gains) and charges of $8.0 in 2023 which is recorded in service and lease cost of sales.

The accompanying notes are an integral part of the consolidated financial statements.

[**Table of Contents**](#Toc)

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

---

| | | | |
|:---|:---|:---|:---|
| (millions) | **2025** | 2024 | 2023 |
| Net income including noncontrolling interest | **$2093.3** | $2131.9 | $1393.0 |
| Other comprehensive income (loss), net of tax |  |  |  |
| &nbsp;&nbsp;Foreign currency translation adjustments |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation | **276.7** | (187.1) | 10.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain (loss) on net investment hedges | **(216.1)** | 52.4 | (73.1) |
| &nbsp;&nbsp;Total foreign currency translation adjustments | **60.6** | (134.7) | (63.1) |
| &nbsp;&nbsp;Derivatives and hedging instruments | **(8.6)** | 8.7 | (7.8) |
| &nbsp;&nbsp;Pension and postretirement benefits | **55.6** | (5.6) | (55.1) |
| Subtotal | **107.6** | (131.6) | (126.0) |
| Total comprehensive income, including noncontrolling interest | **2200.9** | 2000.3 | 1267.0 |
| Comprehensive income attributable to noncontrolling interest | **17.6** | 19.5 | 18.5 |
| Comprehensive income attributable to Ecolab | **$2183.3** | $1980.8 | $1248.5 |

---

The accompanying notes are an integral part of the consolidated financial statements.

[**Table of Contents**](#Toc)

**CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
| (millions, except per share amounts) | **2025** | 2024 |
| **ASSETS** |  |  |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | **$646.2** | $1256.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | **3249.4** | 2865.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | **1490.4** | 1464.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | **569.6** | 439.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets | **5955.6** | 6025.7 |
| Property, plant and equipment, net | **4276.6** | 3752.4 |
| Goodwill | **9227.0** | 7907.3 |
| Other intangible assets, net | **3688.5** | 3308.8 |
| Operating lease assets | **765.9** | 723.2 |
| Other assets | **782.7** | 670.4 |
| Total assets | **$24696.3** | $22387.8 |
| **LIABILITIES AND EQUITY** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term debt | **$870.4** | $615.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | **2071.0** | 1810.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation and benefits | **721.5** | 727.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes | **134.3** | 127.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | **1737.5** | 1512.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | **5534.7** | 4792.8 |
| Long-term debt | **7365.9** | 6949.2 |
| Pension and postretirement benefits | **546.1** | 634.9 |
| Deferred income taxes | **329.9** | 280.0 |
| Operating lease liabilities  | **596.5** | 575.5 |
| Other liabilities | **518.7** | 366.2 |
| Total liabilities | **14891.8** | 13598.6 |
| Commitments and contingencies (Note 15) |  |  |
| Equity (a) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock | **369.4** | 367.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | **7521.3** | 7159.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | **12834.0** | 11517.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | **(1874.3)** | (1982.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Treasury stock | **(9079.6)** | (8305.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Ecolab shareholders' equity | **9770.8** | 8757.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Noncontrolling interest | **33.7** | 31.9 |
| Total equity | **9804.5** | 8789.2 |
| Total liabilities and equity | **$24696.3** | $22387.8 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(a) Common stock, 800.0 shares authorized, $1.00 par value, 282.0 shares outstanding at December 31, 2025 and 283.4 shares outstanding at December 31, 2024. Shares outstanding are net of treasury stock.

The accompanying notes are an integral part of the consolidated financial statements.

[**Table of Contents**](#Toc)

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

---

| | | | |
|:---|:---|:---|:---|
| (millions) | **2025** | 2024 | 2023 |
| **OPERATING ACTIVITIES** |  |  |  |
| Net income including noncontrolling interest | **$2093.3** | $2131.9 | $1393.0 |
| Adjustments to reconcile net income to cash provided by operating activities: |  |  |  |
| &nbsp;&nbsp;Depreciation | **672.6** | 634.9 | 616.7 |
| &nbsp;&nbsp;Amortization | **303.8** | 300.5 | 306.9 |
| &nbsp;&nbsp;Deferred income taxes | **(33.4)** | (190.5) | (55.7) |
| &nbsp;&nbsp;Share-based compensation expense | **136.6** | 134.8 | 95.1 |
| &nbsp;&nbsp;Pension and postretirement plan contributions | **(77.8)** | (54.4) | (109.3) |
| &nbsp;&nbsp;Pension and postretirement plan expense (income), net | **15.0** | 14.3 | 3.1 |
| &nbsp;&nbsp;Restructuring charges, net of cash paid | **18.8** | 23.7 | (32.6) |
| &nbsp;&nbsp;Sale of global surgical solutions business | **1.1** | (381.7) | - |
| &nbsp;&nbsp;Other, net | **28.8** | 24.3 | 31.9 |
| &nbsp;&nbsp;Changes in operating assets and liabilities, net of effect of acquisitions: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | **(185.9)** | (146.7) | (84.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | **36.4** | (115.6) | 320.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets | **83.6** | (24.3) | 72.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | **67.7** | 300.0 | (232.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | **(208.0)** | 162.7 | 86.8 |
| Cash provided by operating activities | **2952.6** | 2813.9 | 2411.8 |
| **INVESTING ACTIVITIES** |  |  |  |
| Capital expenditures | **(1048.3)** | (994.5) | (774.8) |
| Property and other assets sold | **52.3** | 11.3 | 9.9 |
| Acquisitions and investments in affiliates, net of cash acquired | **(1621.3)** | (312.9) | (180.4) |
| Divestiture of businesses, net of cash divested | **(14.9)** | 889.7 | - |
| Other, net | **(75.0)** | (27.4) | (45.2) |
| Cash used for investing activities | **(2707.2)** | (433.8) | (990.5) |
| **FINANCING ACTIVITIES** |  |  |  |
| Net issuances (repayments) of commercial paper and notes payable | **98.2** | 1.9 | (1.9) |
| Long-term debt borrowings | **1045.6** | - | - |
| Long-term debt repayments | **(674.2)** | (630.4) | (500.0) |
| Reacquired shares | **(783.8)** | (986.5) | (13.7) |
| Dividends paid | **(753.6)** | (664.3) | (617.3) |
| Exercise of employee stock options | **228.2** | 259.4 | 96.8 |
| Hedge settlements | **-** | (0.6) | (15.3) |
| Other, net | **(13.7)** | (3.6) | (3.3) |
| Cash used for financing activities | **(853.3)** | (2024.1) | (1054.7) |
| Effect of exchange rate changes on cash and cash equivalents | **(2.7)** | (18.7) | (45.7) |
| (Decrease) Increase in cash and cash equivalents | **(610.6)** | 337.3 | 320.9 |
| Cash and cash equivalents, beginning of period | **1256.8** | 919.5 | 598.6 |
| Cash and cash equivalents, end of period | **$646.2** | $1256.8 | $919.5 |
| **SUPPLEMENTAL CASH FLOW INFORMATION** |  |  |  |
| Income taxes paid | **$548.1** | $647.4 | $469.2 |
| Net interest paid | **302.6** | 342.6 | 324.8 |

---

The accompanying notes are an integral part of the consolidated financial statements.

[**Table of Contents**](#Toc)

**CONSOLIDATED STATEMENTS OF EQUITY**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Year ended December 31, 2025, 2024 and 2023 | Year ended December 31, 2025, 2024 and 2023 | Year ended December 31, 2025, 2024 and 2023 | Year ended December 31, 2025, 2024 and 2023 | Year ended December 31, 2025, 2024 and 2023 | Year ended December 31, 2025, 2024 and 2023 | Year ended December 31, 2025, 2024 and 2023 | Year ended December 31, 2025, 2024 and 2023 |
| (millions, except per share amounts) | Common <br>Stock | Additional <br> Paid-in <br>Capital | Retained <br>Earnings | AOCI <br>(Loss) | Treasury <br>Stock | Ecolab Shareholders' <br>Equity | Non-Controlling <br>Interest | Total <br>Equity |
| Balance, December 31, 2022 | $364.7 | $6580.2 | $9318.8 | ($1726.6) | ($7301.0) | $7236.1 | $22.5 | $7258.6 |
| &nbsp;&nbsp;&nbsp;Net income  |  |  | 1372.3  |  |  | 1372.3  | 20.7  | 1393.0  |
| &nbsp;&nbsp;&nbsp;Other comprehensive income (loss) activity |  |  |  | (123.8) |  | (123.8) | (2.2) | (126.0) |
| &nbsp;&nbsp;&nbsp;Cash dividends declared (a) |  |  | (615.7) |  |  | (615.7) | (13.5) | (629.2) |
| &nbsp;&nbsp;&nbsp;Changes in noncontrolling interests |  | (4.5) |  |  |  | (4.5) |  | (4.5) |
| &nbsp;&nbsp;&nbsp;Stock options and awards | 1.0  | 191.0  |  |  | 2.0  | 194.0  |  | 194.0  |
| &nbsp;&nbsp;&nbsp;Reacquired shares |  |  |  |  | (13.7) | (13.7) |  | (13.7) |
| Balance, December 31, 2023 | 365.7  | 6766.7  | 10075.4  | (1850.4) | (7312.7) | 8044.7  | 27.5  | 8072.2  |
| &nbsp;&nbsp;&nbsp;Net income |  |  | 2112.4  |  |  | 2112.4  | 19.5  | 2131.9  |
| &nbsp;&nbsp;&nbsp;Other comprehensive income (loss) activity |  |  |  | (131.6) |  | (131.6) |  | (131.6) |
| &nbsp;&nbsp;&nbsp;Cash dividends declared (a) |  |  | (670.7) |  |  | (670.7) | (15.1) | (685.8) |
| &nbsp;&nbsp;&nbsp;Stock options and awards | 2.1  | 392.9  |  |  | 3.6  | 398.6  |  | 398.6  |
| &nbsp;&nbsp;&nbsp;Reacquired shares |  |  |  |  | (996.1) | (996.1) |  | (996.1) |
| Balance, December 31, 2024 | 367.8  | 7159.6  | 11517.1  | (1982.0) | (8305.2) | 8757.3  | 31.9  | 8789.2  |
| &nbsp;&nbsp;&nbsp;Net income |  |  | **2075.6** |  |  | **2075.6** | **17.7** | **2093.3** |
| &nbsp;&nbsp;&nbsp;Other comprehensive income (loss) activity |  |  |  | **107.7** |  | **107.7** | **(0.1)** | **107.6** |
| &nbsp;&nbsp;&nbsp;Cash dividends declared (a) |  |  | **(758.7)** |  |  | **(758.7)** | **(16.5)** | **(775.2)** |
| &nbsp;&nbsp;&nbsp;Acquisition of noncontrolling interests |  |  |  |  |  |  | **0.7** | **0.7** |
| &nbsp;&nbsp;&nbsp;Stock options and awards | **1.6** | **361.7** |  |  | **2.8** | **366.1** |  | **366.1** |
| &nbsp;&nbsp;&nbsp;Reacquired shares |  |  |  |  | **(777.2)** | **(777.2)** |  | **(777.2)** |
| Balance, December 31, 2025 | **$369.4** | **$7521.3** | **$12834.0** | **($1874.3)** | **($9079.6)** | **$9770.8** | **$33.7** | **$9804.5** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Dividends declared per common share were $2.68 , $2.36 , and $2.16 in 2025, 2024 and 2023, respectively.

**COMMON STOCK ACTIVITY**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **2025** | **2025** | 2024 | 2024 | 2023 | 2023 |
|  | Common | Treasury | Common | Treasury | Common | Treasury |
| Year ended December 31 | Stock | Stock | Stock | Stock | Stock | Stock |
| Shares, beginning of year | **367818175** | **(84463429)** | 365748640 | (80300109) | 364711841 | (80261501) |
| &nbsp;&nbsp;&nbsp;Stock options | **1308470** | **36586** | 1772396 | 31531 | 802645 | 14629 |
| &nbsp;&nbsp;&nbsp;Stock awards | **288878** | **28586** | 297139 | 51791 | 234154 | 30437 |
| &nbsp;&nbsp;&nbsp;Reacquired shares | **-** | **(2994702)** | - | (4246642) | - | (83674) |
| Shares, end of year | **369415523** | **(87392959)** | 367818175 | (84463429) | 365748640 | (80300109) |

---

The accompanying notes are an integral part of the consolidated financial statements.

[**Table of Contents**](#Toc)

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**1. NATURE OF BUSINESS**

Ecolab is a global leader in water, hygiene and infection prevention solutions and services that protect people and vital resources. The Company delivers comprehensive solutions, data-driven insights and personalized service to advance food safety, maintain clean and safe environments, optimize water and energy use and improve operational efficiencies and sustainability for customers in the food, healthcare, high-tech, life sciences, hospitality and industrial markets in more than 170 countries.

The Company's cleaning and sanitizing programs and products and pest elimination services support customers in the foodservice, food and beverage processing, hospitality, healthcare, government and education, retail, textile care and commercial facilities management sectors. The Company's products and technologies are also used in water treatment, pollution control, energy conservation, refining, primary metals manufacturing, papermaking, mining and other industrial processes.

The Company is aligned into four reportable segments: Global Water, Global Institutional & Specialty, Global Pest Elimination, and Global Life Sciences as discussed in Note 18, "Operating Segments and Geographical Information."

**2. SIGNIFICANT ACCOUNTING POLICIES**

**Principles of Consolidation**

The consolidated financial statements include the accounts of the Company and all subsidiaries in which the Company has a controlling financial interest. Investments in companies, joint ventures or partnerships in which the Company does not have control but has the ability to exercise significant influence over operating and financial decisions, are reported using the equity method of accounting. The measurement alternative is used for investments in companies, joint ventures and partnerships over which the Company has neither control nor significant influence and for which the investment does not have a readily determinable fair value. Under the measurement alternative, investments are recorded at cost and adjusted for impairments, if any, or observable price changes. International subsidiaries are included in the financial statements on the basis of their U.S. GAAP November 30 fiscal year ends to facilitate the timely inclusion of such entities in the Company's consolidated financial reporting. All intercompany transactions and profits are eliminated in consolidation.

**Use of Estimates**

The preparation of the Company's financial statements requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. The Company's critical accounting estimates include, actuarially determined liabilities, income taxes, long-lived assets, intangible assets and goodwill.

**Foreign Currency Translation**

Financial position and reported results of operations of the Company's non-U.S. dollar functional currency international subsidiaries are measured using local currencies as the functional currency. Assets and liabilities of these operations are translated at the exchange rates in effect at each fiscal year end. The translation adjustments related to assets and liabilities that arise from changes in exchange rates from period to period are included in accumulated other comprehensive income (loss) in shareholders' equity. Income statement accounts are translated at average rates of exchange prevailing during the year. As discussed in Note 18, "Operating Segments and Geographic Information," the Company evaluates its international operations based on fixed rates of exchange; however, changes in exchange rates from period to period impact the amount of reported income from consolidated operations.

**Concentration of Credit Risk**

Credit risk represents the accounting loss that would be recognized at the reporting date if counterparties failed to perform as contracted. The Company believes the likelihood of incurring material losses due to concentration of credit risk is minimal. The principal financial instruments subject to credit risk are as follows:

*Cash and Cash Equivalents* - The Company maintains cash deposits with major banks, which from time to time may exceed insured limits. The possibility of loss related to financial condition of major banks has been deemed minimal. Additionally, the Company's investment policy limits exposure to concentrations of credit risk and changes in market conditions.

*Accounts Receivable* - A large number of customers in diverse industries and geographies, as well as the practice of establishing reasonable credit lines, limits credit risk. Based on historical trends and experiences, the allowance for expected credit losses is adequate to cover expected credit risk losses.

*Foreign Currency and Interest Rate Contracts and Derivatives* - Exposure to credit risk is limited by internal policies and active monitoring of counterparty risks. In addition, the Company uses a diversified group of major international banks and financial institutions as counterparties. The Company does not anticipate nonperformance by any of these counterparties.

[**Table of Contents**](#Toc)

**Cash and Cash Equivalents**

Cash equivalents include highly-liquid investments with a maturity of three months or less when purchased.

**Accounts Receivable and Allowance for Expected Credit Losses**

Accounts receivable are carried at the invoiced amounts, less an allowance for expected credit losses, and generally do not bear interest. The Company's allowance for expected credit losses estimates the amount of expected future credit losses by analyzing accounts receivable balances by age and applying historical write-off and collection experience. The Company's estimates separately consider macroeconomic trends, specific circumstances and credit conditions of customer receivables. Account balances are written off against the allowance when it is determined the receivable will not be recovered.

The Company's allowance for credits related to pricing or quantities shipped was $43 million, $53 million and $72 million as of December 31, 2025, 2024 and 2023, respectively. Credit activity is recorded directly as a reduction to revenue.

The following table summarizes the activity in the allowance for expected credit losses:

---

| | | | |
|:---|:---|:---|:---|
| (millions) | **2025** | 2024 | 2023 |
| Beginning balance | **$70.0** | $77.3 | $71.9 |
| &nbsp;&nbsp;Bad debt expense | **51.4** | 46.9 | 54.0 |
| &nbsp;&nbsp;Write-offs | **(48.5)** | (51.0) | (46.2) |
| &nbsp;&nbsp;Other (a) | **1.2** | (3.2) | (2.4) |
| Ending balance | **$74.1** | $70.0 | $77.3 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(a) O ther amounts are primarily the effects of changes in currency translations and acquired balances.

**Inventory Valuations**

Inventories are valued at the lower of cost or net realizable value. Certain U.S. inventory costs are determined on a last-in, first-out ("LIFO") basis. LIFO inventories represented 30% and 31% of consolidated inventories as of December 31, 2025 and 2024, respectively. All other inventory costs are determined using either the average cost or first-in, first-out ("FIFO") methods. Inventory values at FIFO, as shown in Note 5, "Balance Sheet Information," approximate replacement cost.

**Property, Plant and Equipment**

Property, plant and equipment assets are stated at cost. Dispensing and monitoring equipment consists principally of various dispensing systems for the Company's cleaning and sanitizing products, warewashing machines and process control and monitoring equipment. Certain dispensing systems capitalized by the Company are accounted for on a mass asset basis, whereby equipment is capitalized and depreciated as a group and written off when fully depreciated. The Company capitalizes both internal and external costs to develop or purchase computer software. Costs incurred for data conversion, training and maintenance associated with capitalized software are expensed as incurred. Expenditures for major renewals and improvements, which significantly extend the useful lives of existing plant and equipment, are capitalized and depreciated. Expenditures for repairs and maintenance are charged to expense as incurred. Upon retirement or disposition of plant and equipment, the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in income.

Depreciation is charged to operations using the straight-line method over the assets' estimated useful lives ranging from 5 to 40 years for buildings and leasehold improvements, 3 to 20 years for machinery and equipment, 3 to 20 years for dispensing and monitoring equipment and 3 to 7 years for capitalized software. The straight-line method of depreciation reflects an appropriate allocation of the cost of the assets to earnings in proportion to the amount of economic benefits obtained by the Company in each reporting period. Depreciation expense was $673 million, $635 million and $617 million for 2025, 2024 and 2023, respectively.

[**Table of Contents**](#Toc)

**Goodwill and Other Intangible Assets**

***Goodwill***

Goodwill arises from the Company's acquisitions and represents the excess of the fair value of the purchase consideration exchanged over the fair value of net assets acquired. The Company's reporting units are its seven operating segments. The Company assesses goodwill for impairment on an annual basis during the second quarter. If circumstances change or events occur that demonstrate it is more likely than not that the carrying amount of a reporting unit exceeds its fair value, the Company completes an interim goodwill impairment assessment of that reporting unit prior to the next annual assessment. If the results of an annual or interim goodwill impairment assessment demonstrate the carrying amount of a reporting unit is greater than its fair value, the Company will recognize an impairment loss for the amount by which the reporting unit's carrying amount exceeds its fair value, but not to exceed the carrying amount of goodwill assigned to that reporting unit.

During the second quarter of 2025, the Company completed its annual goodwill impairment assessment for its seven reporting units using discounted cash flow analyses that incorporated assumptions regarding future growth rates, terminal values and discount rates. The Company's goodwill impairment assessments for 2025 indicated the estimated fair values of each of these seven reporting units exceeded the carrying amounts of the respective reporting unit by a significant margin. The Company evaluates the need to complete interim goodwill impairment assessments when significant events or changes in business circumstances indicate that it is more likely than not that the carrying amount of a reporting unit may be higher than its fair value. No events were noted during the second half of 2025 that required completion of an interim goodwill impairment assessment for any of the Company's eight reporting units. There has been no impairment of goodwill in any of the periods presented.

The changes in the carrying amount of goodwill for each of the Company's reportable segments were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  | Global | Global |  |  |
|  | Global | Institutional | Pest | Global |  |
| (millions) | Water | & Specialty | Elimination | Life Sciences | Total |
| December 31, 2023 | $4243.5 | $610.0 | $136.3 | $3158.4 | $8148.2 |
| &nbsp;&nbsp;Segment change (a) | - | 717.0 | - | (717.0) | - |
| December 31, 2023 | 4243.5 | 1327.0 | 136.3 | 2441.4 | 8148.2 |
| &nbsp;&nbsp;Current year business combinations (b) | 116.2 | 6.5 | 33.9 | - | 156.6 |
| &nbsp;&nbsp;Prior year business combinations (c)  | 1.2 | - | - | - | 1.2 |
| &nbsp;&nbsp;Divestiture of businesses (d) | - | (305.9) | - | - | (305.9) |
| &nbsp;&nbsp;Effect of foreign currency translation | (56.0) | (3.3) | (0.8) | (32.7) | (92.8) |
| December 31, 2024 | $4304.9 | $1024.3 | $169.4 | $2408.7 | $7907.3 |
| &nbsp;&nbsp;Current year business combinations (b)  | **1105.4** | **-** | **17.4** | **-** | **1122.8** |
| &nbsp;&nbsp;Prior year business combinations (c) | **5.6** | **-** | **0.1** | **-** | **5.7** |
| &nbsp;&nbsp;Effect of foreign currency translation | **89.6** | **17.2** | **2.7** | **81.7** | **191.2** |
| December 31, 2025 | **$5505.5** | **$1041.5** | **$189.6** | **$2490.4** | **$9227.0** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(a) Relates to reclassifications made to reportable segments in the current year. Effective January 1, 2025, the Company's former Global Industrial reportable segment was renamed Global Water and includes the Light & Heavy (previously named Water), Food & Beverage, and Paper operating segments. The Global Institutional & Specialty reportable segment continues to include the Institutional and Specialty operating segments. The Company's former healthcare operating segment moved into the Institutional operating segment. Global Life Sciences (formerly Global Healthcare & Life Sciences) was elevated to a standalone reportable segment. The Global Pest Elimination segment remains a standalone reportable segment. After these changes, the Company has seven operating segments. Refer to Note 18, "Operating Segments and Geographic Information," for further information.

&nbsp;&nbsp;&nbsp;&nbsp;(b) Represents goodwill associated with current year acquisitions. For 2025, approximately $17 million of goodwill related to businesses acquired is expected to be tax deductible. For 2024, approximately $132 million of goodwill related to businesses acquired is expected to be tax deductible related primarily to the acquisition of Barclay Water Management. Refer to Note 4, "Acquisitions and Dispositions," for additional information.

&nbsp;&nbsp;&nbsp;&nbsp;(c) Represents purchase price allocation adjustments for acquisitions deemed preliminary as of the end of the prior year.

&nbsp;&nbsp;&nbsp;&nbsp;(d) Represents goodwill associated with the sale of the global surgical solutions business (refer to Note 4, "Acquisitions and Dispositions," for additional information).

***Other Intangible Assets***

The Nalco trade name is the Company's only indefinite life intangible asset, which is tested for impairment on an annual basis during the second quarter. During the second quarter of 2025, the Company completed its annual impairment assessment of the Nalco trade name using the relief from royalty discounted cash flow method, which incorporates assumptions regarding future sales projections, royalty rate and discount rates. The Company's Nalco trade name impairment assessment for 2025 indicated the estimated fair value of the Nalco trade name exceeded its $1.2 billion carrying amount by a significant margin. No events were noted during the second half of 2025 that required completion of an interim impairment assessment of the Company's Nalco trade name. There has been no impairment of the Nalco trade name intangible asset since it was acquired.

[**Table of Contents**](#Toc)

The Company's intangible assets subject to amortization include customer relationships, trademarks, patents and other technology primarily acquired through business acquisitions. The fair value of intangible assets acquired in business acquisitions are estimated primarily using discounted cash flow valuation methods at the time of acquisition. Intangible assets are amortized on a straight-line basis over their estimated lives. The weighted-average useful life of amortizable intangible assets was 15 years as of both December 31, 2025 and 2024.

The weighted-average useful life by type of amortizable asset at December 31, 2025 were as follows:

(years)

---

| | |
|:---|:---|
| Customer relationships | 16 |
| Patents | 15 |
| Trademarks | 12 |
| Other technology | 11 |

---

The straight-line method of amortization reflects an appropriate allocation of the cost of the intangible assets to earnings in proportion to the amount of economic benefits obtained by the Company in each reporting period. The Company evaluates the remaining useful life of its intangible assets subject to amortization each reporting period to determine whether events and circumstances warrant a change to the estimated remaining period of amortization. If the estimate of an intangible asset's remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over the updated remaining useful life. Amortization expense related to other intangible assets during the last three years and future estimated amortization were as follows:

---

| | |
|:---|:---|
| (millions) |  |
| 2023 | $307 |
| 2024 | 301 |
| 2025 | 304 |
| 2026 | 338 |
| 2027 | 215 |
| 2028 | 207 |
| 2029 | 199 |
| 2030 | 185 |

---

**Long-Lived Assets**

The Company reviews its long-lived and amortizable intangible assets for impairment when significant events or changes in business circumstances indicate that the carrying amount of the assets, or asset group to which it is assigned, may not be recoverable. Such circumstances may include a significant decrease in the market price of an asset or asset group, a significant adverse change in the manner in which the asset or asset group is being used or history of cash flow losses associated with the use of an asset or asset group. Impairment losses could occur when the carrying amount of an asset or asset group exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset or asset group and its eventual disposition. The amount of the impairment loss to be recorded, if any, is calculated by the excess of the asset's or asset group's carrying value over its fair value.

In addition, the Company periodically reassesses the estimated remaining useful lives of its long-lived assets. Changes to estimated useful lives would impact the amount of depreciation and amortization recorded in earnings. The Company has not experienced significant changes in the carrying amount or estimated remaining useful lives of its long-lived or amortizable intangible assets.

**Rental and Leases**

***Lessee***

The Company determines whether a lease exists at the inception of the arrangement. In assessing whether a contract is or contains a lease, the Company evaluates whether the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company accounts for lease components separately from the nonlease components (e.g., common-area maintenance costs, property taxes, parking, etc.). Operating leases are recorded in operating lease assets, other current liabilities and operating lease liabilities in the Consolidated Balance Sheets.

Operating lease assets and operating lease liabilities are measured and recognized based on the present value of the future minimum lease payments over the estimated lease term at the lease commencement date. The Company uses the rate implicit in the lease when available or determinable. When the rate implicit in the lease is not determinable, the Company uses its incremental borrowing rate based on the information available at the lease commencement date to determine the present value of future payments. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Variable lease payments are not included in the lease liability and are recognized as incurred. The Company identified real estate, vehicles and other equipment as the primary classes of its leases. Certain leases with a similar class of underlying assets are accounted for as a portfolio of leases.

The Company does not record operating lease assets or liabilities for leases with terms of twelve months or less. Those lease payments are recognized in the Consolidated Statements of Income over the lease term as incurred.

[**Table of Contents**](#Toc)

Many of the Company's leases include options to renew or cancel, which are at the Company's sole discretion. Renewal terms can extend the lease term from one month to multiple years, whereas, cancellation terms can shorten the lease term by multiple years. The lease start date is the date when the leased asset is available for use and in possession of the Company. The lease end date, which includes any options to renew or cancel that are reasonably certain to be exercised, is based on the terms of the contract. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. The Company's lease agreements do not contain any material restrictive covenants.

***Lessor***

The Company accounts for lease and nonlease components separately. The nonlease components, such as product and service revenue, are accounted for under Topic 606 Revenue from Contracts with Customers, refer to Note 17, "Revenues," for more information. Revenue from leasing equipment is recognized on a straight-line basis over the life of the lease. Cost of sales includes the depreciation expense for assets under operating leases. The assets are depreciated over their estimated useful lives. Initial lease terms range from one year to five years and most leases include renewal options.

Lease contracts convey the right for the customer to control the equipment for a period of time as defined by the contract. There are no options for the customer to purchase the equipment and therefore the equipment remains the property of the Company at the end of the lease term. Refer to Note 13, "Rentals and Leases," for additional information regarding rental and leases.

**Income Taxes**

Income taxes are recognized during the period in which transactions enter into the determination of financial statement income, with deferred income taxes provided for the tax effect of temporary differences between the carrying amount of assets and liabilities and their tax bases. The Company records a valuation allowance to reduce its deferred tax assets when uncertainty regarding their realizability exists. Relevant factors in determining the realizability of deferred tax assets include historical results, sources of future taxable income, the expected timing of the reversal of temporary differences, tax planning strategies and the expiration dates of the various tax attributes. The Company records liabilities for unrecognized tax benefits in accordance with the U.S. GAAP recognition and measurement criteria guidance. The Company has elected the period cost method and considers the estimated global intangible low taxed income ("GILTI") impact in tax expense. The Company recognizes interest and penalties related to unrecognized tax benefits in the income tax provision.

Refer to Note 12, "Income Taxes," for additional information regarding income taxes.

**Share-Based Compensation**

The Company measures compensation expense for share-based awards at fair value at the date of grant and recognizes compensation expense over the service period for awards expected to vest. The majority of grants to retirement eligible recipients (age 55 with required years of service) are recorded to expense using the non-substantive vesting method and are fully expensed over a six-month period following the date of grant. In addition, the Company includes a forfeiture estimate in the amount of compensation expense being recognized based on an estimate of the number of outstanding awards expected to vest.

All excess tax benefits or deficiencies are recognized as discrete income tax items on the Consolidated Statements of Income. The extent of excess tax benefits is subject to variation in stock price and stock option exercises. Refer to Note 11, "Equity Compensation Plans," for additional information regarding equity compensation plans.

**Restructuring Activities**

The Company's restructuring activities are associated with plans to enhance its efficiency, effectiveness and sharpen its competitiveness. These restructuring plans include net costs associated with significant actions involving employee-related severance charges, contract termination costs and asset write-downs and disposals. Employee termination costs are largely based on policies and severance plans, and include personnel reductions and related costs for severance, benefits and outplacement services. These charges are reflected in the quarter in which the actions are probable and the amounts are estimable, which typically is when management approves the associated actions. Contract termination costs include charges to terminate leases prior to the end of their respective terms and other contract termination costs. Asset write-downs and disposals include leasehold improvement write-downs, other asset write-downs associated with combining operations and disposal of assets. Refer to Note 3, "Special (Gains) and Charges," for additional information regarding restructuring activities.

**Revenue Recognition**

Revenue is measured as the amount of consideration expected to be received in exchange for transferring goods or providing service.

***Product and Sold Equipment***

Revenue from product and sold equipment is recognized when obligations under the terms of a contract with the customer are satisfied, which generally occurs with the transfer of the product or delivery of the equipment.

***Service and Lease Equipment***

Service revenue is recognized over time utilizing an input method and aligns with when the services are provided. Typically, revenue is recognized using costs incurred to date because the effort provided by the field selling and service organization represents services provided, which corresponds with the transfer of control. Revenue for leased equipment is accounted for under Topic 842 Leases and recognized on a straight-line basis over the length of the lease contract.

[**Table of Contents**](#Toc)

***Other Considerations***

Contracts with customers may include multiple performance obligations. For contracts with multiple performance obligations, the consideration is allocated between products and services based on their stand-alone selling prices. Stand-alone selling prices are generally based on the prices charged to customers when the good or service is not bundled with other products or services or using an expected cost plus margin. Judgment is used in determining the amount of service that is embedded within the Company's contracts, which is based on the amount of time spent on the performance obligation activities. The level of effort, including the estimated margin that would be charged, is used to determine the amount of service revenue. Depending on the terms of the contract, the Company may defer the recognition of revenue when a future performance obligation has not yet occurred.

Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue-producing transaction, which are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight are recognized in cost of sales when control over the product has transferred to the customer.

Other estimates used in recognizing revenue include variable consideration related to customer programs and incentive offerings, including pricing arrangements, promotions and other volume-based incentives at the time the sale is recorded. These estimates are non-complex in nature and are based primarily on historical experience and anticipated performance over the contract period. In addition, timely sales data is available, limiting estimation uncertainty. Based on the certainty in estimating these amounts, they are included in the transaction price of the contracts and the associated remaining performance obligations.

The Company recognizes revenue when collection of the consideration expected to be received in exchange for transferring goods or providing services is probable.

The Company's revenue policies do not provide for general rights of return. Estimates used in recognizing revenue include the delay between the time that products are shipped and when they are received by customers, when title transfers and the amount of credit memos issued in subsequent periods. Depending on market conditions, the Company may increase customer incentive offerings, which could reduce gross profit margins over the term of the incentive.

**Earnings Per Common Share**

The difference in the weighted average common shares outstanding for calculating basic and diluted earnings attributable to Ecolab per common share is a result of the dilution associated with the Company's equity compensation plans. As noted in the table below, certain stock options and units outstanding under these equity compensation plans were not included in the computation of diluted earnings attributable to Ecolab per common share because they would not have had a dilutive effect.

The computations of the basic and diluted earnings attributable to Ecolab per share amounts were as follows:

---

| | | | |
|:---|:---|:---|:---|
| (millions, except per share) | **2025** | 2024 | 2023 |
| Net income attributable to Ecolab | **$2075.6** | $2112.4 | $1372.3 |
| Weighted-average common shares outstanding |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | **283.3** | 284.3 | 285.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of dilutive stock options and units | **1.9** | 2.3 | 1.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | **285.2** | 286.6 | 286.5 |
| Earnings attributable to Ecolab per common share |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic EPS | **$7.33** | $7.43 | $4.82 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted EPS | **$7.28** | $7.37 | $4.79 |
| Anti-dilutive securities excluded from the computation of diluted EPS | **1.2** | 0.6 | 4.3 |
| Amounts do not necessarily sum due to rounding. |  |  |  |

---

**Assets Held for Sale**

Assets and liabilities are classified as held for sale and presented separately on the balance sheet when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and transfer of the assets is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. Assets held for sale are measured at the lower of carrying value or fair value less costs to sell. Any loss resulting from the measurement is recognized in the period the held-for-sale criteria are met. Gains are not recognized until the date of the sale. When the disposal group is classified as held for sale, depreciation and amortization for long-lived assets ceases and the Company tests the assets for impairment.

[**Table of Contents**](#Toc)

**Supplier Finance**

In 2024, the Company commenced a voluntary supply chain finance program (the "Program") to provide certain suppliers with the opportunity to sell receivables due from the Company to a participating financial institution at the sole discretion of both the suppliers and the financial institution. These participating suppliers negotiate their outstanding receivable arrangements directly with the financial institution, and the Company's obligation to its suppliers, including amounts due and scheduled payment terms, are not impacted by the Company's suppliers' decisions to sell amounts under these arrangements. All Company payments to participating suppliers are paid to the financial institution on the invoice due date, regardless of whether the individual invoice is sold by the supplier to the financial institution. The range of payment terms the Company negotiates with its suppliers is consistent, irrespective of whether a supplier participates in the Program.

All outstanding payments owed under the Program are recorded within Accounts payable in the Consolidated Balance Sheets. The Company accounts for all payments made under the Program as a reduction to operating cash flows in Accounts payable within the Consolidated Statements of Cash Flows. The rollforward of the Company's outstanding obligations confirmed as valid under its Program are as follows:

---

| | | |
|:---|:---|:---|
|  | **2025** | 2024 |
| (millions) |  |  |
| &nbsp;&nbsp;Confirmed obligations outstanding at beginning of year | **$39.9** | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;Invoices confirmed during the year | **193.7** | 57.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Confirmed invoices paid during the year | **(172.4)** | (17.1) |
| &nbsp;&nbsp;Confirmed obligations outstanding at end of year | **$61.2** | $39.9 |

---

**Other Significant Accounting Policies**

The following table includes a reference to additional significant accounting policies that are described in other notes to the financial statements, including the note number:

---

| | |
|:---|:---|
| Policy | Note |
| &nbsp;&nbsp;Fair value measurements | 7 |
| &nbsp;&nbsp;Derivatives and hedging transactions | 8 |
| &nbsp;&nbsp;Share-based compensation | 11 |
| &nbsp;&nbsp;Research and development expenditures | 14 |
| &nbsp;&nbsp;Legal contingencies | 15 |
| &nbsp;&nbsp;Pension and post-retirement benefit plans | 16 |
| &nbsp;&nbsp;Reportable segments | 18 |

---

[**Table of Contents**](#Toc)

**New Accounting Pronouncements**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Standards That Are Not Yet Adopted:** | **Standards That Are Not Yet Adopted:** | **Standards That Are Not Yet Adopted:** | **Standards That Are Not Yet Adopted:** | **Standards That Are Not Yet Adopted:** |
|  | Date of |  | Required Date of | Effect on the |
| Standard | Issuance | Description | Adoption | Financial Statements |
| ASU 2024-03 and ASU 2025-01 Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses  | November 2024 | The amendments in this ASU are intended to improve expense disclosures, primarily by requiring disclosure of disaggregated information about certain income statement expense line items on an annual and interim basis.  | Effective for annual reporting periods beginning after December 15, 2026 and interim periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. | The updates provides for adoption on a prospective basis, but retrospective application is permitted. The Company is currently evaluating the impact of adoption and additional disclosure requirements.  |
| ASU 2025-06 (Topic 350): Targeted Improvements to the Accounting for Internal-Use Software | September 2025 | The amendments modernize the recognition and disclosure framework for internal-use software costs, removing the previous "development stage" model and introducing a more judgment-based approach. | Effective for annual reporting periods beginning after December 15, 2027 and interim reporting periods within annual reporting periods. Early adoption is permitted. | The update provides for adoption on a prospective basis, with retrospective or modified retrospective adoption permitted. The Company is currently evaluating the impact of adoption. |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Standards That Were Adopted:** | **Standards That Were Adopted:** | **Standards That Were Adopted:** | **Standards That Were Adopted:** | **Standards That Were Adopted:** |
|  | Date of |  | Date of | Effect on the |
| Standard | Issuance | Description | Adoption | Financial Statements |
| ASU 2023-09 Income taxes (Topic 740): Improvements to Income Tax Disclosures | December 2023 | The amendments in this Update require that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. | January 1, 2025 | The Company adopted the standard prospectively. Adoption of this standard impacted the disclosures within the financial statements, but did not have an impact on the Company's financial position or the results of operations.  |

---

No other new accounting pronouncement issued or effective has had or is expected to have a material impact on the Company's consolidated financial statements.

[**Table of Contents**](#Toc)

**3. SPECIAL (GAINS) AND CHARGES**

Special (gains) and charges reported on the Consolidated Statements of Income included the following:

---

| | | | |
|:---|:---|:---|:---|
| (millions) | **2025** | 2024 | 2023 |
| Cost of sales |  |  |  |
| &nbsp;&nbsp;One Ecolab | **$7.7** | $1.9 | $- |
| &nbsp;&nbsp;Other restructuring | **-** | 3.4 | 22.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of sales subtotal | **7.7** | 5.3 | 22.5 |
| Special (gains) and charges |  |  |  |
| &nbsp;&nbsp;One Ecolab | **140.2** | 98.3 | - |
| &nbsp;&nbsp;Other restructuring | **(12.0)** | 21.8 | 63.2 |
| &nbsp;&nbsp;Sale of global surgical solutions business | **3.0** | (340.3) | 10.3 |
| &nbsp;&nbsp;Acquisition and integration activities | **36.1** | 12.6 | 16.1 |
| &nbsp;&nbsp;Other | **(12.4)** | 18.7 | 21.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Special (gains) and charges subtotal | **154.9** | (188.9) | 111.4 |
| Total special (gains) and charges | **$162.6** | ($183.6) | $133.9 |

---

For segment reporting purposes, special (gains) and charges are not allocated to reportable segments, which is consistent with the Company's internal management reporting.

***One Ecolab***

On July 30, 2024, the Company announced the One Ecolab initiative, which will enhance its growth and margin expansion journey. As a program within this initiative, the Company also announced that it commenced a restructuring plan to leverage its digital technologies to realign the functional work done in many countries into global centers of excellence. In February 2026, the Company expanded the One Ecolab initiative and anticipates total restructuring costs of $334 million ($261 million after tax) and special charges of $91 million ($71 million after tax) by the end of 2027. The Company anticipates that the restructuring costs will primarily be cash expenditures for severance costs relating to team realignment.

In 2025 and 2024, the Company recorded restructuring charges of $117.0 million ($90.5 million after tax) and $76.5 million ($59.0 million after tax), respectively, related to severance and professional services. In addition, the Company recorded non-restructuring special charges of $30.9 million ($23.4 million after tax) and $23.7 million ($17.9 million after tax) in 2025 and 2024, respectively, primarily related to professional services. The Company has recorded $198.8 million ($153.5 million after tax) of cumulative restructuring charges and $54.6 million ($41.3 million after tax) of cumulative special charges under the One Ecolab initiative. Net cash payments were $75.8 million during 2025.

The net restructuring liability related to the One Ecolab initiative was $96.1 million and $54.9 million as of December 31, 2025 and 2024, respectively. The remaining liability is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities.

Restructuring activity related to the One Ecolab initiative since inception of the underlying actions includes the following items:

---

| | | | |
|:---|:---|:---|:---|
|  | Employee<br>Costs | <br>Other | <br>Total |
| (millions) |  |  |  |
| 2024 Activity |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Recorded expense and accrual | $46.3 | $30.2 | $76.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash payments |  | (26.9) | (26.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-cash net charges | - | - | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Reclassification | - | 5.3 | 5.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring liability, December 31, 2024 | 46.3 | 8.6 | 54.9 |
| 2025 Activity |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Recorded expense (income) and accrual | **$101.9** | **$15.1** | **$117.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash payments | **(55.7)** | **(20.1)** | **(75.8)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-cash net charges | **-** | **-** | **-** |
| &nbsp;&nbsp;&nbsp;&nbsp;Reclassification | **-** | **-** | **-** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring liability, December 31, 2025 | **$92.5** | **$3.6** | **$96.1** |

---

***Other restructuring***

Restructuring activities are primarily related to the Combined Program which is described below. These activities have been included as a component of cost of sales, and special (gains) and charges on the Consolidated Statements of Income. Restructuring liabilities have been classified as a component of other current and other noncurrent liabilities on the Consolidated Balance Sheets.

[**Table of Contents**](#Toc)

In November 2022, the Company approved a Europe cost savings program and subsequently expanded the program to focus on its Institutional and Healthcare businesses in other regions (the "Combined Program"). The Company completed these restructuring charges at the end of 2024, with total costs $184.1 million ($151.5 million after tax). Subsequent to the completion of the Combined Program, the Company finalized the sale of a facility, resulting in a gain of $12.0 million ($9.2 million after tax) in the second quarter of 2025.

In 2024 and 2023, the Company recorded restructuring charges of $25.2 million ($18.6 million after tax) and $77.7 million ($66.4 million after tax), respectively, primarily related to severance and professional services in the Combined Program.

The Company reclassified $5.3 million ($4.0 million after tax) from the Combined restructuring program to other restructuring activities in the second quarter of 2024.

Restructuring activity related to the Combined Program since inception of the underlying actions includes the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Employee | Asset |  |  |
| (millions) | Costs | Disposals | Other | Total |
| 2022-2024 Activity |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Recorded expense and accrual | $118.0 | $15.3 | $36.8 | $170.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net cash payments | (124.5) | - | (31.5) | (156.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-cash charges | - | (15.3) | - | (15.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Reclassification | 19.3 | - | (5.3) | 14.0  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net restructuring liability, December 31, 2024 | 12.8 | - | - | 12.8 |

---

During 2024, the Company recorded restructuring charges of $10.6 million ($8.0 million after tax) related to an immaterial restructuring plan approved in the second quarter. This plan became part of the One Ecolab initiative in the third quarter.

During 2023, the Company recorded restructuring charges of $8.0 million ($6.0 million after tax) related to subsequently concluded restructuring programs. The charges primarily related to severance and asset write-offs.

The restructuring liability balance for all other restructuring plans excluding the One Ecolab Program was $8.8 million and $19.3 million as of December 31, 2025 and 2024, respectively. The remaining liability is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities. Cash payments during 2025 related to all other restructuring plans excluding the One Ecolab Program was $10.4 million.

***Sale of global surgical solutions business***

On April 27, 2024, the Company reached a definitive agreement to sell its global surgical solutions business, which closed on August 1, 2024. During 2024 the Company recorded a gain on sale of $355.9 million ($257.7 million after tax) as described in Note 4 "Acquisitions and Dispositions." During 2025, the Company recorded charges of $3.0 million ($2.3 million after tax), primarily related to professional fees to support the sale. Excluding the gain on sale, the Company recorded charges of $15.6 million ($12.0 million after tax) in 2024, which are primarily related to professional fees to support the sale. During 2023 the Company recorded charges of $10.3 million ($7.7 million after tax) primarily related to professional fees to support the sale.

***Acquisition and integration related costs***

Acquisition and integration related costs reported in special (gains) and charges on the Consolidated Statements of Income in 2025 include $36.1 million ($31.2 million after tax) related primarily to the Ovivo Electronics and Purolite transactions.

Acquisition and integration related costs reported in special (gains) and charges on the Consolidated Statements of Income in 2024 and 2023 include $12.6 million ($9.6 million after tax) and $16.1 million ($12.0 million after tax), respectively, related primarily to the Purolite transaction.

***Other operating activities***

During 2025, the Company recorded other operating activities to special (gains) and charges on the Consolidated Statements of Income of ($12.4 million) ($10.8 million gain after tax), primarily related to the sale of an equity method investment.

During 2024, the Company recorded other operating activities to special (gains) and charges on the Consolidated Statements of Income of $18.7 million ($13.9 million after tax), relating primarily to a liability relating to a prior divestiture, COVID-19 activities, and certain legal charges. During 2023, the Company recorded other operating activities to special (gains) and charges on the Consolidated Statements of Income of $21.8 million ($16.7 million after tax) relating primarily to certain legal charges.

[**Table of Contents**](#Toc)

**4. ACQUISITIONS AND DISPOSITIONS**

**Acquisitions**

The Company makes business acquisitions that align with its strategic business objectives. The assets and liabilities of acquired businesses are recorded in the Consolidated Balance Sheets based on estimates of the fair value of assets acquired, liabilities assumed and noncontrolling interests acquired as of the acquisition date. Goodwill is recognized in the amount that the purchase consideration paid exceeds the fair value of the net assets acquired. Purchase consideration includes both cash paid and the fair value of noncash consideration exchanged, including stock and/or contingent consideration exchanged, and is reduced by the amount of cash or cash equivalents acquired. Acquisitions during 2025, 2024 and 2023 were not significant to the Company's consolidated financial statements; therefore, pro forma financial information is not presented.

***2025 Activity***

***Ovivo Electronics Acquisition***

On December 16, 2025, the Company acquired Ovivo Electronics for total consideration of $1,596 million in cash, net of cash acquired. Ovivo Electronics is a leading and fast-growing global provider of breakthrough ultrapure water technologies for semiconductor manufacturing.

The Ovivo Electronics acquisition has been accounted for as a business combination with the assets acquired and liabilities assumed recognized at fair value as of the acquisition date. The fair values of intangible assets acquired were estimated using discounted cash flow analyses appropriate for the nature of the asset that incorporated projections of future cash flows and other valuation assumptions. Significant inputs and assumptions used in our customer relationship intangible asset valuations include projected revenues, contributory asset charges, tax savings due to amortization, income tax rates, customer attrition rates and discount rates. Significant inputs and assumptions to our trademarks and technology intangible asset valuations include projected revenues, asset life cycle, royalty rates, tax saving due to amortization, income tax rates, discount rates and estimated useful lives. Fair value measurements of certain tangible assets, definite-lived intangible assets, lease right of use assets and liabilities, net pension liabilities, carry over tax attributes, deferred income taxes, income tax uncertainties, and goodwill are preliminary and subject to changes as the information necessary to complete the valuations are obtained and analyzed. Accordingly, purchase accounting for this transaction is not yet complete pending finalization of these valuations and completion of comprehensive accounting policy consistency review. The amounts recorded reflect the Company's best estimates as of December 31, 2025 and are subject to change.

The Company incurred certain transaction and integration costs associated with the acquisition that were expensed and are reflected in the Consolidated Statements of Income. Further information related to the Company's special (gains) and charges is included in Note 3, "Special (Gains) and Charges."

The following table summarizes the preliminary value of Ovivo Electronics assets acquired and liabilities assumed, net of cash acquired, as of the acquisition date:

---

| | |
|:---|:---|
| (millions) | **December 16, 2025** |
| Net tangible assets (liabilities) acquired  | **($128.0)** |
| Identifiable intangible assets |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer relationships  | **444.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;Technology | **131.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;Trademarks | **42.6** |
| Total Intangible Assets | **618.3** |
| Goodwill | **1105.4** |
| Total consideration transferred to sellers, net of cash acquired | **$1595.7** |

---

Tangible assets acquired primarily consist of contract assets of $117.4 million, accounts receivable of $79.4 million, property, plant and equipment of $26.8 million and inventory of $25.0 million. Liabilities assumed primarily consist of deferred tax liabilities of $118.6 million and current liabilities of $262.0 million. Identified intangible assets primarily consist of customer relationships, trademarks, and acquired technologies and are being amortized over average lives of 20, 8, and 8 years, respectively, with a weighted average life of 17 years.

Goodwill of $1,105.4 million arising from the acquisition consists largely of the synergies and economies of scale expected through adding complementary geographies and innovative products to our Light & Heavy businesses. The goodwill arising from this acquisition is not tax deductible. Ovivo Electronics became part of the Global Water reportable segment.

***Other Acquisitions***

During 2025, the Company completed an immaterial acquisition which became part of the Global Pest Elimination reportable segment. The purchase accounting for this acquisition is preliminary and subject to change as the Company finalizes the valuation of intangible assets, income tax balances and working capital. The goodwill arising from this acquisition is tax deductible.

[**Table of Contents**](#Toc)

***2024 Activity***

In November 2024, the Company acquired Barclay Water Management, a fast-growing provider of water safety and digital monitoring solutions for industrial and institutional customers based primarily in the northeastern U.S for total consideration of $262.2 million in cash. The acquisition became part of the Global Water reportable segment. The purchase accounting for this acquisition was finalized in the fourth quarter of 2025 and no further purchase accounting adjustments will be recorded. The goodwill arising from the acquisition of Barclay Water Management is tax deductible.

During 2024, the Company completed an immaterial acquisition which became part of the Global Institutional & Specialty reportable segment. The Company also completed two immaterial acquisitions both of which became part of the Global Pest Elimination reportable segment. The purchase accounting for these acquisitions was finalized in 2025 and no further purchase accounting adjustments will be recorded. The goodwill arising from these acquisitions is tax deductible.

***2023 Activity***

In November 2023, the Company acquired Flottec, LLC, a U.S.-based provider of flotation products and services for the mineral processing industry. The move will expand Nalco Water's flotation offerings and its work to serve the industry from mine to metal. The acquisition became part of the Global Water reportable segment. The purchase accounting for this acquisition was finalized in the fourth quarter of 2024 and no further purchase accounting adjustments will be recorded. The goodwill arising from the acquisition of Flottec, LLC is tax deductible.

In May 2023, the Company acquired Chemlink Laboratories LLC, a U.S.-based producer of small format cleaning solutions. The Company made two other immaterial acquisitions during the second quarter of 2023. All three acquisitions became part of the Global Institutional & Specialty reportable segment. The purchase accounting for these acquisitions was finalized in the second quarter of 2024 and no further purchase accounting adjustments will be recorded. The goodwill arising from the acquisition of Chemlink Laboratories LLC is tax deductible.

***Acquisitions***

The components of the cash paid for acquisitions (excluding Ovivo Electronics, which is separately disclosed above), for 2025, 2024 and 2023, are shown in the following table:

---

| | | | |
|:---|:---|:---|:---|
| (millions) | **2025** | 2024 | 2023 |
| Net tangible assets (liabilities) acquired  | **$1.2** | $22.7 | $20.8 |
| Identifiable intangible assets |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer relationships | **9.8** | 118.3 | 60.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trademarks | **-** | 5.7 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-compete agreements | **-** | 1.6 | 2.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other technologies | **-** | 17.6 | 25.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total intangible assets | **9.8** | 143.2 | 88.7 |
| Goodwill | **17.4** | 156.7 | 70.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total aggregate purchase price | **28.4** | 322.6 | 179.7 |
| Acquisition-related liabilities and contingent consideration | **(3.5)** | (12.9) | (3.9) |
| Total cash paid for acquisitions, including acquisition-related  |  |  |  |
| &nbsp;&nbsp;liabilities and contingent consideration, net of cash acquired | **$24.9** | $309.7 | $175.8 |

---

During 2025, the Company recorded purchase accounting adjustments associated with its 2024 acquisitions. As a result of these purchase accounting adjustments, the Company made $0.7 million of acquisition-related payments, acquisition-related net liabilities decreased by $0.3 million, net tangible assets acquired decreased by $5.3 million, and goodwill increased by $5.7 million.

During 2024, the Company recorded purchase accounting adjustments associated with its 2023 acquisition of Flottec, LLC and two other immaterial acquisitions. As a result of these purchase accounting adjustments, the Company made $3.2 million of acquisition-related payments, acquisition related net tangible assets decreased by $2.5 million, definite-lived intangible assets increased by $1.0 million and goodwill increased by $1.2 million.

During 2023, the Company recorded purchase accounting adjustments. As a result of these purchase accounting adjustments, the Company made $4.1 million of acquisition-related payments, acquisition related net tangible assets increased by $1.7 million, acquisition related liabilities and contingent consideration decreased by $1.7 million and goodwill increased by $0.7 million.

The weighted average useful lives of all identifiable intangible assets acquired during 2025, 2024, and 2023 were 17, 15, and 12 years, respectively.

[**Table of Contents**](#Toc)

**Dispositions**

On April 27, 2024, the Company entered into an agreement to sell its global surgical solutions business for total consideration of $950 million, subject to certain working capital and other purchase price adjustments. On August 1, 2024, the Company closed the sale and received $926 million in cash, after deducting for defined working capital and other purchase price adjustments. In December 2024, the Company recorded an additional purchase price adjustment, reducing the purchase price by approximately $16.1 million, which was paid in cash in the first quarter of 2025. For the year ended December 31, 2024, the Company recorded an associated pre-tax gain within Special (Gains) and Charges in the Consolidated Statements of Income of $355.9 million ($257.7 million after tax), which includes $49.7 million of transaction costs and other adjustments. During 2025, the Company recorded charges of $3.0 million ($2.3 million after tax), primarily related to professional fees to support the sale.

The global surgical solutions business did not meet the criteria to be classified as a discontinued operation. As a result, the Company continued to report its operating results in the Global Institutional & Specialty reportable segment through closing of the transaction on August 1, 2024.

The global surgical solutions business was included in the Company's continuing operations and classified as current assets and current liabilities held for sale on the Company's consolidated balance sheets through the closing of the transaction on August 1, 2024. As a result of closing the transaction, the Company derecognized $504.6 million of net assets, the principal components of which were as follows:

---

| | |
|:---|:---|
|  | **August 1** |
| (millions) | **2024** |
| Assets held for sale |  |
| &nbsp;&nbsp;Cash and cash equivalents | **$36.6** |
| &nbsp;&nbsp;Accounts receivable, net | **55.0** |
| &nbsp;&nbsp;Inventories | **89.0** |
| &nbsp;&nbsp;Other current assets | **7.6** |
| &nbsp;&nbsp;Property, plant and equipment, net | **65.1** |
| &nbsp;&nbsp;Goodwill | **305.9** |
| &nbsp;&nbsp;Other intangible assets, net | **22.4** |
| &nbsp;&nbsp;Operating lease assets | **8.2** |
| &nbsp;&nbsp;Other assets | **43.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets held for sale | **$632.8** |
| Liabilities held for sale |  |
| &nbsp;&nbsp;Accounts payable | **$38.6** |
| &nbsp;&nbsp;Compensation and benefits | **5.9** |
| &nbsp;&nbsp;Other current liabilities | **40.6** |
| &nbsp;&nbsp;Postretirement health care and pension benefits | **6.7** |
| &nbsp;&nbsp;Operating lease liabilities  | **5.6** |
| &nbsp;&nbsp;Other liabilities | **30.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities held for sale | **$128.2** |

---

[**Table of Contents**](#Toc)

**5. BALANCE SHEET INFORMATION**

---

| | | |
|:---|:---|:---|
|  | **December 31** | December 31 |
| (millions) | **2025** | 2024 |
| Accounts receivable, net |  |  |
| &nbsp;&nbsp;Accounts receivable | **$3366.2** | $2987.5 |
| &nbsp;&nbsp;Allowance for expected credit losses and other accruals | **(116.8)** | (122.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | **$3249.4** | $2865.0 |
| Inventories |  |  |
| &nbsp;&nbsp;Finished goods | **$962.1** | $962.2 |
| &nbsp;&nbsp;Raw materials and parts | **620.3** | 607.4 |
| &nbsp;&nbsp;Inventories at FIFO cost | **1582.4** | 1569.6 |
| &nbsp;&nbsp;FIFO cost to LIFO cost difference | **(92.0)** | (104.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | **$1490.4** | $1464.9 |
| Other current assets |  |  |
| &nbsp;&nbsp;Prepaid assets | **$159.5** | $151.4 |
| &nbsp;&nbsp;Taxes receivable | **229.8** | 163.3 |
| &nbsp;&nbsp;Derivative assets | **2.6** | 13.4 |
| &nbsp;&nbsp;Contract assets | **117.4** | - |
| &nbsp;&nbsp;Other | **60.3** | 110.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | **$569.6** | $439.0 |
| Property, plant and equipment, net |  |  |
| &nbsp;&nbsp;Land | **$149.2** | $144.5 |
| &nbsp;&nbsp;Buildings and leasehold improvements | **1242.6** | 1152.8 |
| &nbsp;&nbsp;Machinery and equipment | **2496.4** | 2248.5 |
| &nbsp;&nbsp;Dispensing and monitoring equipment | **3193.1** | 2925.3 |
| &nbsp;&nbsp;Capitalized software | **1176.8** | 1037.8 |
| &nbsp;&nbsp;Construction in progress | **858.1** | 679.3 |
|  | **9116.2** | 8188.2 |
| &nbsp;&nbsp;Accumulated depreciation | **(4839.6)** | (4435.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | **$4276.6** | $3752.4 |
| Other intangible assets, net |  |  |
| &nbsp;&nbsp;Intangible assets not subject to amortization |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Trade names | **$1230.0** | $1230.0 |
| &nbsp;&nbsp;Intangible assets subject to amortization |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer relationships | **3827.3** | 3279.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Patents | **516.1** | 504.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trademarks | **420.6** | 371.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other technologies | **680.2** | 541.8 |
|  | **5444.2** | 4698.1 |
| &nbsp;&nbsp;Accumulated amortization |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer relationships | **(2077.3)** | (1814.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Patents | **(367.4)** | (340.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Trademarks | **(272.0)** | (236.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other technologies | **(269.0)** | (228.3) |
|  | **(2985.7)** | (2619.3) |
| &nbsp;&nbsp;Net intangible assets subject to amortization | **2458.5** | 2078.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | **$3688.5** | $3308.8 |
| Other assets |  |  |
| &nbsp;&nbsp;Deferred income taxes | **$181.0** | $155.5 |
| &nbsp;&nbsp;Pension | **184.3** | 151.0 |
| &nbsp;&nbsp;Derivative asset | **2.9** | 45.1 |
| &nbsp;&nbsp;Other | **414.5** | 318.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | **$782.7** | $670.4 |

---

[**Table of Contents**](#Toc)

---

| | | |
|:---|:---|:---|
|  | **December 31** | December 31 |
| (millions) | **2025** | 2024 |
| Other current liabilities |  |  |
| &nbsp;&nbsp;Discounts and rebates | **$528.4** | $452.2 |
| &nbsp;&nbsp;Dividends payable | **205.9** | 184.2 |
| &nbsp;&nbsp;Interest payable | **64.8** | 62.6 |
| &nbsp;&nbsp;Taxes payable, other than income | **179.5** | 171.8 |
| &nbsp;&nbsp;Derivative liability | **5.4** | 3.0 |
| &nbsp;&nbsp;Restructuring | **102.5** | 71.6 |
| &nbsp;&nbsp;Contract liability | **173.0** | 102.0 |
| &nbsp;&nbsp;Operating lease liabilities | **164.7** | 142.3 |
| &nbsp;&nbsp;Other | **313.3** | 323.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | **$1737.5** | $1512.7 |
| Accumulated other comprehensive income (loss) |  |  |
| &nbsp;&nbsp;Unrealized (loss) gain on derivative financial instruments, net of tax | **($4.0)** | $4.6 |
| &nbsp;&nbsp;Unrecognized pension and postretirement benefit expense, net of tax | **(495.5)** | (538.4) |
| &nbsp;&nbsp;Cumulative translation, net of tax | **(1374.8)** | (1448.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | **($1874.3)** | ($1982.0) |

---

**6. DEBT AND INTEREST**

**Short-term Debt**

The following table provides the components of the Company's short-term debt obligations, along with applicable interest rates as of December 31, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **2025** | **2025** | 2024 | 2024 |
|  |  | Average |  | Average |
|  | Carrying | Interest | Carrying | Interest |
| (millions) | Value | Rate | Value | Rate |
| Short-term debt |  |  |  |  |
| &nbsp;&nbsp;Commercial paper | **$100.0** | **3.90%** | $- | -% |
| &nbsp;&nbsp;Notes payable | **11.0** | **3.94%** | 3.6 | 7.28% |
| &nbsp;&nbsp;Long-term debt, current maturities | **759.4** |  | 612.1 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | **$870.4** |  | $615.7 |  |

---

***Line of Credit***

As of December 31, 2024, the Company had in place a $2.0 billion multi-currency revolving credit facility which was due to expire in April 2026. In March 2025, the Company entered into an amended and restated credit facility which extended the maturity from April 2026 to March 2030. The credit facility has been established with a diverse syndicate of banks and supports the Company's U.S. and Euro commercial paper programs. There were no borrowings under the Company's credit facility as of December 31, 2025 and 2024.

The Company has $428 million of available bank supported letters of credit, surety bonds and guarantees available in support of its commercial business transactions of which $217 million is outstanding as of December 31, 2025.

***Commercial Paper***

The Company's commercial paper program is used as a potential source of liquidity and consists of a $2.0 billion U.S. commercial paper program and a $2.0 billion Euro commercial paper program. The maximum aggregate amount of commercial paper that may be issued by the Company under its commercial paper programs may not exceed $2.0 billion.

The Company had $100 million and zero outstanding commercial paper under its U.S. and Euro commercial paper programs, respectively as of December 31, 2025, and no outstanding commercial paper as of December 31, 2024.

***Notes Payable***

The Company's notes payable consists of uncommitted credit lines with major international banks and financial institutions, primarily to support global cash pooling structures. As of December 31, 2025 and 2024, the Company had $11.0 million and $3.6 million, respectively, outstanding under these credit lines. Approximately $2,191 million and $2,153 million of these credit lines were available for use as of December 31, 2025 and 2024, respectively.

[**Table of Contents**](#Toc)

**Long-term Debt**

The following table provides the components of the Company's long-term debt obligations, along with applicable interest rates as of December 31, 2025 and 2024:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | **2025** | **2025** | **2025** |  | 2024 |  |
|  |  |  | Stated | Effective |  | Stated | Effective |
|  | Maturity | Carrying | Interest | Interest | Carrying | Interest | Interest |
| (millions) | by Year | Value | Rate | Rate | Value | Rate | Rate |
| Long-term debt |  |  |  |  |  |  |  |
| Public notes (2025 principal amount) |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Ten year 2015 senior notes (€575 million) | 2025  | **-** | **-%**  | **-%** | 607.8 | 2.63% | 2.88% |
| &nbsp;&nbsp;Ten year 2016 senior notes ($750 million) | 2026  | **744.4** | **2.70** | **3.50** | 735.2 | 2.70 | 3.96 |
| &nbsp;&nbsp;Ten year 2017 senior notes ($500 million) | 2027  | **477.7** | **3.25** | **7.16** | 456.5 | 3.25 | 8.54 |
| &nbsp;&nbsp;Six year 2021 senior notes ($500 million) | 2027  | **499.1** | **1.65** | **1.82** | 498.2 | 1.65 | 1.73 |
| &nbsp;&nbsp;Five year 2022 senior notes ($500 million) | 2028  | **497.1** | **5.25** | **4.42** | 495.6 | 5.25 | 5.08 |
| &nbsp;&nbsp;Three year 2025 senior notes ($500 million) | 2028  | **496.7** | **4.30** | **4.48** | - | - | - |
| &nbsp;&nbsp;Ten year 2020 senior notes ($698 million) | 2030  | **677.5** | **4.80** | **5.95** | 657.2 | 4.80 | 6.52 |
| &nbsp;&nbsp;Ten year 2020 senior notes ($600 million) | 2031  | **572.3** | **1.30** | **1.92** | 559.3 | 1.30 | 3.17 |
| &nbsp;&nbsp;Eleven year 2021 senior notes ($650 million) | 2032  | **646.4** | **2.13** | **1.59** | 645.8 | 2.13 | 1.59 |
| &nbsp;&nbsp;Ten year 2025 senior notes ($500 million) | 2035  | **495.1** | **5.00** | **5.08** | - | - | - |
| &nbsp;&nbsp;Thirty year 2011 senior notes ($389 million) | 2041  | **385.2** | **5.50** | **5.61** | 385.0 | 5.50 | 5.62 |
| &nbsp;&nbsp;Thirty year 2016 senior notes ($200 million) | 2046  | **197.6** | **3.70** | **3.80** | 197.5 | 3.70 | 3.80 |
| &nbsp;&nbsp;Thirty year 2017 senior notes ($484 million) | 2047  | **429.6** | **3.95** | **4.78** | 428.2 | 3.95 | 4.79 |
| &nbsp;&nbsp;Thirty year 2020 senior notes ($500 million) | 2050  | **491.7** | **2.13** | **2.23** | 491.4 | 2.13 | 2.23 |
| &nbsp;&nbsp;Thirty year 2021 senior notes ($850 million) | 2051  | **840.1** | **2.70** | **2.78** | 839.7 | 2.70 | 2.78 |
| &nbsp;&nbsp;Thirty four year 2021 senior notes ($685 million) | 2055  | **543.4** | **2.75** | **3.86** | 541.2 | 2.75 | 3.86 |
| Finance lease obligations and other |  | **131.4** |  |  | 22.7 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total debt |  | **8125.3** |  |  | 7561.3 |  |  |
| Long-term debt, current maturities |  | **(759.4)** |  |  | (612.1) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total long-term debt |  | **$7365.9** |  |  | $6949.2 |  |  |

---

***Public Notes and Other***

In June 2025, the Company issued $500 million aggregate principal three-year fixed rate notes with a coupon rate of 4.30%. In August 2025, the Company issued $500 million aggregate principal ten-year fixed rate notes with a coupon rate of 5.00%. The proceeds were used for general corporate purposes, which included partial funding of the Ovivo Electronics acquisition.

In July 2025, the Company repaid in full €575 million ($674 million) on its ten-year 2015 senior notes. In January 2024, the Company repaid €575 million ($630 million) of long-term debt.

The Company's public notes may be redeemed by the Company at its option at redemption prices that include accrued and unpaid interest and a make-whole premium. Upon the occurrence of a change of control accompanied by a downgrade of the public notes below investment grade rating, within a specified time period, the Company would be required to offer to repurchase the public notes at a price equal to 101% of the aggregate principal amount thereof, plus any accrued and unpaid interest to the date of repurchase. The public notes are senior unsecured and unsubordinated obligations of the Company and rank equally with all other senior and unsubordinated indebtedness of the Company.

In June 2025, one of the Company's Chinese subsidiaries entered into a construction loan facility that provides up to 1.1 billion in Chinese Yuan ("CNY") ($155 million) of proceeds to fund capital expenditures. This loan facility has a tenor of 13 years and is secured by certain assets of its Chinese subsidiaries. Any borrowings under this facility are included in Finance lease obligations and other in the table above.

**Covenants and Future Maturities**

The Company is in compliance with all covenants under the Company's outstanding indebtedness at December 31, 2025.

As of December 31, 2025, the aggregate annual maturities of long-term debt for the next five years were:

---

| | |
|:---|:---|
| (millions) |  |
| 2026 | $759 |
| 2027 | 1005 |
| 2028 | 1012 |
| 2029 | 12 |
| 2030 | 687 |

---

[**Table of Contents**](#Toc)

**Net Interest Expense**

Interest expense and interest income incurred during 2025, 2024 and 2023 were as follows:

---

| | | | |
|:---|:---|:---|:---|
| (millions) | **2025** | 2024 | 2023 |
| Interest expense | **$306.2** | $340.3 | $348.9 |
| Interest income | **(65.1)** | (57.8) | (52.2) |
| &nbsp;&nbsp;Interest expense, net | **$241.1** | $282.5 | $296.7 |

---

Interest expense generally includes the expense associated with the interest on the Company's outstanding borrowings, including the impact of the Company's interest rate swap agreements. Interest expense also includes the amortization of debt issuance costs and debt discounts, which are both recognized over the term of the related debt.

**7. FAIR VALUE MEASUREMENTS**

The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable, contingent consideration obligations, commercial paper, notes payable, foreign currency forward contracts, interest rate swap agreements, cross-currency swap derivative contracts and long-term debt.

Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring the most observable inputs be used when available. The hierarchy is broken down into three levels:

*Level 1* - Inputs are quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities.

*Level 2* - Inputs include observable inputs other than quoted prices in active markets.

*Level 3* - Inputs are unobservable inputs for which there is little or no market data available.

The carrying amount and the estimated fair value for assets and liabilities measured on a recurring basis were:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| (millions) | Carrying | Fair Value Measurements | Fair Value Measurements | Fair Value Measurements |
|  | Amount | Level 1 | Level 2 | Level 3 |
| Assets |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency forward contracts | **$17.4** | **$-** | **$17.4** | **$-** |
| &nbsp;&nbsp;&nbsp;&nbsp;Cross-currency swap derivative contracts | **11.4** | **-** | **11.4** | **-** |
| Liabilities |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency forward contracts | **20.3** | **-** | **20.3** | **-** |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate swap agreements | **74.4** | **-** | **74.4** | **-** |
| &nbsp;&nbsp;&nbsp;&nbsp;Cross-currency swap derivative contracts | **190.6** | **-** | **190.6** | **-** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | December 31, 2024 | December 31, 2024 | December 31, 2024 | December 31, 2024 |
| (millions) | Carrying | Fair Value Measurements | Fair Value Measurements | Fair Value Measurements |
|  | Amount | Level 1 | Level 2 | Level 3 |
| Assets |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency forward contracts | $38.4 | $- | $38.4 | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;Cross-currency swap derivative contracts | 119.0 | - | 119.0 | - |
| Liabilities |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency forward contracts | 28.0 | - | 28.0 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate swap agreements | 138.5 | - | 138.5 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Cross-currency swap derivative contracts | 56.4 | - | 56.4 | - |

---

The carrying value of foreign currency forward contracts is at fair value, which is determined based on foreign currency exchange rates as of the balance sheet date and classified within Level 2. The carrying value of interest rate swap agreements is at fair value, which is determined based on current forward interest rates as of the balance sheet date and are classified within Level 2. The cross-currency swap derivative contracts are used to partially hedge the Company's net investments in foreign operations against adverse movements in exchange rates between the U.S. dollar and the Euro and the U.S. dollar and CNH (CNH is the Chinese Yuan traded in the offshore market). The carrying value of the cross-currency swap derivative contracts is at fair value, which is determined based on the income approach with the relevant interest rates and foreign currency current exchange rates and forward curves as inputs as of the balance sheet date and are classified within Level 2. For purposes of fair value disclosure above, derivative values are presented gross. Further discussion of gross versus net presentation of the Company's derivatives within Note 8, "Derivatives and Hedging Transactions."

[**Table of Contents**](#Toc)

Contingent consideration obligations are recognized and measured at fair value at the acquisition date and thereafter until settlement or expiration. Contingent consideration is classified within Level 3 as the underlying fair value is determined using income-based valuation approaches appropriate for the terms and conditions of each respective contingent consideration. The consideration expected to be transferred is based on the Company's expectations of various financial measures. The ultimate payment of contingent consideration could deviate from current estimates based on the actual results of these financial measures. Contingent consideration during 2025, 2024 and 2023 were not significant to the Company's consolidated financial statements.

The carrying values of accounts receivable, accounts payable, cash and cash equivalents, commercial paper and notes payable approximate fair value because of their short maturities, and as such are classified within Level 1.

The fair value of long-term debt is based on quoted market prices for the same or similar debt instruments (classified as Level 2). The carrying amount, which includes adjustments related to the impact of interest rate swap agreements, premiums and discounts, and deferred debt issuance costs, and the estimated fair value of long-term debt, including current maturities, held by the Company were:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **December 31, 2025** | **December 31, 2025** | December 31, 2024 | December 31, 2024 |
|  | Carrying<br>Amount | Fair<br>Value | Carrying <br>Amount | Fair<br>Value |
| Long-term debt, including current maturities | **$8125.3** | **$7381.8** | $7561.3 | $6662.1 |

---

**8. DERIVATIVES AND HEDGING TRANSACTIONS**

The Company uses foreign currency forward contracts, foreign currency option contracts, interest rate swap agreements, cross-currency swap derivative contracts and foreign currency debt to manage risks associated with foreign currency exchange rates, interest rates and net investments in foreign operations. The Company does not hold derivative financial instruments of a speculative nature or for trading purposes. The Company records derivatives as assets and liabilities in the Consolidated Balance Sheets at fair value. Changes in fair value are recognized immediately in earnings unless the derivative qualifies and is designated as a hedge. Cash flows from derivatives are classified in the Consolidated Statements of Cash Flows in the same category as the cash flows from the items subject to designated hedge or undesignated (economic) hedge relationships. The Company evaluates hedge effectiveness at inception and on an ongoing basis. If a derivative is no longer expected to be effective, hedge accounting is discontinued.

The Company is exposed to credit risk in the event of nonperformance of counterparties for foreign currency forward exchange contracts and interest rate swap agreements. The Company monitors its exposure to credit risk by using credit approvals and credit limits and by selecting major global banks and financial institutions as counterparties. The Company does not anticipate nonperformance by any of these counterparties, and therefore, recording a valuation allowance against the Company's derivative balance is not considered necessary.

**Derivative Positions Summary**

Certain of the Company's derivative transactions are subject to master netting arrangements that allow the Company to net settle contracts with the same counterparties. These arrangements generally do not call for collateral and as of the applicable dates presented in the following table, no cash collateral had been received or pledged related to the underlying derivatives.

The respective net amounts are included in other current assets, other assets, other current liabilities and other liabilities on the Consolidated Balance Sheets.

The following table summarizes the gross fair value and the net value of the Company's outstanding derivatives:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Derivative Assets | Derivative Assets | Derivative Liabilities | Derivative Liabilities |
|  | **December 31** | December 31 | **December 31** | December 31 |
| (millions) | **2025** | 2024 | **2025** | 2024 |
| Derivatives designated as hedging instruments |  |  |  |  |
| &nbsp;&nbsp;Foreign currency forward contracts | **$2.9** | $11.4 | **$6.5** | $3.2 |
| &nbsp;&nbsp;Interest rate swap agreements | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**-** | - | **74.4** | 138.5 |
| &nbsp;&nbsp;Cross-currency swap derivative contracts | **5.8** | 82.1 | **185.0** | 19.5 |
| Derivatives not designated as hedging instruments |  |  |  |  |
| &nbsp;&nbsp;Foreign currency forward contracts | **14.5** | 27.0 | **13.8** | 24.8 |
| &nbsp;&nbsp;Cross-currency swap derivative contracts | **5.6** | 36.9 | **5.6** | 36.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross value of derivatives | **28.8** | 157.4 | **285.3** | 222.9 |
| Gross amounts offset in the Consolidated Balance Sheets | **(23.3)** | (98.9) | **(23.3)** | (98.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net value of derivatives | **$5.5** | $58.5 | **$262.0** | $124.0 |

---

[**Table of Contents**](#Toc)

The following table summarizes the notional values of the Company's outstanding derivatives:

---

| | | |
|:---|:---|:---|
|  | Notional Values | Notional Values |
|  | **December 31** | December 31 |
| (millions) | **2025** | 2024 |
| Foreign currency forward contracts | **$2525** | $3175 |
| Interest rate swap agreements | **1500** | 1500 |
| Cross-currency swap derivative contracts | **4151** | 2745 |

---

**Cash Flow Hedges**

The Company utilizes foreign currency forward contracts to hedge the effect of foreign currency exchange rate fluctuations on forecasted foreign currency transactions, including inventory purchases and intercompany royalty, intercompany loans, management fee and other payments. These forward contracts are designated as cash flow hedges. The changes in fair value of these contracts are recorded in accumulated other comprehensive income (loss) ("AOCI") until the hedged items affect earnings, at which time the gain or loss is reclassified into the same line item in the Consolidated Statements of Income as the underlying exposure being hedged. Cash flow hedged transactions impacting AOCI are forecasted to occur within the next year. For forward contracts designated as hedges of foreign currency exchange rate risk associated with forecasted foreign currency transactions, the Company excludes the changes in fair value attributable to time value from the assessment of hedge effectiveness. The initial value of the excluded component (i.e., the forward points) is amortized on a straight-line basis over the life of the hedging instrument and recognized in the same line item in the Consolidated Statements of Income as the underlying exposure being hedged for intercompany loans. For all other cash flow hedge types, the forward points are mark-to-market monthly and recognized in the same line item in the Consolidated Statements of Income as the underlying exposure being hedged. The difference between fair value changes of the excluded component and the amount amortized in the Consolidated Statements of Income is recorded in AOCI.

**Fair Value Hedges**

The Company manages interest expense using a mix of fixed and floating rate debt. To help manage exposure to interest rate movements and to reduce borrowing costs, the Company may enter into interest rate swaps under which the Company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed upon notional principal amount. The mark-to-market of these fair value hedges is recorded as gains or losses in interest expense, net and is offset by the gain or loss of the underlying debt instrument, which also is recorded in interest expense, net. These fair value hedges are highly effective and thus, there is no impact on earnings due to hedge ineffectiveness.

In aggregate, the Company has entered into a series of interest rate swap agreements to convert $1.5 billion of its debt from a fixed interest rate to a floating interest rate. The fixed interest rates range from 1.3% to 4.8% and mature between 2026 and 2031. These interest rate swap agreements are designated as fair value hedges.

The following amounts were recorded in the Consolidated Balance Sheets related to cumulative basis adjustments for fair value hedges as of December 31, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Line item in which the hedged item is included | Carrying amount of the hedged liabilities | Carrying amount of the hedged liabilities | Cumulative amount of the fair value hedging adjustment included in the carrying amount of the hedged liabilities | Cumulative amount of the fair value hedging adjustment included in the carrying amount of the hedged liabilities |
| (millions) | **2025** | 2024 | **2025** | 2024 |
| Long-term debt | **$1424.4** | $1361.1 | **($78.0)** | ($141.3) |

---

**Net Investment Hedges**

*Euronotes*

In November 2023, the Company elected to de-designate as a net investment hedge €316 million of its Euro debt maturing on January 15, 2024. In January 2024, the Company repaid €575 million ($630 million) of long-term debt and settled the remaining €259 million net investment hedge related to that Euro debt. The Company designated its remaining outstanding €575 million ($608 million as of year-end 2024) senior notes ("Euronotes") and related accrued interest as a hedge of its Euro denominated exposures from the Company's investments in certain of its Euro denominated functional currency subsidiaries as of December 31, 2024. In April 2025 and June 2025, the Company elected to de-designate as a net investment hedge €300 million and €236 million, respectively, of its Euronote maturing July 2025. In July 2025 upon repayment of the €575 million ($674 million) on the Euronotes, the Company settled the remaining €39 million net investment hedge related to the Euronotes.

[**Table of Contents**](#Toc)

*Cross-currency swap derivative contracts*

The Company maintains Euro ("€"), Chinese Yuan ("CNH"), and Canadian dollar ("CAD") cross-currency swap derivative contracts that are designated as net investment hedges of the Company's related foreign currency denominated exposures from the Company's investments in certain subsidiaries denominated in such functional currencies. During 2024, the Company entered into Euro cross-currency swap derivative contracts with an aggregate notional amount of €950 million, replaced a notional €300 of existing cross-currency swap derivative contracts effectively swapping the notional value, and entered into Chinese Yuan cross-currency swap derivative contracts with an aggregate notional amount of CNH 1,427 million.

During 2025, the Company entered into Euro cross-currency swap derivative contracts with an aggregate notional amount of €700 million, Chinese Yuan cross-currency swap derivative contracts with an aggregate notional amount of CNH 1,080 million, and Canadian dollar cross-currency swap contracts with an aggregate notional value of CAD 280 million. As of December 31, 2025, the Company had €2,275 million ($2,672 million), CNH 3,986 million ($570 million), and CAD 280 million ($204 million) cross-currency swap derivative contracts outstanding as a hedge of the Company's net investment in foreign operations.

The cross-currency swap derivative contracts exchange fixed-rate payments in one currency for fixed-rate payments in another currency. The changes in the spot rate of these instruments are recorded in AOCI in stockholders' equity, partially offsetting the foreign currency translation adjustment of the Company's related net investment that is also recorded in AOCI. Amounts excluded from the assessment of effectiveness are recognized in interest expense on a straight-line basis over the term of the hedge. The interest income or expense from these swaps are recorded in interest expense on the accompanying Consolidated Statements of Income consistent with the classification of interest expense attributable to the underlying debt.

The revaluation gains and losses on the Euronotes and cross-currency swap derivative contracts, which are designated and effective as hedges of the Company's net investments, have been included as a component of the cumulative translation adjustment account, and were as follows:

---

| | | | |
|:---|:---|:---|:---|
| (millions) | **2025** | 2024 | 2023 |
| Revaluation gain (loss), net of tax: |  |  |  |
| &nbsp;&nbsp;Euronotes | **($33.5)** | $12.8 | ($42.3) |
| &nbsp;&nbsp;Cross-currency swap derivative contracts | **(182.6)** | 39.6 | (30.8) |
| Total revaluation gain (loss), net of tax | **($216.1)** | $52.4 | ($73.1) |

---

**Derivatives Not Designated as Hedging Instruments**

The Company also uses foreign currency forward contracts to offset its exposure to the change in value of certain foreign currency denominated assets and liabilities held at foreign subsidiaries, primarily receivables and payables, which are remeasured at the end of each period. Although the contracts are effective economic hedges, they are not designated as accounting hedges. Therefore, changes in the value of these derivatives are recognized immediately in earnings, thereby offsetting the current earnings effect of the related foreign currency denominated assets and liabilities.

**Effect of all Derivative Instruments on Income**

The gain (loss) of all derivative instruments recognized in product and equipment cost of sales ("COS"), selling, general and administrative expenses ("SG&A"), and interest expense, net ("Interest") are summarized below.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **2025** | **2025** | **2025** | 2024 | 2024 | 2024 | 2023 | 2023 | 2023 |
| (millions) | **COS** | **SG&A** | **Interest** | COS | SG&A | Interest | COS | SG&A | Interest |
| Gain (loss) on derivatives designated as hedging instruments: |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign currency forward contracts |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount of gain (loss) reclassified from AOCI to income | **$4.4** | **$0.5** | **$-** | $4.0 | $5.8 | $- | $10.6 | ($18.9) | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount excluded from the assessment of effectiveness recognized in earnings based on changes in fair value | **-** | **-** | **-** | - | - | - | - | - | 7.7 |
| &nbsp;&nbsp;Interest rate swap agreements |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount of (loss) gain reclassified from AOCI to income | **-** | **-** | **(1.5)** | - | - | (1.9) | - | - | (1.9) |
| Gain (loss) on derivatives not designated as hedging instruments: |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign currency forward contracts |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount of gain (loss) recognized in income | **-** | **(2.6)** | **-** | - | (3.4) | - | - | (26.2) | - |
| Total gain (loss) of all derivative instruments | **$4.4** | **($2.1)** | **($1.5)** | $4.0 | $2.4 | ($1.9) | $10.6 | ($45.1) | $5.8 |

---

[**Table of Contents**](#Toc)

**Subsequent Events**

In February 2026, the Company entered into cross-currency swap derivative contracts with aggregate notional amounts of 100 million Swiss Franc ("CHF"). These cross-currency swap derivative contracts are designated as net investment hedges of the Company's CHF denominated exposures from its investments in certain of its CHF denominated functional currency subsidiaries.

**9. OTHER COMPREHENSIVE INCOME (LOSS) INFORMATION**

Other comprehensive income (loss) includes net income, foreign currency translation adjustments, defined benefit pension and postretirement plan adjustments, gains and losses on derivative instruments designated and effective as cash flow hedges and non-derivative instruments designated and effective as foreign currency net investment hedges that are charged or credited to the AOCI account in shareholders' equity.

The following table provides other comprehensive income (loss) information related to the Company's derivatives and hedging instruments and pension and postretirement benefits. Refer to Note 8, "Derivatives and Hedging Transactions," for additional information related to the Company's derivatives and hedging transactions. Refer to Note 16, "Retirement Plans," for additional information related to the Company's pension and postretirement benefits activity.

---

| | | | |
|:---|:---|:---|:---|
| (millions) | **2025** | 2024 | 2023 |
| Derivative and Hedging Instruments |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain (loss) on derivative and hedging instruments  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amount recognized in AOCI  | **($7.0)** | $19.2 | ($12.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss reclassified from AOCI into income |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COS | **(4.4)** | (4.0) | (10.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SG&A | **(0.5)** | (5.8) | 18.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest (income) expense, net | **1.5** | 1.9 | (5.8) |
|  | **(3.4)** | (7.9) | 2.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other activity | **0.2** | - | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax impact | **1.6** | (2.6) | 2.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net of tax | **($8.6)** | $8.7 | ($7.8) |
| Pension and Postretirement Benefits |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount recognized in AOCI |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current period net (loss) gain | **$61.4** | ($19.0) | ($80.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amount reclassified from AOCI into income |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Settlement charge (income)  | **0.5** | 0.9 | (2.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of losses and prior period service credits, net | **9.1** | 10.6 | 6.9 |
|  | **9.6** | 11.5 | 4.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax impact | **(15.4)** | 1.9 | 21.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net of tax | **$55.6** | ($5.6) | ($55.1) |

---

**10. SHAREHOLDERS' EQUITY**

Authorized common stock, par value $1.00 per share, was 800 million shares at December 31, 2025, 2024 and 2023. Treasury stock is stated at cost. Dividends declared per share of common stock were $2.68 for 2025, $2.36 for 2024 and $2.16 for 2023.

The Company has 15 million shares, without par value, of authorized but unissued and undesignated preferred stock.

**Share Repurchase Authorization**

In November 2022, the Company's Board of Directors authorized the repurchase of up to 10,000,000 shares of its common stock, including shares to be repurchased under Rule 10b5-1. As of December 31, 2025, 5,896,821 shares remained to be repurchased under the Company's repurchase authorization. The Company intends to repurchase all shares under its authorization, for which no expiration date has been established, in open market or privately negotiated transactions, subject to market conditions.

**Share Repurchases**

During 2025, 2024 and 2023, the Company reacquired 2,994,702, 4,246,642 and 83,674 shares, respectively, of its common stock, of which 2,884,764, 4,135,512 and 0, respectively, related to share repurchases through open market or private purchases, and 109,938, 111,130 and 83,674, respectively, related to shares withheld for taxes on exercise of stock options and vesting of stock awards and units.

[**Table of Contents**](#Toc)

**11. EQUITY COMPENSATION PLANS**

The Company's equity compensation plans provide for grants of stock options, performance-based restricted stock units ("PBRSUs") and non-performance-based restricted stock units ("RSUs") and restricted stock awards ("RSAs"). Common shares available for grant as of December 31, 2025, 2024 and 2023 were 17,081,775, 18,052,830 and 18,840,265, respectively. The Company generally issues authorized but previously unissued shares to satisfy stock option exercises and stock award vesting.

The Company's annual long-term incentive share-based compensation program is made up of 40% stock options and 60% PBRSUs for 2025, 2024 and 2023. The Company also periodically grants RSUs. Total compensation expense related to all share-based compensation plans was $136.6 million, $134.8 million and $95.1 million for 2025, 2024 and 2023, respectively. As of December 31, 2025, there was $196.3 million of total measured but unrecognized compensation expense related to non-vested share-based compensation arrangements granted under all of the Company's plans. That cost is expected to be recognized over a weighted-average period of 2.0 years.

**Stock Options**

Stock options are granted to purchase shares of the Company's stock at the average daily share price on the date of grant. These options generally expire within ten years from the grant date. The Company generally recognizes compensation expense for these awards on a straight-line basis over the three year vesting period. Stock option grants to retirement eligible recipients are attributed to expense using the non-substantive vesting method.

A summary of stock option activity and average exercise prices is as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **2025** | **2025** | 2024 | 2024 | 2023 | 2023 |
|  | Number of<br>Options | Exercise<br>Price (a) | Number of<br>Options | Exercise<br>Price (a) | Number of<br>Options | Exercise<br>Price (a) |
| Outstanding, beginning of year | **5548270** | **$184.92** | 6921356 | $168.65 | 7031103 | $160.45 |
| &nbsp;&nbsp;Granted | **604836** | **268.27** | 595791 | 247.02 | 861840 | 190.53 |
| &nbsp;&nbsp;Exercised | **(1414518)** | **172.62** | (1838103) | 144.58 | (832050) | 119.41 |
| &nbsp;&nbsp;Canceled | **(84810)** | **199.43** | (130774) | 173.95 | (139537) | 183.77 |
| Outstanding, end of year | **4653778** | **$199.23** | 5548270 | $184.92 | 6921356 | $168.65 |
| Exercisable, end of year | **3496063** | **$183.20** | 4095681 | $178.24 | 5107518 | $165.77 |
| Vested and expected to vest, end of year | **4528202** | **$197.89** |  |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Represents weighted average price per share.

The total aggregate intrinsic value of options (the amount by which the stock price exceeded the exercise price of the option on the date of exercise) that were exercised during 2025, 2024 and 2023 was $132.0 million, $162.4 million and $47.7 million, respectively.

The total aggregate intrinsic value of options outstanding as of December 31, 2025 was $302.8 million, with a corresponding weighted-average remaining contractual life of 6.5 years. The total aggregate intrinsic value of options exercisable as of December 31, 2025 was $281.3 million, with a corresponding weighted-average remaining contractual life of 5.6 years. The total aggregate intrinsic value of options vested and expected to vest as of December 31, 2025 was $300.4 million, with a corresponding weighted-average remaining contractual life of 6.4 years.

The lattice (binomial) option-pricing model is used to estimate the fair value of options at grant date. The Company's primary employee option grant occurs during the fourth quarter. The weighted-average grant-date fair value of options granted and the significant assumptions used in determining the underlying fair value of each option grant, on the date of grant were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **2025** | 2024 | 2023 |
| Weighted-average grant-date fair value of options |  |  |  |
| &nbsp;&nbsp;granted at market prices | **$70.35** | $66.80 | $50.26 |
| Assumptions |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Risk-free rate of return | **3.7%** | 4.1% | 4.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;Expected life | **6**<br> **years** | 6<br> years | 6<br> years |
| &nbsp;&nbsp;&nbsp;&nbsp;Expected volatility | **22.7%** | 22.6% | 22.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Expected dividend yield | **1.1%** | 1.0% | 1.2% |

---

The risk-free rate of return is determined based on a yield curve of U.S. treasury rates from one month to ten years and a period commensurate with the expected life of the options granted. Expected volatility is established based on historical volatility of the Company's stock price. The expected dividend yield is determined based on the Company's annual dividend amount as a percentage of the average stock price at the time of the grant.

[**Table of Contents**](#Toc)

**PBRSUs, RSUs and RSAs**

The expense associated with PBRSUs is based on the average of the high and low share price of the Company's common stock on the date of grant, adjusted for the absence of future dividends. The awards vest based on the Company achieving a defined performance target from 0% to 200% and with continued service for a three year period. Upon vesting and following certification of performance by the Compensation & Human Capital Management Committee of the Board of Directors, the Company issues shares of its common stock such that one award unit equals one share of common stock. The Company assesses the probability of achieving the performance target and recognizes expense over the three year vesting period when it is probable the performance target will be met. PBRSU awards granted to retirement eligible recipients are attributed to expense using the non-substantive vesting method. The awards are generally subject to forfeiture in the event of termination of employment.

The expense associated with shares of non-performance based RSUs and RSAs is based on the average of the high and low share price of the Company's common stock on the date of grant, adjusted for the absence of future dividends and is amortized on a straight-line basis over the periods during which the restrictions lapse. The Company currently has RSUs that vest over periods between 24 and 48 months. The awards are generally subject to forfeiture in the event of termination of employment.

A summary of non-vested PBRSUs and restricted stock activity is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | PBRSU<br>Awards | Grant Date<br>Fair Value (a) | RSAs and<br>RSUs | Grant Date<br>Fair Value (a) |
| December 31, 2022 | 823170 | $181.68 | 385097 | $170.50 |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted | 328739 | 185.10 | 156618 | 165.81 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vested / Earned | (180674) | 178.26 | (61776) | 191.22 |
| &nbsp;&nbsp;&nbsp;&nbsp;Canceled | (26409) | 175.05 | (24449) | 166.22 |
| December 31, 2023 | 944826 | $183.71 | 455490 | $166.31 |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted | 245868 | 240.66 | 78386 | 230.47 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vested / Earned | (180993) | 215.26 | (121400) | 196.78 |
| &nbsp;&nbsp;&nbsp;&nbsp;Canceled | (44499) | 171.30 | (37177) | 160.90 |
| December 31, 2024 | 965202 | $192.87 | 375299 | $170.39 |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted | **249793** | **260.55** | **106254** | **259.17** |
| &nbsp;&nbsp;&nbsp;&nbsp;Vested / Earned | **(154270)** | **217.14** | **(142531)** | **152.93** |
| &nbsp;&nbsp;&nbsp;&nbsp;Canceled | **(41265)** | **190.56** | **(32058)** | **164.42** |
| December 31, 2025 | **1019460** | **$205.86** | **306964** | **$209.84** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Represents weighted average price per share.

**12. INCOME TAXES**

Income before income taxes consisted of:

---

| | | | |
|:---|:---|:---|:---|
| (millions) | **2025** | 2024 | 2023 |
| United States (U.S.) | **$1815.3** | $1522.4 | $782.0 |
| International | **732.6** | 1048.8 | 973.5 |
| &nbsp;&nbsp;Total | **$2547.9** | $2571.2 | $1755.5 |

---

Presentation of prior year amounts relating to U.S. and International income before taxes have been recast to conform with the current year presentation, which is before intercompany eliminations. As a result, prior year amounts presented for U.S. and International current and deferred taxes have also been recast to conform with the current year presentation. This had no effect on the reported results of operations.

The provision (benefit) for income taxes consisted of:

---

| | | | |
|:---|:---|:---|:---|
| (millions) | **2025** | 2024 | 2023 |
| U.S. federal and state | **$265.3** | $278.4 | $158.6 |
| International | **225.5** | 345.5 | 259.0 |
| &nbsp;&nbsp;Total current | **490.8** | 623.9 | 417.6 |
| U.S. federal and state | **(5.5)** | (127.0) | (34.7) |
| International | **(30.7)** | (57.6) | (20.4) |
| &nbsp;&nbsp;Total deferred | **(36.2)** | (184.6) | (55.1) |
| Total U.S. federal and state | **259.8** | 151.4 | 123.9 |
| Total International | **194.8** | 287.9 | 238.6 |
| Total provision for income taxes | **$454.6** | $439.3 | $362.5 |

---

[**Table of Contents**](#Toc)

The Company's overall net deferred tax assets and deferred tax liabilities were comprised of the following:

---

| | | |
|:---|:---|:---|
| December 31 (millions) | **2025** | 2024 |
| Deferred tax assets |  |  |
| &nbsp;&nbsp;Pension and post-retirement benefits | **$32.5** | $68.2 |
| &nbsp;&nbsp;Other accrued liabilities | **155.9** | 152.5 |
| &nbsp;&nbsp;Lease liability | **181.4** | 176.7 |
| &nbsp;&nbsp;Credit carryforwards | **132.2** | 105.1 |
| &nbsp;&nbsp;Capitalization of R&D costs | **270.7** | 246.5 |
| &nbsp;&nbsp;Loss carryforwards | **189.8** | 92.9 |
| &nbsp;&nbsp;Share-based compensation | **61.1** | 54.2 |
| &nbsp;&nbsp;Deferred income | **88.6** | 72.4 |
| &nbsp;&nbsp;Deferred interest | **144.8** | 85.2 |
| &nbsp;&nbsp;Other, net | **78.3** | 32.8 |
| &nbsp;&nbsp;Valuation allowance | **(90.8)** | (77.8) |
| Total deferred tax assets  | **1244.5** | 1008.7 |
| Deferred tax liabilities |  |  |
| &nbsp;&nbsp;Goodwill | **(170.0)** | (133.9) |
| &nbsp;&nbsp;Intangible assets | **(485.5)** | (410.4) |
| &nbsp;&nbsp;Property, plant and equipment | **(371.6)** | (310.7) |
| &nbsp;&nbsp;Lease asset | **(182.6)** | (177.8) |
| &nbsp;&nbsp;Financing | **(41.6)** | (43.3) |
| &nbsp;&nbsp;Tax on undistributed earnings | **(100.1)** | - |
| &nbsp;&nbsp;Other, net | **(42.0)** | (57.1) |
| Total deferred tax liabilities | **(1393.4)** | (1133.2) |
| Net deferred tax liabilities balance | **($148.9)** | ($124.5) |

---

As of December 31, 2025, the Company has tax effected federal, state and international net operating loss carryforwards of $21.8 million, $16.0 million and $135.7 million, respectively, and tax effected federal and state tax capital loss carryforwards of $14.3 million and $2.0 million, respectively, which will be available to offset future taxable income. The federal net operating loss carryforwards of $9.4 million have no expiration and $12 million expire from 2036 to 2037. State net operating losses of $16.0 million expire from 2026 to 2046. The international loss carryforwards of $92.6 million expire from 2026 to 2046 and $43.1 million have no expiration. The federal and state capital loss carryforwards of $16.3 million expire from 2026 to 2039. The tax loss carryforwards expiring in 2026 are not material.

Additionally, the Company has $132.2 million of net credit carryforwards that are primarily related to U.S. foreign tax credits and various state and international credits. The U.S. foreign tax credit carryforwards of $117.2 million expire from 2030 to 2036. Other state and international credit carryforwards will expire from 2026 to 2034. The tax credit carryforwards expiring in 2026 are not material.

The Company has valuation allowances on certain deferred tax assets of $90.8 million and $77.8 million at December 31, 2025 and 2024, respectively. The increase in valuation allowance was primarily related to acquired international net operating loss carryforwards of Ovivo Electronics.

In connection with the implementation of Organization for Economic Co-operation and Development ("OECD") global minimum tax initiative known as Pillar Two, any existing deferred taxes not disclosed in the Company's financial statements will not be available in the future to reduce tax otherwise due under Pillar Two. Accordingly, the Company is disclosing the existence of gross tax loss carryforwards in Luxembourg of $1.5 billion. The losses are determined to have a remote possibility of realization and, therefore, are not reported in the table above.

On July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was enacted in the U.S. The OBBBA includes significant provisions, such as permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. An estimate of the financial impact has been included in operating results as of December 31, 2025. While the Company expects certain provisions of OBBBA to change the timing of U.S. cash taxes related to the current and future periods, OBBBA did not have a material impact to the Company's income tax expense.

[**Table of Contents**](#Toc)

The Company has elected to prospectively adopt the guidance in ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Taxes Disclosures, or ASU 2023-09. The following table is a reconciliation of the U.S. federal statutory rate of 21% to the Company's effective rate for the year ended December 31, 2025, in accordance with ASU 2023-09.

---

| | | |
|:---|:---|:---|
|  | **2025** | **2025** |
|  | Amount | Percent |
| U.S Federal Statutory Income Tax Rate | **535.0** | **21.0%**  |
| Domestic Federal  |  |  |
| &nbsp;&nbsp;State and local income tax, net of federal income tax effect (a) | **42.0** | **1.6** |
| &nbsp;&nbsp;Effect of cross-border tax laws |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Subpart F Income  | **58.7** | **2.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign Derived Intangible Income  | **(40.5)** | **(1.6)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other  | **13.0** | **0.5** |
| &nbsp;&nbsp;Tax credits |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign Tax Credit  | **(183.0)** | **(7.2)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and Development Credit | **(33.6)** | **(1.3)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Tax Credits | **(14.0)** | **(0.5)** |
| &nbsp;&nbsp;Changes in valuation allowances | **(9.6)** | **(0.4)** |
| &nbsp;&nbsp;Nontaxable or nondeductible items | **5.6** | **0.2** |
| &nbsp;&nbsp;Other Adjustments  | **2.3** | **0.1** |
| Changes in unrecognized tax benefits | **14.6** | **0.6** |
| Foreign tax effects | **64.1** | **2.5** |
| &nbsp;&nbsp;Effective income tax rate | **454.6** | **17.8%** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The majority of 2025 state income tax expense is comprised of state taxes in California, Illinois, Minnesota, New Jersey, New York and Wisconsin.

The following table is a reconciliation of the U.S. federal statutory rate of 21% to the Company's effective rate for the years ended December 31, 2024, and 2023 prior to the adoption of ASU 2023-09:

---

| | | |
|:---|:---|:---|
|  | 2024 | 2023 |
| Statutory U.S. rate | 21.0% | 21.0% |
| State income taxes, net of federal benefit | 1.5 | 1.4 |
| Foreign operations | (1.2) | (0.5) |
| Excess stock benefits | (0.7) | (0.3) |
| R&D credit | (0.9) | (1.3) |
| Foreign derived intangible income | (1.9) | (1.2) |
| Change in valuation allowance | 0.6 | 0.5 |
| Legal entity rationalization | - | 0.1 |
| Sale of global surgical solutions business | 1.1 | - |
| Capital losses | (3.4) | - |
| Other, net | 1.0 | 0.9 |
| &nbsp;&nbsp;Effective income tax rate | 17.1% | 20.6% |

---

The change in the Company's effective income tax rate includes the tax impact of special (gains) and charges and discrete tax items, which have impacted the comparability of the Company's historical effective income tax rates, as amounts included in special (gains) and charges are derived from tax jurisdictions with rates that vary from the statutory U.S. rate, and discrete tax items are not necessarily consistent across periods. The tax impact of special (gains) and charges and discrete tax items will likely continue to impact comparability of the Company's effective income tax rate in the future.

The Company's 2025 effective tax rate of 17.8% includes $35.2 million of net tax benefits on special (gains) and charges, a net tax benefit of $57.5 million associated with discrete items, and $1.0 million of net tax benefits from Ovivo Electronics. Discrete items include a tax benefit of $21.5 million associated with recognition of deferred tax attributes and $16.8 million related to share-based compensation excess tax benefits. The remaining net discrete tax benefit of $19.2 million was primarily related to the filing of federal, state and foreign tax returns and other income tax adjustments including the impact of changes in tax laws, audit settlements, and other changes in estimates.

The Company's 2024 effective tax rate of 17.1% includes $56.9 million of net tax expenses on special (gains) and charges, and net tax benefit of $78.6 million associated with discrete items. Discrete items include a tax benefit of $62.1 million associated with a change to the tax classification of a wholly-owned non-US subsidiary that resulted in recognizing a capital loss and benefit of $30.4 million due to an increase in the tax basis of foreign intangible assets. The remaining net discrete tax expense of $13.9 million was primarily related to the filing of federal, state and foreign tax returns and other income tax adjustments including the impact of changes in tax laws, audit settlements, share-based compensation excess tax benefit and other changes in estimates.

[**Table of Contents**](#Toc)

The Company's 2023 effective tax rate of 20.6% includes $24.7 million of net tax benefits on special (gains) and charges, and net tax expense of $11.2 million associated with discrete items. The net discrete tax expense was primarily related to the filing of federal, state and foreign tax returns and other income tax adjustments including the impact of changes in tax laws, audit settlements, share-based compensation excess tax benefit and other changes in estimates.

In 2025, the Company recorded a deferred tax liability of $100.1 million associated with undistributed earnings of international affiliates. The Company also recognized a deferred tax asset of $72.2 million related to foreign net operating losses available to offset taxable earnings no longer considered permanently reinvested. The Company otherwise continues to assert permanent reinvestment of the undistributed earnings of international affiliates unless the earnings can be remitted in a net income tax benefit or tax-neutral manner. If there are policy changes, the Company would record the applicable taxes in the period of change.

A reconciliation of the beginning and ending amount of gross liability for unrecognized tax benefits is as follows:

---

| | | | |
|:---|:---|:---|:---|
| (millions) | **2025** | 2024 | 2023 |
| Balance at beginning of year | **$34.1** | $24.2 | $24.9 |
| &nbsp;&nbsp;Additions based on tax positions related to the current year | **7.1** | 4.6 | 5.8 |
| &nbsp;&nbsp;Additions for tax positions of prior years | **9.4** | 11.6 | 1.7 |
| &nbsp;&nbsp;Current year acquisitions | **9.0** | - | - |
| &nbsp;&nbsp;Reductions for tax positions of prior years | **-** | - | - |
| &nbsp;&nbsp;Reductions for tax positions due to statute of limitations | **(1.3)** | (0.7) | (2.7) |
| &nbsp;&nbsp;Settlements | **(5.3)** | (5.3) | (5.5) |
| &nbsp;&nbsp;Foreign currency translation | **0.9** | (0.3) |  |
| Balance at end of year | **$53.9** | $34.1 | $24.2 |

---

The total amount of unrecognized tax benefits, if recognized, would affect the effective tax rate by $50.6 million as of December 31, 2025, $31.5 million as of December 31, 2024 and $21.6 million as of December 31, 2023.

The Company files U.S. federal income tax returns and income tax returns in various U.S. state and non- U.S. jurisdictions. With few exceptions, the Company is no longer subject to state and foreign income tax examinations by tax authorities for years before 2018. The IRS has completed examinations of the Company's U.S. federal income tax returns through 2018, and the years 2019 through 2020 are currently under audit. The U.S. federal audit of tax years 2021 through 2024 is expected to begin in 2026. In addition to the U.S. federal examination, there is ongoing audit activity in several U.S. state and foreign jurisdictions.

The Company recognizes interest and penalties related to unrecognized tax benefits in its provision for income taxes. The Company had $8.7 million, $5.5 million and $4.0 million of accrued interest, including minor amounts for penalties, at December 31, 2025, 2024 and 2023, respectively.

The Company paid cash income taxes of $548.1 million, $647.4 million and $469.2 million in 2025, 2024 and 2023, respectively. The payments in 2025 include $126.4 million, $60.5 million, $361.2 million in U.S. federal, state, and international jurisdictions, respectively. International payments are further comprised of income tax payments in Switzerland, China and other international jurisdictions of $37.4 million, $35.6 million and $288.2 million, respectively.

**13. RENTALS AND LEASES**

**Lessee**

The Company leases sales and administrative office facilities, distribution centers, research and manufacturing facilities, as well as vehicles and other equipment under operating leases. Certain of the Company's lease arrangements are finance leases, which are immaterial individually and in the aggregate.

The Company's operating lease cost was as follows:

---

| | | | |
|:---|:---|:---|:---|
| (millions) | **2025** | 2024 | 2023 |
| Operating lease cost\* | **$230.0** | $218.0 | $215.4 |

---

\*Includes immaterial short-term and variable lease costs

[**Table of Contents**](#Toc)

Future maturity of operating lease liabilities as of December 31, 2025 were as follows:

---

| | |
|:---|:---|
| (millions) |  |
| 2026 | $197 |
| 2027 | 174 |
| 2028 | 126 |
| 2029 | 82 |
| 2030 | 59 |
| Thereafter | 252 |
| Total lease payments | 890 |
| Less: imputed interest | 129 |
| Present value of lease liabilities | $761 |

---

The Company's operating leases term and discount rate were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **December 31**<br>**2025** | December 31<br>2024 | December 31<br>2023 |
| Weighted-average remaining lease term (years) | **6.69** | 7.01 | 6.44 |
| Weighted-average discount rate | **4.84%** | 4.76% | 4.02% |

---

The Company's other lease information was as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **December 31** | December 31 | December 31 |
| (millions) | **2025** | 2024 | 2023 |
| Cash paid for amounts included in the measurement of lease liabilities: |  |  |  |
| &nbsp;&nbsp;Operating cash flows from operating leases | **$225.8** | $207.7 | $170.6 |
| Leased assets obtained in exchange for new operating lease liabilities | **152.5** | 336.0 | 251.5 |

---

**Lessor**

The Company leases warewashing and water treatment equipment to customers under operating leases.

Gross assets under operating leases recorded in Property, plant and equipment, net is $1,563.2 million and $1,481.7 million, and related accumulated depreciation is $954.5 million and $932.9 million, as of December 31, 2025 and 2024, respectively.

The Company's operating lease revenue was as follows:

---

| | | | |
|:---|:---|:---|:---|
| (millions) | **2025** | 2024 | 2023 |
| Operating lease revenue\* | **$562.1** | $534.9 | $511.8 |

---

\*Includes immaterial variable lease revenue

Future revenue from operating leases for existing contracts as of December 31, 2025 were as follows:

---

| | |
|:---|:---|
| (millions) |  |
| 2026 | $467 |
| 2027 | 341 |
| 2028 | 275 |
| 2029 | 191 |
| 2030 | 105 |
| Thereafter | 68 |
| Total lease revenue | $1447 |

---

The Company mitigates the risk of residual value subsequent to the lease term by redeploying assets. As such, the Company expects to receive revenue from the operating lease assets through the remaining useful life and therefore subsequent to the initial contract termination date.

**14. RESEARCH AND DEVELOPMENT EXPENDITURES**

Research expenditures that relate to the development of new products and processes, including significant improvements and refinements to existing products, are expensed as incurred. Such costs were $202 million in 2025, $207 million in 2024 and $192 million in 2023. The Company did not participate in any material customer sponsored research during any of the years presented.

[**Table of Contents**](#Toc)

**15. COMMITMENTS AND CONTINGENCIES**

The Company is subject to various claims and contingencies related to, among other things, workers' compensation, general liability (including product liability), automobile claims, health care claims, environmental matters and lawsuits. The Company is also subject to various claims and contingencies related to income taxes, which are discussed in Note 12, "Income Taxes." The Company also has contractual obligations including lease commitments, which are discussed in Note 13, "Rentals and Leases."

The Company records liabilities when a contingent loss is probable and can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred.

**Insurance**

Globally, the Company has insurance policies with varying deductible levels for property and casualty losses. The Company is insured for losses in excess of these deductibles, subject to policy terms and conditions and has recorded both a liability and an offsetting receivable for amounts in excess of these deductibles. The Company is self-insured for health care claims for eligible participating employees, subject to certain deductibles and limitations. The Company determines its liabilities for claims on an actuarial basis.

**Litigation and Environmental Matters** 

The Company and certain subsidiaries are party to various lawsuits, claims and environmental actions that have arisen in the ordinary course of business. These include from time to time antitrust, employment, commercial, patent infringement, tort, product liability and wage hour lawsuits, as well as possible obligations to investigate and mitigate the effects on the environment of the disposal or release of certain chemical substances at various sites, such as Superfund sites and other operating or closed facilities. The Company has established accruals for certain lawsuits, claims and environmental matters. The Company currently believes that there is not a reasonably possible risk of material loss in excess of the amounts accrued related to these legal matters. Because litigation is inherently uncertain, and unfavorable rulings or developments could occur, there can be no certainty that the Company may not ultimately incur charges in excess of recorded liabilities. A future adverse ruling, settlement or unfavorable development could result in future charges that could have a material adverse effect on the Company's results of operations or cash flows in the period in which they are recorded. The Company currently believes that such future charges related to suits and legal claims, if any, would not have a material adverse effect on the Company's consolidated financial position.

***TPC Group Litigation***

On November 27, 2019, a Butadiene production plant owned and operated by TPC Group, Inc. ("TPC") in Port Neches, Texas, experienced an explosion and fire that resulted in personal injuries, the release of chemical fumes and extensive property damage to the plant and surrounding areas in and near Port Neches, Texas.

Nalco Company LLC, a subsidiary of Ecolab, supplied process chemicals to TPC used in TPC's production processes. Nalco did not operate, manage, maintain or control any aspect of TPC's plant operations.

In connection with its provision of process chemicals to TPC, Nalco was named in numerous lawsuits stemming from the plant explosion. Nalco has been named a defendant, along with TPC and other defendants, in multi-district litigation ("MDL") proceedings pending in Orange County, Texas, alleging among other things claims for personal injury, property damage and business losses (In re TPC Group Litigation – A2020-0236-MDL, Orange County, Texas). Numerous other lawsuits were filed against Nalco, including TPC Group v. Nalco, E0208239, Jefferson County, Texas, a subrogation claim by TPC's insurers seeking reimbursement for property damage losses. Over 5,000 plaintiffs (including the subrogation matter) asserted claims against Nalco. All claims have been consolidated for pretrial purposes into the MDL.

All of these cases make similar allegations and seek damages for personal injury, property damage, business losses and other damages, including exemplary damages.

On June 1, 2022, TPC and seven of its affiliated companies filed for bankruptcy under Chapter 11 (Case No. 22-10493-CTG, United States Bankruptcy Court for the District of Delaware). In connection with the bankruptcy cases, TPC disclosed an estimated range of its liability related to the Port Neches incident to individuals and homeowners (including subrogation claims) of approximately $152 million to $520 million. As part of their bankruptcy plan, TPC and its affiliates announced a settlement which allows the MDL plaintiffs a $500 million claim solely for purposes of claim allowance in the chapter 11 case and distribution of value pursuant to TPC's bankruptcy plan. Other key terms of the settlement between TPC and the MDL plaintiffs include the establishment of a settlement trust for the benefit of certain general unsecured creditors, which is funded with $30 million and the assignment of TPC's claims and causes of action, if any, against certain third parties, including Nalco, related to the TPC plant explosion. As part of the bankruptcy process, TPC and its debtor affiliates received a discharge of all MDL related claims, as did certain non-debtor affiliates to the extent third parties did not opt out of the non-debtor releases. As a result, TPC is no longer a defendant in the MDL. Nalco opted out of these releases, preserving any direct causes of action it may have against non-debtors. Furthermore, the allowance of the $500 million claim should have no effect on any claims or defenses asserted against or by Nalco in the MDL litigation. On December 1, 2022, the bankruptcy court confirmed the TPC bankruptcy plan, including the approval of the settlement and establishment of the aforementioned settlement trust. On December 16, 2022, the TPC bankruptcy plan went effective. As a result of the bankruptcy, the MDL was stayed. The stay was lifted in the fourth quarter of 2023 and various activities advancing discovery have resumed.

[**Table of Contents**](#Toc)

In July 2025, Nalco executed a settlement with a portion of the plaintiffs in the MDL. The Company continues to believe the claims asserted against Nalco are without merit and intends to defend the remaining claims vigorously. The Company also believes any potential loss should be covered by insurance subject to deductibles. However, the Company cannot predict the outcome of these lawsuits, the involvement the Company might have in these matters in the future or the potential for future litigation. Due to the large number of remaining plaintiffs and the fact that many of the claims do not specify an amount of supported damages, any estimate of any further loss or range of losses cannot be made at this time.

***Vehicle Accident Litigation***

In June 2024, an Ecolab employee was driving a company vehicle when it collided with another vehicle, resulting in fatalities and serious injuries. The Company was named in a lawsuit arising out of the collision in which the plaintiffs seek monetary damages. The Company finalized a settlement with the plaintiffs in December 2025 fully resolving plaintiffs' claims. The loss was covered by insurance subject to the Company's deductible.

***Environmental Matters***

The Company is currently participating in environmental assessments and remediation at approximately 25 locations, the majority of which are in the U.S., and environmental liabilities have been accrued reflecting management's best estimate of future costs. Potential insurance reimbursements are not anticipated in the Company's accruals for environmental liabilities.

**16. RETIREMENT PLANS**

**Pension and Postretirement Health Care Benefits Plans**

The Company has a non-contributory, qualified, defined benefit pension plan covering the majority of its U.S. employees. The Company also has U.S. non-contributory, non-qualified, defined benefit pension plans, which provide for benefits to employees in excess of limits permitted under its pension plans. The U.S. non-qualified plans are not funded and the recorded benefit obligations for the non-qualified plans were $79 million and $78 million at December 31, 2025 and 2024, respectively. The U.S. qualified obligation was $1,738 million and $1,712 million at December 31, 2025 and 2024, respectively. The measurement date used for determining the U.S. pension plan assets and obligations is December 31.

Various international subsidiaries have defined benefit pension plans. International plans are funded based on local country requirements. The measurement date used for determining the international pension plan assets and obligations is November 30, the fiscal year end of the Company's international subsidiaries.

The Company provides postretirement health care and life insurance benefits to certain U.S. employees and retirees. The U.S. postretirement health care plans are contributory based on years of service and choice of coverage (family or single), with retiree contributions adjusted annually. The Company also maintains several U.S. postretirement life insurance plans. The measurement date used to determine the U.S. postretirement health care and life insurance plan assets and obligations is December 31. Certain employees outside the U.S. are covered under government-sponsored programs, which are not required to be fully funded. The expense and obligation for providing international postretirement health care benefits are not significant.

[**Table of Contents**](#Toc)

The following table sets forth financial information related to the Company's pension and postretirement benefit plans:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | U.S. | U.S. | International | International | U.S. Postretirement | U.S. Postretirement |
|  | Pensions | Pensions | Pensions | Pensions | Benefits | Benefits |
| (millions) | **2025** | 2024 | **2025** | 2024 | **2025** | 2024 |
| Accumulated benefit obligation, end of year | **$1818.0** | $1790.6 | **$1114.3** | $1123.4 | **$100.4** | $101.4 |
| Projected benefit obligation |  |  |  |  |  |  |
| &nbsp;&nbsp;Projected benefit obligation, beginning of year | **$1790.6** | $1859.5 | **$1166.6** | $1174.0 | **$101.4** | $112.0 |
| &nbsp;&nbsp;Service cost  | **46.9** | 46.3 | **19.3** | 19.0 | **0.2** | 0.3 |
| &nbsp;&nbsp;Interest cost | **91.7** | 87.0 | **45.4** | 48.9 | **5.1** | 5.2 |
| &nbsp;&nbsp;Participant contributions | **-** | - | **3.0** | 2.9 | **2.5** | 3.0 |
| &nbsp;&nbsp;Plan amendments | **-** | - | **0.9** | (0.5) | **-** | - |
| &nbsp;&nbsp;Actuarial (gain) loss | **41.0** | (68.4) | **(83.3)** | 14.8 | **1.8** | (8.0) |
| &nbsp;&nbsp;Acquisitions and divestitures | **-** | - | **-** | (13.3) | **-** | - |
| &nbsp;&nbsp;Other events | **-** | - | **(0.4)** | 1.6 | **-** | - |
| &nbsp;&nbsp;Benefits paid | **(152.2)** | (133.8) | **(68.5)** | (58.1) | **(10.6)** | (11.1) |
| &nbsp;&nbsp;Foreign currency translation | **-** | - | **77.4** | (22.7) | **-** | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Projected benefit obligation, end of year | **$1818.0** | $1790.6 | **$1160.4** | $1166.6 | **$100.4** | $101.4 |
| Plan assets |  |  |  |  |  |  |
| &nbsp;&nbsp;Fair value of plan assets, beginning of year | **$1639.0** | $1719.7 | **$910.9** | $871.2 | **$1.6** | $2.4 |
| &nbsp;&nbsp;Actual returns on plan assets | **223.1** | 45.1 | **0.4** | 76.5 | **0.2** | - |
| &nbsp;&nbsp;Company contributions | **35.0** | 8.0 | **32.2** | 35.3 | **10.4** | 10.3 |
| &nbsp;&nbsp;Participant contributions | **-** | - | **3.0** | 2.9 | **-** | - |
| &nbsp;&nbsp;Acquisitions and divestitures | **-** | - | **-** | (6.3) | **-** | - |
| &nbsp;&nbsp;Benefits paid | **(152.2)** | (133.8) | **(68.7)** | (57.9) | **(10.6)** | (11.1) |
| &nbsp;&nbsp;Foreign currency translation | **-** | - | **50.7** | (10.8) | **-** | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Fair value of plan assets, end of year | **$1744.9** | $1639.0 | **$928.5** | $910.9 | **$1.6** | $1.6 |
| Funded Status, end of year | **($73.1)** | ($151.6) | **($231.9)** | ($255.7) | **($98.8)** | ($99.8) |
| Amounts recognized in the Consolidated Balance Sheets: |  |  |  |  |  |  |
| &nbsp;&nbsp;Other assets | **$6.4** | $- | **$177.9** | $151.0 | **-** | $- |
| &nbsp;&nbsp;Other current liabilities | **(12.6)** | (8.8) | **(26.1)** | (36.2) | **(8.1)** | (8.3) |
| &nbsp;&nbsp;Pension and postretirement benefits | **(66.9)** | (142.8) | **(383.7)** | (370.5) | **(90.7)** | (91.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net liability | **($73.1)** | ($151.6) | **($231.9)** | ($255.7) | **($98.8)** | ($99.8) |
| Amounts recognized in accumulated other comprehensive loss (income): |  |  |  |  |  |  |
| &nbsp;&nbsp;Unrecognized net actuarial loss (gain) | **$485.8** | $526.5 | **$225.0** | $253.5 | **($40.1)** | ($45.4) |
| &nbsp;&nbsp;Unrecognized net prior service (benefits) costs | **(7.6)** | (12.1) | **-** | (1.1) | **-** | - |
| &nbsp;&nbsp;Tax (benefit) expense | **(122.6)** | (131.6) | **(50.9)** | (58.1) | **5.9** | 6.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss (income), net of tax | **$355.6** | $382.8 | **$174.1** | $194.3 | **($34.2)** | ($38.7) |
| Change in accumulated other comprehensive loss (income): |  |  |  |  |  |  |
| &nbsp;&nbsp;Amortization of net actuarial gain (loss) | **($8.6)** | ($6.1) | **($9.0)** | ($12.2) | **$3.6** | $3.2 |
| &nbsp;&nbsp;Amortization of prior service credits | **4.6** | 4.6 | **0.3** | (0.1) | **-** | - |
| &nbsp;&nbsp;Current period net actuarial loss (gain) | **(32.2)** | 37.4 | **(31.8)** | (10.1) | **1.7** | (7.8) |
| &nbsp;&nbsp;Current period prior service costs | **-** | - | **0.9** | (0.5) | **-** | - |
| &nbsp;&nbsp;Curtailments and settlements | **-** | - | **(0.5)** | (0.9) | **-** | - |
| &nbsp;&nbsp;Tax (benefit) expense | **9.0** | (8.8) | **7.2** | 6.3 | **(0.8)** | 0.5 |
| &nbsp;&nbsp;Foreign currency translation | **-** | - | **12.7** | (1.9) | **-** | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive loss (income) | **($27.2)** | $27.1 | **($20.2)** | ($19.4) | **$4.5** | ($4.1) |

---

Estimate amounts in accumulated other comprehensive loss expected to be reclassified to net period cost during 2026 were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | U.S. Post- |
|  | U.S. | International | Retirement |
| (millions) | Pensions | Pensions | Benefits |
| Net actuarial loss (gain) | $26.1 | $8.0 | ($3.2) |
| Net prior service benefits | (4.6) | (0.2) | - |
| Total | $21.5 | $7.8 | ($3.2) |

---

Service cost is included with employee compensation cost in either cost of sales and selling, general and administrative expenses in the Consolidated Statements of Income based on employee roles in the Company while all non-service components are included in other (income) expense in the Consolidated Statements of Income.

[**Table of Contents**](#Toc)

The aggregate projected benefit obligation, accumulated benefit obligation and fair value of pension plan assets for plans with accumulated benefit obligations in excess of plan assets were as follows:

---

| | | |
|:---|:---|:---|
| December 31, (millions) | **2025** | 2024 |
| Aggregate projected benefit obligation | **$524.2** | $2292.5 |
| Accumulated benefit obligation | **493.5** | 2265.5 |
| Fair value of plan assets | **38.2** | 1738.6 |

---

The projected benefit obligation and fair value of pension plan assets for plans with projected benefit obligations in excess of plan assets were as follows:

---

| | | |
|:---|:---|:---|
| December 31, (millions) | **2025** | 2024 |
| Projected benefit obligations | **$578.3** | $2373.4 |
| Fair value of plan assets | **89.1** | 1815.1 |

---

These plans include the U.S. non-qualified pension plans which are not funded as well as various international pension plans which are funded consistent with local practices and requirements.

***Net Periodic Benefit Costs and Plan Assumptions***

Pension and postretirement benefits expense for the Company's operations were as follows:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | U.S. | U.S. | U.S. | International | International | International | U.S. Postretirement | U.S. Postretirement | U.S. Postretirement |
|  | Pensions | Pensions | Pensions | Pensions | Pensions | Pensions | Benefits | Benefits | Benefits |
| (millions) | **2025** | 2024 | 2023 | **2025** | 2024 | 2023 | **2025** | 2024 | 2023 |
| Service cost  | **$46.9** | $46.3 | $40.9 | **$19.3** | $19.0 | $21.7 | **$0.2** | $0.3 | $0.4 |
| Interest cost on benefit obligation | **91.7** | 87.0 | 88.1 | **45.4** | 48.9 | 45.9 | **5.1** | 5.2 | 5.6 |
| Expected return on plan assets | **(150.5)** | (150.8) | (145.1) | **(52.3)** | (50.1) | (56.1) | **(0.1)** | (0.2) | (0.2) |
| Recognition of net actuarial loss (gain) | **8.6** | 6.1 | 0.2 | **8.7** | 9.6 | 12.5 | **(3.6)** | (3.2) | (3.1) |
| Amortization of prior service benefit | **(4.6)** | (4.6) | (4.5) | **(0.3)** | (0.1) | (0.5) | **-** | - | - |
| Curtailments and settlements | **-** | - | - | **0.5** | 0.9 | (2.7) | **-** | - | - |
| &nbsp;&nbsp;Total expense (benefit) | **($7.9)** | ($16.0) | ($20.4) | **$21.3** | $28.2 | $20.8 | **$1.6** | $2.1 | $2.7 |

---

The Company has historically recognized settlements and curtailment gains and losses associated with its U.S. nonqualified pension plans and international pension plans, the amounts of which have been historically not material. These charges have been included as a component of other (income) expense on the Consolidated Statements of Income.

The measurement of the Company's pension and postretirement benefit obligations are dependent on a variety of assumptions determined by management and used by actuaries in their valuation method and calculations. The significant assumptions used in developing the required estimates of the projected benefit obligations are the discount rates, expected returns on assets, and projected salary increases. Assumptions for the Company were as follows:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Plan Assumptions | U.S. | U.S. | U.S. | International | International | International | U.S. Postretirement | U.S. Postretirement | U.S. Postretirement |
|  | Pensions | Pensions | Pensions | Pensions | Pensions | Pensions | Benefits | Benefits | Benefits |
| (percent) | **2025** | 2024 | 2023 | **2025** | 2024 | 2023 | **2025** | 2024 | 2023 |
| Weighted-average actuarial assumptions |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;used to determine benefit obligations |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;as of year end: |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Discount rate | **5.28%**  | 5.58% | 4.95% | **4.46%**  | 3.99% | 4.34% | **5.27%**  | 5.58% | 4.95% |
| &nbsp;&nbsp;&nbsp;&nbsp;Projected salary increase | **3.60** | 3.60 | 4.03 | **2.68** | 2.69 | 2.84 |  |  |  |
| Weighted-average actuarial assumptions |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;used to determine net cost: |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest credit rate for cash balance plans | **4.36** | 4.50 | 3.89 | **N/A** | N/A | N/A | **N/A** | N/A | N/A |
| &nbsp;&nbsp;&nbsp;&nbsp;Discount rate | **5.58** | 4.95 | 5.17 | **3.99** | 4.34 | 3.70 | **5.58** | 4.95 | 5.14 |
| &nbsp;&nbsp;&nbsp;&nbsp;Expected return on plan assets | **8.25** | 8.00 | 7.75 | **5.81** | 6.00 | 6.27 | **8.25** | 8.00 | 7.75 |
| &nbsp;&nbsp;&nbsp;&nbsp;Projected salary increase | **3.60** | 4.03 | 4.03 | **2.69** | 2.84 | 3.08 |  |  |  |

---

Discount rate assumptions for the U.S. plans are developed using a bond yield curve constructed from a population of high-quality, non-callable, corporate bonds with maturities ranging from six months to thirty years. Discount rates are estimated for the U.S. plans based on the timing of the expected benefit payments.

The Company measures service and interest costs by applying the specific spot rates along that yield curve to the plans' liability cash flows. The Company believes this approach provides a more precise measurement of service and interest costs by aligning the timing of the plans' liability cash flows to the corresponding spot rates on the yield curve.

[**Table of Contents**](#Toc)

The expected long-term rate of return used for the U.S. plans is based on the respective pension plan's asset mix. The Company considers expected long-term real returns on asset categories, expectations for inflation, and estimates of the impact of active management of the assets in determining the expected long-term rate of return to use. The Company also considers historical returns.

The expected long-term rate of return used for the Company's international plans is determined in each local jurisdiction and is based on the assets held in that jurisdiction, the expected rate of returns for the type of assets held and any guaranteed rate of return provided by the investment. The other assumptions used to measure the international pension obligations, including discount rate, vary by country based on specific local requirements and information.

For postretirement benefit measurement purposes as of December 31, 2025, the annual rates of increase in the per capita cost of covered health care were assumed to be 8.15% for pre-65 costs. Post-65 costs are no longer used. The rates are assumed to decrease each year until they reach 4.5% in 2036 and remain at those levels thereafter. Health care costs for certain employees which are eligible for subsidy by the Company are limited by a cap on the subsidy.

***Plan Asset Management***

The Company's U.S. investment strategy and policies are designed to maximize the possibility of having sufficient funds to meet the long-term liabilities of the qualified pension plan, while achieving a balance between the goals of asset growth of the qualified pension plan and keeping risk at a reasonable level. Investment income is not a primary goal of the policy.

The asset allocation position reflects the Company's ability and willingness to accept relatively more short-term variability in the performance of the qualified pension plan asset portfolio in exchange for the expectation of better long-term returns, lower pension costs and better funded status in the long run. The U.S. qualified pension plan's assets are diversified across a number of asset classes and securities. Selected individual portfolios within the asset classes may be undiversified while maintaining the diversified nature of total plan assets. The Company has no significant concentration of risk in its U.S. qualified pension plan assets.

Assets of funded international retirement plans are managed in each local jurisdiction and asset allocation strategy is set in accordance with local rules, regulations and practices; therefore, no overall target asset allocation is presented. Although foreign equity securities are all considered international for the Company, some equity securities are considered domestic for the local plan. The funds are invested in a variety of equities, bonds and real estate investments and, in some cases, the assets are managed by insurance companies which may offer a guaranteed rate of return. The Company has no significant concentration of risk in the assets of its international pension plans.

The fair value hierarchy is used to categorize investments measured at fair value in one of three levels in the fair value hierarchy. This categorization is based on the observability of the inputs used in valuing the investments. Refer to Note 7, "Fair Value Measurements," for definitions of these levels.

The fair value of the Company's U.S. plan assets were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Fair Value as of** | **Fair Value as of** | **Fair Value as of** | Fair Value as of | Fair Value as of | Fair Value as of |
| (millions) | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | December 31, 2024 | December 31, 2024 | December 31, 2024 |
|  | **Level 1** | **Level 2** | **Total** | Level 1 | Level 2 | Total |
| Cash | **$47.7** | **$-** | **$47.7** | $41.5 | $- | $41.5 |
| Equity securities: |  |  |  |  |  |  |
| &nbsp;&nbsp;Large cap equity | **408.4** | **-** | **408.4** | 367.1 | - | 367.1 |
| &nbsp;&nbsp;Small cap equity | **12.8** | **31.7** | **44.5** | 12.1 | 26.4 | 38.5 |
| &nbsp;&nbsp;International equity | **103.9** | **152.8** | **256.7** | 93.8 | 137.4 | 231.2 |
| Fixed income: |  |  | **-** |  |  |  |
| &nbsp;&nbsp;Core fixed income | **214.0** | **365.9** | **579.9** | 183.2 | 371.3 | 554.5 |
| &nbsp;&nbsp;High-yield bonds | **43.3** | **-** | **43.3** | 38.8 | - | 38.8 |
| &nbsp;&nbsp;Emerging markets | **-** | **44.3** | **44.3** | - | 42.0 | 42.0 |
| &nbsp;&nbsp;Total investments at fair value | **830.1** | **594.7** | **1424.8** | 736.5 | 577.1 | 1313.6 |
| Investments measured at net asset value |  |  | **321.7** |  |  | 327.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | **$830.1** | **$594.7** | **$1746.5** | $736.5 | $577.1 | $1640.6 |

---

The Company had no Level 3 assets as part of its U.S. qualified pension plan assets as of December 31, 2025 or 2024.

[**Table of Contents**](#Toc)

The allocation of the Company's U.S. plan assets plans were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Target Asset | Target Asset |  |  |
| Asset Category | Allocation | Allocation | Percentage | Percentage |
|  | Percentage | Percentage | of Plan Assets | of Plan Assets |
| December 31 | **2025** | 2024 | **2025** | 2024 |
| Cash | **-%**  | -% | **3%**  | 3% |
| Equity securities: |  |  |  |  |
| &nbsp;&nbsp;Large cap equity | **27** | 27 | **23** | 22 |
| &nbsp;&nbsp;Small cap equity | **3** | 3 | **3** | 2 |
| &nbsp;&nbsp;International equity | **17** | 17 | **15** | 14 |
| Fixed income: |  |  |  |  |
| &nbsp;&nbsp;Core fixed income | **35** | 35 | **33** | 34 |
| &nbsp;&nbsp;High-yield bonds | **3** | 3 | **2** | 2 |
| &nbsp;&nbsp;Emerging markets | **3** | 3 | **2** | 3 |
| Other: |  |  |  |  |
| &nbsp;&nbsp;Real estate | **3** | 3 | **3** | 3 |
| &nbsp;&nbsp;Private equity | **6** | 6 | **14** | 14 |
| &nbsp;&nbsp;Distressed debt | **3** | 3 | **2** | 3 |
| Total | **100%** | 100% | **100%** | 100% |

---

The fair value of the Company's international plan assets for its defined benefit pension plans were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Fair Value as of** | **Fair Value as of** | **Fair Value as of** | Fair Value as of | Fair Value as of | Fair Value as of |
| (millions) | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | December 31, 2024 | December 31, 2024 | December 31, 2024 |
|  | **Level 1** | **Level 2** | **Total** | Level 1 | Level 2 | Total |
| Cash | **$10.3** | **$-** | **$10.3** | $8.1 | $- | $8.1 |
| Equity securities: |  |  |  |  |  |  |
| &nbsp;&nbsp;International equity | **-** | **192.5** | **192.5** | - | 193.9 | 193.9 |
| Fixed income: |  |  |  |  |  |  |
| &nbsp;&nbsp;Corporate bonds | **-** | **153.7** | **153.7** | - | 157.5 | 157.5 |
| &nbsp;&nbsp;Government bonds | **-** | **356.5** | **356.5** | - | 339.6 | 339.6 |
| Insurance company accounts | **-** | **164.1** | **164.1** | - | 163.2 | 163.2 |
| &nbsp;&nbsp;Total investments at fair value | **10.3** | **866.8** | **877.1** | 8.1 | 854.2 | 862.3 |
| Investments measured at net asset value |  |  | **51.4** |  |  | 48.6 |
| Total | **$10.3** | **$866.8** | **$928.5** | $8.1 | $854.2 | $910.9 |

---

The Company had no Level 3 assets as part of its international plan assets as of December 31, 2025 or 2024.

The allocation of plan assets of the Company's international plan assets for its defined benefit pension plans were as follows:

---

| | | |
|:---|:---|:---|
|  | Percentage | Percentage |
| Asset Category | of Plan Assets | of Plan Assets |
| December 31 | **2025** | 2024 |
| Cash | **1%** | 1% |
| Equity securities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;International equity | **21** | 21 |
| Fixed income: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate bonds | **16** | 17 |
| &nbsp;&nbsp;&nbsp;&nbsp;Government bonds | **38** | 37 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total fixed income | **54** | 54 |
| Other: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Insurance contracts | **18** | 18 |
| &nbsp;&nbsp;&nbsp;&nbsp;Real estate | **6** | 6 |
| Total | **100%** | 100% |

---

[**Table of Contents**](#Toc)

**Cash Flows**

As of year-end 2025, the Company's estimate of pension and postretirement benefits expected to be paid in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter are as follows:

---

| | |
|:---|:---|
| (millions) | All Plans |
| 2026 | $256 |
| 2027 | 256 |
| 2028 | 257 |
| 2029 | 258 |
| 2030 | 259 |
| 2031 - 2035 | 1283 |

---

Depending on plan funding levels, the U.S. qualified pension plan provides certain terminating participants with an option to receive their pension benefits in the form of a lump sum payout.

The Company is currently in compliance with all funding requirements of its U.S. pension and postretirement benefit plans. A $25.0 million voluntary contribution was made to its non-contributory qualified U.S. pension plan in 2025. The Company is required to fund certain international pension benefit plans in accordance with local legal requirements. The Company estimates contributions to be made to its international plans will approximate $39 million in 2026.

The Company seeks to maintain balance in its U.S. assets that meet the long-term funding requirements identified by the projections of the pension plans' actuaries while simultaneously satisfying the fiduciary responsibilities prescribed in ERISA. The Company also takes into consideration the tax deductibility of contributions to the benefit plans.

**Savings Plan and ESOP** 

The Company provides a 401(k) savings plan for the majority of its U.S. employees under the Company's 401(k) savings plans, the Ecolab Savings Plan and ESOP (the "Ecolab Savings Plan").

Under the Ecolab Savings Plan, Employee before-tax contributions of up to 4% of eligible compensation are matched 100% by the Company and employee before-tax contributions over 4% and up to 8% of eligible compensation are matched 50% by the Company.

The Company's matching contributions are 100% vested immediately. The Company's matching contribution expense was $97.0 million, $92.4 million and $88.2 million in 2025, 2024 and 2023, respectively.

**17. REVENUES**

**Revenue Recognition**

***Product and Sold Equipment***

Product revenue is generated from sales of cleaning, sanitizing, water treatment, process treatment and colloidal silica products. In addition, the Company sells equipment which may be used in combination with its specialized products. Revenue from product and sold equipment is recognized when obligations under the terms of a contract with the customer are satisfied, which generally occurs with the transfer of the product or delivery of the equipment.

***Service and Lease Equipment***

Service and lease equipment revenue is generated from providing services or leasing equipment to customers. Service offerings include installing or repairing certain types of equipment, activities that supplement or replace headcount at the customer location, or fulfilling deliverables included in the contract. Global Water segment services are associated with water treatment and paper process applications. Global Institutional & Specialty segment services include cleaning and sanitizing programs and wash process solutions. Global Life Sciences segment services include pharmaceutical and personal care solutions. Revenues included in Global Pest Elimination primarily relate to services designed to detect, eliminate and prevent pests. Revenue from service and leased equipment is recognized when the services are provided, or the customer receives the benefit from the leased equipment, which is over time. Service revenue is recognized over time utilizing an input method and aligns with when the services are provided. Typically, revenue is recognized using costs incurred to date because the effort provided by the field selling and service organization represents services provided, which corresponds with the transfer of control. Revenue for leased equipment is accounted for under Topic 842 Leases and recognized on a straight-line basis over the length of the lease contract. Refer to Note 13, "Rentals and Leases," for additional information related to lease equipment.

[**Table of Contents**](#Toc)

**Practical Expedients and Exemptions**

The revenue standard can be applied to a portfolio of contracts with similar characteristics if it is reasonable that the effects of applying the standard at the portfolio level would not be significantly different than applying the standard at the individual contract level. The Company applies the portfolio approach primarily within each operating segment by geographical region. Application of the portfolio approach was focused on those characteristics that have the most significant accounting consequences in terms of their effect on the timing of revenue recognition or the amount of revenue recognized. The Company determined the key criteria to assess with respect to the portfolio approach, including the related deliverables, the characteristics of the customers and the timing and transfer of goods and services, which most closely aligned within the operating segments. In addition, the accountability for the business operations, as well as the operational decisions on how to go to market and the product offerings, are performed at the operating segment level.

The following table shows principal activities, separated by reportable segments, from which the Company generates its revenue. The reportable segments have been revised to align with the Company's reportable segments in the current year. Corporate includes sales to ChampionX under the transitional supply agreement entered into as part of the ChampionX Separation. For more information about the Company's reportable segments, refer to Note 18, "Operating Segments and Geographic Information."

Net sales at public exchange rates by reportable segment were as follows:

---

| | | | |
|:---|:---|:---|:---|
| (millions) | **2025** | 2024 | 2023 |
| **Global Water** |  |  |  |
| &nbsp;&nbsp;Product and sold equipment | **$6958.7** | $6809.6 | $6709.8 |
| &nbsp;&nbsp;Service and lease equipment | **1023.7** | 966.3 | 915.7 |
| **Global Institutional & Specialty** |  |  |  |
| &nbsp;&nbsp;Product and sold equipment | **4950.4** | 5000.0 | 4920.5 |
| &nbsp;&nbsp;Service and lease equipment | **1154.2** | 1103.4 | 990.3 |
| **Global Pest Elimination** |  |  |  |
| &nbsp;&nbsp;Product and sold equipment | **-** | - | - |
| &nbsp;&nbsp;Service and lease equipment | **1246.3** | 1162.8 | 1066.0 |
| **Global Life Sciences** |  |  |  |
| &nbsp;&nbsp;Product and sold equipment | **709.4** | 664.0 | 644.0 |
| &nbsp;&nbsp;Service and lease equipment | **38.5** | 35.3 | 31.4 |
| **Corporate** |  |  |  |
| &nbsp;&nbsp;Product and sold equipment | **-** | - | 42.5 |
| **Total** |  |  |  |
| &nbsp;&nbsp;Total product and sold equipment | **$12618.5** | $12473.6 | $12316.8 |
| &nbsp;&nbsp;Total service and lease equipment | **3462.7** | 3267.8 | 3003.4 |

---

[**Table of Contents**](#Toc)

Net sales at public exchange rates by geographic region were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | Global Water | Global Water | Global Water | Global Institutional & Specialty | Global Institutional & Specialty | Global Institutional & Specialty |
| (millions) | **2025** | 2024 | 2023 | **2025** | 2024 | 2023 |
| United States | **$3415.1** | $3306.7 | $3218.1 | **$3996.0** | $3992.0 | $3856.9 |
| Europe | **1661.1** | 1593.7 | 1573.0 | **1026.1** | 1037.5 | 1033.2 |
| Asia Pacific | **945.7** | 947.6 | 946.4 | **329.2** | 322.4 | 308.2 |
| Latin America | **816.7** | 810.5 | 772.5 | **205.8** | 209.6 | 212.0 |
| India, Middle East and Africa | **501.1** | 493.0 | 491.8 | **99.1** | 105.1 | 98.6 |
| Greater China | **410.4** | 400.4 | 407.0 | **198.1** | 182.7 | 165.7 |
| Canada | **232.3** | 224.0 | 216.7 | **250.3** | 254.1 | 236.2 |
| &nbsp;&nbsp;Total | **$7982.4** | $7775.9 | $7625.5 | **$6104.6** | $6103.4 | $5910.8 |
|  | Global Pest Elimination | Global Pest Elimination | Global Pest Elimination | Global Life Sciences | Global Life Sciences | Global Life Sciences |
| (millions) | **2025** | 2024 | 2023 | **2025** | 2024 | 2023 |
| United States | **$864.0** | $805.6 | $733.6 | **$205.1** | $187.3 | $187.2 |
| Europe | **205.7** | 187.5 | 171.0 | **382.4** | 374.4 | 368.6 |
| Asia Pacific | **35.1** | 32.1 | 28.7 | **54.5** | 37.2 | 33.9 |
| Latin America | **60.4** | 58.7 | 57.5 | **18.3** | 21.1 | 21.3 |
| India, Middle East and Africa | **7.0** | 7.1 | 6.9 | **31.0** | 22.4 | 9.6 |
| Greater China | **61.3** | 60.0 | 57.4 | **52.6** | 54.1 | 52.2 |
| Canada | **12.8** | 11.8 | 10.9 | **4.0** | 2.8 | 2.6 |
| &nbsp;&nbsp;Total | **$1246.3** | $1162.8 | $1066.0 | **$747.9** | $699.3 | $675.4 |
|  | Corporate | Corporate | Corporate |  |  |  |
| (millions) | **2025** | 2024 | 2023 |  |  |  |
| United States | **$-** | $- | $38.4 |  |  |  |
| Europe | **-** | - | 2.7 |  |  |  |
| Asia Pacific | **-** | - | 0.2 |  |  |  |
| Latin America | **-** | - | 1.1 |  |  |  |
| Canada | **-** | - | 0.1 |  |  |  |
| &nbsp;&nbsp;Total | **$-** | $- | $42.5 |  |  |  |

---

Net sales by geographic region were determined based on sales destination. There were no sales from a single foreign country or individual customer that were material to the Company's consolidated net sales. Sales of warewashing products were approximately 13% of consolidated net sales in 2025 and 12% in 2024 and 2023.

**Contract Asset and Liability**

Payments received from customers are based on invoices or billing schedules as established in contracts with customers. Accounts receivable are recorded when the right to consideration becomes unconditional. The Company has contract assets which relate to performance under the contract in advance of billings. Contract assets were $117.4 million as of December 31, 2025 and immaterial as of December 31, 2024. Contract assets are recorded in Other current assets within the Consolidated Balance Sheets. Current year contract assets arose as a result of current year acquisitions. In addition, the Company has contract liabilities which relate to billings in advance of performance (primarily service obligations) under the contract. Contract liabilities are recognized as revenue when the performance obligation has been performed, which primarily occurs during the subsequent quarter. Contract liabilities are recorded in Other current liabilities within the Consolidated Balance Sheets.

---

| | | |
|:---|:---|:---|
|  | **December 31** | December 31 |
| (millions) | **2025** | 2024 |
| Contract liability as of beginning of the year | **$102.0** | $110.9 |
| Revenue recognized in the year from: |  |  |
| &nbsp;&nbsp;Amounts included in the contract liability at the beginning of the year | **(102.0)** | (110.9) |
| Increases due to billings excluding amounts recognized as revenue during the year ended | **113.7** | 102.0 |
| Business combinations | **59.3** | - |
| Contract liability as of end of year | **$173.0** | $102.0 |

---

[**Table of Contents**](#Toc)

**18. OPERATING SEGMENTS AND GEOGRAPHIC INFORMATION**

The Company's organizational structure consists of global business units and market-based leadership teams. The Company's seven operating segments follow its commercial and product-based activities and are based on engagement in business activities, availability of discrete financial information and review of operating results by the Chief Operating Decision Maker ("CODM") at the identified operating segment level. The CODM is the Company's Chief Executive Officer.

The Company's operating segments that share similar economic characteristics and future prospects, nature of the products and production processes, end-use markets, channels of distribution and regulatory environment have been aggregated into four reportable segments: Global Water, Global Institutional & Specialty, Global Pest Elimination and Global Life Sciences

The Company's operating segments are aggregated as follows:

***Global Water***

Includes the Light & Heavy, Food & Beverage and Paper operating segments, which provide water treatment and process applications, and cleaning and sanitizing solutions, primarily to large industrial customers within the manufacturing, food and beverage processing, transportation, chemical, primary metals and mining, power generation, global refining, petrochemical, pulp and paper industries. The underlying operating segments exhibit similar manufacturing processes, distribution methods and economic characteristics.

***Global Institutional & Specialty***

Includes the Institutional and Specialty operating segments, which provide specialized cleaning and sanitizing products to the foodservice, healthcare, hospitality, lodging, government, education and retail industries. The underlying operating segments exhibit similar manufacturing processes, distribution methods and economic characteristics.

***Global Pest Elimination***

Includes the Pest Elimination operating segment which provides services to detect, prevent and eliminate pests, such as rodents and insects, in full-service and quick-service restaurants, food and beverage processors, hotels, grocery operations and other commercial segments including education, life sciences and healthcare. No other operating segments are aggregated into the Global Pest Elimination reportable segment.

***Global Life Sciences***

Includes the Life Sciences operating segment which provides end-to-end cleaning and contamination control solutions to pharmaceutical and personal care manufacturers. No other operating segments are aggregated into the Global Life Sciences reportable segment.

***Corporate***

Consistent with the Company's internal management reporting, Corporate amounts in the table below include sales to ChampionX under the transitional supply agreement entered into as part of the ChampionX Separation. Corporate also includes intangible asset amortization specifically from the Nalco, Purolite and Ovivo Electronics acquisitions and special (gains) and charges, as discussed in Note 3, "Special (Gains) and Charges," that are not allocated to the Company's reportable segments.

**Comparability of Reportable Segments**

Effective January 1, 2025, the Company's former Global Industrial reportable segment was renamed Global Water and includes the Light & Heavy (previously named Water), Food & Beverage, and Paper operating segments. The Global Institutional & Specialty reportable segment continues to include the Institutional and Specialty operating segments. The Company's former healthcare operating segment moved into the Institutional operating segment. Global Life Sciences was elevated to a standalone reportable segment. The Global Pest Elimination segment remains a standalone reportable segment. The Company made other immaterial changes, including the movement of certain customers and cost allocations between reportable segments. These changes are presented in the "Other" column of the tables below. Prior period amounts have been recast to conform with current period presentation.

The Company evaluates the performance of its non-U.S. dollar functional currency international operations based on fixed currency exchange rates, which eliminates the impact of exchange rate fluctuations on its international operations. Fixed currency amounts are updated annually at the beginning of each year based on translation into U.S. dollars at foreign currency exchange rates established by management, with all periods presented using such rates. The "Fixed Currency Rate Change" column shown in the following table reflects international operations at fixed currency exchange rates established by management at the beginning of 2025, rather than the 2024 established rates. The difference between the fixed currency exchange rates and the actual currency exchange rates is reported within the "Effect of foreign currency translation" row in the following table.

[**Table of Contents**](#Toc)

The impact of the preceding changes on previously reported full year 2024 and 2023 reportable segment information is summarized as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | December 31, 2024 | December 31, 2024 | December 31, 2024 | December 31, 2024 |
|  | 2024 Reported |  | Fixed | 2024 Reported |
|  | Valued at 2024 |  | Currency | Valued at 2025 |
| (millions) | Fixed Currency Rates | Other | Rate Change | Fixed Currency Rates |
| Net Sales |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Water | $7857.2 | ($1.2) | ($372.6) | $7483.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Institutional & Specialty | 5413.9 | 726.0 | (160.5) | 5979.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Pest Elimination | 1167.8 | - | (27.7) | 1140.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Life Sciences | 1434.1 | (724.8) | (38.8) | 670.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subtotal at fixed currency rates | 15873.0 | - | (599.6) | 15273.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of foreign currency translation | (131.6) | - | 599.6 | 468.0 |
| &nbsp;&nbsp;Consolidated reported GAAP net sales | $15741.4 | $- | $- | $15741.4 |
| Cost of Sales |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Water | $4691.2 | $2.0 | ($222.3) | $4470.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Institutional & Specialty | 2727.5 | 490.6 | (87.1) | 3131.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Pest Elimination | 655.0 | 0.1 | (15.3) | 639.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Life Sciences | 895.1 | (492.7) | (19.8) | 382.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate | 5.4 | - | (0.2) | $5.2 |
| &nbsp;&nbsp;Subtotal at fixed currency rates | $8974.2 | $- | ($344.7) | $8629.5 |
| Selling, General and Administrative Expenses  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Water | $1865.4 | $3.1 | ($63.2) | $1805.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Institutional & Specialty | 1503.7 | 181.2 | (38.7) | 1646.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Pest Elimination | 292.4 | 5.1 | (6.9) | 290.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Life Sciences | 391.8 | (189.4) | (6.3) | 196.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate | 199.3 | - | (3.7) | 195.6 |
| &nbsp;&nbsp;Subtotal at fixed currency rates | $4252.6 | $- | ($118.8) | $4133.8 |
| Special (Gains) and Charges |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate | (188.9) | - | 0.2 | (188.7) |
| &nbsp;&nbsp;Subtotal at fixed currency rates | ($188.9) | $- | $0.2 | ($188.7) |
| Operating Income |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Water | $1300.6 | ($6.3) | ($87.1) | $1207.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Institutional & Specialty | 1182.7 | 54.2 | (34.7) | 1202.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Pest Elimination | 220.4 | (5.2) | (5.5) | 209.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Life Sciences | 147.2 | (42.7) | (12.7) | 91.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate | (15.8) | - | 3.7 | (12.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subtotal at fixed currency rates | 2835.1 | - | (136.3) | 2698.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of foreign currency translation | (32.7) | - | 136.3 | 103.6 |
| &nbsp;&nbsp;Consolidated reported GAAP operating income | $2802.4 | $- | $- | $2802.4 |

---

[**Table of Contents**](#Toc)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | December 31, 2023 | December 31, 2023 | December 31, 2023 | December 31, 2023 |
|  | 2023 Reported |  | Fixed | 2023 Reported |
|  | Valued at 2024 |  | Currency | Valued at 2025 |
| (millions) | Fixed Currency Rates | Other | Rate Change | Fixed Currency Rates |
| Net Sales |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Water | $7640.5 | ($1.0) | ($355.4) | $7284.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Institutional & Specialty | 5014.6 | 920.7 | (155.9) | 5779.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Pest Elimination | 1070.2 | - | (25.9) | 1044.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Life Sciences | 1607.5 | (919.7) | (37.0) | 650.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate | 42.7 | - | (0.3) | 42.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subtotal at fixed currency rates | 15375.5 | - | (574.5) | 14801.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of foreign currency translation | (55.3) | - | 574.5 | 519.2 |
| &nbsp;&nbsp;Consolidated reported GAAP net sales | $15320.2 | $- | $- | $15320.2 |
| Cost of Sales |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Water | $4769.7 | $2.4 | ($223.5) | $4548.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Institutional & Specialty | 2727.3 | 664.6 | (91.9) | 3300.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Pest Elimination | 595.0 | 0.1 | (14.1) | 581.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Life Sciences | 1026.9 | (667.1) | (18.3) | 341.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate | 63.3 | - | (0.3) | 63.0 |
| &nbsp;&nbsp;Subtotal at fixed currency rates | $9182.2 | $- | ($348.1) | $8834.1 |
| Selling, General and Administrative Expenses  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Water | $1748.8 | $3.2 | ($58.6) | $1693.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Institutional & Specialty | 1445.5 | 215.4 | (38.0) | 1622.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Pest Elimination | 264.8 | 4.3 | (6.7) | 262.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Life Sciences | 419.8 | (222.9) | (6.5) | 190.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate | 200.8 | - | (3.7) | 197.1 |
| &nbsp;&nbsp;Subtotal at fixed currency rates | $4079.7 | $- | ($113.5) | $3966.2 |
| Special (Gains) and Charges |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate | 111.4 | - | (0.1) | 111.3 |
| &nbsp;&nbsp;Subtotal at fixed currency rates | $111.4 | $- | ($0.1) | $111.3 |
| Operating Income |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Water | $1122.0 | ($6.6) | ($73.3) | $1042.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Institutional & Specialty | 841.8 | 40.7 | (26.0) | 856.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Pest Elimination | 210.4 | (4.4) | (5.1) | 200.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Global Life Sciences | 160.8 | (29.7) | (12.2) | 118.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate | (332.8) | - | 3.8 | (329.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subtotal at fixed currency rates | 2002.2 | - | (112.8) | 1889.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of foreign currency translation | (9.9) | - | 112.8 | 102.9 |
| &nbsp;&nbsp;Consolidated reported GAAP operating income | $1992.3 | $- | $- | $1992.3 |

---

[**Table of Contents**](#Toc)

**Reportable Segment Information**

The Company has determined its significant segment expenses are cost of sales ("COS") and selling, general and administrative expenses ("SG&A"), which are regularly provided to the CODM at fixed currency exchange rates. Financial information for each of the Company's reportable segments were as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| (millions) | **Net Sales** | **COS** | **SG&A** | **Special (gains) and charges** | **Operating Income (Loss)** |
| Global Water | **$7679.9** | **$4585.9** | **$1830.1** | **$-** | **$1263.9** |
| Global Institutional & Specialty | **5962.0** | **2977.7** | **1626.5** | **-** | **1357.8** |
| Global Pest Elimination | **1219.2** | **686.3** | **295.8** | **-** | **237.1** |
| Global Life Sciences | **706.1** | **382.6** | **202.8** | **-** | **120.7** |
| Corporate  | **-** | **7.7** | **195.2** | **150.3** | **(353.2)** |
| &nbsp;&nbsp;Subtotal at fixed currency rates | **$15567.2** | **$8640.2** | **$4150.4** | **$150.3** | **$2626.3** |
| Effect of foreign currency translation | **514.0** |  |  |  | **111.3** |
| &nbsp;&nbsp;Consolidated reported GAAP | **$16081.2** |  |  |  | **$2737.6** |
|  | December 31, 2024 | December 31, 2024 | December 31, 2024 | December 31, 2024 | December 31, 2024 |
| (millions) | Net Sales | COS | SG&A | Special (gains) and charges | Operating Income (Loss) |
| Global Water | $7483.4 | $4470.9 | $1805.3 | $- | $1207.2 |
| Global Institutional & Specialty | 5979.4 | 3131.0 | 1646.2 | - | 1202.2 |
| Global Pest Elimination | 1140.1 | 639.8 | 290.6 | - | 209.7 |
| Global Life Sciences | 670.5 | 382.6 | 196.1 | - | 91.8 |
| Corporate  | - | 5.2 | 195.6 | (188.7) | (12.1) |
| &nbsp;&nbsp;Subtotal at fixed currency rates | $15273.4 | $8629.5 | $4133.8 | ($188.7) | $2698.8 |
| Effect of foreign currency translation | 468.0 |  |  |  | 103.6 |
| &nbsp;&nbsp;Consolidated reported GAAP | $15741.4 |  |  |  | $2802.4 |
|  | December 31, 2023 | December 31, 2023 | December 31, 2023 | December 31, 2023 | December 31, 2023 |
| (millions) | Net Sales | COS | SG&A | Special (gains) and charges | Operating Income (Loss) |
| Global Water | $7284.1 | $4548.6 | $1693.4 | $- | $1042.1 |
| Global Institutional & Specialty | 5779.4 | 3300.0 | 1622.9 | - | 856.5 |
| Global Pest Elimination | 1044.3 | 581.0 | 262.4 | - | 200.9 |
| Global Life Sciences | 650.8 | 341.5 | 190.4 | - | 118.9 |
| Corporate  | 42.4 | 63.0 | 197.1 | 111.3 | (329.0) |
| &nbsp;&nbsp;Subtotal at fixed currency rates | $14801.0 | $8834.1 | $3966.2 | $111.3 | $1889.4 |
| Effect of foreign currency translation | 519.2 |  |  |  | 102.9 |
| &nbsp;&nbsp;Consolidated reported GAAP | $15320.2 |  |  |  | $1992.3 |

---

The profitability of the Company's operating segments is evaluated by management based on operating income. On a monthly basis, the CODM primarily reviews variances in operating income compared to last year and forecast to assess segment performance, including to determine operational targets, make strategic decisions for the organization, and allocate capital and resources to the segments. Segment operating income is also used in determining the compensation of certain employees.

Consistent with the Company's internal management reporting, Corporate amounts in the table above include sales to ChampionX in accordance with the transitional supply agreement entered into with the Transaction, as discussed in Note 17, "Revenues." Corporate also includes intangible asset amortization specifically from the Nalco, Purolite and Ovivo Electronics acquisitions and special (gains) and charges, as discussed in Note 3, "Special (Gains) and Charges," that are not allocated to the Company's reportable segments.

[**Table of Contents**](#Toc)

The Company has an integrated supply chain function that serves all of its reportable segments. As such, asset and capital expenditure information by reportable segment has not been provided and is not available, since the Company does not produce or utilize such information internally. In addition, although depreciation and amortization expense is a component of each reportable segment's operating results, it is not discretely identifiable.

**Geographic Information**

Long-lived assets, which includes property, plant and equipment and right of use assets, at public exchange rates by geographic region were as follows:

---

| | | |
|:---|:---|:---|
|  | Long-Lived Assets, net | Long-Lived Assets, net |
| (millions) | **2025** | 2024 |
| United States | **$3302.0** | $3075.4 |
| Europe | **798.9** | 660.6 |
| Greater China | **273.3** | 176.0 |
| Asia Pacific | **262.6** | 241.6 |
| Latin America | **208.5** | 170.1 |
| India, Middle East and Africa | **118.6** | 78.6 |
| Canada | **78.6** | 73.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | **$5042.5** | $4475.6 |

---

Geographic data for long-lived assets is based on physical location of those assets. Refer to Note 17, "Revenues," for net sales by geographic region.

[**Table of Contents**](#Toc)

**Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.**

None.

**Item 9A. Controls and Procedures.**

***Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures*** 

As of December 31, 2025, we carried out an evaluation, under the supervision and with the participation of our management, including our Chairman and Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 as amended). Based upon that evaluation, our Chairman and Chief Executive Officer and our Chief Financial Officer concluded that, as of December 31, 2025, our disclosure controls and procedures were effective.

***Management's Report on Internal Control Over Financial Reporting***

Refer to page 47 of this Annual Report for "Management's Report on Internal Control Over Financial Reporting."

***Report of Independent Registered Public Accounting Firm***

Refer to page 48 of this Annual Report for the "Report of Independent Registered Public Accounting Firm."

***Changes in Internal Control Over Financial Reporting.***

During the period October 1, 2025 through December 31, 2025, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We are continuing our implementation of our enterprise resource planning ("ERP") system upgrades, which are expected to occur in phases over the next several years. These upgrades, which include supply chain and certain finance functions, are expected to improve the efficiency of certain financial and related transactional processes. These upgrades of the ERP systems will affect the processes that constitute our internal control over financial reporting and will require testing for effectiveness.

**Item 9B. Other Information.**

Rule 10b5-1 Plan Adoptions and Modifications.

None.

**Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.**

Not applicable.

[**Table of Contents**](#Toc)

**PART III**

**Item 10. Directors, Executive Officers and Corporate Governance.**

Information about our directors is incorporated by reference from the discussion under the heading "Proposal 1: Election of Directors" located in the Proxy Statement. Information about compliance with Section 16(a) of the Securities Exchange Act of 1934, as amended, is incorporated by reference from the discussion under the heading "Delinquent Section 16(a) Reports" located in the Proxy Statement. Information about our Audit Committee, including the members of the Committee, and our Audit Committee financial experts, is incorporated by reference from the discussion under the heading "Corporate Governance," and sub-headings "Board Committees" and "Audit Committee," located in the Proxy Statement. Information about our Code of Conduct is incorporated by reference from the discussion under the heading "Corporate Governance" located in the Proxy Statement. Information regarding our executive officers is presented under the heading "Information about our Executive Officers" in Part I, Item 1 of this Form 10-K, and is incorporated herein by reference.

The Company's Global Insider Trading Policy governs the trading of our securities by our directors, officers, employees, and consultants. It also requires the Company to comply with all applicable securities and state laws when engaging in transactions in its own securities. We believe that the policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, and listing standards applicable to the Company. A copy of the Global Insider Trading Policy is filed as Exhibit 19.1 to this Form 10-K.

**Item 11. Executive Compensation.**

Information appearing under the following headings of the Proxy Statement is incorporated herein by reference:

● Director Compensation for 2025

● Compensation & Human Capital Management Committee Interlocks and Insider Participation

● Compensation & Human Capital Management Committee Report

● Compensation Discussion and Analysis

● Compensation Tables

● Pay Ratio Disclosure

**Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.**

Information appearing under the heading entitled "Security Ownership" and "Equity Compensation Plan Information" located in the Proxy Statement is incorporated herein by reference.

A total of 34,633,342 shares of Common Stock held by our directors and executive officers, some of whom may be deemed to be "affiliates" of the Company, have been excluded from the computation of market value of our Common Stock on the cover page of this Form 10-K. This total represents that portion of the shares reported as beneficially owned by our directors and executive officers as of June 30, 2025 which are actually issued and outstanding.

**Item 13. Certain Relationships and Related Transactions, and Director Independence.**

Information appearing under the headings entitled "Director Independence" and "Related Person Transactions" located in the Proxy Statement is incorporated herein by reference.

**Item 14. Principal Accounting Fees and Services.**

Information appearing under the heading entitled "Audit Fees" located in the Proxy Statement is incorporated herein by reference..

[**Table of Contents**](#Toc)

**PART IV**

**Item 15. Exhibit and Financial Statement Schedules.**

---

| | | |
|:---|:---|:---|
| Do<br>|  |  |
|  | The following information required under this item is filed as part of this report: | The following information required under this item is filed as part of this report: |
| (a)(1) | Financial Statements. |  |
|  | **Document:** | &nbsp;&nbsp;&nbsp;&nbsp;**Page:** |
| <br> (i) | [Report of Independent Registered Public Accounting Firm](#Item8ReportofCPA). (PCAOB ID 238) | &nbsp;&nbsp;&nbsp;&nbsp;48 |
| (ii) | [Consolidated Statements of Income for the years ended December 31, 2025, 2024 and 2023.](#ConsolidatedStatementsofIncome) | &nbsp;&nbsp;&nbsp;&nbsp;50 |
| (iii) | [Consolidated Statements of Comprehensive Income for the years ended December 31, 2025, 2024 and 2023.](#ConsolidatedStatementsofComprehensiveInc) | &nbsp;&nbsp;&nbsp;&nbsp;51 |
| (iv) | [Consolidated Balance Sheets at December 31, 2025 and 2024.](#CONSOLIDATEDBALANCESHEET_843105) | &nbsp;&nbsp;&nbsp;&nbsp;52 |
| (v) | [Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023.](#ConsolidatedStatementsofCashFlows) | &nbsp;&nbsp;&nbsp;&nbsp;53 |
| (vi) | [Consolidated Statements of Equity for the years ended December 31, 2025, 2024 and 2023.](#CONSOLIDATEDSTATEMENTOFEQUITY_341682) | &nbsp;&nbsp;&nbsp;&nbsp;54 |
| (vii) | [Notes to Consolidated Financial Statements](#NotesToConsolidatedFinancialStatements). | &nbsp;&nbsp;&nbsp;&nbsp;55 |

---

---

| | | |
|:---|:---|:---|
| <br>**Exhibit No.:** | <br>**Document:** | <br>**Method of Filing:** |
| (a)(2) | Financial Statement Schedules. | Financial Statement Schedules. |
|  | All financial statement schedules are omitted because they are not applicable or the required information is shown in the consolidated financial statements or the accompanying notes to the consolidated financial statements. The separate financial statements and summarized financial information of subsidiaries not consolidated and of fifty percent or less owned persons have been omitted because they do not satisfy the requirements for inclusion in this Form 10-K. | All financial statement schedules are omitted because they are not applicable or the required information is shown in the consolidated financial statements or the accompanying notes to the consolidated financial statements. The separate financial statements and summarized financial information of subsidiaries not consolidated and of fifty percent or less owned persons have been omitted because they do not satisfy the requirements for inclusion in this Form 10-K. |
| (a)(3) | The documents below are filed as exhibits to this Report. We will, upon request and payment of a fee not exceeding the rate at which copies are available from the Securities and Exchange Commission, furnish copies of any of the following exhibits to stockholders. | The documents below are filed as exhibits to this Report. We will, upon request and payment of a fee not exceeding the rate at which copies are available from the Securities and Exchange Commission, furnish copies of any of the following exhibits to stockholders. |
| (2.1) | [Agreement and Plan of Merger and Reorganization, dated December 18, 2019, by and among Ecolab Inc., ChampionX Holding Inc., Apergy Corporation and Athena Merger Sub, Inc.](http://www.sec.gov/Archives/edgar/data/31462/000110465919075311/tm1926593d16_ex2-1.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (2.1) of our Form 8-K, dated December 18, 2019. |
| (2.2) | [Separation and Distribution Agreement, dated December 18, 2019, by and among Ecolab Inc., ChampionX Holding Inc. and Apergy Corporation](http://www.sec.gov/Archives/edgar/data/31462/000110465919075311/tm1926593d16_ex2-2.htm). | &nbsp;&nbsp;Incorporated by reference to Exhibit (2.2) of our Form 8-K, dated December 18, 2019. |
| (2.3) | [Stock and Asset Purchase Agreement, dated October 28, 2021, by and among Ecolab Inc., Purolite Corporation, a Delaware corporation ("Purolite"), Stefan E. Brodie and Don B. Brodie (the "Founder Sellers" and together with Purolite, the "Sellers") and Stefan E. Brodie, solely in his capacity as the representative of the Sellers.](https://www.sec.gov/Archives/edgar/data/31462/000155837021016420/ecl-20211201xex2d1.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (2.1) of our Form 8-K, dated December 1, 2021. |
| (3.1) | [Restated Certificate of Incorporation of Ecolab Inc., as amended and in effect as of May 8, 2025.](https://www.sec.gov/Archives/edgar/data/31462/000155837025007184/ecl-20250507xex3d1.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (3.1) of our Form 8-K, dated May 9, 2025. |
| (3.2) | [By-Laws, as amended through May 24, 2023.](https://www.sec.gov/Archives/edgar/data/31462/000110465923056030/tm2314173d1_ex3-1.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (3.1) of our Form 8-K, dated May 4, 2023. |
| (4.1) | Common Stock. | &nbsp;&nbsp;See Exhibits (3.1) and (3.2) |

---

[**Table of Contents**](#Toc)

---

| | | |
|:---|:---|:---|
| <br>**Exhibit No.:** | <br>**Document:** | <br>**Method of Filing:** |
| (4.2) | [Amended and Restated Indenture, dated January 9, 2001, between Ecolab Inc. and The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.) (as successor in interest to J.P. Morgan Trust Company, N.A. and Bank One, N.A.), as Trustee.](http://www.sec.gov/Archives/edgar/data/31462/000091205701002671/a2035733zex-4_a.txt) | &nbsp;&nbsp;Incorporated by reference to Exhibit (4)(A) of our Form 8-K, dated January 23, 2001. |
| (4.3) | [Second Supplemental Indenture, dated December 8, 2011, between Ecolab Inc., Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as Trustee and The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.) (as successor in interest to J.P. Morgan Trust Company, N.A. and Bank One, N.A.), as original trustee.](http://www.sec.gov/Archives/edgar/data/31462/000110465911068432/a11-31315_1ex4d2.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (4.2) of our Form 8-K, dated December 5, 2011. |
| (4.4) | Form of 5.500% Notes due 2041. | &nbsp;&nbsp;Included in Exhibit (4.3) above. |
| (4.5) | [Indenture, dated January 12, 2015, between Ecolab Inc. and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as Trustee.](http://www.sec.gov/Archives/edgar/data/31462/000110465915002678/a15-1358_5ex4d1.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit 4.1 of our Form 8-K, dated January 15, 2015. |
| (4.6) | [Fourth Supplemental Indenture, dated October 18, 2016, between Ecolab Inc. and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as Trustee.](http://www.sec.gov/Archives/edgar/data/31462/000110465916150736/a16-19670_3ex4d2.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (4.2) of our Form 8-K, dated October 13, 2016. |
| (4.7) | Forms of 2.700% Notes due 2026. | &nbsp;&nbsp;Included in Exhibit (4.6) above. |
| (4.8) | Forms of 3.700% Notes due 2046. | &nbsp;&nbsp;Included in Exhibit (4.6) above. |
| (4.9) | [Seventh Supplemental Indenture, dated November 27, 2017, between Ecolab Inc. and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as Trustee.](http://www.sec.gov/Archives/edgar/data/31462/000155837017009111/ex-4d2.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (4.2) of our Form 8-K, dated November 30, 2017. |
| (4.10) | Form of 3.250% Notes due 2027. | &nbsp;&nbsp;Included in Exhibit (4.9) above. |
| (4.11) | Form of 3.950% Notes due 2047. | &nbsp;&nbsp;Included in Exhibit (4.9) above. |
| (4.12) | [Eighth Supplemental Indenture, dated March 24, 2020, between Ecolab Inc. and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as Trustee.](https://www.sec.gov/Archives/edgar/data/31462/000110465920037828/tm2012952d5_ex4-2.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (4.2) of our Form 8-K filed on March 24, 2020. |
| (4.13) | Form of 4.800% Notes due 2030. | &nbsp;&nbsp;Included in Exhibit (4.12) above. |
| (4.14) | [Ninth Supplemental Indenture, dated August 13, 2020, between Ecolab Inc. and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as Trustee](https://www.sec.gov/Archives/edgar/data/31462/000110465920094714/tm2026912d5_ex4-2.htm). | &nbsp;&nbsp;Incorporated by reference to Exhibit (4.2) of our Form 8-K filed on August 13, 2020. |
| (4.15) | Form of 1.300% Notes due 2031. | &nbsp;&nbsp;Included in Exhibit (4.14) above. |
| (4.16) | Form of 2.125% Notes due 2050. | &nbsp;&nbsp;Included in Exhibit (4.14) above. |
| (4.17) | [Tenth Supplemental Indenture, dated August 18, 2021, between Ecolab Inc. and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as Trustee.](https://www.sec.gov/Archives/edgar/data/0000031462/000155837021011959/ecl-20210809xex4d2.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (4.2) of our Form 8-K filed on August 19, 2021. |
| (4.18) | Form of 2.750% Notes due 2055. | &nbsp;&nbsp;Included in Exhibit (4.17) above. |
| (4.19) | [Eleventh Supplemental Indenture, dated December 15, 2021, between Ecolab Inc. and Computershare Trust Company, N.A., as Trustee.](https://www.sec.gov/Archives/edgar/data/0000031462/000155837021016826/ecl-20211215xex4d2.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (4.2) of our Form 8-K filed on December 15, 2021. |

---

[**Table of Contents**](#Toc)

---

| | | | |
|:---|:---|:---|:---|
| <br>**Exhibit No.:** | **Document:** | **Document:** | <br>**Method of Filing:** |
|  |  | <br><BORDER_TOP>.1 |  |
| (4.20) | Form of 1.650% Notes due 2027. | Form of 1.650% Notes due 2027. | &nbsp;&nbsp;Included in Exhibit (4.19) above. |
| (4.21) | Form of 2.125% Notes due 2032. | Form of 2.125% Notes due 2032. | &nbsp;&nbsp;Included in Exhibit (4.19) above. |
| (4.22) | Form of 2.700% Notes due 2051. | Form of 2.700% Notes due 2051. | &nbsp;&nbsp;Included in Exhibit (4.19) above. |
| (4.23) | [Twelfth Supplemental Indenture, dated as of November 17, 2022, between Ecolab Inc. and Computershare Trust Company, N.A., as Trustee.](https://www.sec.gov/Archives/edgar/data/31462/000155837022018040/ecl-20221117xex4d2.htm)  | [Twelfth Supplemental Indenture, dated as of November 17, 2022, between Ecolab Inc. and Computershare Trust Company, N.A., as Trustee.](https://www.sec.gov/Archives/edgar/data/31462/000155837022018040/ecl-20221117xex4d2.htm)  | &nbsp;&nbsp;Incorporated by reference to Exhibit (4.2) of our Form 8-K filed on November 17, 2022. |
| (4.24) | Form of 5.250% Notes due 2028. | Form of 5.250% Notes due 2028. | &nbsp;&nbsp;Included in Exhibit (4.23) above. |
| (4.25) | [Thirteenth Supplemental Indenture, dated as of June 5, 2025, between Ecolab Inc. and Computershare Trust Company, N.A., as Trustee.](https://www.sec.gov/Archives/edgar/data/31462/000110465925056841/tm2517075d1_ex4-2.htm) | [Thirteenth Supplemental Indenture, dated as of June 5, 2025, between Ecolab Inc. and Computershare Trust Company, N.A., as Trustee.](https://www.sec.gov/Archives/edgar/data/31462/000110465925056841/tm2517075d1_ex4-2.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (4.2) of our Form 8-K, dated June 5, 2025. |
| (4.26) | Form of 4.300% Notes due 2028. | Form of 4.300% Notes due 2028. | &nbsp;&nbsp;Included in Exhibit (4.25) above. |
| (4.27) | [Fourteenth Supplemental Indenture, dated as of August 27, 2025, between Ecolab Inc. and Computershare Trust Company, N.A., as Trustee.](https://www.sec.gov/Archives/edgar/data/31462/000110465925084059/tm2523475d5_ex4-2.htm) | [Fourteenth Supplemental Indenture, dated as of August 27, 2025, between Ecolab Inc. and Computershare Trust Company, N.A., as Trustee.](https://www.sec.gov/Archives/edgar/data/31462/000110465925084059/tm2523475d5_ex4-2.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (4.2) of our Form 8-K, dated August 27, 2025. |
| (4.28) | Form of 5.000% Notes due 2035. | Form of 5.000% Notes due 2035. | &nbsp;&nbsp;Included in Exhibit (4.27) above. |
| (4.29) | [Description of Securities.](ecl-20251231xex4d29.htm) | [Description of Securities.](ecl-20251231xex4d29.htm) | &nbsp;&nbsp;Filed herewith electronically. |
|  | Copies of other constituent instruments defining the rights of holders of our long-term debt are not filed herewith, pursuant to Section (b)(4)(iii) of Item 601 of Regulation S-K, because the aggregate amount of securities authorized under each of such instruments is less than 10% of our total assets on a consolidated basis. We will, upon request by the Securities and Exchange Commission, furnish to the Commission a copy of each such instrument. | Copies of other constituent instruments defining the rights of holders of our long-term debt are not filed herewith, pursuant to Section (b)(4)(iii) of Item 601 of Regulation S-K, because the aggregate amount of securities authorized under each of such instruments is less than 10% of our total assets on a consolidated basis. We will, upon request by the Securities and Exchange Commission, furnish to the Commission a copy of each such instrument. | Copies of other constituent instruments defining the rights of holders of our long-term debt are not filed herewith, pursuant to Section (b)(4)(iii) of Item 601 of Regulation S-K, because the aggregate amount of securities authorized under each of such instruments is less than 10% of our total assets on a consolidated basis. We will, upon request by the Securities and Exchange Commission, furnish to the Commission a copy of each such instrument. |
| (10.1) | [Fourth Amended and Restated Multicurrency Credit Agreement, dated as of March 24, 2025, among Ecolab Inc., the lenders party thereto, the issuing lenders party thereto, and Bank of America, N.A., as administrative agent and swing line bank.](https://www.sec.gov/Archives/edgar/data/31462/000155837025004012/ecl-20250324xex10d1.htm) | [Fourth Amended and Restated Multicurrency Credit Agreement, dated as of March 24, 2025, among Ecolab Inc., the lenders party thereto, the issuing lenders party thereto, and Bank of America, N.A., as administrative agent and swing line bank.](https://www.sec.gov/Archives/edgar/data/31462/000155837025004012/ecl-20250324xex10d1.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.1) of our Form 8-K, dated March 28, 2025. |
| (10.2) | Documents comprising global Commercial Paper Programs. | Documents comprising global Commercial Paper Programs. |  |
|  | U.S. $2,000,000,000 Euro-Commercial Paper Programme. | U.S. $2,000,000,000 Euro-Commercial Paper Programme. | U.S. $2,000,000,000 Euro-Commercial Paper Programme. |
|  | (a)  | [Amended and Restated Dealer Agreement, dated 30 October 2023, between Ecolab Inc., Ecolab NL 10 B.V., Ecolab NL 11 B.V. and Nalco Overseas Holding B.V. (as Issuers), Ecolab Inc. (as Guarantor in respect of the notes issued by Ecolab NL 10 B.V., Ecolab NL 11 B.V. and Nalco Overseas Holding B.V.), Barclays Bank PLC (as Arranger), and Barclays Bank Ireland PLC, Barclays Bank PLC, Citigroup Global Markets Europe AG and Citigroup Global Markets Limited (as Dealers).](https://www.sec.gov/Archives/edgar/data/31462/000155837024001581/ecl-20231231xex10d2ia.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.2)(i)(a) of our Form 10-K Annual Report for the year ended December 31, 2023. |
|  | (b) | [Amended and Restated Note Agency Agreement, dated 30 October 2023, between Ecolab Inc., Ecolab NL 10 B.V. Ecolab NL 11 B.V. and Nalco Overseas Holding B.V. (as Issuers), Ecolab Inc. (as Guarantor in respect of the notes issued by Ecolab NL 10 B.V., Ecolab NL 11 B.V. and Nalco Overseas Holding B.V.), and Citibank, N.A., London Branch (as Issue and Paying Agent).](https://www.sec.gov/Archives/edgar/data/31462/000155837024001581/ecl-20231231xex10d2ib.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.2)(i)(b)of our Form 10-K Annual Report for the year ended December 31, 2023. |
|  | (c) | [Deed of Covenant made on 30 October 2023 by Ecolab Inc., Ecolab NL 10 B.V., Ecolab NL 11 B.V. and Nalco Overseas Holding B.V. (as Issuers).](https://www.sec.gov/Archives/edgar/data/31462/000155837024001581/ecl-20231231xex10d2ic.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.2)(i)(c) of our Form 10-K Annual Report for the year ended December 31, 2023. |

---

[**Table of Contents**](#Toc)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| <br>**Exhibit No.:** |  | **Document:** | **Document:** | **Document:** | <br>**Method of Filing:** |
|  |  |  |  | <br><BORDER_TOP>.1 |  |
|  |  |  | (d) | [Deed of Guarantee made on 30 October 2023 by Ecolab Inc. (in respect of notes issued by Ecolab NL 10 B.V., Ecolab NL 11 B.V. and Nalco Overseas Holding B.V.).](https://www.sec.gov/Archives/edgar/data/31462/000155837024001581/ecl-20231231xex10d2id.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.2)(i)(d)of our Form 10-K Annual Report for the year ended December 31, 2023. |
|  |  | (ii) | U.S. $2,000,000,000 U.S. Commercial Paper Program. | U.S. $2,000,000,000 U.S. Commercial Paper Program. | U.S. $2,000,000,000 U.S. Commercial Paper Program. |
|  |  |  | (a) | [Form of Commercial Paper Dealer Agreement for 4(a)(2) Program, dated September 22, 2014. The dealers for the program are Barclays Capital Inc., Citigroup Global Markets Inc., BofA Securities, Inc., and Wells Fargo Securities, LLC.](http://www.sec.gov/Archives/edgar/data/31462/000110465914075274/a14-19657_1ex10d1a.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.1)(a) of our Form 10-Q for the quarter ended September 30, 2014. |
|  |  |  | (b) | [Issuing and Paying Agent Agreement, dated September 18, 2017, between Ecolab Inc. and U.S. Bank National Association, as Issuing and Paying Agent (as successor, effective as of June 7, 2021, to MUFG Union Bank, N.A.).](https://www.sec.gov/Archives/edgar/data/0000031462/000155837017008023/ecl-20170930ex101ae3437.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.1)(a) of our Form 10 Q for the quarter ended September 30, 2017. |
|  |  |  | (c) | [Corporate Commercial Paper – Master Note, dated June 7, 2021, together with annex thereto.](https://www.sec.gov/Archives/edgar/data/0000031462/000155837021010420/ecl-20210630xex10d3ii.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.3)(ii) of our Form 10 Q for the quarter ended June 30, 2021. |
| (10.3) | † | (i) | [Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan, as amended and restated, effective as of August 1, 2013.](http://www.sec.gov/Archives/edgar/data/31462/000110465914014489/a13-25814_1ex10d6.htm) | [Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan, as amended and restated, effective as of August 1, 2013.](http://www.sec.gov/Archives/edgar/data/31462/000110465914014489/a13-25814_1ex10d6.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.6) of our Form 10-K Annual Report for the year ended December 31, 2013. |
|  | † | (ii) | [Declaration of Amendment, dated May 5, 2016, to Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan, as amended and restated, effective as of August 1, 2013.](http://www.sec.gov/Archives/edgar/data/31462/000155837016007312/ecl-20160630ex101fe13fc.htm) | [Declaration of Amendment, dated May 5, 2016, to Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan, as amended and restated, effective as of August 1, 2013.](http://www.sec.gov/Archives/edgar/data/31462/000155837016007312/ecl-20160630ex101fe13fc.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.1) of our Form 10-Q for the quarter ended June 30, 2016. |
|  | † | (iii) | [Declaration of Amendment No. 2, dated December 4, 2025, to Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan, as amended and restated, effective as of August 1, 2023.](ecl-20251231xex10diii.htm) | [Declaration of Amendment No. 2, dated December 4, 2025, to Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan, as amended and restated, effective as of August 1, 2023.](ecl-20251231xex10diii.htm) | &nbsp;&nbsp;Filed herewith electronically. |
|  | † | (iv) | [Sample form of Master Agreement Relating to Periodic Options.](ecl-20251231xex10div.htm) | [Sample form of Master Agreement Relating to Periodic Options.](ecl-20251231xex10div.htm) | &nbsp;&nbsp;Filed herewith electronically. |
| (10.4) | † | [Form of Indemnification Agreement, effective as of December 7, 2023. Substantially identical agreements are in effect as to each of our directors and certain of our officers.](https://www.sec.gov/Archives/edgar/data/31462/000155837024001581/ecl-20231231xex10d4.htm) | [Form of Indemnification Agreement, effective as of December 7, 2023. Substantially identical agreements are in effect as to each of our directors and certain of our officers.](https://www.sec.gov/Archives/edgar/data/31462/000155837024001581/ecl-20231231xex10d4.htm) | [Form of Indemnification Agreement, effective as of December 7, 2023. Substantially identical agreements are in effect as to each of our directors and certain of our officers.](https://www.sec.gov/Archives/edgar/data/31462/000155837024001581/ecl-20231231xex10d4.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.4) of our Form 10-K Annual Report for the year ended December 31, 2023. |
| (10.5) | † | (i) | [Ecolab Executive Death Benefits Plan, as amended and restated, effective as of March 1, 1994.](http://www.sec.gov/Archives/edgar/data/31462/000110465907015053/a07-5385_1ex10dhi.htm) | [Ecolab Executive Death Benefits Plan, as amended and restated, effective as of March 1, 1994.](http://www.sec.gov/Archives/edgar/data/31462/000110465907015053/a07-5385_1ex10dhi.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10)H(i) of our Form 10-K Annual Report for the year ended December 31, 2006. See also Exhibit (10.12) hereof. |
|  | † | (ii) | [Amendment No. 1 to Ecolab Executive Death Benefits Plan, effective as of July 1, 1997.](http://www.sec.gov/Archives/edgar/data/31462/0001047469-99-012518.txt) | [Amendment No. 1 to Ecolab Executive Death Benefits Plan, effective as of July 1, 1997.](http://www.sec.gov/Archives/edgar/data/31462/0001047469-99-012518.txt) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10)H(ii) of our Form 10-K Annual Report for the year ended December 31, 1998. |
|  | † | (iii) | [Second Declaration of Amendment to Ecolab Executive Death Benefits Plan, effective as of March 1, 1998.](http://www.sec.gov/Archives/edgar/data/31462/0001047469-99-012518.txt) | [Second Declaration of Amendment to Ecolab Executive Death Benefits Plan, effective as of March 1, 1998.](http://www.sec.gov/Archives/edgar/data/31462/0001047469-99-012518.txt) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10)H(iii) of our Form 10-K Annual Report for the year ended December 31, 1998. |
|  | † | (iv) | [Amendment No. 3 to the Ecolab Executive Death Benefits Plan, effective as of August 12, 2005.](http://www.sec.gov/Archives/edgar/data/31462/000110465905061316/a05-21896_1ex10db.htm) | [Amendment No. 3 to the Ecolab Executive Death Benefits Plan, effective as of August 12, 2005.](http://www.sec.gov/Archives/edgar/data/31462/000110465905061316/a05-21896_1ex10db.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10)B of our Form 8-K, dated December 13, 2005. |
|  | † | (v) | [Amendment No. 4 to the Ecolab Executive Death Benefits Plan, effective as of January 1, 2005.](http://www.sec.gov/Archives/edgar/data/31462/000110465910010302/a09-36096_1ex10dhdv.htm) | [Amendment No. 4 to the Ecolab Executive Death Benefits Plan, effective as of January 1, 2005.](http://www.sec.gov/Archives/edgar/data/31462/000110465910010302/a09-36096_1ex10dhdv.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10)H(v) of our Form 10-K Annual Report for the year ended December 31, 2009. |
|  | † | (vi) | [Amendment No. 5 to the Ecolab Executive Death Benefits Plan, effective as of May 6, 2015.](http://www.sec.gov/Archives/edgar/data/31462/000110465915056831/a15-11987_1ex10d2.htm) | [Amendment No. 5 to the Ecolab Executive Death Benefits Plan, effective as of May 6, 2015.](http://www.sec.gov/Archives/edgar/data/31462/000110465915056831/a15-11987_1ex10d2.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit 10.2 of our Form 10-Q for the quarter ended June 30, 2015. |

---

[**Table of Contents**](#Toc)

---

| | | | | |
|:---|:---|:---|:---|:---|
| <br>**Exhibit No.:** |  | **Document:** | **Document:** | <br>**Method of Filing:** |
|  | † | (vii) | [Amendment No. 6 to the Ecolab Executive Death Benefits Plan, effective as of June 23, 2017](http://www.sec.gov/Archives/edgar/data/31462/000155837017004928/ex-10d1vii.htm). | &nbsp;&nbsp;Incorporated by reference to Exhibit 10.1(vii) of Ecolab's Form 8-K dated June 23, 2017. |
| (10.6) | † | (i) | [Ecolab Executive Long-Term Disability Plan, as amended and restated, effective as of January 1, 1994.](http://www.sec.gov/Archives/edgar/data/31462/000110465905009384/a05-1766_1ex10di.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10)I of our Form 10-K Annual Report for the year ended December 31, 2004. See also Exhibit (10.12) hereof. |
|  | † | (ii) | [Amendment No. 1 to the Ecolab Executive Long-Term Disability Plan, effective as of August 21, 2015.](http://www.sec.gov/Archives/edgar/data/31462/000110465915074906/a15-17904_1ex10d1.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit 10.1 of our Form 10-Q for the quarter ended September 30, 2015. |
| (10.7) | † | (i) | [Ecolab Supplemental Executive Retirement Plan, as amended and restated, effective as of January 1, 2022.](https://www.sec.gov/Archives/edgar/data/31462/000155837022002059/ecl-20211231xex10d7.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.7) of our Form 10-K Annual Report for the year ended December 31, 2021. |
| (10.8) | † | (i) | [Ecolab Mirror Savings Plan, as amended and restated, effective as of January 1, 2022.](https://www.sec.gov/Archives/edgar/data/31462/000155837022002059/ecl-20211231xex10d8.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.8) of our Form 10-K Annual Report for the year ended December 31, 2021. |
| (10.9) | † | (i) | [Ecolab Mirror Pension Plan, as amended and restated, effective as of January 1, 2022.](https://www.sec.gov/Archives/edgar/data/31462/000155837022002059/ecl-20211231xex10d9.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.9) of our Form 10-K Annual Report for the year ended December 31, 2021. |
| (10.10) | † | (i) | [Ecolab Inc. Administrative Document for Non-Qualified Plans, as amended and restated, effective as of January 1, 2022.](https://www.sec.gov/Archives/edgar/data/31462/000155837022002059/ecl-20211231xex10d10.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.10) of our Form 10-K Annual Report for the year ended December 31, 2021. |
| (10.11) | † | (i) | [Ecolab Inc. Change in Control Severance Compensation Policy, as amended and restated, effective as of February 26, 2010.](http://www.sec.gov/Archives/edgar/data/31462/000110465910010733/a10-4808_1ex10.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10) of our Form 8-K, dated February 26, 2010. |
|  | † | (ii) | [Amendment No. 1 to Ecolab Inc. Change-in-Control Severance Policy, as amended and restated, effective as of February 26, 2010.](http://www.sec.gov/Archives/edgar/data/31462/000110465912014104/a11-30850_1ex10d18dii.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.18)(ii) of our Form 10-K Annual Report for the year ended December 31, 2011. |
| (10.12) | † | [Description of Ecolab Management Incentive Plan.](https://www.sec.gov/Archives/edgar/data/31462/000155837025001263/ecl-20241231xex10d12.htm) | [Description of Ecolab Management Incentive Plan.](https://www.sec.gov/Archives/edgar/data/31462/000155837025001263/ecl-20241231xex10d12.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.12) of our Form 10-K Annual Report for the year ended December 31, 2024. |
| (10.13) | † | (i) | [Ecolab Inc. 2010 Stock Incentive Plan, as amended and restated, effective as of May 2, 2013.](https://www.sec.gov/Archives/edgar/data/31462/000110465913037176/a13-11488_1ex10d1.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.1) of our Form 8-K, dated May 2, 2013. |
|  | † | (ii) | [Declaration of Amendment, effective as of February 22, 2019, to Ecolab Inc. 2010 Stock Incentive Plan, as amended and restated, effective as of May 2, 2013.](http://www.sec.gov/Archives/edgar/data/31462/000155837019003797/ecl-20190331ex103a84689.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.3) of our Form 10-Q, for the quarter ended March 31, 2019. |
|  | † | (iii) | [Sample form of Non-Statutory Stock Option Agreement under the Ecolab Inc. 2010 Stock Incentive Plan, adopted May 6, 2010.](https://www.sec.gov/Archives/edgar/data/31462/000110465910027659/a10-9867_1ex10db.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10)B of our Form 8-K, dated May 6, 2010. |
|  | † | (iv) | [Sample form of Restricted Stock Unit Award Agreement under the Ecolab Inc. 2010 Stock Incentive Plan, adopted August 4, 2010.](http://www.sec.gov/Archives/edgar/data/31462/000110465910056085/a10-17257_1ex10da.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10)A of our Form 10-Q, for the quarter ended September 30, 2010. |
|  | † | (v)  | [Sample form of Performance-Based Restricted Stock Unit Award Agreement under the Ecolab Inc. 2010 Stock Incentive Plan, adopted December 1, 2021.](https://www.sec.gov/Archives/edgar/data/31462/000155837022002059/ecl-20211231xex10d13ix.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.13)(ix) of our Form 10-K Annual Report for the year ended December 31, 2021. |
| (10.14) | † | (i) | [Ecolab Inc. 2023 Stock Incentive Plan, effective as of May 4, 2023.](https://www.sec.gov/Archives/edgar/data/31462/000155837023013204/ecl-20230630xex10d1.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.1) of our Form 10-Q, for the quarter ended June 30, 2023. |
|  | † | (ii) | [Amendment No. 1 to Ecolab Inc. 2023 Stock Incentive Plan, adopted December 4, 2024.](https://www.sec.gov/Archives/edgar/data/31462/000155837025001263/ecl-20241231xex10d14ii.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.14)(ii) of our Form 10-K Annual Report for the year ended December 31, 2024. |

---

[**Table of Contents**](#Toc)

---

| | | | | |
|:---|:---|:---|:---|:---|
| <br>**Exhibit No.:** |  | **Document:** | **Document:** | <br>**Method of Filing:** |
|  | † | (iii) | [Sample form of Non-Statutory Stock Option Agreement under the Ecolab Inc. 2023 Stock Incentive Plan, adopted May 4, 2023.](https://www.sec.gov/Archives/edgar/data/31462/000155837023013204/ecl-20230630xex10d2.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.2) of our Form 10-Q, for the quarter ended June 30, 2023. |
|  | † | (iv) | [Sample form of Restricted Stock Unit Award Agreement under the Ecolab Inc. 2023 Stock Incentive Plan, adopted May 4, 2023.](https://www.sec.gov/Archives/edgar/data/31462/000155837023013204/ecl-20230630xex10d4.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.4) of our Form 10-Q, for the quarter ended June 30, 2023. |
|  | † | (v) | [Sample form of Performance-Based Restricted Stock Unit Award Agreement under the Ecolab Inc. 2023 Stock Incentive Plan, adopted December 6, 2023.](https://www.sec.gov/Archives/edgar/data/31462/000155837024001581/ecl-20231231xex10d14iv.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.14)(iv) of our Form 10-K Annual Report for the year ended December 31, 2023. |
| (10.15) | † | [Nalco Company Supplemental Retirement Income Plan, as Amended and Restated effective as of December 31, 2012.](https://www.sec.gov/Archives/edgar/data/31462/000155837023008089/ecl-20230331xex10d3.htm) | [Nalco Company Supplemental Retirement Income Plan, as Amended and Restated effective as of December 31, 2012.](https://www.sec.gov/Archives/edgar/data/31462/000155837023008089/ecl-20230331xex10d3.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.3) of our Form 10-Q, for the quarter ended March 31, 2023.  |
| (10.16) | † | [Nalco Company Supplemental Profit Sharing Plan, as Amended and Restated effective as of December 31, 2012.](https://www.sec.gov/Archives/edgar/data/31462/000155837023008089/ecl-20230331xex10d4.htm) | [Nalco Company Supplemental Profit Sharing Plan, as Amended and Restated effective as of December 31, 2012.](https://www.sec.gov/Archives/edgar/data/31462/000155837023008089/ecl-20230331xex10d4.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.4) of our Form 10-Q, for the quarter ended March 31, 2023.  |
| (10.17) | † | [Form of Nalco Company Death Benefit Agreement and Addendum to Death Benefit Agreement.](http://www.sec.gov/Archives/edgar/data/1298341/000129834105000049/ex99_2deathbenefitagr.htm) | [Form of Nalco Company Death Benefit Agreement and Addendum to Death Benefit Agreement.](http://www.sec.gov/Archives/edgar/data/1298341/000129834105000049/ex99_2deathbenefitagr.htm) | &nbsp;&nbsp;Incorporated by reference from Exhibit (99.2) on Form 8-K of Nalco Holding Company filed on May 11, 2005. (File No. 001-32342) |
| (10.18) | † | [Death Benefit Agreement between Nalco Company and Laurie M. Marsh effective as of December 17, 2009.](https://www.sec.gov/Archives/edgar/data/31462/000155837023008089/ecl-20230331xex10d5.htm) | [Death Benefit Agreement between Nalco Company and Laurie M. Marsh effective as of December 17, 2009.](https://www.sec.gov/Archives/edgar/data/31462/000155837023008089/ecl-20230331xex10d5.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (10.5) of our Form 10-Q, for the quarter ended March 31, 2023. |
| (19.1) | † | [Ecolab Inc. Global Insider Trading Policy, effective December 5, 2024.](https://www.sec.gov/Archives/edgar/data/31462/000155837025001263/ecl-20241231xex19d1.htm) | [Ecolab Inc. Global Insider Trading Policy, effective December 5, 2024.](https://www.sec.gov/Archives/edgar/data/31462/000155837025001263/ecl-20241231xex19d1.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (19.1) of our Form 10-K Annual Report for the year ended December 31, 2024. |
| (21.1) |  | [List of Subsidiaries.](ecl-20251231xex21d1.htm) | [List of Subsidiaries.](ecl-20251231xex21d1.htm) | &nbsp;&nbsp;Filed herewith electronically. |
| (23.1) |  | [Consent of Independent Registered Public Accounting Firm.](ecl-20251231xex23d1.htm) | [Consent of Independent Registered Public Accounting Firm.](ecl-20251231xex23d1.htm) | &nbsp;&nbsp;Filed herewith electronically. |
| (24.1) |  | [Powers of Attorney.](ecl-20251231xex24d1.htm) | [Powers of Attorney.](ecl-20251231xex24d1.htm) | &nbsp;&nbsp;Filed herewith electronically. |
| (31.1) |  | [Rule 13a-14(a) CEO Certification.](ecl-20251231xex31d1.htm) | [Rule 13a-14(a) CEO Certification.](ecl-20251231xex31d1.htm) | &nbsp;&nbsp;Filed herewith electronically. |
| (31.2) |  | [Rule 13a-14(a) CFO Certification.](ecl-20251231xex31d2.htm) | [Rule 13a-14(a) CFO Certification.](ecl-20251231xex31d2.htm) | &nbsp;&nbsp;Filed herewith electronically. |
| (32.1) |  | [Section 1350 CEO and CFO Certifications.](ecl-20251231xex32d1.htm) | [Section 1350 CEO and CFO Certifications.](ecl-20251231xex32d1.htm) | &nbsp;&nbsp;Filed herewith electronically. |
| (97.1) |  | [Ecolab Inc. Rule 10D-1 Clawback Policy, adopted November 2, 2023.](https://www.sec.gov/Archives/edgar/data/31462/000155837024001581/ecl-20231231xex97d1.htm) | [Ecolab Inc. Rule 10D-1 Clawback Policy, adopted November 2, 2023.](https://www.sec.gov/Archives/edgar/data/31462/000155837024001581/ecl-20231231xex97d1.htm) | &nbsp;&nbsp;Incorporated by reference to Exhibit (97.1) of our Form 10-K Annual Report for the year ended December 31, 2023. |
| (101.INS) |  | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | &nbsp;&nbsp;Filed herewith electronically. |
| (101.SCH) |  | Inline XBRL Taxonomy Extension Schema. | Inline XBRL Taxonomy Extension Schema. | &nbsp;&nbsp;Filed herewith electronically. |
| (101.CAL) |  | Inline XBRL Taxonomy Extension Calculation Linkbase. | Inline XBRL Taxonomy Extension Calculation Linkbase. | &nbsp;&nbsp;Filed herewith electronically. |
| (101.DEF) |  | Inline XBRL Taxonomy Extension Definition Linkbase. | Inline XBRL Taxonomy Extension Definition Linkbase. | &nbsp;&nbsp;Filed herewith electronically. |
| (101.LAB) |  | Inline XBRL Taxonomy Extension Label Linkbase. | Inline XBRL Taxonomy Extension Label Linkbase. | &nbsp;&nbsp;Filed herewith electronically. |
| (101.PRE) |  | Inline XBRL Taxonomy Extension Presentation Linkbase. | Inline XBRL Taxonomy Extension Presentation Linkbase. | &nbsp;&nbsp;Filed herewith electronically. |
| (104) |  | Cover Page Interactive Data File. | Cover Page Interactive Data File. | &nbsp;&nbsp;Formatted as Inline XBRL and contained in Exhibit 101. |

---

† This exhibit is an executive compensation plan or arrangement.

[**Table of Contents**](#Toc)

**Item 16. Form 10-K Summary.**

None.

[**Table of Contents**](#Toc)

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, Ecolab Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on the 23<sup>rd</sup> day of February, 2026.

---

| | |
|:---|:---|
| ECOLAB INC. | ECOLAB INC. |
| (Registrant) | (Registrant) |
| By:  | /s/ Christophe Beck |
|  | Christophe Beck |
|  | Chairman and Chief Executive Officer |

---

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of Ecolab Inc. and in the capacities indicated, on the 23<sup>rd</sup> day of February, 2026.

---

| | |
|:---|:---|
| /s/ Christophe Beck | Chairman and Chief Executive Officer |
| Christophe Beck | (Principal Executive Officer and Director) |
| /s/ Scott D. Kirkland | Chief Financial Officer |
| Scott D. Kirkland | (Principal Financial Officer) |
| /s/ Jennifer J. Bradway | Senior Vice President and Corporate Controller |
| Jennifer J. Bradway | (duly authorized officer and Principal Accounting Officer) |
| /s/ Jandeen M. Boone | Directors |
| Jandeen M. Boone |  |
| as attorney-in-fact for: |  |
| Judson B. Althoff, Shari L. Ballard, Michel D. Doukeris, Eric M. Green, Marion K. Gross, Michael Larson, David W. MacLennan, Tracy B. McKibben, Lionel L. Nowell, III, Victoria J. Reich, Suzanne M. Vautrinot, Julie P. Whalen and John J. Zillmer |  |

---

## Exhibit 4.29

**EXHIBIT (4.29)**

**DESCRIPTION OF ECOLAB INC. COMMON STOCK**

The following description of Ecolab common stock, which is registered under Section 12 of the Securities Exchange Act of 1934, as amended, is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to Ecolab's Restated Certificate of Incorporation (the "Certificate of Incorporation") and Ecolab's By-Laws (the "Bylaws"), each of which is an exhibit to Ecolab's Annual Report on Form 10-K. We encourage you to read our Certificate of Incorporation, our Bylaws and the applicable provisions of the Delaware General Corporation Law, Title 8, Chapter 1 of the Delaware Code ("DGCL") for additional information.

References herein to "we," "our," "us," the "Company" or "Ecolab" refers to Ecolab Inc., a Delaware corporation.

**Authorized Capital Stock**

Under Ecolab's Certificate of Incorporation, Ecolab's authorized capital stock consists of 800,000,000 shares of common stock, par value $1.00 per share, and 15,000,000 shares of preferred stock, no par value.

**Common Stock**

Under Ecolab's Bylaws, the holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. Ecolab's Bylaws establish that directors shall be elected by the vote of the majority of the votes cast at any meeting for the election of directors at which a quorum is present; provided, however, that directors shall be elected by a plurality of the votes cast at any meeting of stockholders for which the number of nominees exceeds the number of directors to be elected as of the 10th day preceding the date Ecolab first mails its notice of meeting for such meeting to the stockholders. Holders of common stock do not have cumulative voting rights.

Subject to preferences that may be applicable to any outstanding preferred stock, holders of common stock are entitled to receive ratably such dividends as may be declared by the board of directors out of funds legally available therefor. In the event of our liquidation or dissolution, holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preference of any outstanding preferred stock.

Holders of common stock have no preemptive rights and have no rights to convert their common stock into any other securities. Ecolab common stock is not redeemable and is not subject to any sinking fund provisions.

**Preferred Stock**

Our board of directors is authorized without further action of the stockholders to issue preferred stock in one or more series and may fix the designations and the powers, preferences and rights of the preferred stock. No class of preferred stock is currently outstanding.

------

**Certain Provisions of Ecolab's Certificate of Incorporation, Bylaws and the DGCL**

*State Antitakeover Statute*

Ecolab is subject to Section 203 of the DGCL, which, subject to certain exceptions, prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years following the time such stockholder became an interest stockholder.

*Amendments to Certificate of Incorporation and Bylaws*

The DGCL generally permits the adoption of amendments to the Certificate of Incorporation if those amendments are approved and declared advisable by the board of directors of the corporation and adopted by the holders of a majority of the outstanding shares of stock of the corporation, unless the Certificate of Incorporation requires a greater vote. Under Ecolab's Certificate of Incorporation and Bylaws, the Ecolab Board of Directors may, by vote of a majority of its members, alter, amend or rescind all or any of its Bylaws, as permitted by law, subject to the power of the stockholders to change or repeal a particular bylaw.

*Special Meetings of Stockholders*

Under Ecolab's Bylaws, special meetings of the Ecolab stockholders may be called at any time by Ecolab's Board of Directors or by the Chairman of the Ecolab Board, or at the written request of stockholders owning capital stock having 25% of the voting power of the entire issued and outstanding capital stock of Ecolab.

*Action by Written Consent*

Ecolab's Bylaws provide that any action required or permitted to be taken at any annual or special meeting of stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of outstanding Ecolab stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted.

*Advance Notice Requirements of Stockholder Nominations and Proposals*

------

In the case of a special meeting of stockholders for the purpose of electing directors, a nominating stockholder must give notice not later than the close of business on the 10th day following the day on which notice of the date of the special meeting was mailed or public disclosure of the date of the special meeting was made, whichever first occurs. A stockholder's notice must set forth the information required by Ecolab's Bylaws with respect to each matter the stockholder proposes to bring before an annual or special meeting.

*Proxy Access*

Whenever the Ecolab Board of Directors solicits proxies with respect to the election of directors at an annual meeting of stockholders, Ecolab shall include in its proxy statement for such annual meeting, in addition to any persons nominated for election by or at the direction of the Ecolab Board of Directors, the name, together with other required information, of any person nominated for election to the Board of Directors by an eligible stockholder who expressly elects at the time of providing the required notice to have such nominee included in Ecolab's proxy materials. An "eligible stockholder" is a stockholder or a group of no more than 20 stockholders that (i) has owned (and continues to own through the date of the annual meeting) at least 3% of the number of outstanding shares of Ecolab's stock continuously for at least three years as of the date the notice of proxy access nomination is received by Ecolab's Secretary and (ii) satisfies all of the other requirements with respect to proxy access as set forth in Ecolab's Bylaws.

*Exclusive Forum*

Ecolab's Bylaws provide that, unless Ecolab consents in writing to the selection of alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of Ecolab, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer, stockholder, employee or agent of Ecolab to Ecolab or Ecolab's stockholders, (iii) any action asserting a claim against Ecolab or any director, officer, stockholder, employee or agent of Ecolab arising out of or relating to any provision of the DGCL or Ecolab's Certificate of Incorporation or Ecolab's Bylaws, or (iv) any action asserting a claim against Ecolab or any director, officer, stockholder, employee or agent of Ecolab governed by the internal affairs doctrine of the State of Delaware; provided, however, that, in the event that the Court of Chancery of the State of Delaware lacks subject matter jurisdiction over any such action or proceeding, the sole and exclusive forum for such action or proceeding shall be another state or federal court located within the State of Delaware, in each such case, unless the Court of Chancery (or such other state or federal court located within the State of Delaware, as applicable) has dismissed a prior action by the same plaintiff asserting the same claims because such court lacked personal jurisdiction over an indispensable party named as a defendant therein.

**Listing**

Our common stock is listed and traded on the New York Stock Exchange under the symbol "ECL."

**Transfer Agent and Registrar**

The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.

------

## Ex-10.(Iii)

**EXHIBIT (10.3)(iii)**

**ECOLAB INC. 2001 NON-EMPLOYEE DIRECTOR STOCK OPTION AND**

**DEFERRED COMPENSATION PLAN**

(as amended and restated effective as of August 1, 2013 and

further amended as of May 5, 2016)

**DECLARATION OF AMENDMENT NO. 2**

Pursuant to the amending power reserved to the Board of Directors of Ecolab Inc. (the "Company") by section 14.1 of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan (as amended and restated effective as of August 1, 2013 and further amended as of May 5, 2016) (the "Plan"), the Company hereby amends the Plan effective as to all Periodic Options granted on and after December 4, 2025 by amending and restating Section 9.3 in its entirety to read as follows:

"9.3 Exercisability of Options. Unless otherwise determined by the Board, each Periodic Option granted under the Plan will vest and become exercisable, on a cumulative basis, as to 25% of the Shares (excluding any fractional portion less than one share), on the last day of each of the first, second and third three-month periods following its Date of Grant and as to the remaining Shares on the earlier of the last day of the fourth three-month period following the Date of Grant or the Company's next Annual Meeting Date; provided, however, that if a Change in Control of the Company occurs then such Periodic Option will become immediately vested and exercisable in full."

**IN WITNESS WHEREOF,** the Company has caused this instrument to be executed by its duly authorized officers and its corporate seal to be affixed.

Dated: December 4, 2025

---

| |
|:---|
| &nbsp;&nbsp;ECOLAB INC. |
| &nbsp;&nbsp;/s/ Christophe Beck |
| &nbsp;&nbsp;Christophe Beck<br>Chairman of the Board and <br>Chief Executive Officer |

---

---

| |
|:---|
| &nbsp;&nbsp;Attest:  |
| &nbsp;&nbsp;/s/ Jandeen M. Boone |
| &nbsp;&nbsp;Jandeen M. Boone |
| &nbsp;&nbsp;Executive Vice President, <br>General Counsel and Secretary |

---

------

## Ex-10.(Iv)

**EXHIBIT (10.3)(iv)**

MASTER AGREEMENT

RELATING TO PERIODIC OPTIONS GRANTED UNDER THE

ECOLAB INC. 2001 NON-EMPLOYEE DIRECTOR STOCK OPTION

AND DEFERRED COMPENSATION PLAN

THIS AGREEMENT is entered into and effective as of _______________, by and between Ecolab Inc. (the "Company") and _________________ (the "Optionee").

The Company has adopted the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan, as amended and restated effective as of August 1, 2013 and as further amended as of May 5, 2016 and December 4, 2025 (the "Plan"), authorizing the Board of Directors of the Company, or a committee as provided for in the Plan (the Board or such a committee to be referred to as the "Committee"), to grant from time to time Periodic Options to Qualified Directors.

Accordingly, the parties agree as follows:

ARTICLE 1.<u>GRANT OF PERIODIC OPTIONS</u>.

Effective as of each of the dates (each, a "Date of Grant") set forth in a written notification of the grant, which written notification will be provided by the Company to the Optionee from time to time as Periodic Options are granted under the Plan, the Company hereby grants to the Optionee the right, privilege, and option to purchase that number of shares (the "Option Shares") of the Company's common stock, $1.00 par value (the "Common Stock") as set forth opposite such Date of Grant on the written notification, according to the terms and subject to the conditions hereinafter set forth and as set forth in the Plan. None of the Periodic Options are intended to be "incentive stock options," as that term is used in Section 422 of the Internal Revenue Code of 1986, as amended (the "Code").

ARTICLE 2.<u>EXERCISE PRICE</u>.

The per share price to be paid by the Optionee in the event of an exercise of any of the Periodic Options will be the respective price set forth opposite such Periodic Option in the written notification of grant referred to in Article 1 above.

ARTICLE 3.<u>DURATION OF PERIODIC OPTIONS AND TIME OF EXERCISE</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1<u>Exercisability and Duration</u>. Each Periodic Option will become exercisable, on a cumulative basis, as to 25% of the Shares (excluding any fractional portion less than one share), on the last day of each of the first, second and third three-month periods following its Date of Grant, and as to the remaining Shares, on (a) the last day of the fourth three-month period following the Date of Grant with respect to each Periodic Option granted prior to December 4, 2025 or (b) the earlier of the last day of the fourth three-month period following the Date of Grant or the Company's next Annual Meeting Date with respect to each Periodic Option granted on or after December 4, 2025; provided, however, that if a Change in Control of the Company occurs then such Periodic Option will become immediately vested and exercisable in full. Each Periodic

------

Option will remain exercisable until 5:00 p.m. (St. Paul, Minnesota time) on the tenth anniversary of such Periodic Option's respective Date of Grant ("Time of Termination"). At the Time of Termination of a Periodic Option, such Option will become void and expire as to all unexercised Option Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2<u>Termination of Service as a Director of the Company</u>. If the Optionee ceases to serve as a director of the Company for any reason, then each Periodic Option will remain exercisable to the extent exercisable as of such cessation of service until the earlier of the expiration of five years after the date the Optionee ceased to serve as a director of the Company or the remaining term of such Periodic Option, at which time such Periodic Option will terminate and no longer be exercised.

ARTICLE 4.<u>MANNER OF</u> <u>Periodic</u> <u>OPTION EXERCISE</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1<u>Notice</u>. Each Periodic Option may be exercised by the Optionee in whole or in part from time to time, subject to the conditions contained in the Plan and in this Agreement, by delivering, in person, by facsimile or electronic transmission or through the mail, a written notice of exercise to the Company at its principal executive office in St. Paul, Minnesota (Attention: Corporate Secretary, or such other person as may, from time to time, be authorized by the Corporate Secretary to receive such notices). Such notice must be in a form satisfactory to the Committee, identify the particular Periodic Option that is being exercised (by the Date of Grant and total number of Option Shares subject to such Periodic Option), specify the number of Option Shares with respect to which such Periodic Option is being exercised, and signed by the person or persons so exercising such Periodic Option. Such notice must be accompanied by payment in full of the total purchase price of the Option Shares purchased. In the event that a Periodic Option is being exercised, as provided by the Plan and Sections 5.2 and 5.3 below, by any person or persons other than the Optionee, the notice must be accompanied by appropriate proof of right of such person or persons to exercise such Periodic Option. As soon as practicable after the effective exercise of such Periodic Option, the Optionee will be recorded on the stock transfer books of the Company as the owner of the Option Shares purchased, and the Company will deliver to the Optionee one or more duly issued stock certificates evidencing such ownership. In the event that such Periodic Option is being exercised, as provided by resolutions of the Committee and Section 4.2 below, by tender of a Broker Exercise Notice, the Company will deliver such stock certificates directly to the Optionee's broker or dealer or their nominee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2At the time of exercise of a Periodic Option, the Optionee will pay the total purchase price of the Option Shares to be purchased entirely in cash (including a check, bank draft or money order, payable to the order of the Company); provided, however, that the Committee, in its sole discretion and upon terms and conditions established by the Committee, may allow such payment to be made, in whole or in part, by tender of a Broker Exercise Notice, by tender, or attestation as to ownership, of Previously Acquired Shares, or by a combination of such methods. In the event the Optionee is permitted to pay the total purchase price of such Periodic Option in whole or in part by tender or attestation as to ownership of Previously Acquired Shares, the value of such Previously Acquired Shares will be equal to their Market Price on the date of exercise of such Periodic Option.

------

ARTICLE 5.<u>RESTRICTIONS ON TRANSFER</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1<u>General Restriction on Transfer</u>. Except as otherwise provided in the Plan and this section, none of the Periodic Options nor the Option Shares acquired upon exercise of the Periodic Options may be transferred by the Optionee, either voluntarily or involuntarily, or subjected to any lien, directly or indirectly, by operation of law or otherwise. Any attempt to transfer or encumber any of the Periodic Options or the Option Shares other than in accordance with this section and the Plan will be null and void and will void such Periodic Option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2<u>Designation of Beneficiary</u>. The Optionee is entitled to designate a beneficiary to receive a Periodic Option upon the Optionee's death, and in the event of the Optionee's death, payment of any amounts due under the Plan will be made to, and exercise of any of the Periodic Options (to the extent permitted pursuant to Article 3) may be made by, the Optionee's legal representatives, heirs and legatees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3<u>Gifts to Related Parties</u>. So long as the Optionee is a director of the Company, the Optionee is entitled to transfer all or a portion of a Periodic Option, other than for value, to the Optionee's child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, any person sharing the Optionee's household (other than a tenant or employee), a trust in which any of the foregoing have more than fifty percent of the beneficial interests, a foundation in which any of the foregoing (or the Optionee) control the management of assets, and any other entity in which these persons (or the Optionee) own more than fifty percent of the voting interests. Any permitted transferee will remain subject to all the terms and conditions applicable to the Optionee prior to the transfer. A permitted transfer may be conditioned upon such requirements as the Committee may, in its sole discretion, determine, including, but not limited to execution and/or delivery of appropriate acknowledgements, opinion of counsel, or other documents by the transferee.

ARTICLE 6.<u>LIMITATION OF RIGHTS</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1<u>No Right to Continue As a Director</u>. Neither the Plan, nor the granting of any of the Periodic Options under the Plan and this Agreement, nor any other action taken pursuant to the Plan, will constitute or be evidence of any agreement or understanding, express or implied, that the Company will retain the Optionee as a director of the Company for any period of time, or at any particular rate of compensation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2<u>Rights as a Stockholder</u>. The Optionee will have no rights as a stockholder with respect to any Option Shares covered by a Periodic Option until the Optionee has exercised such Periodic Option, paid the exercise price and become the holder of record of such Option Shares, and, except as otherwise provided in Article 8 below, no adjustment will be made for dividends or other distributions or other rights as to which there is a record date preceding the date the Optionee becomes the holder of record of such Option Shares.

ARTICLE 7.<u>WITHHOLDING TAXES</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1<u>General Rules</u>. The Company is entitled to (a) withhold and deduct from the Optionee's compensation and all other amounts which may be due and owing to the Optionee

------

from the Company), or make other arrangements for the collection of, all legally required amounts necessary to satisfy any federal, state or local withholding and other tax requirements attributable to the grant or exercise of any Periodic Option or otherwise incurred with respect to such Periodic Option, or (b) require the Optionee promptly to remit the amount of such withholding to the Company before taking any action on the Optionee's notice of exercise of any Periodic Option, including issuing any Option Shares, with respect to such Periodic Option. In the event that the Company is unable to withhold such amounts, for whatever reason, the Optionee hereby agrees to pay to the Company an amount equal to the amount the Company would otherwise be required to withhold under federal, state or local law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2<u>Special Rules</u>. The Committee may, in its sole discretion and upon terms and conditions established by the Committee, permit or require the Optionee to satisfy, in whole or in part, any withholding or other tax obligation as described in Section 7.1 above by remitting such amounts to the Company, by electing to tender, or attest as to ownership of, Previously Acquired Shares, by delivery of a Broker Exercise Notice or a combination of such method. For purposes of satisfying the Optionee's withholding or other tax obligation, Previously Acquired Shares tendered or covered by an attestation will be valued at their Market Price.

ARTICLE 8.<u>ADJUSTMENTS</u>.

In the event of any reorganization, merger, consolidation, recapitalization, liquidation, reclassification, stock dividend, stock split, combination of shares, rights offering, divestiture or extraordinary dividend (including a spin-off), or any other similar change in the corporate structure or shares of the Company, the Committee (or, if the Company is not the surviving corporation in any such transaction, the board of directors of the surviving corporation), in order to prevent dilution or enlargement of the rights of the Optionee, will make appropriate adjustment (which determination will be conclusive) as to the number, kind and exercise price of securities subject to each Periodic Option.

ARTICLE 9.<u>SUBJECT TO PLAN</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1<u>Terms of Plan Prevail</u>. Each Periodic Option and the Option Shares granted and issued pursuant to this Agreement have been granted and issued under, and are subject to the terms of, the Plan. The terms of the Plan are incorporated by reference in this Agreement in their entirety, and the Optionee, by execution of this Agreement, acknowledges having received a copy of the Plan. The provisions of this Agreement will be interpreted as to be consistent with the Plan, and any ambiguities in this Agreement will be interpreted by reference to the Plan. In the event that any provision of this Agreement is inconsistent with the terms of the Plan, the terms of the Plan will prevail.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2<u>Definitions</u>. Unless otherwise defined in this Agreement, the terms capitalized in this Agreement will have the same meaning as given to such terms in the Plan.

ARTICLE 10.<u>MISCELLANEOUS</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1<u>Binding Effect</u>. This Agreement will be binding upon the heirs, executors, administrators, designated beneficiaries and successors of the parties to this Agreement.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2<u>Governing Law</u>. This Agreement and all rights and obligations under this Agreement will be construed in accordance with the Plan and governed by the laws of the State of Minnesota without regard to conflicts of laws provisions. Any legal proceedings related to this Agreement will be brought in an appropriate Minnesota court, and the parties to this Agreement consent to the exclusive jurisdiction of the court for this purpose.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.3<u>Entire Agreement</u>. This Agreement (including any written notification of the grant of a Periodic Option) and the Plan set forth the entire agreement and understanding of the parties to this Agreement with respect to the grant and exercise of each Periodic Option and the administration of the Plan and supersede all prior agreements, arrangements, plans and understandings relating to the grant and exercise of such Periodic Option and the administration of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.4<u>Amendment and Waiver</u>. This Agreement may be amended, waived, modified or canceled only by a written instrument executed by the parties hereto or, in the case of a waiver, by the party waiving compliance.

The parties to this Agreement have executed this Agreement effective the day and year first above written.

---

| | |
|:---|:---|
| &nbsp;&nbsp;ECOLAB INC. | &nbsp;&nbsp;ECOLAB INC. |
| &nbsp;&nbsp;By |  |
|  | &nbsp;&nbsp;Jandeen M. Boone |
|  | &nbsp;&nbsp;Executive Vice President, <br>General Counsel and Secretary |

---

By execution of this Agreement, the Optionee acknowledges havingreceived a copy of the Plan. <u>OPTIONEE</u>

------

## Exhibit 21.1

---

| | |
|:---|:---|
|  | &nbsp;&nbsp;**EXHIBIT (21.1)** |
| &nbsp;&nbsp;**SUBSIDIARIES OF ECOLAB INC.** | &nbsp;&nbsp;**SUBSIDIARIES OF ECOLAB INC.** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;<br>| &nbsp;&nbsp;<br>|
| &nbsp;&nbsp;**Entity Name** | &nbsp;&nbsp;**State or Other**<br> **Jurisdiction of**<br> **Incorporation**<br>|
| &nbsp;&nbsp;NLC Process and Water Services SARL | &nbsp;&nbsp;Algeria |
| &nbsp;&nbsp;Ecolab (Antigua) Ltd. | &nbsp;&nbsp;Antigua & Barbuda |
| &nbsp;&nbsp;Anios America S.A. | &nbsp;&nbsp;Argentina |
| &nbsp;&nbsp;Ecolab Argentina S.R.L. | &nbsp;&nbsp;Argentina |
| &nbsp;&nbsp;Ecolab Services Argentina S.R.L. | &nbsp;&nbsp;Argentina |
| &nbsp;&nbsp;Ecolab (Aruba) N.V. | &nbsp;&nbsp;Aruba |
| &nbsp;&nbsp;Ecolab (Fiji) Pty Limited | &nbsp;&nbsp;Australia |
| &nbsp;&nbsp;Ecolab AU2 Pty Ltd | &nbsp;&nbsp;Australia |
| &nbsp;&nbsp;Ecolab AU3 Pty Ltd | &nbsp;&nbsp;Australia |
| &nbsp;&nbsp;Ecolab AU4 Pty Ltd | &nbsp;&nbsp;Australia |
| &nbsp;&nbsp;Ecolab Pty Ltd. | &nbsp;&nbsp;Australia |
| &nbsp;&nbsp;Purolite Pty Ltd | &nbsp;&nbsp;Australia |
| &nbsp;&nbsp;Aqua Holding Technical Materials GmbH | &nbsp;&nbsp;Austria |
| &nbsp;&nbsp;Christ Water Technology GmbH | &nbsp;&nbsp;Austria |
| &nbsp;&nbsp;Ecolab GmbH | &nbsp;&nbsp;Austria |
| &nbsp;&nbsp;Nalco Holdings GmbH | &nbsp;&nbsp;Austria |
| &nbsp;&nbsp;NALCO ÖSTERREICH GmbH | &nbsp;&nbsp;Austria |
| &nbsp;&nbsp;Ovivo Aqua Austria GmbH | &nbsp;&nbsp;Austria |
| &nbsp;&nbsp;Ecolab Limited | &nbsp;&nbsp;Bahamas |
| &nbsp;&nbsp;Ecolab Bahrain W.L.L | &nbsp;&nbsp;Bahrain |
| &nbsp;&nbsp;Ecolab (Barbados) Limited | &nbsp;&nbsp;Barbados |
| &nbsp;&nbsp;CID LINES NV | &nbsp;&nbsp;Belgium |
| &nbsp;&nbsp;Ecolab B.V. | &nbsp;&nbsp;Belgium |
| &nbsp;&nbsp;Ecolab Production Belgium B.V. | &nbsp;&nbsp;Belgium |
| &nbsp;&nbsp;Kay BV | &nbsp;&nbsp;Belgium |
| &nbsp;&nbsp;NALCO BELGIUM B.V. | &nbsp;&nbsp;Belgium |
| &nbsp;&nbsp;Ecolab Quimica Ltda. | &nbsp;&nbsp;Brazil |
| &nbsp;&nbsp;Purolite do Brasil Ltda | &nbsp;&nbsp;Brazil |
| &nbsp;&nbsp;Nalco (BN) SDN BHD | &nbsp;&nbsp;Brunei Darussalam |
| &nbsp;&nbsp;17162979 Canada Limited | &nbsp;&nbsp;Canada |
| &nbsp;&nbsp;Ecolab CDN 2 Co. | &nbsp;&nbsp;Canada |
| &nbsp;&nbsp;Ecolab CDN 4 ULC | &nbsp;&nbsp;Canada |
| &nbsp;&nbsp;Ecolab Co. Compagnie Ecolab | &nbsp;&nbsp;Canada |
| &nbsp;&nbsp;Nalco Canada ULC | &nbsp;&nbsp;Canada |
| &nbsp;&nbsp;Ovivo Inc. | &nbsp;&nbsp;Canada |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;<br>| &nbsp;&nbsp;<br>|
| &nbsp;&nbsp;**Entity Name** | &nbsp;&nbsp;**State or Other**<br> **Jurisdiction of**<br> **Incorporation**<br>|
| &nbsp;&nbsp;Ecolab SpA | &nbsp;&nbsp;Chile |
| &nbsp;&nbsp;NALCO INDUSTRIAL SERVICES (SUZHOU) CO., LTD. | &nbsp;&nbsp;China |
| &nbsp;&nbsp;Ovivo Chengdu Co., Ltd | &nbsp;&nbsp;China |
| &nbsp;&nbsp;Ovivo Shenzhen Co., Ltd | &nbsp;&nbsp;China |
| &nbsp;&nbsp;Purolite (China) Co., Ltd. | &nbsp;&nbsp;China |
| &nbsp;&nbsp;Purolite (Zhejiang) Technology Co., Ltd. | &nbsp;&nbsp;China |
| &nbsp;&nbsp;Xi'an Purovo Material Co., Ltd | &nbsp;&nbsp;China |
| &nbsp;&nbsp;Zhejiang Purosoft Environment Engineering Co., Ltd | &nbsp;&nbsp;China |
| &nbsp;&nbsp;Ecolab (GZ) Chemicals Limited | &nbsp;&nbsp;China |
| &nbsp;&nbsp;Ecolab (Taicang) Technology Co., Ltd. | &nbsp;&nbsp;China |
| &nbsp;&nbsp;Jianghai Environmental Protection Co., Ltd. | &nbsp;&nbsp;China |
| &nbsp;&nbsp;NALCO INDUSTRIAL SERVICES (NANJING) CO., LTD. | &nbsp;&nbsp;China |
| &nbsp;&nbsp;Ovivo Dalian Co., Ltd | &nbsp;&nbsp;China |
| &nbsp;&nbsp;Aqua Technical Materials Shanghai Co., Ltd | &nbsp;&nbsp;China |
| &nbsp;&nbsp;Ecolab (China) Investment Co., Ltd | &nbsp;&nbsp;China |
| &nbsp;&nbsp;Nalco (China) Environmental Solution Co. Ltd. | &nbsp;&nbsp;China |
| &nbsp;&nbsp;NALCO (SHANGHAI) TRADING CO. LTD. | &nbsp;&nbsp;China |
| &nbsp;&nbsp;Ovivo China Co., Ltd. | &nbsp;&nbsp;China |
| &nbsp;&nbsp;Ecolab Colombia S. A. | &nbsp;&nbsp;Colombia |
| &nbsp;&nbsp;Ecolab SRL | &nbsp;&nbsp;Costa Rica |
| &nbsp;&nbsp;Purolite s.r.o. | &nbsp;&nbsp;Czech Republic |
| &nbsp;&nbsp;Chamtech, L.L.C. | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Chemlink Laboratories, LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Ecolab Acquisition LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Ecolab Holdings (Europe) LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Ecolab Holdings Inc. | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Ecolab Israel Holdings LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Ecolab Lux Partner LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Ecolab Manufacturing Inc. | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Ecolab Production LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Ecolab U.S. 12 LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Ecolab U.S. 2 Inc. | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Ecolab U.S. 6 LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Ecolab U.S. 9 LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Ecolab US 1 GP | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Ecolab USA Inc. | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;NALCO CHINA HOLDINGS LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Nalco Company LLC (1) | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Nalco Contract Operations, LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;NALCO HOLDING COMPANY | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;NALCO INDUSTRIAL OUTSOURCING COMPANY | &nbsp;&nbsp;Delaware |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;<br>| &nbsp;&nbsp;<br>|
| &nbsp;&nbsp;**Entity Name** | &nbsp;&nbsp;**State or Other**<br> **Jurisdiction of**<br> **Incorporation**<br>|
| &nbsp;&nbsp;Nalco Production LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;NALCO PWS, INC. | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;NALCO TWO, INC. | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;NALCO WORLDWIDE HOLDINGS LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Ovivo Electronics USA LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Ovivo US Holding Inc. | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Pest Management LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Purolite LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Quantum Technical Services, LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Wabasha Leasing LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Wastech Systems LLC | &nbsp;&nbsp;Delaware |
| &nbsp;&nbsp;Ecolab ApS | &nbsp;&nbsp;Denmark |
| &nbsp;&nbsp;NALCO DANMARK APS | &nbsp;&nbsp;Denmark |
| &nbsp;&nbsp;Ecolab Ecuador Cia. Ltda. | &nbsp;&nbsp;Ecuador |
| &nbsp;&nbsp;NALCO EGYPT TRADING | &nbsp;&nbsp;Egypt |
| &nbsp;&nbsp;NALCO EGYPT, LTD. | &nbsp;&nbsp;Egypt |
| &nbsp;&nbsp;Ecolab, S.A. de C.V. | &nbsp;&nbsp;El Salvador |
| &nbsp;&nbsp;Ecolab Pte Ltd | &nbsp;&nbsp;Fiji |
| &nbsp;&nbsp;NALCO FINLAND MANUFACTURING OY | &nbsp;&nbsp;Finland |
| &nbsp;&nbsp;NALCO FINLAND OY | &nbsp;&nbsp;Finland |
| &nbsp;&nbsp;Oy Ecolab AB | &nbsp;&nbsp;Finland |
| &nbsp;&nbsp;Anios Diffusion SAS | &nbsp;&nbsp;France |
| &nbsp;&nbsp;Anios Manufacturing SAS | &nbsp;&nbsp;France |
| &nbsp;&nbsp;DMD | &nbsp;&nbsp;France |
| &nbsp;&nbsp;Ecolab FR 1 SAS | &nbsp;&nbsp;France |
| &nbsp;&nbsp;Ecolab FR 4 SAS | &nbsp;&nbsp;France |
| &nbsp;&nbsp;Ecolab Pest France SAS | &nbsp;&nbsp;France |
| &nbsp;&nbsp;Ecolab Production France SAS | &nbsp;&nbsp;France |
| &nbsp;&nbsp;Ecolab SAS | &nbsp;&nbsp;France |
| &nbsp;&nbsp;Ecolab Services SNC | &nbsp;&nbsp;France |
| &nbsp;&nbsp;Ecolab SNC | &nbsp;&nbsp;France |
| &nbsp;&nbsp;Hydenet SAS | &nbsp;&nbsp;France |
| &nbsp;&nbsp;Laboratoires Anios SAS | &nbsp;&nbsp;France |
| &nbsp;&nbsp;Laboratoires Anios-Distribution SAS | &nbsp;&nbsp;France |
| &nbsp;&nbsp;NALCO FRANCE SAS | &nbsp;&nbsp;France |
| &nbsp;&nbsp;Ovivo France SAS | &nbsp;&nbsp;France |
| &nbsp;&nbsp;Purolite SAS | &nbsp;&nbsp;France |
| &nbsp;&nbsp;Soluscope SAS | &nbsp;&nbsp;France |
| &nbsp;&nbsp;Ecolab U.S. 14 Inc. | &nbsp;&nbsp;Georgia |
| &nbsp;&nbsp;Ecolab DE 1 GmbH | &nbsp;&nbsp;Germany |
| &nbsp;&nbsp;Ecolab Deutschland GmbH | &nbsp;&nbsp;Germany |

---

------

---

| | |
|:---|:---|
| ('&nbsp;&nbsp;<br>', '&nbsp;&nbsp;**Entity Name**<br>') | ('&nbsp;&nbsp;<br>', '&nbsp;&nbsp;**State or Other**<br>**Jurisdiction of**<br>**Incorporation**<br>') |
| &nbsp;&nbsp;Ecolab Engineering GmbH | &nbsp;&nbsp;Germany |
| &nbsp;&nbsp;Ecolab Export GmbH | &nbsp;&nbsp;Germany |
| &nbsp;&nbsp;Ecolab Pest Deutschland GmbH | &nbsp;&nbsp;Germany |
| &nbsp;&nbsp;Nalco Deutschland GmbH | &nbsp;&nbsp;Germany |
| &nbsp;&nbsp;Nalco Deutschland Manufacturing GmbH | &nbsp;&nbsp;Germany |
| &nbsp;&nbsp;Nalco Manufacturing Beteiligungs GmbH | &nbsp;&nbsp;Germany |
| &nbsp;&nbsp;Nalco Real Estate GmbH | &nbsp;&nbsp;Germany |
| &nbsp;&nbsp;Ovivo Deutschland GmbH | &nbsp;&nbsp;Germany |
| &nbsp;&nbsp;Purolite GmbH | &nbsp;&nbsp;Germany |
| &nbsp;&nbsp;Ecolab A.E. | &nbsp;&nbsp;Greece |
| &nbsp;&nbsp;Ecolab (Guam) LLC | &nbsp;&nbsp;Guam |
| &nbsp;&nbsp;Ecolab, Sociedad Anonima | &nbsp;&nbsp;Guatemala |
| &nbsp;&nbsp;Quimicas Ecolab S.A. de C.V. | &nbsp;&nbsp;Honduras |
| &nbsp;&nbsp;Aqua Asia Limited | &nbsp;&nbsp;Hong Kong |
| &nbsp;&nbsp;Ecolab Limited | &nbsp;&nbsp;Hong Kong |
| &nbsp;&nbsp;Ecolab Name Holding Limited | &nbsp;&nbsp;Hong Kong |
| &nbsp;&nbsp;Ecolab Water Holding Limited | &nbsp;&nbsp;Hong Kong |
| &nbsp;&nbsp;NALCO HONG KONG LIMITED | &nbsp;&nbsp;Hong Kong |
| &nbsp;&nbsp;Ovivo HK Limited | &nbsp;&nbsp;Hong Kong |
| &nbsp;&nbsp;Ecolab Global Business Services Kft. | &nbsp;&nbsp;Hungary |
| &nbsp;&nbsp;Ovivo Hungary Kft. | &nbsp;&nbsp;Hungary |
| &nbsp;&nbsp;Ecolab Food Safety & Hygiene Solutions Private Limited | &nbsp;&nbsp;India |
| &nbsp;&nbsp;Ecolab Global Services Private Limited | &nbsp;&nbsp;India |
| &nbsp;&nbsp;Nalco Water India Private Limited | &nbsp;&nbsp;India |
| &nbsp;&nbsp;Purolite Private Limited | &nbsp;&nbsp;India |
| &nbsp;&nbsp;PT Ecolab International Indonesia | &nbsp;&nbsp;Indonesia |
| &nbsp;&nbsp;PT Ecolab Synergy Indonesia | &nbsp;&nbsp;Indonesia |
| &nbsp;&nbsp;Ecolab Finance Company Designated Activity Company | &nbsp;&nbsp;Ireland |
| &nbsp;&nbsp;Ecolab Limited | &nbsp;&nbsp;Ireland |
| &nbsp;&nbsp;Ecolab Manufacturing IE Limited | &nbsp;&nbsp;Ireland |
| &nbsp;&nbsp;Ecolab JVZ Limited | &nbsp;&nbsp;Israel |
| &nbsp;&nbsp;NALCO ISRAEL INDUSTRIAL SERVICES LTD | &nbsp;&nbsp;Israel |
| &nbsp;&nbsp;Ovivo Israel Ltd. | &nbsp;&nbsp;Israel |
| &nbsp;&nbsp;Ecolab Holding Italy S.R.L. | &nbsp;&nbsp;Italy |
| &nbsp;&nbsp;Ecolab Production Italy S.R.L. | &nbsp;&nbsp;Italy |
| &nbsp;&nbsp;Ecolab S.R.L. | &nbsp;&nbsp;Italy |
| &nbsp;&nbsp;Nalco Italiana Holdings S.R.L. | &nbsp;&nbsp;Italy |
| &nbsp;&nbsp;Nalco Italiana Manufacturing S.R.L. | &nbsp;&nbsp;Italy |
| &nbsp;&nbsp;Nalco Italiana S.R.L. | &nbsp;&nbsp;Italy |
| &nbsp;&nbsp;Nuova Farmec S.r.l. | &nbsp;&nbsp;Italy |
| &nbsp;&nbsp;Ecolab Limited | &nbsp;&nbsp;Jamaica |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;<br>| &nbsp;&nbsp;<br>|
| &nbsp;&nbsp;**Entity Name** | &nbsp;&nbsp;**State or Other**<br> **Jurisdiction of**<br> **Incorporation**<br>|
| &nbsp;&nbsp;Ecolab G.K. | &nbsp;&nbsp;Japan |
| &nbsp;&nbsp;KATAYAMA NALCO INC. | &nbsp;&nbsp;Japan |
| &nbsp;&nbsp;Nalco Japan G.K. | &nbsp;&nbsp;Japan |
| &nbsp;&nbsp;Purolite KK | &nbsp;&nbsp;Japan |
| &nbsp;&nbsp;Aqua Environmental Limited | &nbsp;&nbsp;Jersey |
| &nbsp;&nbsp;Cymru Holdings Limited | &nbsp;&nbsp;Jersey |
| &nbsp;&nbsp;Company Ecolab LLP | &nbsp;&nbsp;Kazakhstan |
| &nbsp;&nbsp;QazSorbent LLP | &nbsp;&nbsp;Kazakhstan |
| &nbsp;&nbsp;Ecolab East Africa (Kenya) Limited | &nbsp;&nbsp;Kenya |
| &nbsp;&nbsp;ECOLAB KOREA LIMITED | &nbsp;&nbsp;Korea, Republic Of |
| &nbsp;&nbsp;Ecolab Water CO., LTD. | &nbsp;&nbsp;Korea, Republic Of |
| &nbsp;&nbsp;Purolite LLC | &nbsp;&nbsp;Korea, Republic Of |
| &nbsp;&nbsp;Ovivo Malaysia Sdn Bhd | &nbsp;&nbsp;Kuala Lumpur |
| &nbsp;&nbsp;Ecolab, SIA | &nbsp;&nbsp;Latvia |
| &nbsp;&nbsp;Nalco Libya | &nbsp;&nbsp;Libya |
| &nbsp;&nbsp;Ecolab LUX & Co Holdings S.C.A. | &nbsp;&nbsp;Luxembourg |
| &nbsp;&nbsp;Ecolab LUX 1 Sarl | &nbsp;&nbsp;Luxembourg |
| &nbsp;&nbsp;Ecolab Lux 10 Sarl | &nbsp;&nbsp;Luxembourg |
| &nbsp;&nbsp;Ecolab Lux 12 SCA | &nbsp;&nbsp;Luxembourg |
| &nbsp;&nbsp;Ecolab Lux 13 Sarl | &nbsp;&nbsp;Luxembourg |
| &nbsp;&nbsp;Ecolab Lux 14 Sarl | &nbsp;&nbsp;Luxembourg |
| &nbsp;&nbsp;Ecolab Lux 16 Sarl | &nbsp;&nbsp;Luxembourg |
| &nbsp;&nbsp;Ecolab Lux 17 Sarl | &nbsp;&nbsp;Luxembourg |
| &nbsp;&nbsp;Ecolab Lux 18 Sarl | &nbsp;&nbsp;Luxembourg |
| &nbsp;&nbsp;Ecolab LUX 2 Sarl | &nbsp;&nbsp;Luxembourg |
| &nbsp;&nbsp;Ecolab LUX 4 Sarl | &nbsp;&nbsp;Luxembourg |
| &nbsp;&nbsp;Ecolab LUX 7 Sarl | &nbsp;&nbsp;Luxembourg |
| &nbsp;&nbsp;Ecolab Lux 9 Sarl | &nbsp;&nbsp;Luxembourg |
| &nbsp;&nbsp;Ecolab LUX Sarl | &nbsp;&nbsp;Luxembourg |
| &nbsp;&nbsp;Nalco Worldwide Holdings S.a r.l./B.V. | &nbsp;&nbsp;Luxembourg |
| &nbsp;&nbsp;Ecolab Limitada | &nbsp;&nbsp;Macau |
| &nbsp;&nbsp;Ecolab International SDN BHD | &nbsp;&nbsp;Malaysia |
| &nbsp;&nbsp;Ecolab Sdn. Bhd. | &nbsp;&nbsp;Malaysia |
| &nbsp;&nbsp;Ecolab Services Malaysia SDN. BHD. | &nbsp;&nbsp;Malaysia |
| &nbsp;&nbsp;Ecolab Malta 1 Limited | &nbsp;&nbsp;Malta |
| &nbsp;&nbsp;Ecolab Malta 2 Limited | &nbsp;&nbsp;Malta |
| &nbsp;&nbsp;Ecolab Malta 3 Limited | &nbsp;&nbsp;Malta |
| &nbsp;&nbsp;Ecolab Malta 4 Limited | &nbsp;&nbsp;Malta |
| &nbsp;&nbsp;Ecolab Malta GPS Limited | &nbsp;&nbsp;Malta |
| &nbsp;&nbsp;Ecolab MT Limited | &nbsp;&nbsp;Malta |
| &nbsp;&nbsp;Barclay Water Management, Inc. | &nbsp;&nbsp;Massachusetts |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;<br>| &nbsp;&nbsp;<br>|
| &nbsp;&nbsp;**Entity Name** | &nbsp;&nbsp;**State or Other**<br> **Jurisdiction of**<br> **Incorporation**<br>|
| &nbsp;&nbsp;Barclay Water Treatment Company, Inc. | &nbsp;&nbsp;Massachusetts |
| &nbsp;&nbsp;Abednego de Mexico S. de R.L. de C.V. | &nbsp;&nbsp;Mexico |
| &nbsp;&nbsp;CID Lines Mexico, S.A. DE C.V. | &nbsp;&nbsp;Mexico |
| &nbsp;&nbsp;Ecolab, S. de R.L. de C.V. | &nbsp;&nbsp;Mexico |
| &nbsp;&nbsp;NALCO DE MEXICO, S. de R. L. de C.V. | &nbsp;&nbsp;Mexico |
| &nbsp;&nbsp;Productos Químicos Flottec, S. de R.L. de C.V. | &nbsp;&nbsp;Mexico |
| &nbsp;&nbsp;Purolite, S. de R.L. de C.V. | &nbsp;&nbsp;Mexico |
| &nbsp;&nbsp;Abednego Environmental Services, LLC | &nbsp;&nbsp;Michigan |
| &nbsp;&nbsp;Abednego Mexico Holdings, LLC | &nbsp;&nbsp;Michigan |
| &nbsp;&nbsp;Ecolab Maroc Société à Responsabilité Limitée | &nbsp;&nbsp;Morocco |
| &nbsp;&nbsp;Ecolab B.V. | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;ECOLAB NL 10 B.V. | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;Ecolab NL 11 B.V. | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;Ecolab NL 15 BV | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;Ecolab NL 16 B.V. | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;Ecolab NL 23 B.V. | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;Ecolab NL 3 BV | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;Ecolab Production Netherlands B.V. | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;Ecolabone B.V. | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;NALCO DUTCH HOLDINGS B.V. | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;NALCO EUROPE B.V. | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;NALCO GLOBAL HOLDINGS B.V. | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;Nalco Holding B.V. | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;Nalco International Holdings B.V. | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;NALCO NETHERLANDS B.V. | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;NALCO OVERSEAS HOLDING B.V. | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;NALCO UNIVERSAL HOLDINGS B.V. | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;Ovivo Holland B.V. | &nbsp;&nbsp;Netherlands |
| &nbsp;&nbsp;Nalco Wastewater Contract Operations, Inc. | &nbsp;&nbsp;New York |
| &nbsp;&nbsp;Ecolab New Zealand | &nbsp;&nbsp;New Zealand |
| &nbsp;&nbsp;Purolite NZ Limited | &nbsp;&nbsp;New Zealand |
| &nbsp;&nbsp;Ecolab y Compañia Colectiva de Responsabilidad Limitada | &nbsp;&nbsp;Nicaragua |
| &nbsp;&nbsp;MOBOTEC AB, LLC | &nbsp;&nbsp;North Carolina |
| &nbsp;&nbsp;Ecolab AS | &nbsp;&nbsp;Norway |
| &nbsp;&nbsp;NALCO PAKISTAN (PRIVATE) LIMITED | &nbsp;&nbsp;Pakistan |
| &nbsp;&nbsp;Ecolab S.A. | &nbsp;&nbsp;Panama |
| &nbsp;&nbsp;Ecolab Paraguay S.R.L. | &nbsp;&nbsp;Paraguay |
| &nbsp;&nbsp;NANOSPECIALTIES, LLC | &nbsp;&nbsp;Pennsylvania |
| &nbsp;&nbsp;Ecolab Peru Holdings S.R.L. | &nbsp;&nbsp;Peru |
| &nbsp;&nbsp;Ecolab Philippines Inc. | &nbsp;&nbsp;Philippines |
| &nbsp;&nbsp;NALCO PHILIPPINES INC. | &nbsp;&nbsp;Philippines |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;<br>| &nbsp;&nbsp;<br>|
| &nbsp;&nbsp;**Entity Name** | &nbsp;&nbsp;**State or Other**<br> **Jurisdiction of**<br> **Incorporation**<br>|
| &nbsp;&nbsp;CID Lines Sp. z o. o. | &nbsp;&nbsp;Poland |
| &nbsp;&nbsp;Ecolab Services Poland Sp. z o o | &nbsp;&nbsp;Poland |
| &nbsp;&nbsp;Ecolab Sp. z o o | &nbsp;&nbsp;Poland |
| &nbsp;&nbsp;Nalco Polska Sp. z o. o. | &nbsp;&nbsp;Poland |
| &nbsp;&nbsp;Purolite sp. z o.o. | &nbsp;&nbsp;Poland |
| &nbsp;&nbsp;NALCO PORTUGUESA (QUÍMICA INDUSTRIAL), UNIPESSOAL LDA | &nbsp;&nbsp;Portugal |
| &nbsp;&nbsp;Ecolab Water and Hygiene Trading W.L.L. | &nbsp;&nbsp;Qatar |
| &nbsp;&nbsp;Purolite SRL | &nbsp;&nbsp;Romania |
| &nbsp;&nbsp;AO Ecolab | &nbsp;&nbsp;Russian Federation |
| &nbsp;&nbsp;CID Lines LLC | &nbsp;&nbsp;Russian Federation |
| &nbsp;&nbsp;Meratech Rus Group LLC | &nbsp;&nbsp;Russian Federation |
| &nbsp;&nbsp;NALCO COMPANY OOO | &nbsp;&nbsp;Russian Federation |
| &nbsp;&nbsp;Ecolab (St. Lucia) Limited | &nbsp;&nbsp;Saint Lucia |
| &nbsp;&nbsp;Ecolab Arabia Regional Headquarters LLC | &nbsp;&nbsp;Saudi Arabia |
| &nbsp;&nbsp;NALCO SAUDI CO. LTD. | &nbsp;&nbsp;Saudi Arabia |
| &nbsp;&nbsp;Ecolab Hygiene d.o.o. | &nbsp;&nbsp;Serbia |
| &nbsp;&nbsp;Ecolab Pte. Ltd. | &nbsp;&nbsp;Singapore |
| &nbsp;&nbsp;NALCO ASIA HOLDING COMPANY PTE. LTD. | &nbsp;&nbsp;Singapore |
| &nbsp;&nbsp;Ovivo Singapore Pte Ltd. | &nbsp;&nbsp;Singapore |
| &nbsp;&nbsp;Purolite Pte. Ltd. | &nbsp;&nbsp;Singapore |
| &nbsp;&nbsp;Ecolab d.o.o. | &nbsp;&nbsp;Slovenia |
| &nbsp;&nbsp;Ecolab (Proprietary) Limited | &nbsp;&nbsp;South Africa |
| &nbsp;&nbsp;Ecolab Investment Holdings Proprietary Limited | &nbsp;&nbsp;South Africa |
| &nbsp;&nbsp;Lobster Ink Africa (Pty.) Ltd. | &nbsp;&nbsp;South Africa |
| &nbsp;&nbsp;NALCO AFRICA (PTY.) LTD. | &nbsp;&nbsp;South Africa |
| &nbsp;&nbsp;Purolite (Pty) Ltd | &nbsp;&nbsp;South Africa |
| &nbsp;&nbsp;DERYPOL SA | &nbsp;&nbsp;Spain |
| &nbsp;&nbsp;Ecolab Hispano-Portuguesa S.L. | &nbsp;&nbsp;Spain |
| &nbsp;&nbsp;Ecolab Spain Services S.L.U. | &nbsp;&nbsp;Spain |
| &nbsp;&nbsp;Hicopla SL | &nbsp;&nbsp;Spain |
| &nbsp;&nbsp;NALCO ESPANOLA MANUFACTURING, S.L.U. | &nbsp;&nbsp;Spain |
| &nbsp;&nbsp;NALCO ESPAÑOLA, S.L. | &nbsp;&nbsp;Spain |
| &nbsp;&nbsp;Ecolab AB | &nbsp;&nbsp;Sweden |
| &nbsp;&nbsp;NALCO AB | &nbsp;&nbsp;Sweden |
| &nbsp;&nbsp;Ovivo Europe Holding AB | &nbsp;&nbsp;Sweden |
| &nbsp;&nbsp;Ecolab (Schweiz) GmbH | &nbsp;&nbsp;Switzerland |
| &nbsp;&nbsp;Ecolab CH 1 GmbH | &nbsp;&nbsp;Switzerland |
| &nbsp;&nbsp;Ecolab CH 2 GmbH | &nbsp;&nbsp;Switzerland |
| &nbsp;&nbsp;Ecolab CH 6 GmbH | &nbsp;&nbsp;Switzerland |
| &nbsp;&nbsp;Ecolab Europe GmbH | &nbsp;&nbsp;Switzerland |
| &nbsp;&nbsp;Lobster International S.A. | &nbsp;&nbsp;Switzerland |

---

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;<br>| &nbsp;&nbsp;<br>|
| &nbsp;&nbsp;**Entity Name** | &nbsp;&nbsp;**State or Other**<br> **Jurisdiction of**<br> **Incorporation**<br>|
| &nbsp;&nbsp;Nalco Schweiz GmbH | &nbsp;&nbsp;Switzerland |
| &nbsp;&nbsp;Ovivo Switzerland AG | &nbsp;&nbsp;Switzerland |
| &nbsp;&nbsp;Purolite SARL | &nbsp;&nbsp;Switzerland |
| &nbsp;&nbsp;Ecolab Ltd. | &nbsp;&nbsp;Taiwan |
| &nbsp;&nbsp;NALCO TAIWAN CO., LTD. | &nbsp;&nbsp;Taiwan |
| &nbsp;&nbsp;Ovivo Taiwan Co. Ltd. | &nbsp;&nbsp;Taiwan |
| &nbsp;&nbsp;Ecolab East Africa (Tanzania) Limited | &nbsp;&nbsp;Tanzania |
| &nbsp;&nbsp;Flottec, LLC | &nbsp;&nbsp;Texas |
| &nbsp;&nbsp;Ecolab Limited | &nbsp;&nbsp;Thailand |
| &nbsp;&nbsp;NALCO INDUSTRIAL SERVICES (THAILAND) CO. LTD. | &nbsp;&nbsp;Thailand |
| &nbsp;&nbsp;Ecolab (Trinidad and Tobago) Unlimited | &nbsp;&nbsp;Trinidad And Tobago |
| &nbsp;&nbsp;Purolite LLC | &nbsp;&nbsp;Tunisia |
| &nbsp;&nbsp;Ecolab Temizleme Sistemleri Limited Sirketi | &nbsp;&nbsp;Turkey |
| &nbsp;&nbsp;Nalco Anadolu Kimya Sanayi ve Ticaret Limited Sirketi | &nbsp;&nbsp;Turkey |
| &nbsp;&nbsp;Oksa Kimya Sanayi A.S. | &nbsp;&nbsp;Turkey |
| &nbsp;&nbsp;Purolite Ileri Kimyasal Ticaret Ltd | &nbsp;&nbsp;Turkey |
| &nbsp;&nbsp;Ecolab East Africa (Uganda) Limited | &nbsp;&nbsp;Uganda |
| &nbsp;&nbsp;Ecolab TZOV | &nbsp;&nbsp;Ukraine |
| &nbsp;&nbsp;Ecolab Emirates General Trading LLC | &nbsp;&nbsp;United Arab Emirates |
| &nbsp;&nbsp;Ecolab Gulf FZE | &nbsp;&nbsp;United Arab Emirates |
| &nbsp;&nbsp;Nalco Emirates General Trading LLC | &nbsp;&nbsp;United Arab Emirates |
| &nbsp;&nbsp;Nalco Middle East FZE | &nbsp;&nbsp;United Arab Emirates |
| &nbsp;&nbsp;Bro-Tech Limited | &nbsp;&nbsp;United Kingdom |
| &nbsp;&nbsp;Ecolab (U.K.) Holdings Limited | &nbsp;&nbsp;United Kingdom |
| &nbsp;&nbsp;Ecolab GB 1 Limited | &nbsp;&nbsp;United Kingdom |
| &nbsp;&nbsp;Ecolab Limited | &nbsp;&nbsp;United Kingdom |
| &nbsp;&nbsp;Ecolab Manufacturing UK Limited | &nbsp;&nbsp;United Kingdom |
| &nbsp;&nbsp;LHS (UK) Limited | &nbsp;&nbsp;United Kingdom |
| &nbsp;&nbsp;NALCO ACQUISITION ONE | &nbsp;&nbsp;United Kingdom |
| &nbsp;&nbsp;NALCO INVESTMENTS U.K. LIMITED | &nbsp;&nbsp;United Kingdom |
| &nbsp;&nbsp;NALCO LIMITED | &nbsp;&nbsp;United Kingdom |
| &nbsp;&nbsp;NALCO MANUFACTURING LTD. | &nbsp;&nbsp;United Kingdom |
| &nbsp;&nbsp;Purolite (Int.) Ltd | &nbsp;&nbsp;United Kingdom |
| &nbsp;&nbsp;Purolite Ltd | &nbsp;&nbsp;United Kingdom |
| &nbsp;&nbsp;Technical Textile Services Limited | &nbsp;&nbsp;United Kingdom |
| &nbsp;&nbsp;Ecolab S.R.L. | &nbsp;&nbsp;Uruguay |
| &nbsp;&nbsp;Ecolab S.A. | &nbsp;&nbsp;Venezuela |
| &nbsp;&nbsp;Ecolab Viet Nam Company Limited | &nbsp;&nbsp;Viet Nam |
| &nbsp;&nbsp;(1) This subsidiary also conducts business under the assumed name of NALCO Water, An Ecolab Company. | &nbsp;&nbsp;(1) This subsidiary also conducts business under the assumed name of NALCO Water, An Ecolab Company. |

---

------

## Exhibit 23.1

**EXHIBIT (23.1)**

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-275302) and Form S-8 (Nos. 2-90702; 33-18202; 33-55986; 33-56101; 33-34000; 33-56151; 33-60266; 333-95043; 333-109890; 333-18627; 333-109891; 333-95041; 333-40239; 333-95037; 333-50969; 333-58360; 333-97927; 333-115567; 333-129427; 333-129428; 333-140988; 333-115568; 333-132139; 333-147148; 333-163837; 333-165130; 333-165132; 333-166646; 333-174028; 333-178300; 333-178302; 333-190317; 333-199730; 333-199732; 333-226534; 333-250090; 333-271653; 333-271654; and 333-281207) of Ecolab Inc. of our report dated February 23, 2026 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP

Minneapolis, Minnesota

February 23, 2026

------

## Exhibit 24.1

**EXHIBIT (24.1)**

**POWER OF ATTORNEY**

**KNOW ALL MEN BY THESE PRESENTS**, that the undersigned, a director of Ecolab Inc., a Delaware corporation, does hereby make, nominate and appoint CHRISTOPHE BECK, JANDEEN M. BOONE and YOUHAO DONG, and each of them, to be my attorney-in-fact, with full power and authority to sign his name to the Annual Report on Form 10-K of Ecolab Inc. for the fiscal year ended December 31, 2025, and all amendments thereto, provided that the Annual Report and any amendments thereto, in final form, be approved by said attorney-in-fact, and his name, when thus signed, shall have the same force and effect as though I had manually signed said document.

**IN WITNESS WHEREOF**, I have hereunto affixed my signature this 23<sup>rd</sup> day of February, 2026.

---

| |
|:---|
| /s/ Judson B. Althoff |
| Judson B. Althoff |
| /s/ Shari L. Ballard |
| Shari L. Ballard |
| /s/ Michel D. Doukeris |
| Michel D. Doukeris |
| /s/ Eric M. Green |
| Eric M. Green |
| /s/ Marion K. Gross |
| Marion K. Gross |
| /s/ Michael Larson |
| Michael Larson |
| /s/ David W. MacLennan |
| David W. MacLennan |
| /s/ Tracy B. McKibben |
| Tracy B. McKibben |
| /s/ Lionel L. Nowell, III |
| Lionel L. Nowell, III |
| /s/ Victoria J. Reich |
| Victoria J. Reich |
| /s/ Suzanne M. Vautrinot |
| Suzanne M. Vautrinot |
| /s/ Julie P. Whalen |
| Julie P. Whalen |
| /s/ John J. Zillmer |
| John J. Zillmer |

---

------

## Exhibit 31.1

**EXHIBIT (31.1)**

**CERTIFICATION**

I, Christophe Beck, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this annual report on Form 10-K of Ecolab Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| Date: February 23, 2026 |
| /s/ Christophe Beck |
| Christophe Beck  |
| Chief Executive Officer |

---

------

## Exhibit 31.2

**EXHIBIT (31.2)**

**CERTIFICATION**

I, Scott D. Kirkland, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this annual report on Form 10-K of Ecolab Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| Date: February 23, 2026 |
| /s/ Scott D. Kirkland |
| Scott D. Kirkland  |
| Chief Financial Officer |

---

------

## Exhibit 32.1

**EXHIBIT (32.1)**

**SECTION 1350 CERTIFICATIONS**

Pursuant to 18 U.S.C. Section 1350, each of the undersigned officers of Ecolab Inc. does hereby certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Annual Report on Form 10-K of Ecolab Inc. for the year ended December 31, 2025 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Ecolab Inc.

---

| | |
|:---|:---|
| Dated: February 23, 2026 | /s/ Christophe Beck |
|  | Christophe Beck |
|  | Chief Executive Officer |
| Dated: February 23, 2026 | /s/ Scott D. Kirkland |
|  | Scott D. Kirkland |
|  | Chief Financial Officer |

---

------